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II 
Abstract 
Decision analytic modelling (DAM) is a mathematical technique which is used to 
structure and synthesise evidence in order to inform decision making, given 
uncertainty.  Decision models are an ideal tool for undertaking economic 
evaluations as they enable a wide range of data on costs and effects to be 
synthesised within the model in order to derive cost-effectiveness outcomes.  
The iterative framework for economic appraisal has been proposed as good 
practice for undertaking economic evaluations (1), and DAM plays a key role 
within this framework.  In particular there is a role for early stage DAM prior to 
primary research, to provide an indication of the potential cost-effectiveness 
of a new health technology (2) given current evidence, and the use of value of 
information (VOI) techniques to help inform further research priority setting. In 
practice, support and funding for early stage DAM and full exploitation of VOI 
techniques is rare. 
The aim of this thesis is to examine the role for early decision analytic 
modelling in informing research priorities and the design of future studies in a 
health care setting. This thesis explores the feasibility, merits and drawbacks 
of undertaking early DAM and considers potential reasons as to why it has not 
been more widely implemented.   
This thesis demonstrates the value and importance of early DAM; in both an 
‘ideal’ setting and also in a less desirable, time-constrained setting. Applying 
early DAM and VOI techniques enables researchers to provide relevant 
conclusions and recommendations to decision makers, who can make informed 
decisions as to whether a new intervention should be adopted (or rejected), or 
whether further information is required to help make the decision; as opposed 
to making decisions based on subjective reasoning.  There is considerable merit 
with employing early DAM for health care research, such as reduced 
uncertainty, reduction of costs and efficiency gains, however, some drawbacks 
exist in terms of whether it is always viable to fully exploit VOI analyses, which 
may hinder widespread support both inside and out-with the health economics 
community. 
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reimbursement decision body, NICE (12); gaining some recognition of its 
benefits within the health economics community, however since this time 
there have been few other practical applications in published research.  In 
practice, support and financial funding for early stage decision analytic 
modelling (and full exploitation of VOI techniques) is rare, and in the health 
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1 
1 Introduction 
1.1 Rationale 
The UK National Health Service (NHS) spends in excess of £100 billion each year 
providing health care for UK residents (14). New health technologies are 
continually emerging and even the large public NHS budget is limited; and 
therefore, there is a need for decision-making and prioritisation of health care.   
Throughout the 1990s economic evaluation became a widely used tool in health 
care to aid decision making regarding value for money in new and existing 
health technologies (15).  Economic evaluation compares the costs and benefits 
of health technologies in order to aid reimbursement agencies, such as the 
National Institute for Health and Clinical Excellence (NICE) in the UK, and the 
Pharmaceutical Benefits Scheme (PBS) in Australia; in determining which 
alternatives are cost-effective and can be considered to represent good value 
for money (16;17).  Economic evaluations are undertaken for a range of 
reasons, however their primary role is to inform decision making given limited 
health care budgets (15;18;19).  They provide a systematic approach to 
comparing alternative drugs or health technologies in terms of their costs and 
outcomes.   
Many economic evaluations that are commissioned by healthcare funding 
bodies or pharmaceutical companies are often not considered until the later 
phases of clinical trials (20), and in the case of publicly funded research, 
explorative research budgets rarely leave adequate financing to incorporate 
economic analyses.  Therefore, economic evaluations are commonly 
incorporated at the end of large trials in order to support a case for 
reimbursement. Sculpher et al. (1) suggest that as national health care 
decision making agencies are increasingly requiring evidence on cost-
effectiveness prior to reimbursement, this has triggered a mind-set amongst 
the health care sector that the function of health economics is to use clinical 
trial data for economic evaluations in order to support a case for 
reimbursement.  The authors contend (1) that such trial based evaluations 
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represent a partial or limited form of economic analysis, due to the 
‘effectiveness’ focus of the trial design and other constraints of using a trial 
designed without economic evaluation in mind.  Such a trial may not reflect 
real life clinical practice. 
An iterative approach to economic appraisal is a framework that has been 
proposed as good practice (1;3) for evaluating health technologies.  The 
framework proposes that the process of health care evaluation should begin 
with an explorative modelling approach using indicative studies, and progress 
to more rigorous assessments, updating the model over time as more data 
becomes available (1;3).  The iterative approach to evaluation provides a 
structure in which evidence from a range of sources can be synthesised and 
continually updated in order to answer cost-effectiveness decision problems 
for a defined context and population.  The premise is that rather than using 
economic evaluation as a restrictive, one-off analysis it should be an iterative 
process conducted throughout the research process.   
Decision analytic modelling (DAM) is a key process within the iterative 
framework.  An ‘early’ DAM, undertaken prior to primary research, allows 
explorative evaluation of cost-effectiveness based on existing evidence and can 
be used to assess any uncertainty surrounding the cost-effectiveness decision 
(21-23).  Developing a DAM and undertaking probabilistic analysis at an early 
stage also enables the use of value of information analyses (VOI) (9;12;13) 
which is a set of techniques used to determine the amount society would be 
willing to pay for information, prior to seeking out that information.  VOI can 
help inform research priorities, which is recommended as part of the iterative 
framework. If developed in advance of primary research, a decision model can 
enable full exploitation of VOI techniques and therefore help determine 
whether further research is potentially worthwhile. VOI can help explore the 
type of research required to address uncertainty in current evidence, and even 
help design a trial with regards to an appropriate sample size, allocation to 
arms, data to collect, etc.  Despite these advantages, in practice support and 
funding for early stage decision analytic modelling (and full exploitation of VOI 
techniques) is rare, and in the health care sector economic evaluations still 
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tend to be funded as a one-off exercise alongside a trial to justify 
reimbursement.   
The aim of this thesis is to examine the role of early decision analytic 
modelling for informing research priorities and the design of future studies in 
health care within the context of an iterative framework for economic 
evaluation. The thesis will explore the feasibility, merit and drawbacks of 
undertaking early decision analytic modelling in practice, and consider 
potential reasons as to why it has not been more widely implemented. 
 
1.2 Economic evaluation in health care 
An economic evaluation requires the comparison of two or more alternative 
interventions, as well as consideration of both the costs and outcomes of the 
interventions.  Rather than a cost reducing exercise, economic evaluation is 
concerned with the incremental difference between two or more alternatives, 
i.e. what additional health benefit can we get for what additional cost?   There 
are various forms of economic evaluation; most commonly cost-benefit analysis 
(CBA), cost-effectiveness analysis (CEA) and cost-utility analysis (CUA) (15;18).  
These three forms of evaluation vary in terms of how they measure health 
outcomes.  CBA measures costs and benefits in the same units (monetary) and 
therefore the cost can be subtracted from the monetarised health benefit of 
an intervention to determine a monetary gain or loss.  CEA measures health 
outcomes in natural units, such as reduction in blood pressure, life years 
gained, or number of cases avoided in preventative interventions.  CEA results 
are presented in terms of the incremental cost per unit of health gain, known 
as an incremental cost effectiveness ratio (ICER), which is calculated by 
dividing the difference in cost between two interventions by the difference in 
effect.  CUA is often seen as an extension of CEA, whereby health gains are 
measured in terms of utility, i.e. quality adjusted life year gains (QALYs) and 
therefore the ICER outcome would be the incremental cost per QALY gained. 
QALYs are a generic outcome measure and therefore enable comparison of 
ICERs across disease areas, which is of particular use to decision making bodies 
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(24;25). Less common forms of economic type analyses include cost 
minimisation analysis whereby the outcomes are assumed to be identical and 
therefore the evaluation is simply focussed on minimising cost, or cost-
consequence analysis (CCA) where an array of outcomes are presented in 
tabular form, but not combined with cost (and is therefore often not 
considered to be a formal evaluation).   
CEA is a popular form of evaluation in health care evaluations because disease 
specific outcomes can be readily modified to include QALYs and they avoid the 
difficulty of implicit valuation of benefits in a CBA (15). With regards to the 
ICER outcome, the larger the value of the ICER the more it costs per unit of 
effectiveness and therefore the less cost-effective the intervention is in 
comparison to the alternative. The ICER value must be compared against a 
monetary threshold of maximum willingness to pay (ceiling ratio) per unit of 
effectiveness to help aid decisions regarding appropriate resource allocation. 
I.e. if the ceiling ratio (λ) was £50,000 per QALY gained, then an intervention 
which cost an additional £9,000 (∆C) and increased QALYs by 0.2 (∆ QALYs), 
would have a resultant ICER of £45,000 per QALY and would be considered to 
be cost-effective in comparison to the alternative, at that ceiling ratio.  If the 
ceiling ratio were £20,000 per QALY, then an ICER of £45,000 per QALY would 
not be considered cost-effective.  Equation 1.1 details this decision rule which 
determines whether an intervention is cost-effective (if the ICER value is less 
than or equal to the ceiling ratio) 
λ
∆
∆
<
E
C
:ICER          (1.1). 
A CEA can also report outcomes in terms of the net monetary benefit (NMB) of 
an intervention.  The incremental NMB is calculated by monetarising the 
measure of effectiveness1, i.e. incorporating the ceiling ratio explicitly in the 
ICER calculation to determine the maximum amount that the measure of 
effectiveness is worth.  This is illustrated in Equation 1.2, which is simply a 
rearrangement of the ICER algorithm detailed in Equation 1.1.  The 
                                         
1
 Presenting CEA results as a net monetary benefit (NMB) is different from a CBA.  In a CBA the 
benefits are measured and valued in monetary terms, where as in CEA the benefits are 
measured in terms of effectiveness, then transformed into a monetary value using a societal 
willingness to pay value, per unit of that effect.   
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intervention is cost-effective if the incremental NMB is greater than zero. The 
decision rule is now:  
0>CE*:NMB ∆∆λ -         (1.2). 
The incremental NMB portrays any inequalities on the cost scale; i.e. the NMB 
values represent monetary costs.  Alternatively the ICER can be re-arranged to 
express inequalities on the effect scale (whereby the values represent units of 
effect) using the Net Health benefit (NHB) approach (4;26) as illustrated in 
Equation 1.3. The decision rule now is: 
0>
C
-E:NHB λ
∆∆          (1.3). 
These two alternative decision rules (Equation 1.2 and 1.3) are equivalent to 
the decision rule based on the ICER, only they express cost-effectiveness in 
terms of net monetary benefit or net health benefit.  These approaches can be 
advantageous over the ratio led ICER (4), as the net benefit for each individual 
intervention can be calculated making comparisons with more than two 
interventions easier. They also have additional advantages over an ICER 
presentation when dealing with the outcomes from a probabilistic sensitivity 
analysis (4) and when calculating cost-effectiveness acceptability curves 
(CEACs) (7).  
Cost-effectiveness analyses can be undertaken using a variety of techniques 
(27). When economic evaluation was emerging in the area of health care, it 
developed recognition through two methods: decision modelling and trial based 
evaluations.  Evaluations were initially undertaken with a retrospective 
approach, using decision models to synthesise existing evidence in order to 
evaluate health interventions; or alternatively, evaluations were undertaken 
prospectively alongside randomised controlled trials (RCTs).  These two 
methods were viewed as alternative approaches to economic evaluation, with 
trial based evaluations growing in popularity and establishing a reputation for 
being more robust than the modelling approach (28).  The main critique of 
modelling was that the analyses relied heavily upon assumptions (29).   In the 
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mid 1990’s however, a different perspective emerged, proposing that the two 
alternative methods should not be viewed as alternatives, but rather, as 
complimentary approaches (3).  The two methods have different purposes; 
trials aim to estimate particular parameters or the effects of a health care 
intervention, whereas, modelling provides a framework based on assumptions 
in which available evidence can be combined. Therefore they are not 
alternative methods for economic evaluation in which one can be viewed as 
‘better’ than the other, but rather they should be viewed as complementary 
approaches (18;22).  It is possible, and more beneficial, to use a mixture of the 
two approaches, with prospective trial information supporting wider secondary 
evidence to provide a more robust analysis (1).   
1.2.1 Modelling 
Adopting a retrospective outlook, a cost-effectiveness analysis can be 
undertaken utilising a variety of published data and literature to provide 
information on costs, resource use, quality of life and effectiveness 
information which can then be synthesised in a decision analytic model (30).  
Decision analytic modelling (DAM) in health economics refers to a 
mathematical decision making tool which structures evidence on clinical and 
economic outcomes, to inform health care resource use and clinical practices 
(30).  A decision model is a framework for undertaking an economic evaluation, 
which can be structured in different ways; however, the role of a model is as a 
means of synthesising evidence on health outcomes and costs from a variety of 
sources.  Brennan & Akehurst (31) discuss the many roles of economic 
modelling, and how models can vary substantially with regards to structure and 
complexity, some being nothing more than extended spreadsheet calculations.  
Brennan et al. (32) classify various model structures to indicate the range of 
modelling approaches and their structural relationships to one another. The 
authors also provide some guidance on choice of model structure, and highlight 
that different modelling approaches can produce very different results.  The 
choice of model depends on various factors but is predominantly determined 
by the decision makers’ requirements, the complexity of disease area, and 
even modellers expertise or preference (32).  
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In the mid 1990s the discretionary nature of modelling was used to question its 
credibility (28;29), and since then considerable effort has focussed on 
promoting consistency in the process of modelling, particularly with regards to 
developing general principles for identifying and synthesising evidence. 
Sculpher et al. (33) considered what constitutes good practice in modelling, 
along with issues around validity and quality in modelling.  In 2003 the 
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 
published guidelines for conducting and reporting economic models in response 
to issues of appropriateness and consistency (30).  Philips et al. (34) continued 
to explore good practices in modelling and commented that despite the 
prevalence of various guidelines for the assessment of decision models since 
1985, there was still no standard definition of what good practice should mean 
in an economic model.  In response to this Philips et al. (34) continued earlier 
work by Sculpher et al. (33) and attempted to provide such a framework.  The 
authors reviewed and consolidated the range of existing guidelines and 
developed a standard framework for how ‘good practice’ should be defined for 
DAM.  The framework was developed around three key areas: structure, data, 
and consistency; and provides a practical and systematic means for critical 
assessment of decision analytic models.  The authors caution that it is 
unrealistic to expect all studies to adhere to every point in the framework, but 
stress that systematic application of the framework will allow the strengths 
and weaknesses of models under review to be identified.  
More recently, Petrou & Gray (35) published a review in the British Medical 
Journal to highlight issues relating to the design, conduct and analysis of 
economic evaluations using DAM and to create awareness in the wider medical 
community.  As computing capacity has increased over the last two decades, so 
have modelling methods (36) and therefore guidelines to promote good 
modelling methods have also had to adapt and be updated as more complex 
forms of modelling become ever more popular (37).  
1.2.2 Trial based 
Throughout the last two decades trial based economic evaluations have 
become fundamental as health care decision making bodies have specified a 
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requirement for evidence of cost-effectiveness to support reimbursement 
decisions.  Therefore economic evaluations have been incorporated into 
randomised controlled trials for pharmacologies and medical therapies (28;38).  
This type of evaluation is undertaken prospectively, utilising effectiveness data 
directly from a trial, and therefore can potentially collect resource use, cost 
and quality of life data directly related to the health technology under 
evaluation.    
Clinical trials are frequently viewed as the ‘best vehicle’ for economic 
evaluations as they ensure internal validity, through prospective collection of 
patient specific data, and they also present the opportunity to collect 
‘additional’ economic data (such as cost and utility information) at a low 
marginal cost alongside a large scale trial.  Therefore, large trials have many 
potential benefits for conducting economic analyses if the economic 
component is integrated into the study protocol appropriately, rather than 
added on as an extra component at a late stage.  It is important that the 
economic requirements contribute to the study design to ensure that the 
structure of the trial will provide the necessary data for a high quality 
economic study (39). Incorporation of economic relevant data into the trial 
dataset enables statistical analyses on the cost, effect and quality of life data, 
rather than just the effectiveness data.  Glick and colleagues (40) set out the 
methodology for undertaking economic evaluations alongside clinical trials, 
including details for analysing the data, calculating within trial ICERs and 
exploring uncertainty in the cost-effectiveness outcomes. 
Glick et al. (38;40) specify some ‘gold standard’ characteristics for conducting 
an economic evaluation as part of an RCT, detailing six steps for an 
appropriate analysis.  Despite such attempts to promote consistency and 
improvements in the methods for the design, conduct and analysis of economic 
data collected alongside clinical trials over the last two decades, there remains 
a great deal of variation in methodology and reporting of these types of studies 
(39).  In response to this the ISPOR task force developed guidelines for 
reporting and conduct of economic evaluations alongside trials, in an attempt 
to improve quality and enhance the credibility of cost-effectiveness analysis 
(39).  More recently Petrou & Gray (41) published a review of the methods for 
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research and reporting of evaluations alongside RCTS (alongside their review 
for DAM (35)) to highlight good practice and create awareness in the wider 
medical community.   
Despite the various guidelines, integrating economic evaluations into trial 
protocols remains challenging (42) and as the primary focus of the trial 
research is typically on effectiveness (as opposed to cost-effectiveness), it is 
likely the sample size will be determined considering only the effectiveness 
outcome.  This can potentially result in a trial that is underpowered to detect 
cost-effectiveness (43;44). Additionally, trials alone rarely provide sufficient 
evidence to fully inform an economic evaluation (38;39).  A single trial may not 
compare all relevant alternatives, may not collect important quality of life 
data, or may have a restricted follow-up time period which is inadequate. For 
example a lifetime horizon follow-up is appropriate for an economic analysis 
but the cost and feasibility of conducting an RCT in practice restricts follow-up 
periods, with three to five years being considered a long duration.  Such 
restrictions necessitate extrapolation of trial data over longer time periods, 
typically using some form of modelling technique. Therefore economic 
evaluations alongside trials are rarely undertaken solely on the trial data.  
External information for economic modelling is required, particularly for 
extrapolation (28) and therefore decision analytic modelling is used to 
incorporate additional supplementary evidence for the economic evaluation. 
Throughout the last two decades the role for cost-effectiveness analysis in 
health technology assessment has developed substantially (18) and while some 
may still hold to the view that clinical trials are the ‘best vehicle’ for economic 
evaluation, it is recognised within the health economics community that a 
mixture of trial based and modelling approaches is required for a robust 
analysis (1;39;41). Regardless of whether a modelling, trial based or mixed 
approach is used to undertake an economic evaluation, various good practice 
guidelines and checklists exist (15;30;34;37;39;45) as well as various decision 
making body guidelines (24;25); which promote a systematic and rigorous 
approach to data collection, analysis, synthesis of cost and effect 
data/evidence, reporting of outcomes and exploration of uncertainty and 
heterogeneity.  
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1.2.3 DAM in economic evaluation using an iterative approach  
In exploring a framework for quality assessment in DAM, Sculpher et al. (33) 
explain that models and trials have a separate purposes; the purpose of a 
model is to combine all available information at the time (t) the decision must 
be made to predict the impact.  The purpose of a trial based economic 
evaluation is to generate new information about one or more parameters at 
time t+1 that was not available at time t.  Therefore, rather than be viewed as 
alternative methods for economic evaluation, they should be viewed as 
complementary approaches at different time points.  They can both be used to 
fully inform a decision; i.e. in practice a short-term trial based analysis is often 
followed by a longer term decision model utilising other evidence to 
extrapolate the trial findings into a lifetime horizon, providing a more robust 
analysis.  However, rather than merely supporting a mixed methods one-off 
approach to evaluation, Sculpher and colleagues (3) outline an iterative 
process for economic evaluation, progressing from early indicative studies, to 
more rigorous assessments as more data becomes available, reducing 
uncertainty surrounding the cost-effectiveness estimates over a long time 
period.  Bayesian techniques for economic evaluation developed and promoted 
throughout the 1990s; such as probabilistic sensitivity analysis for exploring 
uncertainty in parameter estimates and the model (5;46), and value of 
information analyses (VOI) (9;13) are ideal tools for facilitating such an 
iterative process.  
Sculpher et al. (3) consider the best way to combine economic and clinical 
research.  They highlight that economic evaluation is perceived as a one-off 
exercise and attempt to dispel this perception through proposing an iterative 
process.  Claxton promotes an iterative approach through a Bayesian 
framework for decision making, exploring the uncertainty surrounding a cost-
effectiveness decision based on current information (9;13). The authors 
propose formal VOI assessments to value further research on its potential 
ability to reduce the expected costs of uncertainty surrounding the decision, 
rather than deciding on further research and its design through arbitrary 
means.  
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Fenwick et al. (21) further support the role of iterative decision analytic 
modelling, suggesting that as new health technologies emerge, DAM should be 
undertaken and updated regularly as new information becomes available.  The 
authors demonstrate the application of this process and propose the case for 
integrating such a framework into the HTA process.  The iterative approach 
recommends a process of ‘early’ modelling prior to the design of any clinical 
trials (7;47;48), whereby a decision analytic model is developed based on 
existing evidence on the costs and effectiveness of an intervention.  This 
provides a preliminary assessment of the level of uncertainty surrounding the 
costs, effects and cost-effectiveness of the intervention and which can then be 
used to provide information on whether a trial is required, and if so the 
appropriate design using VOI methods.  
Some researchers have used this approach in practice, however it was not 
widely adopted and the one-off attitude towards economic evaluation 
highlighted by Sculpher et al. (3) in 1997, prevailed in economic evaluations 
undertaken alongside clinical trials (28).  The iterative approach was 
demonstrated for the Health Technology Assessment programme in the UK (10) 
and for the UK reimbursement decision body, NICE (12); gaining some 
recognition of its benefits within the health economics community, however 
since this time there have been few other practical applications in published 
research.  
Fenwick and colleagues continue to support the iterative approach, 
particularly in the context of ‘early’ pre-trial modelling followed by VOI 
analysis to determine whether a trial was worthwhile (11); and in 2006 
Sculpher et al. (1) set out a framework for the iterative process, defining it in 
to five distinct stages.  In 2007 Briggs provided further support for the iterative 
approach, highlighting in the British Medical Journal that VOI must be 
integrated into the process of commissioning primary research (49). However, 
despite these latter developments, there is little evidence of funding and 
support for an iterative approach to economic evaluation in the health care 
sector. There remains a need for wider acknowledgement and incorporation of 
the iterative approach in the health care community, particular amongst the 
range of health care research funding bodies and the pharmaceutical industry.   
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In practice, support and funding for early stage decision analytic modelling 
(and full exploitation of VOI techniques) is rare, and in the health care sector 
economic evaluations still tend to be funded as a one-off exercise alongside a 
trial to justify reimbursement.  Therefore, the aim of this thesis is to examine 
the role of early decision analytic modelling for informing research priorities 
and the design of future studies in health care, within the context of an 
iterative framework for economic evaluation. The thesis will explore the 
feasibility, merit and drawbacks of undertaking early decision analytic 
modelling in practice, and consider potential reasons as to why it has not been 
widely implemented. 
 
1.3 Thesis outline 
The thesis is split into five main chapters.   Chapter 2 introduces economic 
evaluation in the context of publicly and commercially funded health care 
research. The chapter outlines the methodology used in building a decision 
analytic model, undertaking probabilistic sensitivity analysis, analysing 
uncertainty, and using value of information techniques to explore potential 
future research concerns. These methods are used throughout the remainder of 
the thesis. The iterative approach to economic appraisal is discussed and the 
advantages of employing such an approach to funding health care research are 
highlighted.  This chapter supports the case for early stage decision analytic 
modelling in health care research within the context of an iterative economic 
framework. 
Chapters 3 and 4 demonstrate a case study of good practice in developing an 
early decision analytic model. The case study details a piece of research that 
was funded by the National Institute for Health Research Health Technology 
Assessment programme (50) to build a decision model and undertake an 
economic evaluation of an emerging technology.  This research remit 
corresponds with the early stages of the iterative economic approach, 
developing an early decision analytic model to undertake an economic 
evaluation to determine whether the technology is cost-effective given current 
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information.  Chapter 3 details the development and parameterisation of three 
economic models, reporting the deterministic results, while Chapter 4 reports 
the probabilistic results from the models and explores uncertainty and VOI 
analyses to help inform future research priorities.  Chapter 4 demonstrates the 
importance of exploring uncertainty and how the application of value of 
information analyses, with early decision analytic models can help to inform 
the researchers, decision makers and funders on the appropriate next steps to 
take.  
Chapter 5 demonstrates the practicalities of designing clinical trials from an 
economic perspective.  The chapter offers a case study, reporting on an 
atypical real life case in which a clinical and cost-effectiveness trial was 
designed and powered to determine the sample size with regards to cost-
effectiveness.  The desire for a trial had been decided upon without prior 
economic involvement, i.e. neglecting the iterative economic approach, 
however, even when the iterative approach has been overlooked, involvement 
in the conventional design of a trial from an economic perspective is still 
desirable.  This chapter details the development of a simple DAM to inform a 
sample size calculation for the trial as the research proposal was being 
prepared.  This chapter therefore demonstrates the feasibility of developing 
decision models without prior funding and how simple models can be used to 
help design a trial and inform calculations in a real life setting.  The chapter 
simultaneously highlights limitations with undertaking sample size calculations 
and demonstrates the role for economic considerations to guide non-inferiority 
margins. 
Chapter 6 follows on from the previous (Chapter 5) case study considering 
whether the same, or an alternative conclusion would have been drawn had it 
been possible to adopt an iterative economic approach for the study; i.e. if 
pre-trial modelling had been undertaken in advance to help set research 
priorities, enabling the use of expected value of perfect information (EVPI) 
analysis to explore whether further research was of potential value, and if so 
using expected value of sample information (EVSI) to estimate an appropriate 
sample size for the RCT.   The chapter undertakes a re-analysis of the study 
from Chapter 5, adapting it in line with the iterative framework to compare 
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the resultant research priorities and sample size requirements under an 
iterative approach with the outcomes that were determined using the 
conventional framework from the trial proposal in Chapter 5.  
Chapter 7 provides a summary of the thesis.  This final chapter also proposes 
areas for further research and offers the overall conclusions. 
15 
2 DAM for economic evaluation in health care    
2.1 Introduction  
The UK National Health Service (NHS) spends in excess of £100 billion each year 
providing ‘free’ health care for UK residents (51).  The NHS is the largest 
publicly funded health care service in the world but is subject to an annual 
budget and therefore is vulnerable to the two fundamental economic concepts 
of scarcity and choice.  Decisions must be made regarding the choice of which 
health care products and services to offer, given the limited financial budget.  
Prioritisation of health care requires decisions or decision-making regarding 
which illnesses and disease areas should be allocated resources, and within 
specific disease areas, which treatments, interventions and health services to 
offer.  Therefore, there is a need to decide on the best mix of health 
technologies, especially as new technologies become available.  The term 
‘health technology’ covers a range of methods used to promote health, prevent 
and treat disease and improve rehabilitation (50). It is often used to represent 
all health care goods and services, such as pharmacologies, surgical 
techniques, intervention packages, or technologies.  Economic evaluation is a 
means of assessing alternative health technologies by comparing their costs 
and health benefits, and is increasingly being used as a major input for 
decision making bodies and reimbursement agencies throughout various 
countries for determining which interventions and health technologies 
represent good value for money (16;17).    
Economic evaluations are undertaken for a range of reasons, however their 
primary role is to inform decision making given limited health care budgets 
(15;19), through providing a systematic approach to comparing alternative 
drugs or health technologies in terms of their costs and consequences.  
Economic evaluations are not used for informing decisions regarding individual 
patients, but rather, they are undertaken to help guide drug formularies, 
disease-specific guidelines, the development of patient services, justification 
for existing or new services and also drug reimbursement decisions (19).  In the 
UK, decision making bodies for health technology reimbursement, such as the 
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National Institute for Health and Clinical Excellence (NICE) and the Scottish 
Medicines Consortium (SMC), require economic evaluation as part of their 
decision making process (24;25).    
There is a formal requirement for economic evaluation to be an integral 
component of NHS research and development funded projects (52).  However, 
health care research from other publicly funded research bodies and within the 
commercial sector is not subject to such requirements and therefore, may or 
may not include economic components within their research.  
The National Institute for Health Research (NIHR) is an NHS funded research 
body who support various research programmes (52), such as the Public Health 
Research (PHR) programme and the Health Technology Assessment (HTA) 
programme (50).  The HTA produces independent research about the 
effectiveness, cost-effectiveness and broader impacts of health care 
treatments and technologies.  The research generated is intended for an NHS 
audience, particularly those who plan and provide care in the NHS.  They 
commission both primary research and evidence synthesis, and the research 
topics are identified and prioritised to meet the needs of the NHS. The HTA 
identify evidence gaps or decision problems, for which they commission 
research, through various means such as consultation with key NHS 
stakeholders, extracting research recommendations from various resources, 
direct recommendations and communication with researchers (50).   
The Medical Research Council (MRC) is another publicly funded health care 
research body, and is one of seven research councils in the UK who are 
responsible for investing money in research in the UK (53).  The MRC aims to 
support medical research in order to ‘increase the pace of transition to better 
health’.  They set their research priorities in order to support scientists and 
deliver improved health outcomes across society. The MRC funds research 
through a range of grants, commissioned calls, and fellowships and have a 
range of board panels and groups to decide on what research should be funded 
or not (54).  The Chief Scientist Office (CSO) is a Scottish government funded 
research body who support and promote research aimed at improving the 
quality and cost-effectiveness of health services and health care offered by 
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NHS Scotland (55).  The CSO funds research through a variety of research 
grants and fellowships.  It is commonly the case that health care funding 
bodies such as the HTA, MRC and CSO define an overall research question and 
commission research (normally through a call to researchers) on specific health 
care topics to meet their organisations priorities; however, some funding 
bodies also issue open calls with an overall theme or disease area, which 
encourage researchers to identify specific decision problems within that broad 
area which need to be addressed.  
In the pharmaceutical industry, research decisions are undertaken internally, 
and drug development follows a well known and formally recognised process 
consisting of four distinct phases of clinical assessment (51;56-58). Within each 
phase rigorous testing is undertaken in order to reduce uncertainty, and ensure 
that only the safest and most marketable drug will proceed to market.  
This chapter introduces economic evaluation in the context of public and 
commercial health care research.  An overview of economic evaluation in the 
health care sector is provided followed by an outline of the methodologies 
used in decision analytic modelling for an economic evaluation in health care.  
The methodologies include building a decision analytic model, undertaking 
probabilistic sensitivity analysis, analysing decision uncertainty, and using 
value of information (VOI) techniques to explore potential future research 
concerns.  Following the decision modelling methodology, section 2.9 
introduces the iterative approach to economic appraisal as an appropriate 
framework for undertaking research in the health care sector.  The advantages 
of employing such an approach to funding health care research (both private 
and public) are highlighted, in terms of reducing uncertainty, reduction of 
costs and efficiency gains.  This chapter supports the case for early stage 
decision modelling in health care research within the context of an iterative 
economic approach.  
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2.2 Economic evaluation in health care 
Economic evaluations are undertaken to help inform decision making, for 
example to help determine which drugs or health technologies to fund given 
limited health care budgets (15).  As discussed in Chapter 1, cost-effectiveness 
analyses can be undertaken using a variety of techniques (27), most notably 
using decision analytic modelling, trial based evaluations, or a combination of 
the two.  It is this latter approach which utilises prospective trial information 
to support wider secondary evidence to promote a robust economic analysis 
(1).   
Reimbursement agencies across the world, such as the Australian 
Pharmaceutical Benefits Scheme (PBS) and the National Institute of Health and 
Clinical Excellence (NICE) in the UK, require evidence on cost-effectiveness for 
their reimbursement decisions.  In response to such requirements, the 
pharmaceutical industry has added a ‘fourth hurdle’ (59) to their drug 
development and licensing process; while publicly funded health care research 
has begun to incorporate economic components in large scale (Phase III) 
studies and occasionally in Phase II studies.  In addition to providing evidence 
of quality, safety and effectiveness, value for money must also be 
demonstrated.   
Numerous countries have introduced reimbursement policies over the last two 
decades, requiring some form of economic analysis to support the introduction 
of new drugs, (and some also have the same requirements in support of new 
health care technologies or interventions (17)), however, the stringency and 
rigour of guidelines for undertaking the analyses vary from country to country 
(16;17).  Many economic evaluations that are undertaken or commissioned by 
pharmaceutical companies are often not considered until the latter phases of 
clinical trials (20) and in the case of publicly funded research, Phase II and 
explorative research budgets rarely leave adequate financing to incorporate 
economic analyses.  Therefore, economic evaluations are commonly 
incorporated at the end of a larger scale phase III or phase IV trials utilising 
effectiveness, quality of life and cost data from the trial in order to support a 
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case for reimbursement.  Large scale Phase III trials are designed to show 
evidence surrounding the clinical effectiveness of a new intervention in 
comparison to a control to support the case for regulatory submission, and the 
economic component is often ‘piggy-backed’ on to the end of the trial (28).   
Sculpher et al. (1) suggest that reimbursement agencies’ requirements may 
have triggered a commercial mind-set that the function of health economics is 
to use RCT data for economic evaluations in order to support a business case 
for reimbursement; however, some agencies such as NICE in the UK require a 
more comprehensive approach using decision analytic modelling to synthesise 
trial information with other evidence (24).  An approach in which decisions are 
based upon economic evaluations which only incorporate RCT data can be 
considered short-sighted with regards to the purpose of and approach taken 
towards economic evaluation.  Sculpher et al. (1) argue that such trial based 
evaluations represent a partial or limited form of economic analysis, due to the 
‘effectiveness’ focus of the trial design and other constraints of using a single 
trial designed without economic evaluation in mind.  Such a trial may not 
reflect real life clinical practice, costs may not be the same, it may not 
consider all relevant alternatives, may have a limited time horizon, lack 
relevance to the decision context, or in general may not adhere to the gold 
standard characteristics for economic evaluation within a trial (40).     
A more comprehensive approach to economic evaluation involves using decision 
analytic modelling to synthesise evidence from a variety of information sources 
followed by an exploration of uncertainty, including uncertainty surrounding 
the cost-effectiveness decision.   
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2.3 Decision Analytic Modelling 
Decision analysis represents a technique for structuring decision problems.  It 
is an approach that has been used in a range of disciplines such as Engineering, 
Law, Business (60), and more recently environmental remediation.  It has also 
been adopted in health care as a framework for making decisions under 
uncertainty. A succinct definition is provided by Snider et al. (page 27) (61): 
“Decision analysis is an explicit, quantitative and systematic approach to 
decision making under conditions of uncertainty”  
Within health care, decision analysis has been adopted as a framework for 
conducting health care evaluations and economic evaluations (4;61).  An 
economic evaluation can be designed using a decision model, enabling a wide 
range of data on costs and effects to be synthesised within the model in order 
to derive cost-effectiveness outcomes. Therefore, in the context of economic 
evaluation, a decision analytic model (DAM) is a mathematical tool used to 
structure a problem regarding two or more interventions for a specific patient 
group.  The model uses mathematical relationships to synthesise input 
information (such as clinical and cost inputs) from numerous sources and 
defines a series of possible consequences depending on the options being 
compared (4).   
The basic steps for building a decision analytic model involve specifying the 
decision problem, defining the boundaries, specifying the model structure, 
identifying and synthesising evidence and dealing with uncertainty. Assessing 
the value of additional research is also a key component of the modelling 
process (4), given that the point in decision analysis is to inform decision 
making given uncertainty.  These key components are now discussed.  
2.3.1 Specifying the problem  
This stage involves considering the objective of the evaluation, so as to clearly 
define the relevant aspects of the question to be addressed by the analysis.  
The alternative interventions or health technologies being evaluated need to 
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be specified, which is likely to be the new intervention compared to a control 
or current practice, however, the evaluation may involve more than two 
alternatives.  The outcome measures should be defined, i.e. what will be the 
primary measure of effectiveness. Additionally the relevant disease area and 
patient population should be specified.  Other aspects to be included are the 
setting (i.e. primary care) and the perspective of the analysis. The perspective 
will tend to be determined by who is funding the research (i.e. an NHS funded 
research project may request a NHS perspective as opposed to a societal 
perspective which could incorporate ‘indirect’ costs incurred by patients and 
carers). 
2.3.2 Defining boundaries 
This stage involves considering what is relevant and not relevant to be included 
in the analysis, i.e. what time horizon is relevant to the model.  Should the 
outcomes be modelled over the patients’ lifetime or is a shorter duration more 
appropriate to answer the research question?  This will relate to the outcome 
of interest, for example, is it life expectancy or quality adjusted life years 
(QALYs) that is the effectiveness endpoint of interest, or is it an outcome 
which requires a shorter duration, i.e. cases of morbidity post-surgery?   
Defining boundaries for the model also relates to the potential impacts of the 
interventions under evaluation, and whether they need to be included in the 
model.  For example is it relevant to incorporate negative side-effects from 
the interventions?  If the interventions under evaluation involve treatment with 
drugs, are there any possible side-effects and if so, are they relevant to 
incorporate in the analysis?  Researchers should ask, ‘do they impact on the 
costs or patient quality of life within the time horizon relevant to the model?’  
In some cases side-effects may be negligible and not expected to have a large 
impact on the patient population; or alternatively may be longer-term impacts 
out-with the relevant model timeframe.  In such cases it may be appropriate to 
consider such impacts to be out-with the boundaries of the model. 
Defining boundaries ensures that the model is representative, and an 
appropriate (yet simplified) reflection of real life. It is important that the 
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model adheres to quality assurance in that the boundaries are not so restrictive 
that they bias the analysis by excluding important factors.  
2.3.3 Structuring the problem  
An appropriate structure for the model should be determined based on the 
problem specification and model boundaries already identified. A model can be 
as simple or as complex as required, as long as it is fit for purpose. 
Decision Trees are a common structure used for simple analyses or those with 
short time horizons. A decision tree is a model which maps the patient 
pathway, assigning cost and outcomes to alternative pathways or ‘branches’ 
throughout the tree (36).  Decision trees are popular due to their simple 
structure, and the transparent nature of the tree which makes them useful for 
short term analyses; however, they are less valuable for modelling complicated 
disease conditions or over long time durations as they can become ‘bushy’ very 
quickly if there are numerous decision options (decision nodes) at different 
stages in the model, and they lack an explicit time variable (35). 
Markov models are more useful for analyses over a longer duration, involving 
transitions between various health states and outcomes over time (62).  The 
main limitation with Markov models is that they do not account for the history 
of progression in the model.  This is known as the Markovian assumption (63) 
and means that transition probabilities between health states are independent 
of the history of the patient and depend only on the current health state. 
Despite this limitation, Markov models remain a common structure for 
modelling lifetime outcomes, however, in recent years more complex forms of 
modelling have become ever more popular (37).  
Over the last decade Discrete Event Simulations (32;36;64) have grown in 
popularity, simulating the progress of individuals through a health care system.  
The nature of DES allows complex modelling, memory of patient history in the 
model and interaction between patients over long time durations, thereby 
overcoming some of the restrictions of Markov modelling; however they require 
specialist software and programming skills to develop and run (36). Dynamic 
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modelling is an alternative method of complex modelling which allows for 
impacts to affect the behaviour of an entire population or an entire health 
system, accounting for evolving factors and effects over long time durations.  
These traits have made dynamic models popular for modelling infectious 
diseases.  Although these more complex modelling methods require 
programming skills, they have considerable value to researchers and therefore 
encourage improvements in researchers’ computational skills (35;36). 
The choice of model structure depends on various factors but they are 
predominantly determined by the decision makers’ requirements, the 
complexity of disease area, and even modellers expertise or preference (32).  
The type of model used is subjective to the modeller, but as different 
modelling approaches can produce very different results it is important for 
researchers to be explicit in the reasoning for choice of model structure.  
2.3.4 Synthesising evidence 
This stage involves the systematic combination of evidence from a range of 
sources in order to populate the decision model. There needs to be a 
systematic approach taken to identifying all the relevant evidence for the 
model.  The model input evidence is classified into parameters which are used 
to reflect the data on clinical events, effectiveness, utility information, 
resource use, and unit cost information. 
Clinical parameters tend to be incorporated as probabilities, i.e. the 
probability of a clinical event occurring (where a probability is a number 
between zero and 1 which reflects the likelihood of a specific event occurring) 
such as disease prevalence to define whether the population has a specific 
disease or not.  An example of parameters represented by probabilities could 
be for patients with a specific disease that has three alternative treatment 
options: A, B or C.  The probability of receiving one of the three treatments (A, 
B or C) is a number between zero and 1 which reflects the likelihood that a 
patient will receive one of these treatments rather than the other two.  I.e. 
there is a probability of 0.3 that a patient will receive treatment A, a 0.6 
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probability of receiving treatment B and a probability of 0.1 that treatment C 
will be given.   
Some parameters may be reported as rates rather than probabilities and 
therefore it is important to note the distinction between the two.  A rate is the 
instantaneous potential for the occurrence of an event, expressed per number 
of patients at risk (4), whereas a probability is the likelihood of an event 
occurring over a specific time period.  Government statistics tend to report 
population level mortality rates which can be useful in economic models, 
however they may require to be converted into transition probabilities.  It is 
possible to convert a rate to a probability over a specified time period, if the 
rate can be assumed to be constant over that time period: (4). Equation 2.1 
details how the probability (p) can be calculated given the instantaneous rate 
(r) and time period (t) of interest for which the rate is assumed to be constant:  
{ }rt-exp-1=p          (2.1). 
The probabilities and other parameters (effectiveness, survival, utility, 
resource use) in the model are assigned from various sources such as medical 
literature, expert opinion, and statistical analysis.  For example, utility for the 
patient population may be derived from a survey or from an observational 
study; the probability of different treatment options for a specific disease may 
be informed by a combination of published disease guidelines and clinical 
expert opinion, while effectiveness data may be derived from one or more 
clinical trials.  
The synthesis of data from various sources gives rise to potential issues, such as 
no direct comparisons from RCTs for the interventions of interest, different 
follow-up times from different studies and heterogeneity (where there is a 
difference in patient characteristics between trials).  Such issues are dealt 
with through a variety of methods including indirect and mixed treatment 
comparisons and meta-regression (65;66).   
Once the model has been developed and populated with evidence relating to 
the mean value for each of the model parameters, the economic evaluation is 
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undertaken to calculate the outcomes, which in a cost-effectiveness analysis 
would be the incremental cost-effectiveness ratio or the incremental net 
benefit of the new intervention(s) in comparison to the alternative(s).  This is a 
basic ‘deterministic’ analysis which uses point estimates to represent the 
evidence for the parameters in the model.  The next step involves handling 
uncertainty in the model, and in particular the method used to deal with 
uncertainty in the model parameters.  
2.3.5 Handling Uncertainty  
Regardless of whether an economic evaluation is undertaken based on a 
decision analytic model, or informed solely from a single clinical trial, it will 
be subject to uncertainty. Han et al. (67) highlight that there is a wide variety 
of uncertainty referred to in health care research, spanning different types, 
sources and manifestations of uncertainty.  The authors propose a conceptual 
taxonomy of different types with the intention of encouraging an organised 
approach to dealing with uncertainty (67).  With regards to decision modelling, 
uncertainty can pertain to sampling variation, heterogeneity, methodological 
uncertainty, structural uncertainty, parameter uncertainty and decision 
uncertainty; each of which requires to be dealt with differently(4-6).   
In clinical studies, variability in individual patients is normally addressed 
through randomisation and analysis of baseline statistics.  Sensitivity analysis 
can be undertaken with access to patient level data, but in a model where the 
data has been derived from published evidence, this may or may not have been 
addressed by those reporting the evidence, and it cannot be addressed through 
collection of more data (4).  
Assessing heterogeneity requires consideration of various study population 
subgroups to assess whether other factors inherent to these groups influence 
the study outcomes by confounding or overriding the actual treatment effects, 
i.e. different age groups, differences in gender or disease specification.  The 
National Institute for Health and Clinical Excellence (NICE) formally recognised 
the importance of heterogeneity and subgroup analysis in their 2004 Health 
Technology Appraisal guidance.  More recently this guidance was revised and 
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now specifically recommends subgroup analysis in all technology appraisals 
submitted to NICE for consideration (24).   
Methodological uncertainty refers to uncertainty regarding whether the 
methods used were the most appropriate.  Methodological uncertainties can be 
dealt with through the use of a benchmark approach or reference case for 
appropriate methodology, i.e. by following good practice guidelines for 
undertaking modelling (34;37).  The generalisability of model results can be 
explored by altering parameters in the model that may have been specific to a 
particular setting.  Uncertainty regarding the structure of the model (68) can 
be dealt with by one-way sensitivity analyses and scenario analyses, modifying 
one or more structural aspects or assumptions of the model and determining 
the impact on outcomes.  More recently it has been suggested that a formal 
framework is required to addressed structural uncertainty, whereby a global 
model could be developed including parameters which encompass all possible 
structural choices so that they can be addressed using probabilistic 
methods(69).    
Parameter uncertainty refers to uncertainty in the point estimates used to 
reflect the specific parameters in the model, i.e. uncertainty in the mean 
utility value assigned to a specific disease group, or uncertainty in the 
probability of an event.  Parameter uncertainty can be dealt with 
deterministically through univariate and multivariate sensitivity analysis, 
however, probabilistic sensitivity analysis (PSA) can also be undertaken to 
adequately address this, which is discussed in the next section.  Finally, 
decision uncertainty should also be explored.  Decision uncertainty refers to 
the level of uncertainty in the cost-effectiveness outcome from the model, i.e. 
uncertainty in the estimated cost-effectiveness of the treatment in comparison 
to the alternative(s) (70;71).  Parameter uncertainty is now discussed in more 
detail followed by decision uncertainty.  
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2.4 Assessing parameter uncertainty 
Parameters in a model are represented by point estimates, which reflect the 
mean value for each parameter and cost-effectiveness is determined based on 
the mean value for each of the parameter inputs.  This is known as a 
deterministic analysis.  In a probabilistic sensitivity analysis (PSA), uncertainty 
in the mean parameter estimates is accounted for by assigning a distribution to 
each parameter and drawing a random estimate from that distribution to 
represent the point estimate.  By drawing randomly from the parameter 
distributions simultaneously for all parameters in the model and repeating this 
random draw numerous times (in a Monte Carlo simulation) uncertainty in the 
parameter estimates is accounted for and the resultant cost, effect and cost-
effectiveness outcomes from the model can be calculated for each 
simultaneous random draw (iteration) (4-6). The average cost, effect and cost-
effectiveness across all the iterations in the Monte Carlo simulation are taken 
to represent the probabilistic outcomes which account for uncertainty in the 
input parameters.   
Using any number of iterations greater than 1000 is generally considered to be 
acceptable (4) to reflect uncertainty in the model parameters, however it is 
wise to test the stability of results over a varying number of iterations, i.e. 
1000, 2000, 5000, and 10,000 iterations.  If there are negligible or minimal 
changes to the incremental cost and incremental effectiveness outcomes 
between variations in the number of iterations then the outcomes can be 
considered stable; however, if there is variation in outcomes between the 
different number of iterations (i.e. between 1000, 2000 and 5000 iterations), 
then a greater number of iterations may be required, such as 10,000, and 
20,000 before the results can be considered stable.  The time taken to run the 
Monte Carlo simulation will depend on the complexity of the model, the 
computing software used and also on the number of iterations specified for the 
Monte Carlo simulation. As the number of iterations increases, the time taken 
to run the simulation will also increase, so it is important to find a balance 
between checking the stability of PSA results and needlessly running very time 
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consuming simulations; for example checking results at 100,000 iterations is 
unnecessary if they were found to be stable at 10,000 and 20,000 iterations.  
In making parameters probabilistic, there are a variety of distributional forms 
to choose from.  Briggs and colleagues (4) explain that the type of parameter 
and its method of estimation provide an indication of the appropriate 
distributional form to use. Let us first consider the different distributional 
forms available, followed by a discussion of fitting parameters to the forms.    
2.4.1 Distributional forms 
A distribution shows how the total probability of a random variable (i.e. the 
parameter of interest) is distributed. This will vary depending on the family or 
form of distribution (72), each of which will reflect different points on a scale.   
Continuous parameters (such as cost) require a continuous scale and therefore 
a distributional form that is appropriate to capture that scale.  Likewise non-
continuous parameters (such as a proportion, which will fall between zero and 
1) will require a distributional form that lies on a scale bound between zero 
and 1.  
Normal (Gaussian) distribution 
The most commonly used continuous distribution is the normal distribution, 
often referred to as the Gaussian distribution (72). The Standard Normal 
Distribution has an expected mean value of zero, and a variance of one N(0,1), 
however, a random variable (parameter) from the normal distribution is 
capable of assuming any value between negative infinity and infinity (-∞, ∞).  
Specifying the Normal distribution requires a mean value of the parameter of 
interest and the standard deviation (73).   
Many distributions can be approximated to the normal distribution (73), under 
an assumption based on the central limit theorem (CLT) which assumes that as 
a sample size gets very large (tending towards infinity) the sampling 
distribution of the mean will be normally distributed regardless of the 
underlying distribution of the data (4).   Therefore, in a decision analytic 
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model, the normal distribution can be considered a candidate for any of the 
parameters in the model; however, this is only so long as the data informing 
the parameter is of a large enough sample size to justify a normal assumption.   
Lognormal 
The Lognormal distribution is a continuous probability distribution of a random 
variable (parameter) whose logarithm is normally distributed. The lognormal 
scale is confined from zero to infinity (0, ∞), and therefore variables on this 
scale cannot have negative values.   The lognormal distribution is represented 
by the parameter mean (ų) and standard deviation (σ). Lognormal distributions 
are appropriate for parameters that are non-negative, highly skewed or have a 
multiplicative format, i.e. ratios, and as they are on the log scale, they enable 
transformation to and from the normal scale.  
Gamma distribution  
The Gamma distribution is another continuous distribution, which is on a scale 
from zero to infinity (0, ∞), and therefore allows for data that has a positive 
right skew.  Gamma distributions are defined by two parameters: a shape 
parameter (α) and a scale parameter (β).  The Gamma distribution is 
represented by Gamma (α, β).  
Beta (Binomial) distribution 
The Beta distribution is characterised by two parameters: alpha (α) and beta 
(β) such that the Beta distribution is represented by Beta (α,β). Alpha is 
considered the lower bound (location parameter) and beta the upper bound 
(scale parameter). The standard Beta distribution is constrained on the interval 
zero to one (0, 1) (where α =0 and β=1), and is therefore appropriate for 
binomial data, such as parameters represented by proportions.  However, the 
Beta distribution is not necessarily binomial; the distribution depends on the 
value of the scale (β) parameter (74).  
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Dirichlet distribution  
A Dirichlet distribution can be considered as the multinomial equivalent to the 
Beta distribution (75).  It is used to represent multinomial data where there 
are numerous categories, each represented by a proportion, of which the 
proportions sum to 1.  Therefore, the Dircihlet distribution is characterised by 
a vector of positive real values (α), such that the distribution is represented by 
Dir(α).  
2.4.2 Fitting parameters to distributions 
Briggs et al.(4) explain that the type of parameter and its method of 
estimation provide an indication of the appropriate distributional form for each 
parameter in a decision model.  A Bayesian approach is recommended (6;76) 
whereby the choice of distribution is based on prior beliefs about the 
parameter.  Therefore the characteristics of the parameter of interest should 
be considered when deciding upon an appropriate distribution. For example, 
with cost parameters, the minimal value a cost will be is zero (as it is not 
possible to have a negative cost) but the cost could potentially range up to 
infinity, in which case it would be appropriate to consider either gamma or a 
lognormal distribution for cost variables, based on the prior beliefs about the 
cost parameter characteristics.  Likewise where the parameter of interest is 
represented by a probability (and the parameter is binomial in nature), such as 
a probability of having a disease, the probability is bound on an interval 
between zero and 1, and therefore, based on this prior knowledge of the 
parameter characteristics, it is appropriate to assume a Beta distribution, 
which is also bounded on the 0-1 interval. Where parameter estimates are 
derived using multivariate logistic regression, these can be represented by a 
lognormal distribution. By following the standard distributional assumptions 
and considering the characteristics of the specific parameters in the model, 
there are only a few possible candidate distributions for most parameters in a 
model.  
Table 2-1 details a list of common parameters used in decision analytic models 
(DAM) and the distributional forms that are commonly used to represent them.  
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Table 2-1: Typical parameters and their distributional forms in a DAM  
Common Parameters Possible Distribution Distribution scale 
      
Costs Gamma ( 0, ∞) 
  Lognormal ( 0, ∞) 
  Normal ( -∞, ∞) 
      
Utilities Beta  (0, 1) 
Disutilities Gamma on disutility ( 0, ∞) 
  Lognormal on disutility ( 0, ∞) 
      
Prevalence Beta (0, 1) 
  Dirichlet (0, 1) 
      
Treatment Probabilities Beta (0, 1) 
  Dirichlet (0, 1) 
      
Mortality Probabilities Beta (0,1) 
      
Relative Risks Lognormal ( 0, ∞) 
      
 
Examples of parameters which are commonly represented by Beta distributions 
are prevalence parameters (to represent the proportion of patients who have 
or do not have a disease) and diagnostic test accuracy (DTA).  Utility 
parameters are commonly represented by the beta distribution; however this 
distribution can only be used if it is appropriate to assume utility is bound on 
the interval zero to one.  Utility values are actually bound on the scale 
negative infinity to one (-∞, 1), and therefore in cases where very low or 
negative utilities are possible (such as in cancer or other severe and life 
threatening disease areas) the beta distribution is not appropriate.  In such 
situations the distribution is better represented by a gamma or lognormal 
distribution, bound on disutility.  I.e. where disutility (D) is equivalent to 1 
minus the utility value (D = 1-utility), thereby bounding the distribution on the 
scale zero to infinity (0, ∞) (4).  
In fitting a Beta distribution: Beta (α, β), the alpha parameter (α) is 
represented by the number of events of interest, while Beta (β) is equivalent 
Chapter 2   32 
to the sample size minus the events.  If the sample size and number of events 
of interest are reported in a publication (or other source of evidence), then 
these are used to represent the alpha and calculate the beta for the Beta 
distribution.  Alternatively if the published evidence only reports the mean and 
standard error for a parameter point estimate then the Method of Moments can 
be used to derive the alpha and beta estimates from the mean and standard 
error and are then fitted to the Beta distribution (4).   
The Dirichlet distribution is used to represent multinomial data where there 
are numerous categories, each represented by a proportion, of which the 
proportions sum to 1. If the overall sample size and the number of events of 
interest for each category are reported, then these can be used to calculate 
the proportion for each category and fit the Dirichlet distribution.  The 
Dirichlet distribution enables the proportion within each category to vary, but 
in relation to the other categories so that they all sum to 1. Briggs and 
colleagues (4;75) provide further details on the Dirichlet distribution and a step 
by step approach for fitting the distribution.  
In fitting a Gamma distribution: Gamma (α, β), a similar approach is adopted 
to that of the Beta, whereby the sample mean (parameter point estimate) and 
variance reported in published data can be used to determine the shape (α) 
and  scale (β) parameters using the gamma Method of Moments (4).  
Costs tend to be represented by gamma or lognormal distributions, however, 
where it is unlikely that costs will be highly skewed and the data used to derive 
cost estimates is symmetric around the mean (and sufficiently large), the 
central limit theorem (CLT) can be assumed to apply and a normal distribution 
fitted, using the mean value and standard deviation for the cost estimate.  For 
the normal and lognormal distributions the mean and standard deviation are 
adequate to fit the distribution.  
In cases where only partial evidence has been reported, i.e. a mean value with 
no standard error, assumptions can be used to determine an appropriate 
standard error (which is large enough to reflect a wide range of uncertainty). 
Additionally if 95% confidence intervals have been reported rather than a 
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specification of the standard error, then the standard error can be calculated 
using the 95% confidence limits, however, it is important to note that these 
calculations will differ for each distribution, based on the standard 
distributional assumptions (72).   
2.4.3 Illustrating parameter uncertainty 
Once distributions have been applied to each of the appropriate parameters in 
the decision model, the probabilistic sensitivity analysis can be performed.   
Monte Carlo simulation is used with a minimum of 1000 iterations to sample 
random values from each parameter distribution simultaneously to provide 
different cost, effect and cost-effectiveness outcomes for each vector of input 
parameters.  The average cost, effect and cost-effectiveness outcomes across 
all 1000 iterations represent the probabilistic outcomes.  The incremental costs 
and effect outcomes for each of the 1000 iterations can be plotted on a cost-
effectiveness plane to illustrate the uncertainty (5).  95% confidence intervals 
(uncertainty intervals) can be represented using the lower and upper 
percentiles from the simulation results using the percentile method, i.e. taking 
the 0.025 and 0.975 percentiles (4).  Figure 2-1 illustrates a cost-effectiveness 
plane, which has been used to plot the range of incremental cost and 
incremental effect outcomes from a Monte Carlo simulation.  
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Figure 2-1: The cost-effectiveness plane 
 
The cost-effectiveness plane illustrates the difference in effectiveness 
(Intervention minus Control) per patient on the horizontal axis against the 
difference in cost per patient (Intervention minus Control) on the vertical axis.   
If the cost-effectiveness estimates fall into the North West (NW) quadrant, this 
demonstrates that the new intervention is less effective than the control, but 
costs more, and is therefore dominated by the control.   Alternatively if the 
outcomes fall into the South East (SE) quadrant, this represents improved 
effectiveness with the new intervention, yet it is also cost saving, and 
therefore the new intervention is the cost-effective strategy and it dominates 
the Control.   
If the outcomes fall into either the North East (NE) or South West (SW) 
quadrants this represents a situation where a trade-off is required, i.e. 
improved effectiveness but at a greater cost in the NE quadrant, or a cost 
saving but at the expense of reduced effectiveness in the SW quadrant.  In the 
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NE and SW quadrants a value judgement regarding societies willingness to pay 
(or willingness to accept savings) per unit of effectiveness gained (lost) is 
required in order to determine cost-effectiveness.  The maximum acceptable 
cost-effectiveness ratio or ceiling ratio (λ) represents societies willingness to 
pay, and is illustrated in Figure 2-1 by the thick black line that crosses through 
the origin of the cost-effectiveness plane splitting the NE and SW quadrants.  
While the value of the ceiling ratio can be considered subjective or a value 
judgement, such as the UK recommended acceptable range of £20,000-£30,000 
per QALY (24) which has no firm basis in evidence or theory (77); it can also be 
considered to be a reflection of opportunity cost. I.e. the opportunity cost is 
the technologies that are displaced at the margin, by those technologies which 
are recommended by NICE.  In principle the ceiling ratio can be estimated 
using willingness to accept or willingness to pay, for example society’s 
willingness to pay for improved health care through increased taxation (15). 
Indeed, numerous attempts have been made to measure consumers’ and 
society’s monetary valuation of improved health or valuation of a quality 
adjusted life year (QALY) (78;79).  
The ceiling ratio is considered to be symmetrical for both the NE and SW 
quadrants, so that incremental values below the ceiling ratio (values which fall 
to the right of the ceiling ratio (λ) in Figure 2-1) will be considered cost-
effective, and those that are greater than the ceiling ratio (values that fall to 
the left of the ceiling ratio (λ) in Figure 2-1) will not be considered cost-
effective.   The UK decision making body NICE, recommends a monetary 
threshold of approximately £30,000 per QALY gained (24), and therefore 
interventions with an ICER of less than £30,000 are considered to be cost-
effective in the UK. 
The joint distribution of the costs and effects from the Monte Carlo simulation 
are plotted on the cost-effectiveness plane to demonstrate the impact of 
uncertainty in the model parameters on uncertainty in the model outcomes 
(expected incremental cost and effects). Uncertainty in incremental outcomes 
is demonstrated when the results spread across the y-axis.  Likewise a spread 
through the origin passing through the horizontal axis represents uncertainty in 
the incremental cost of the intervention.  The 95 percentile intervals for the 
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incremental costs and incremental effects from the probabilistic sensitivity 
analyses can be calculated; however it is not straightforward to calculate 95% 
intervals for the joint incremental cost-effectiveness ratio when the joint 
distribution crosses into more than one quadrant.  
In situations where the range of outcomes spread from either the NE or SW 
quadrants across the origin into the NW or SE quadrants (dominant quadrants), 
some of the ICER values will be negative, and this will cause problems for 
establishing confidence intervals around the ICER (4;40).  Therefore it is 
recommended to represent uncertainty in the cost-effectiveness estimate using 
a cost-effectiveness acceptability curve (CEAC) (4;7;71).   
 
2.5 Decision uncertainty: CEAC 
The cost-effectiveness plane was useful in terms of illustrating the impact of 
individual parameter uncertainty (within the model) on the model outcomes, 
i.e. uncertainty as to the existence and extent of any difference in costs and 
uncertainty as to the existence and extent of any difference in effect between 
the Intervention and Control.  However, any uncertainty in these may or may 
not impact on decision uncertainty.   Decision uncertainty refers to uncertainty 
in whether the intervention can be considered cost-effective in comparison to 
the alternative(s), i.e. uncertainty in answer to the question: is the 
intervention cost-effective?  When probabilistic outcomes spread into more 
than one quadrant of the cost-effectiveness plane, it can be difficult to 
determine whether the intervention is cost-effective or not and therefore 
CEACs can be used to illustrate the level of uncertainty in the estimated cost-
effectiveness of the treatment in comparison to the alternative(s) (7;70;71).   
Having undertaken an economic analysis and presented cost-effectiveness, it is 
important to address the initial research question, which was: ‘is the new 
intervention cost-effective in comparison to the control’?  To answer this 
question and give useful outcomes to decision-makers we need to consider two 
underlying questions: Given the current evidence and decision uncertainty, 
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should the technology be adopted (or not)? and, Is further research required to 
help support this decision? (4) If these underlying questions are not addressed, 
decision makers may struggle to interpret the cost-effectiveness results, 
particularly regarding how to make the decision to adopt or reject the 
intervention given the uncertainty.  In answering these questions the 
researchers can help inform funders and decision makers on how to interpret 
the model results and the appropriate next steps to take.    
A cost-effectiveness acceptability curve (CEAC) is an ideal tool for illustrating 
decision uncertainty (uncertainty around the question of whether or not the 
intervention is cost-effective) across a wide range of alternative ceiling ratios 
(7;11). As demonstrated in Figure 2-1 a monetary threshold of willingness to 
pay (the ceiling ratio) is required to determine cost-effectiveness and ICER 
values that fall below the ceiling ratio (values which fall to the right of the 
ceiling ratio (λ) in Figure 2-1) will be considered cost-effective, and those that 
are greater than the ceiling ratio (values that fall to the left of the ceiling ratio 
(λ) in Figure 2-1) will not be considered cost-effective.  Therefore the ceiling 
ratio can be varied across a range of different values to illustrate how the 
evidence in favour of cost-effectiveness of the intervention varies at different 
monetary thresholds (4)  
The effect, cost and joint cost-effectiveness results from the probabilistic 
analysis are used to derive a cost effectiveness acceptability curve (CEAC) 
which represents the probability that the intervention is cost-effective at 
different monetary thresholds of willingness to pay (7;11).  The process of 
generating a CEAC involves calculating the proportion of iterations (from the 
PSA) where the intervention is cost-effective, given a specified ceiling ratio, 
and then re-calculating the proportion at a variety of different ceiling ratios.  
The CEAC plots the proportion of cost-effective iterations against the ceiling 
ratio. The proportion of cost-effective iterations can be calculated for the 
intervention and the alternative(s), so that they can both (all) be plotted 
graphically, as illustrated in Figure 2-2.  
For example, given two interventions (Treatment and Control), the net benefit 
for treatment (NBT) and control (NBC) can be calculated as well as the 
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incremental net benefit ( )CEINMB ∆−∆∗λ= ; and the ceiling ratio (λ) can be 
varied across a range of values, i.e. from £0 to £100,000 in increments of £500.  
In this way the NMB from the net benefit calculation varies with the ceiling 
ratio (λ).  For each of the alternative ceiling ratios the net benefit under the 
treatment (NBT) and control (NBC) interventions are calculated across all the 
1000 Monte Carlo simulations and the average is taken (ENBT) (ENBC) to 
determine which has the highest expected net benefit.  At each ceiling ratio, 
the intervention with the greatest expected net benefit ( )[ ]CT ENB:ENBmax is 
the most cost-effective and is therefore the optimal choice at that specific 
ceiling ratio.  The proportion of cost-effective iterations for the Treatment and 
Control at each ceiling ratio can be plotted to illustrate the CEACs for each 
intervention, as illustrated in Figure 2-2. 
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Figure 2-2: CEAC for Treatment versus Control 
 
Figure 2-2 illustrates a hypothetical CEAC, showing the probability of each 
intervention being cost-effective at different ceiling ratios.  At a ceiling ratio 
of £10,000 there is an 85% probability that the Control is cost-effective and 
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only a 15% probability that Treatment is cost-effective.  The Control would be 
considered the optimal choice at this ceiling ratio (as it has the greatest 
expected net benefit and is therefore the most cost-effective at this ceiling 
ratio), and the CEAC characterises the uncertainty in this optimal choice.  At a 
ceiling ratio of £50,000 Treatment is the cost-effective strategy, but the CEAC 
shows that this is only with an 80% probability; there remains a 20% probability 
that Treatment is the wrong choice, which is the uncertainty in the decision. 
The aim of calculating a CEAC is to summarise and illustrate graphically the 
probability that a particular intervention is the optimal choice over a wide 
range of values for the ceiling ratio (λ) (7). Fenwick and colleagues (11) 
demonstrate this process with a clinical example and present the CEAC. 
The CEAC is straightforward to calculate, construct and interpret (11) and is 
therefore an ideal technique for presenting uncertainty in the cost-
effectiveness outcome from a PSA to decision makers who have to make the 
choice of whether to adopt or reject a new intervention, based on the current 
evidence.  Uncertainty over the results of an analysis leads to the possibility of 
incorrect decision making, which has a cost in terms of benefits from the 
correct decision forgone.  Decision makers want to avoid incorrect decisions 
and therefore a CEAC can be a useful means of summarising the uncertainty 
surrounding the cost-effectiveness decision.  
In order to adequately address the initial research question (‘is the new 
intervention cost-effective in comparison to the control?’) we need to consider 
two underlying questions: Given the current evidence and decision uncertainty, 
should the technology be adopted (or not)?; and secondly, is further research 
required to help support this decision? (4).  Summarising decision uncertainty 
with a CEAC can be considered to be a first step in addressing the second 
important question; however, further techniques are required to answer the 
question in full (71).  
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2.6 Value of Information  
Having developed a decision analytic model, undertaken probabilistic 
sensitivity analysis and considered decision uncertainty; the PSA results can 
also be used to undertake Value of Information analyses (VOI).  VOI is based on 
the rationale that decisions based on existing information will be uncertain and 
given this uncertainty, there is a chance that the wrong decision will be made 
which will have a cost in terms of health implications for patients receiving 
suboptimal care and inefficient use of health care resources (10;12). VOI 
analyses value further research on its potential ability to reduce the expected 
costs of uncertainty surrounding the cost-effectiveness decision, rather than 
deciding on further research and its design through arbitrary means (9;12;13). 
Claxton and colleagues (22) promote VOI within a Bayesian framework for 
economic evaluation and decision making, in order to address uncertainty 
surrounding a cost-effectiveness decision and address whether the intervention 
should be adopted based on current evidence, or whether more evidence is 
required to support this decision. 
VOI is based on the concept of the opportunity cost of making a wrong 
decision, given uncertainty. The Expected Value of Perfect Information (EVPI) 
is a methodological approach which uses the uncertainty surrounding the cost-
effectiveness decision based on current evidence, the patient population, and 
technology lifespan and societies willingness to pay; to place a monetary value 
on the worth of further research. VOI techniques can be used in combination 
with evidence from a CEAC to make informed decisions as to whether a new 
intervention should be adopted (or rejected) based on current evidence, or 
whether further information is required to help make the decision, as opposed 
to making research decisions subjectively. The expected cost of uncertainty is 
determined jointly by the probability that a decision based on existing 
information will be wrong and the consequences of a wrong decision.  
Decisions based on existing information will always have some uncertainty (as 
represented by the inverse of the CEAC) and therefore there will be a chance 
that the wrong decision will be made. In choosing whether or not to adopt an 
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intervention (Treatment) that had, for example, an 80% probability of being 
cost effective at society’s willingness to pay threshold (λ), such as that 
illustrated on the CEAC in Figure 2-2, there is uncertainty.  At a ceiling ratio of 
£50,000 the Treatment intervention would be considered the optimal choice 
(as it has the greatest expected net benefit [ ]CT>ENBENB and is therefore the 
most cost-effective at this ceiling ratio), however, it has only an 80% 
probability of being cost-effective in comparison to the alternative (Control).  
While Treatment is the optimal choice, 20% of the time it would have been the 
wrong decision, and this represents uncertainty in the decision to adopt the 
Treatment strategy. Uncertainty over the results of an analysis implies the 
possibility of incorrect decision making which imposes a cost in terms of the 
benefits forgone (9).  Therefore, there may be value in obtaining more 
information, if it will reduce this uncertainty.  Claxton and colleagues (4;9;21) 
provide a thorough description and worked examples of the VOI process. 
2.6.1 EVPI per decision/patient 
In a perfect world where there is perfect information, the optimal (most cost-
effective) intervention would be chosen every time, however, in an imperfect 
world there is uncertainty and in choosing an intervention which on average is 
optimal, there is a probability that it will be the sub-optimal choice. The 
expected value of perfect information (EVPI) calculates the opportunity cost of 
making the wrong decision.  
The EVPI process within the context of an iterative (Bayesian) framework for 
economic evaluation has been promoted throughout the last fifteen years 
(1;8;13;80), however it is not utilised in practice very often. The application of 
the value of information approach was demonstrated for the Health 
Technology Assessment programme in the UK (10) and for the UK 
reimbursement decision body, the National Institute for Health and Clinical 
Excellence (NICE) (12); and has gained recognition, however, practical 
applications of EVPI in published literature, while increasing in number in 
recent years, remain limited. 
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The process of calculating the EVPI follows on from calculating the CEAC using 
the results from a probabilistic sensitivity analysis.  As discussed in section 2.5, 
in determining the CEAC from the probabilistic sensitivity analysis results, the 
net benefit can be calculated for each intervention (Treatment (NBT) and 
Control (NBC)) for all 1000 iterations of the Monte Carlo simulation, and the 
average of these is taken to calculate the expected net benefit for each, in 
order to determine the optimal strategy.  Given current evidence the optimal 
intervention is the intervention which has the highest expected net benefit 
across all 1000 Monte Carlo iterations ( )[ ]CT ENB:ENBmax .  The ENB for the 
optimal strategy is the value of the decision given current information.  Under 
perfect information, the optimal strategy would be chosen each time, and this 
can be accounted for by choosing the strategy which maximises net benefit for 
each iteration of the Monte Carlo simulation, from iteration 1 through to 1000: 
( )[ ]
1C1T
NB:NBmax , ( )[ ]
2C2T
NB:NBmax ….. ( )[ ]
1000C1000T
NB:NBmax . The mean of 
the 1000 optimal NB choices is the expected value of the decision given perfect 
information ( )[ ][ ]CT NB:NBmaxE .  The expected value of perfect information is 
the difference between the value of the decision with and without perfect 
information, as detailed in Equation 2.2 (4;9) 
( )[ ] ( )cTCT ENB:ENBmaxNB:NBmaxEEVPI −=      (2.2). 
This gives the expected value of perfect information per decision, i.e. the EVPI 
surrounding the decision as a whole for each time this decision is made for an 
individual patient or patient episode.  The EVPI is re-calculated for a wide 
range of alternative ceiling ratios (λ), and can be represented graphically to 
illustrate how the value of perfect information varies at different ceiling 
ratios.  
2.6.2 EVPI population level 
Having calculated the EVPI per decision/patient, it is important to account for 
what this represents in terms of the relevant patient population who would 
benefit from the additional information.   The ‘effective population’ must be 
determined.  This is the population of patients over the expected lifetime of 
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the technology who would benefit from further information about the 
technology (4). The EVPI per decision/patient can be multiplied by the 
‘effective population’ to generate the population level EVPI.   
As a first step, the annual population of patients should be determined. 
Published data on the annual incidence (I) for the specific disease of interest is 
an ideal way of estimating the annual patient population. The expected 
lifetime of the intervention or technology can then be estimated in years (t).  
While this is likely to be an assumption, it is possible to make a realistic 
assessment of the intervention or technology lifetime by considering the period 
over which the information about the decision will be useful (t) (4).  For 
example, a technology that will be undergoing continual development and 
upgrading is likely to have a short lifetime as it will be replaced every few 
years by newer more advanced models.  Therefore, an appropriate timeframe 
would be one where the estimates of effectiveness for the technology used in 
the model are relevant and unlikely to change.  Given an annual disease 
incidence (I) and a technology or intervention lifetime of T years (t), the 
effective population can be calculated, applying a discount rate (r) for patients 
in future years, and summing the population across the years (t). The effective 
population is multiplied with the EVPI per decision to give the population level 
EVPI (EVPIpop).  Equation 2.3 details the population level EVPI calculation (4;9).  
( )∑ = +∗= T,...2,1t t
t
pop
r1
I
EVPIEVPI         (2.3) 
The population level EVPI can then be plotted on a graph, as with the EVPI per 
decision/patient, to represent how population EVPI varies with alternative 
ceiling ratios (λ).  At societies’ maximum ceiling ratio, the population level 
EVPI can be interpreted as the maximum amount the health care system should 
be willing to pay for additional evidence to inform this decision in the future.  
This can be considered to be an upper bound on the value of conducting 
further research (4;9), a necessary but not specific condition for determining 
the worth of future research.     
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The EVPI can be used to indicate whether further research is likely to be 
worthwhile; however, it does not take into account the cost or type of further 
research (81).  This may be construed as a drawback to EVPI, however it is still 
useful in providing an indication of whether further research is worthwhile or 
not and is an important step in the stages of VOI analyses.  For example, very 
low population level EVPI values can be used to suggest whether further 
research is worthwhile or not.  A population EVPI of £8000 indicates that 
research is very unlikely to be worthwhile, and the optimal intervention should 
be adopted based on current evidence.   In contrast a population EVPI of £30 
million indicates that further research is very likely to be worthwhile.  
However, for a mid range population level EVPI of say, £800,000, it is more 
difficult to decide whether research would be worthwhile.  Depending on the 
disease area and the type and scale of research, it may cost less or more than 
the £800,000 EVPI, which is interpreted as the maximum amount the health 
care system should be willing to pay for additional evidence to inform this 
decision in the future.  
An intuitive explanation of EVPI is that it puts a monetary value on the worth 
of further research dependent on how much that research will reduce current 
uncertainty by.   A systematic (or non systematic) literature review can tell 
you there is a lack of evidence from randomised controlled trials (RCTs), but it 
does not tell you the worth or value of undertaking a further RCT to address 
the lack of current evidence.  The added value of EVPI (compared to not doing 
EVPI) is that it explicitly values potential research in terms of addressing 
current uncertainty, and can then be used to compare with the potential cost 
of further research. If EVPI is not undertaken then further research is decided 
upon arbitrarily.  
Nosyk, et al. (82) provide a recent example of employing EVPI techniques in a 
study on dosing strategies for an influenza vaccine for individuals with human 
immunodeficiency virus (HIV).  This publication highlights some of the 
advantages of undertaking an EVPI, as the authors found that the likely cost of 
further research would have been much greater than the expected value of any 
further research.  The authors model the cost-effectiveness of three 
alternative dosing strategies for an influenza vaccine.  Strategy C was found to 
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be the most effective, while strategy A was also potentially cost-effective in a 
patient sub-group.  The authors report substantial uncertainty surrounding the 
potential cost-effectiveness of strategy A compared to strategy C, in one of the 
patient sub-groups.  Rather than recommending another trial to address this 
outright, the authors undertook an EVPI to establish a maximum acceptable 
cost of further research to reduce uncertainty surrounding the implementation 
of strategy A versus C. The population EVPI was estimated to be $418,000 US 
dollars, considerably less than the cost of a large scale trial for the patient 
sub-group.  The authors highlight that the cost of further research is likely to 
be much greater than the value of that research, and therefore recommend 
adopting strategy C based on current evidence.  
This case study of a practical application of EVPI highlights the merit and 
importance of undertaking EVPI analyses.  Even though EVPI does not explicitly 
account for the cost of further research, and can therefore only indicate 
whether further research is potentially worthwhile; when the cost of a trial is 
likely to be substantially higher than the maximum willingness to pay for 
further research (EVPI), then the optimal intervention can be adopted based on 
current evidence.  EVPI helps ensure research resources are not wasted on 
further trials that have little value.  EVPI provides a justification for spending 
large amounts of (scarce) research money on one trial rather than another.  
Without EVPI, it is only assumed that further research will add value, it is not 
explicitly checked. 
2.6.3 EVPI for parameters (EVPPI) 
In circumstances where the EVPI analysis indicates further research is 
potentially worthwhile, the next step involves identifying what type of 
research.  ‘Further research’ does not necessarily mean that a large scale, 
randomised controlled trial is required.  To define the type, and possibly the 
scale, of further research (to reduce uncertainty in the cost-effectiveness 
decision), researchers need to consider what information it is that is required?  
The requirement for further information is driven by uncertainty; so in 
considering what further research is potentially of value, the parameters that 
are driving uncertainty in the cost-effectiveness model need to be identified.  
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It is these parameters that would add the most value through further 
information.  Expected value of perfect parameter information (EVPPI) is used 
to identify parameters for which more precise estimates would potentially be 
most valuable (4;21;83). 
The value of reducing uncertainty surrounding particular parameters in the 
model (EVPPI) can be determined using an approach similar to the EVPI.  In 
fact the EVPPI is the difference in expected value of the decision with perfect 
information for some parameters and the expected value of the decision with 
current information about the parameters.  Equation 2.4 details the EVPPI 
algorithm. 
( )( )[ ] ( )[ ]θ−θ= θθθ ,tNBEmax,tNBEmaxEEVPPI t      (2.4) 
The various steps in the EVPPI process are now outlined: 
1. The first step involves choosing a parameter of interest for which perfect 
information is required, drawing a random value from its probabilistic 
distribution and then holding this value constant, to represent ‘perfect’ 
information for the parameter of interest.   
2. The Monte Carlo simulation is re-run holding the ‘perfect’ parameter 
constant but allowing the probabilistic draws from all other parameters.   
3. The average NB under the treatment and control (average NBT) (average 
NBC) from the 1000 iteration Monte Carlo simulation is then recorded along 
with the intervention identity that gives the maximum expected net 
benefit[ ])NB:NBmax( CT .  
4. Following the Monte Carlo simulation a second random draw is undertaken 
for the ‘perfect’ parameter of interest, to represent a new ‘perfect’ value 
which can be held constant. Steps 1 through to 3 are repeated 1000 times, 
each time holding a different value for the perfect parameter estimate 
constant while the other parameters in the Monte Carlo simulation vary.  
For each Monte Carlo simulation the mean net benefit for Treatment and 
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Control is recorded along with the intervention identity that gives the 
maximum net benefit.   
5. Once the process has been completed, the 1000 stored mean NBs for 
Treatment and Control and maximum intervention identities are used to 
calculate the expected net benefit (ENB) for each intervention [ ]CT ENB,ENB  
and the expected maximum net benefit ( )[ ][ ]CT NB:NBmaxE  across the 1000 
Monte Carlo simulations outcomes. 
6. The intervention with the greatest ENB [ ])ENB:ENBmax( CT is the expected 
value of a decision based on current information, i.e. the intervention 
which has the greatest ENB and would therefore be the optimal (cost-
effective) choice.   
7. The expected maximum net benefit ( )[ ][ ]CT NB:NBmaxE  is the average of 
the 1000 maximum net benefit interventions from each of the Monte Carlo 
simulations. This is the expected net benefit with perfect parameter 
information.   
8. The final stage in the EVPPI process is to subtract the ENB of the decision 
under current information from the ENB of the decision with perfect 
parameter information to give the expected value of perfect parameter 
information (4).    
Equation 2.4 detailed the EVPPI algorithm with the parameters of the model 
represented by (θ) including the perfect parameter of interest and the other 
parameters which keep their distributions from the PSA.  NB(t,θ) is the net 
benefit of an intervention (t) if the parameters of the model take the value θ 
(4). 
The EVPPI can be run for specific parameters in the model, but also for groups 
of parameters, where a specified group are held constant rather than a single 
parameter.  It is useful to begin EVPPI with groups of parameters, for example 
some parameters may have been estimated from the same data source and it 
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may not make sense to consider them individually, such as parameters from a 
survival analysis.  If parameters are correlated it is also important to group 
them together, so as to preserve the correlation structure (4).  If a parameter 
is included in a group, but its correlated parameters are not included in that 
group, the correlation with those parameters may be broken and the EVPPI 
could potentially be over or under estimated depending on the type and 
direction of the correlation relationship (4).  Additionally, it is useful to 
consider small groups of parameters in order to scope out what types of 
parameters are driving uncertainty, rather than undertake the process for 
every individual parameter in the model, which would be exceptionally time 
consuming (4). Parameter groups for EVPPI should be grouped logically, i.e. 
running all the utility parameters together and all the mortality parameters 
together.  Claxton and colleagues recommend that the groups should be chosen 
to match the type of research that would be conducted (4;9), e.g. clinical 
parameters.  It must be noted that the EVPPI for individual parameters do not 
sum to the overall EVPI, and likewise the EVPPI for groups of parameters is not 
equal to the sum of the individual parameter EVPPIs, because when considered 
in isolation individual parameters do not impact on the difference in net 
benefits in the same way (4).   
The EVPPI calculated is the value surrounding the decision as a whole for each 
time this decision is made for an individual patient or patient episode (4), and 
therefore (following the same approach used to determine EVPI) it is important 
to account for what this represents in terms of the relevant patient population 
who would benefit from the additional parameter information.   The ‘effective 
population’ can be determined in the same way as described for EVPI in 
Equation 2.3.  If undertaken directly following the EVPI calculation it is likely 
that the same effective population is relevant for the EVPPI however, it may 
well be that the relevant patient population who would benefit from the 
additional parameter information is different from that used for the EVPI. For 
example if the parameter or group of parameters of interest are specific to 
one sub-group of patients. The relevant population of patients should be 
considered who would benefit from further information about the technology, 
over the expected lifetime of the technology (4). 
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The EVPPI between the different parameters or parameter groups is compared, 
and the research planned (and designed if worthwhile) based around the 
parameters of interest that will provide the most value in seeking further 
research, although it must be noted that this is still only potentially 
worthwhile.  The EVPI and EVPPI place an upper bound on the potential value 
of further research, which provides a necessary but not sufficient condition for 
acquiring further information (4;9).  To establish a sufficient condition, i.e. to 
determine if research will be worthwhile and identify an efficient research 
design, the marginal benefit and marginal cost of further research needs to be 
accounted for (9).   
 
2.7 EVSI 
Having determined that further research is potentially required, and having 
used EVPPI to specify the most likely type of information and type of study 
(i.e. an RCT to gain clinical information on diagnostic test accuracy, or a 
survey used to determine patient quality of life) that is potentially required, 
VOI techniques can also be used to help design a trial with regards to 
identifying an optimal design and sample size. The expected value of sampling 
(EVSI) (9) is the technique used to quantify the expected value to the decision 
maker of obtaining sample information before making a decision (84).  The 
EVSI is the difference between the expected value of a decision after the 
proposed research (with sample information) and the expected value of the 
decision given current information (83). Calculating the EVSI follows a similar 
approach to that used in calculating the EVPPI.  
Ades et al. (83) describe the framework for the expected value of sample 
information (EVSI) approach, detailing the various stages involved in a step by 
step outline, with the accompanying algorithms.  These are briefly summarised 
here.  The EVSI process is based around specific parameters of interest, which 
are the uncertain parameters (θi) that require further information from the 
proposed piece of research.   
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1. For an assumed new sample size (N), the initial step of the EVSI involves 
drawing a sample of the parameters of interest (θi) from the prior 
distribution, i.e. from the probabilistic Monte Carlo simulation undertaken 
for the pre-trial model; draw the parameters of interest from the first 
iteration.  These mean estimates from the first iteration represent the prior 
estimates for the parameters of interest.   
2. Secondly, draw a random sample (for example from a Beta binomial 
distribution) to simulate the true events (x) given the sample size (N) and 
the probability estimate of the parameter of interest (θi).  I.e. for the 
specified sample size and the mean estimates from the first Monte Carlo 
iteration; generate one draw from the binomial likelihood to represent the 
number of events (x). Using this draw and the prior mean for the parameter 
of interest, calculate a posterior estimate (θip). 
3. The third step is to put the posterior probabilities for the parameters of 
interest (θip) back into the model (replacing the prior estimates for the 
parameters of interest) and recalculate the net benefit (NB) for each 
intervention (t), NB(t,θip) using the posterior probabilities for the 
parameters of interest and the prior probabilities of the other parameters 
in the model.  If the model is linear, then re-calculating the NB for each 
intervention requires only the posterior probability point estimate for the 
parameter(s) of interest, while a non-linear model requires the use of the 
posterior distribution to re-run the Monte Carlo simulation, making the 
process considerably more time consuming for non-linear models.  
4. The net benefit for each intervention is calculated and stored, identifying 
the intervention (t) which maximises the net benefit.    
5. This process is repeated again (steps 1-4), using the second iteration of 
prior means from the Monte Carlo simulation, and continually repeated for 
all of the prior estimates, storing the net benefit for each intervention and 
the intervention identity that gives the maximum expected net benefit for 
each. 
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6. Once the process has been repeated for all of the prior iterations in the 
Monte Carlo simulation the stored NBs and maximum intervention identities 
are used to calculate the expected net benefit (ENB) for each intervention. 
7. The intervention with the greatest ENB is the expected value of a decision 
based on current information, i.e. the intervention which has the greatest 
ENB and would therefore be the optimal choice.   
8. The expected maximum net benefit is calculated (i.e. the average of the 
maximum NBs from step 4); this is the expected value of a decision based 
on sample information for the selected sample size N.   
9. The ENB of a decision under current information is subtracted from the ENB 
of a decision based on sample information to give the expected value of 
sample information.    
Equation 2.5 below details this EVSI algorithm with the parameters of the 
model represented by (θ) including parameters of interest for which we are 
uncertain and complimentary parameters for which we do not seek further 
information.  NB(t,θ) is the net benefit of an intervention (t) if the parameters 
of the model take the value θ: 
( )( )[ ] ( )[ ]θθ θθθ ,tNBEmax,tNBEmaxEEVSI t −=      (2.5) 
This EVSI calculation can be repeated for different sample sizes, so as to 
generate different EVSI values for a range of sample sizes, i.e. N = 10, 50, 100, 
250, 500, 1000, 1500, 2000.  The EVSI can be plotted on a graph to 
demonstrate how it varies with increasing sample size.  As sample size 
becomes very large, EVSI should tend towards the EVPI and level off, but may 
not necessarily reach the same value as EVPI (9;85).  
The EVSI calculated is the value per decision, and therefore (following the 
same approach used to determine EVPI and EVPPI) it is important to account 
for what this represents in terms of the relevant patient population who would 
benefit from the additional parameter information.   The ‘effective 
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population’ can be determined in the same way as described in Equation 2.3, 
to estimate the population of patients over the expected lifetime of the 
technology who would benefit from further information (4;9). However, when 
calculating the population EVSI, Claxton cautions that consideration should to 
be given to patients in the effective population who would be in the trial, and 
therefore have already benefitted from the treatment, so can potentially be 
subtracted from the effective future population (9). 
 
2.8 ENBS  
The greater the sample size, the less uncertainty around the variables of 
interest, however, as sample size increases, so does the cost of the study.  
Therefore the optimal sample size of a study can only be determined once the 
cost of the research is accounted for.  The difference between the expected 
benefits of sample information (EVSI) and the cost of acquiring the sample 
information is the expected net benefit of sampling (ENBS) (4;9). The ENBS is 
concerned with finding an appropriate balance between reducing uncertainty 
and an escalating sample requirement.  The optimal sample size for the 
proposed trial is the value of n (sample size) that generates the maximum 
ENBS. 
The traditional approach to designing and selecting an optimal trial sample size 
(72) gives no consideration to the marginal costs and benefits of sample 
information (13), however, ENBS does.  Claxton et al. (86) explain that 
calculating the expected value of sample information and then considering the 
ENBS produces a technically efficient research design, by considering the 
willingness to pay for the proposed research.  The ENBS is the difference 
between the EVSI and the cost of acquiring the sample information (9); with 
the optimal sample being the value of N that generates the maximum expected 
net benefit of sampling.  The ENBS of any sample size (n) can be calculated 
given the population EVSI for that sample size and the cost of research at that 
sample size (Cn), as described in Equation 2.6: 
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nnn CpopEVSIENBS −=         (2.6). 
Having undertaken the population level EVSI calculation, the effective 
population will be defined (but may be modified as the sample size increases 
to exclude members of the effective population who take part in the trial).  
The research costs will entail a variety of costs such as research staff time, 
administration, etc. that can be classified as fixed, however there will 
inevitably be some variable costs such as treatment costs, medical materials, 
and potentially a small administrative cost per additional person recruited into 
the sample.  Therefore, the cost of the study is likely to increase marginally as 
the sample size rises.   The ENBS should be calculated across a wide range of 
sample sizes, and where ENBS reaches its maximum, that is the optimal sample 
size.  The cost of the research, ENBS and EVSI can be plotted on a graph for a 
wide range of sample sizes to demonstrate how these three components 
interact and illustrate the optimal sample size.  
Essentially, the EVSI approach is used to measure the value of a range of 
sample sizes for a proposed study, and then compare those values against the 
likely cost of the study at the different sample sizes, to help identify an 
optimal (efficient) sample size.  EVSI and ENBS techniques are used to establish 
the efficiency of the proposed research design, ensuring a cost-effective use of 
research funding. Typically economic evaluation is concerned with the cost-
effectiveness of health technologies to ensure efficient use of health care 
budgets, but in using VOI techniques, EVSI and ENBS in particular, we are 
concerned with the efficient use of research funds for funding potential studies 
and trials.  
An example of a recent practical application of EVSI is provided by Stevenson 
et al. (87) in the disease area of osteoporosis. The authors employ VOI and EVSI 
techniques to establish whether an RCT of two alternative treatments for bone 
fracture prevention in postmenopausal women with previous fractures would 
be cost-effective.  The authors’ model the cost-effectiveness of Vitamin K 
compared to Alendronate based on existing information, and found that while 
Vitamin K dominated Alendronate, this cost-effectiveness outcome was subject 
to considerable uncertainty. Using VOI techniques, the authors established that 
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further research was potentially worthwhile to reduce uncertainty in the cost-
effectiveness decision.  The authors then undertook an EVSI calculation to 
establish whether a head to head RCT would be an efficient (cost-effective) 
use of research funding.  After calculating the EVSI across a range of sample 
sizes, the cost of the research design is incorporated to calculate the ENBS 
across the range of sample sizes.  The authors conclude that a sample size 
between 2000 and 5000 per arm would be sufficient to answer the cost-
effectiveness question, and is efficient in terms of a valuable use of research 
money.  The authors highlight that their case study allows the evidence base 
for decision making to be strengthened while prohibiting research that is likely 
to provide no additional value.  
 
2.9 An Iterative Approach to Economic Evaluation 
Having provided an overview of the methodologies used in decision analytic 
modelling for economic evaluations, this chapter now reconsiders the research 
context within which economic evaluations are undertaken and supports the 
iterative approach to economic appraisal as an appropriate framework for 
undertaking research in the health care sector.   
Health care decision making bodies and reimbursement agencies in different 
countries have varying requirements and different degrees of stringency for 
determining whether health technologies represent good value for money 
(16;17). In the UK there is a formal requirement for economic evaluation to be 
an integral component of NHS research and development funded projects (52), 
however, health care research from other publicly funded research bodies and 
within the commercial sector is not subject to such requirements.  Therefore 
research undertaken in the health care sector may or may not include 
economic components, in the various phases of the research process.  Many 
economic evaluations that are commissioned by healthcare funding bodies or 
pharmaceutical companies are often not considered until the latter phases of 
clinical trials (20;28).  Even in publicly funded research, explorative and Phase 
II research budgets rarely leave adequate financing to incorporate economic 
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components.  Therefore, economic evaluations are commonly only 
incorporated in the latter phases of the research process, using information 
from larger scale definitive trials in order to support a case for reimbursement 
(1).  Theoretically this one-off approach to economic evaluation is inefficient, 
as it only enables identification of new health technologies/services as unlikely 
to be cost-effective at a late phase of the research process. Sculpher et al. (1) 
caution that such a viewpoint also potentially limits the quality of an economic 
evaluation, leading to incomplete economic analyses base primarily on data 
from one large scale RCT.  A robust economic analysis requires modelling and 
data synthesis of all available data, for example with prospective trial 
information supporting a wider secondary evidence base (1;39).   
An iterative approach to economic appraisal is a framework that has been 
proposed as best practice (1;3) for evaluating health care technologies.  The 
framework proposes that the process of health care evaluation should begin 
with an explorative modelling approach using indicative studies to assess cost-
effectiveness based on existing information, and progress to more rigorous 
assessments, updating a decision model over time as more data becomes 
available (1;3).  The iterative approach to evaluation provides a structure in 
which evidence from a range of sources can be synthesised and continually 
updated in order to answer cost-effectiveness decision problems for a defined 
context and population.  The premise is that rather than using economic 
evaluation as a restrictive, one-off analysis it should be an iterative process 
conducted alongside all stages of healthcare research.   
The iterative framework has five main stages and utilises the key 
methodologies for decision analytic modelling which were outlined in sections 
2.3 to 2.8 in this chapter. The iterative economic framework utilises decision 
analytic modelling as a key tool for evidence synthesis along with Bayesian 
updating in order to answer cost-effectiveness decision problems, as illustrated 
in Figure 2.3.      
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Figure 2-3: The iterative approach to economic appraisal   
Adapted from Sculpher et al. (2006) 
Figure 2.3 is based upon the five stage iterative approach initially illustrated 
by Sculpher et al. (1) and adapted to present the economic tools and decision 
modelling processes undertaken at each stage.  The five stages of the iterative 
framework presented by Sculpher et al. are now discussed, providing some 
further detail regarding how the economic tools and methodologies for decision 
analytic modelling fit in with each stage.  
2.9.1 Stages of the iterative approach 
Stage 1: Identify decision problems 
This first stage of the iterative framework is an explorative stage, focussing on 
identifying potentially important decision problems for different patient 
populations and sub-populations within various healthcare areas.  Similar to 
the explorative nature of pre-clinical research and phase I in the drug 
development process, stage 1 of the iterative economic approach is used to 
explore the decision area and formulate an appropriate (economic) question.   
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This stage of the iterative process is also similar to the first two steps in 
building a decision analytic model: ‘specifying the problem’ whereby the 
objective of the evaluation is specified in order to ‘define boundaries’ whereby 
relevant aspects of the analysis are clearly defined such as comparators, 
outcome measures, disease area, patient population and perspective of the 
analysis.  An economic analysis informing decisions needs to be clear about 
which patient populations are being considered, the treatments, therapies and 
technologies currently available to the specified patient population, and the 
role for any new treatment.  The iterative process therefore begins by 
exploring the literature and existing information to identify the decision 
problem and specify the details.  
This stage of economic appraisal is often, but not necessarily, pre-determined 
by public funding bodies and agencies who have identified the decision 
problem through various means, such as consultation with key NHS 
stakeholders, extracting research recommendations from various resources  
and communication with researchers (52).  They may or may not have already 
defined the relevant interventions of interest and identified the relevant 
patient groups. 
Stage 2: Synthesis and modelling given available evidence 
Once a specific decision problem has been identified, stage 2 will explore any 
existing and available information, including expert opinion, and then 
undertake evidence synthesis and early economic modelling based on this 
evidence.  Undertaking systematic reviews and meta-analyses on the 
effectiveness of the current standard of care and the new drug or health 
technology can generate evidence for use in a probabilistic decision model (5).  
Meta-analyses are a useful means of synthesising evidence on a primary 
effectiveness outcome, however, decision analytic modelling in itself is a 
mechanism for evidence synthesis and therefore a wide range of relevant 
information (such as costs, outcomes and longer term impacts) from a range of 
sources can be gathered at this stage and synthesised in the early decision 
model. 
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With regards to the decision modelling methodology, stage 2 of the iterative 
economic process uses many of the tools, such as synthesising information from 
a variety of sources to building a deterministic decision model, fitting 
distributions to the model parameters and undertaking probabilistic sensitivity 
analysis.  In building an early DAM, expert opinion may be required where 
evidence is limited and this can be appropriately reflected in the use of wide 
confidence intervals around the base case estimate in the probabilistic 
sensitivity analysis.   
Developing an early decision model can provide an indication of whether the 
new drug or technology is expected to be cost-effective (2) and the associated 
uncertainty.  
Stage 3: Setting of research priorities 
This stage involves a formal process of research prioritisation determined by 
the current evidence and early decision model outcomes from stage 2; i.e. 
whether we require further information to reduce the uncertainty surrounding 
cost-effectiveness, and if so, to identify the focus of further research and an 
appropriate research design (2).    
Considering the decision modelling methodology outlined earlier in this 
chapter, value of information analysis (9;10;12) is an ideal tool for addressing 
such questions and setting research priorities.  VOI is based on the rationale 
that decisions based on existing information will be uncertain and given this 
uncertainty, there is a chance that the wrong decision will be made which will 
have a cost in terms of health implications for patients receiving suboptimal 
care and inefficient use of health care resources (10;12).  The expected cost of 
uncertainty is therefore based on the probability that a decision based on 
current information will be wrong, and the consequences of the wrong 
decision.  This can be interpreted as the expected value of perfect information 
(EVPI), because perfect information can eliminate the possibility of making the 
wrong decision (10;12).  If the EVPI exceeds the expected costs of additional 
research then it is potentially worthwhile undertaking further research to 
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gather more information. EVPI can only inform on whether further research is 
potentially worthwhile, because perfect information doesn’t exist. 
This approach can also be applied to specific parameters of interest, to help 
determine the focus of further research.  Expected value of perfect 
information for parameters (EVPPI) is used to identify which parameters (or 
groups of parameters) in the model have the greatest uncertainty, and impact 
on decision uncertainty in the model outcome (2).  If there is little impact on 
decision uncertainty from the specific model parameters, then it is unlikely to 
be worthwhile undertaking further research, however, some parameters 
uncertainty may translate into considerable decision uncertainty for the cost-
effectiveness decision, indicating a potential need for further research in these 
specific parameters.  Therefore undertaking early modelling (at stage 2 of the 
iterative process) which incorporates sensitivity analysis or formal value of 
information analysis, provides a means to identify such parameters through 
assessing the EVPPI (2), and enables appropriate priority setting at stage 3. 
Once EVPI and EVPPI have been undertaken and an indication of the potential 
value of further research in a specific parameter(s) has been identified (e.g. 
potential further exploration of the main treatment effect of a new drug 
compared to the current standard drug) the optimal study design must be 
determined.  For example, if the treatment parameter is likely to be subject 
to selection bias then an RCT design may be appropriate.  Any trial or study 
deemed to be a research priority should be powered and designed 
appropriately. For example, if primary research is commissioned based on 
insufficient data surrounding the treatment effect parameter, then the study 
should be powered to detect a difference in effectiveness.  However, if 
insufficient information surrounding cost-effectiveness was highlighted from 
stages 2 and 3, then the research should be powered to detect an economic 
difference between the alternatives under comparison, i.e. a difference in 
cost-effectiveness (44).  
Having used EVPPI to indicate the type of information and type of study of 
potential value (i.e. an RCT to gain clinical information on diagnostic test 
accuracy, or a survey used to determine patient quality of life), VOI techniques 
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can again be used to aid optimal study design.  The expected value of sample 
information (EVSI) (9;83) and the expected net benefit of sampling (ENBS) can 
be calculated to determine an appropriate sample size.   
Stage 4: Primary research (e.g. RCTs) 
Trials in this stage should have been designed and powered appropriately to 
detect a difference in the key parameter driving the primary research, based 
on the stage 2 early model outcomes and the research priorities established in 
stage 3, using VOI analyses.   
If an economic evaluation is being undertaken alongside the primary research, 
attempts should be made to adhere to the gold standard characteristics for 
economic evaluations within clinical trials as suggested by Glick et al. (38;40).   
The gold standard economic evaluation within a clinical trial will use an 
appropriate comparator, such as current practice or a commonly used cost-
effective alternative.  The trial will be adequately powered to assess 
homogeneity of economic results across a range of clinical settings, will 
provide detailed cost information and will allow adequate follow-up time to 
assess the full impact of the therapy. This will strengthen the design of the 
research and improve the quality of the economic evaluation. 
Stage 5: Synthesis and modelling with updated evidence 
In this stage new evidence is incorporated into the information set used within 
the model, i.e. the early decision model from stage 2 can be updated with the 
data generated in the primary trials undertaken in stage 4, and any other 
evidence published during the interim.  This is based on a Bayesian concept 
(8;88) whereby evidence or knowledge about each parameter in the model can 
be updated by new information as it becomes available.   Having synthesised 
the primary research outcomes with any other relevant data in stage 5, the 
iterative process then loops back to stage 2 again.   It is important to consider 
whether the decision problem specified in stage 1 was answered adequately, 
and if not, does it need re-defined given any changes to the technology or 
disease field?   
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2.9.2 Benefits of the Iterative Approach 
The iterative economic framework is gradually becoming recognised by some 
funding and decision making bodies in the UK, such as the Medical Research 
Council in the case of complex interventions (89). However, funding for 
economic evaluation of new health care technologies by both the 
pharmaceutical industry and publicly funded research bodies remains 
predominantly a one-off exercise. Vallejo-Torres et al. (20) support the 
iterative economic approach and explain that it can offer advantages in three 
specific ways: (i) by allowing the estimation of potential cost-effectiveness to 
be part of the investment/research decision process (which will improve 
internal efficiency and potentially save money, avoiding investment in health 
care technologies or interventions which could never be cost-effective), (ii) by 
supporting health care research bodies to prioritise between several competing 
and possibly cost-effective alternatives, and (iii) by enabling identification of 
the parameters that have the largest impact on the likely cost-effectiveness of 
a specific health technology or intervention from an early stage, it promotes 
efficient allocation of scarce public and private resources.  
The key advantages of employing an iterative economic approach to funding 
research in the health care sector are now discussed, in terms of reducing 
uncertainty, reduction of costs and efficiency gains.  
Improve decision making / reduce uncertainty 
The research process is based on a step wise approach, each stage feeding 
information into the next in order to reduce uncertainty and aid decision 
making throughout.  For example, in order to introduce one new drug a 
pharmaceutical company will begin with thousands of new chemical entities 
and will eliminate many through pre-clinical research.  In the drug 
development process four phases are used to improve the decision making 
process further regarding the most effective, safest, highest quality and most 
marketable drug for the patient population.  Likewise research funders such as 
the HTA identify evidence gaps or decision problems for which they commission 
research through various means, (52) in order to identify the most important 
Chapter 2   62 
research questions to fund. Economic appraisal also requires a step wise 
approach. There should be various stages to improve information regarding the 
important parameters and comparators in the model and the uncertainty 
surrounding the cost-effectiveness of the drug or health technology.  Given the 
iterative approach for economic appraisal, the use of a single one-off trial is 
inadequate as a sole input for economic appraisal. 
An early stage probabilistic decision model can help set research priorities and 
inform whether further primary research is required.  If undertaken, further 
research such as an RCT will provide information on effectiveness, cost and 
other important parameters which can then be used directly to update the 
original model.  Following, this a second iteration of stages 3 to 5 of the 
iterative approach would follow, whereby the probabilistic economic model is 
updated and VOI is undertaken to explore whether any further information is 
needed to reduce uncertainty.  If there is a potential need for further research 
a decision model can again help inform the design of the further studies, for 
example; if quality of life, cost or subgroup populations information is required  
then the analysis may highlight that an RCT is not an optimal study design at 
this stage, given strong evidence from an earlier RCT.  It may be more 
appropriate to undertake an observational study or evidence on other 
parameters, negating the demand for another large scale, expensive, RCT. 
Thus, adopting an iterative economic approach in the health care research 
process can improve decision making.    
Reduction of costs 
The drug development process involves a four phased step wise approach to 
reduce uncertainty and improve decision making regarding which drugs to 
proceed with, however, it is also time consuming, costly and of high risk to 
pharmaceutical companies (58).  In pre-clinical research only a few potentially 
suitable drugs will be identified from amongst thousands, incurring huge sunk 
cost for the investment in unsuccessful medicines.  The drugs that progress to 
clinical assessment undergo rigorous testing throughout the four phases, and as 
the certainty of success in one particular drug increases, the number of 
participants required for trials increases, as does the trial length and the 
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coinciding expenditure.  It is the rigorous nature of this process which requires 
major time and cost investment in the development of a new drug.  DiMasi et 
al. (90) estimated the total cost of research and development for a new drug 
to be approximately $802million, for the price year 2000.   
Considering this huge research expenditure incurred mainly by the 
pharmaceutical industry it may appear reasonable to limit economic evaluation 
to a one-off trial based exercise, as routinely adding in stages 2, 3 and 5 of the 
iterative approach into this research process will have further cost implications 
(1); however, earlier modelling at stage 2 (an early DAM) could reduce the 
subsequent evaluation and research costs further down the process. For 
example, by eliminating the need for a large scale RCT further down the line 
or establishing cost-effectiveness earlier.  Sculpher et al. (1) note that any cost 
implications of incorporating the iterative economic framework are likely to be 
a small proportion of the cost of any subsequent primary RCT, and a sensible 
investment to ensure appropriate primary studies are funded.  Likewise in 
publicly funded health care research, incorporating an economic evaluation 
and modelling exercise (in advance of) and alongside an explorative Phase II 
research study could reduce (or possibly eliminate if found to be not 
worthwhile) the cost of any subsequent larger scale Phase III trials.  
The main purpose of the iterative economic approach is to identify priorities 
for research at the later, more expensive stages of evaluation.  The framework 
therefore helps avoid undertaking costly time consuming studies; i.e. avoiding 
trials for an intervention or technology that has little chance of being cost-
effective; or indeed avoiding a study which is not necessary given current 
evidence and therefore is unlikely to be a cost-effective use of resources.  
Investment in early stage modelling and value of information analysis can lower 
costs later on for public and private health care research bodies and any 
further economic evaluations.  
Efficiency gain with an iterative approach 
Earlier funding for economic analysis improves the economic evaluation 
process, benefitting the NHS and reimbursement decision making bodies 
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through early assessment of potential cost-effectiveness and helping to identify 
and set research priorities.  This process can help public initiatives to speed up 
approval decisions on important healthcare technologies or sought after drugs 
and make faster termination decisions for cost-ineffective drugs.  Likewise, in 
the case of publicly funded health care research, an iterative approach will 
encourage considerations of cost-effectiveness earlier in the research process 
and interventions unlikely to be cost-effective can be set aside for those with 
more promise. Involving decision modelling in early stage explorative research 
will encourage efficient allocation of publicly funded research finances.  
In the pharmaceutical industry decisions on the success of a drug are made at 
each phase based on a mix of objective and subjective information regarding 
safety, effectiveness, appropriateness for patient population, cost and 
potential future benefits of the drug (20).  The focus of these decisions is on 
potential for success in the regulatory submission, however, decisions to 
terminate development on investigational drugs primarily for economic reasons 
(with the reimbursement submission in mind) has historically occurred very 
late in the clinical testing process (3;20).  Through using the iterative 
framework for economic evaluation these decisions can be addressed much 
earlier and the health care sector can benefit by identifying which 
interventions to progress through to further research, based on potential cost-
effectiveness as well as effectiveness.  The impact on research and 
development costs can be substantial while the impact on efficiency could 
result in more innovation and new therapies reaching patients sooner (91).   
Hill & Freemantle (92) note that some health technology companies are 
beginning to use economic evaluation at earlier stages to help decision making 
regarding clinical trial parameters, and informing termination decisions on 
products in development.  Value of information analysis is an ideal tool for 
these kinds of decisions.  As illustrated in Figure 2.3, VOI can be used in stage 
3 of the iterative economic approach as a tool for setting research priorities 
and estimating the value of additional research to society; however, publicly 
funded research bodies and the pharmaceutical industry could adopt this 
approach within their internal decision making process for whether or not they 
should fund additional research and also for prioritising health care 
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technologies with the greatest potential for cost-effectiveness.  This could 
reduce the cost of investment and reduce uncertainty regarding the final 
reimbursement decision. In the case of private health care research 
organisations, VOI analysis can be adapted to a companies’ perspective to 
assess the value of undertaking further research in a commercial context (20), 
and the value of further information to society could be considered in the 
spending of public research monies.   
Currently, research funding bodies may implicitly determine the value of 
proposed research projects, based on a variety of internal decision making 
criteria and subjective expert opinions; however, the value is not explicitly 
determined. If VOI techniques were applied to all project proposals submitted 
to funding bodies, then alternative research projects could be compared 
incrementally in terms of their value or net benefit to society.  Such an 
approach would encourage efficient use of research money.  
In the commercial context, Hill & Freemantle (92) suggest interim 
reimbursement decision making for pharmaceuticals in order to improve 
efficiency.  The authors propose this would shorten time to purchase through a 
two-stage process of economic modelling and reimbursement decision making 
prior to a randomised controlled trial, and post-trial to confirm or revoke the 
interim decision.  This approach could benefit the pharmaceutical industry, but 
may have detrimental effects for poor decision making in the interim based on 
uncertain cost-effectiveness estimates.  However, as Vallejo-Torres (20) 
suggest, an iterative approach to economic evaluation throughout the lifecycle 
of a drug or health technology accounts for all new evidence as it becomes 
available.  This is the same regardless of whether the research is regarding 
drug development or wider sector health care technologies and services.  
Incorporating the iterative economic approach in both a commercial and public 
funding context can further improve efficiency and decision making.  With 
regards to the current state of play in the publicly funded research arena, on 
paper funders do ‘encourage’ incorporation of an economic component in early 
stage and explorative research; however explorative research budgets 
(particularly for Phase I and phase II studies) rarely include adequate financing 
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to incorporate economic analyses, which as a result inevitably end up excluded 
at this stage.   With regards to the current state of play in a commercial 
context there is little evidence of incorporation of the iterative approach in 
the drug development industry, however some authors note pharmaceuticals 
are beginning to consider economic considerations at earlier stages, such as 
including the selection of compounds to develop, the choice of clinical trial 
parameters, and ‘go/no-go’ decisions on products in development (92).  To 
encourage support of an iterative approach in the commercial context, the UK 
reimbursement agency NICE set up a scientific advice consultancy service in 
2008, specifically to provide advice to pharmaceutical companies who have 
products in development that may be referred for technical appraisal (93).  
This promotes efficiency and saves time for both pharmaceutical companies 
and decision making bodies such as NICE.  For example, through seeking advice 
from NICE early in the drug development process, for example at phase II, 
pharmaceutical companies can ensure that any clinical and cost-effective 
studies undertaken at phase III onwards meet the requirements for the NICE 
technology appraisal. 
By adopting an iterative approach to economic evaluation in health care 
research, not only will economic evaluation be more useful and of better 
quality, it will also be advantageous to the research funders whether they be 
private or public.  These various advantages support the case for an iterative 
economic framework for undertaking research in the health care sector.  Early 
decision analytic modelling, in which the DAM is built in advance of primary 
research, is a key process of the iterative approach.  The framework allows a 
decision model to be developed on existing evidence and fully exploited in 
terms of addressing uncertainty given current information. VOI techniques can 
also be applied to help set research priorities and inform on the potential value 
and design of future studies.  Applying early stage DAM and VOI techniques 
enables meaningful recommendations to decision makers, who can then make 
informed decisions as to whether a new intervention should be adopted (or 
rejected) based on current evidence, or whether further information is 
required to help make the decision, as opposed to making research funding 
decisions based on subjective reasoning.   
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Despite the advantages of employing early DAM, in practice, support and 
financial funding for early stage modelling and full exploitation of VOI 
techniques is rare in the health care sector.  Given this disparity; the 
remainder of this thesis examines the role of early DAM for informing research 
priorities in the health care sector and considered potential reasons as to why 
it is not more widely implemented.  The thesis uses practical applications of 
building early decision analytic models, in which the various DAM tools 
described in sections 2.3 to 2.8 are applied, to demonstrate the feasibility and 
importance of early DAM and the design of future studies in the health care 
sector.  
 
2.10 Summary 
This chapter introduced economic evaluation in the context of public and 
commercial health care research and discussed the methods for undertaking 
decision analytic modelling for economic evaluation.  Following a review of the 
methodology, the iterative approach to economic appraisal was put forward as 
an appropriate framework for undertaking research in the health care sector 
and the benefits of such an approach were highlighted in terms of reduced 
uncertainty, reduction of costs and efficiency gains.   Incorporating an iterative 
economic framework into both private and publicly funded research in the 
health care sector can improve efficiency, research design and decision 
making.  Early decision analytic modelling, prior to primary research, is a key 
process within the iterative framework, and enables exploration of uncertainty 
and the use of VOI techniques to inform future research priorities.  However, 
in practice early DAM has been less well supported and funding for early DAM is 
rare. This thesis now explores the feasibility, merit and drawbacks of 
undertaking early decision analytic modelling through practical applications 
and considers potential reasons as to why it is not more widely implemented.  
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3 Early DAM: a case of good practice 
3.1 Introduction 
This chapter demonstrates a case of good practice in utilising early decision 
analytic modelling to help inform the design of future research.  The case 
study details a piece of research that was funded by the National Institute for 
Health Research Health Technology Assessment programme (50) to undertake a 
systematic literature review and economic evaluation of an emerging 
technology which showed potential benefit as an addition to current 
technology, rather than as a replacement.  This research remit corresponds 
with stages 2 and 3 of the iterative economic approach, developing an early 
decision analytic model based on existing evidence to undertake an economic 
evaluation to determine whether the technology is cost-effective given current 
information and whether further information is needed to make a more 
informed decision.   In this case, the decision problem had been identified and 
pre-specified by the funding body, that is, stage 1 of the iterative approach.  
As discussed in Chapter 2 this is often, but not necessarily always, the case.   
3.1.1 The decision problem 
Worldwide, colorectal cancer (CRC) accounts for more than one million cancers 
per year or 9% of all new cancer cases.   In the UK, CRC is the third most 
common malignancy after lung and breast cancer, with 37,514 new cases 
registered in 2006: around two-thirds (23,384) in the colon and one-third 
(14,130) in the rectum (94).  For patients with CRC there are a wide range of 
clinical scenarios and various treatment options with different timings, 
dependent on the stage of the cancer and also the extent of the cancer growth 
within each stage.  Therefore, accurate staging once the cancer has been 
diagnosed is necessary to help identify the most appropriate patient treatment 
(95).  The Tumour, Node, Metastases (TNM) staging classification is the 
internationally accepted cancer staging system.  The TNM system classifies the 
extent of the tumour (T); the extent of spread (if any) to nearby lymph nodes 
(N); and whether or not the cancer has spread to other organs in the body, i.e. 
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the presence of metastases (M) (95;96). Numbers from 0 through to 4 appear 
after T, N and M to indicate the presence of and increasing severity of the 
cancer within each stage.  The American Joint Committee on Cancer (AJCC) 
uses these TNM classifications to provide a uniform description of cancers 
within broader categories, known as the four AJCC stages: I II III and IV (95).   
Table 3-1 details the AJCC stages with the different TNM classifications for 
colorectal cancer, describing the extent of disease within each.  
Table 3-1: Staging colorectal cancer using AJCC and TNM classifications 
 
AJCC 
stage Description of cancer 
Tumour 
category 
Node 
category 
Metastases 
category 
I 
Invasion of inner layer of bowel & the 
bowel muscle T1-T2 N0 M0 
II 
Invasion of outer lining of bowel wall & 
other parts of the bowel T3-T4 N0 M0 
III 
Invasion of bowel & spread to lymph 
nodes T1-T4 N1-N4 M0 
IV 
Invasion of bowel, spread to lymph 
nodes & distant metastases (spread 
to one or more other sites in the body) T1-T4 N1-N4 M1a - M1b 
          
Table developed based on information from Edge et al. (95) & CRUK (96) 
Over the past two decades, a number of diagnostic tools have entered clinical 
practice and now facilitate the process of pre-operative staging for CRC.  A 
number of imaging modalities are used including: computerised tomography 
(CT), contrast enhanced computerised tomography (ceCT), magnetic resonance 
imaging (MRI), ultrasound imaging, and positron emission tomography (PET).  
Recently there has been an emerging role for CT in combination with PET 
scanning (‘hybrid’ scan) in pre-operative staging for colorectal cancer. 
PET and CT are complementary imaging techniques that, when combined, can 
maximise their individual advantages while minimising their respective 
disadvantages (97). Several studies have shown PET/CT to be more accurate 
than diagnostic CT and stand-alone PET for cancer staging including colorectal 
cancer (98;99), and the recommendation from the Royal College of Radiologists 
now is that every new PET scanner should be a PET/CT scanner and that every 
cancer network should have access to PET/CT services (97).  However, PET/CT 
scanning is considerably more time consuming than either imaging device 
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alone, and for CRC it is recommended as an addition to routine imaging 
devices, and therefore as an ‘add-on’ technology it carries a heavy cost 
burden.  Additionally, the diagnostic accuracy and therapeutic impacts of 
PET/CT in colorectal cancer are varied and currently unclear.  Therefore, the 
HTA commissioned a systematic literature review of the evidence on 
effectiveness (diagnostic test accuracy) along with an economic modelling 
component to explore potential cost-effectiveness of the PET/CT hybrid scan 
as an addition to current practice. This is slightly different from a typical 
health sector evaluation whereby a new technology is compared directly 
against current practice, and cost-effectiveness is determined as a 
replacement technology.  In this case, current practice with the addition of 
PET/CT was compared against current practice alone; therefore the cost-
effectiveness of PET/CT was determined as an ‘add-on’ technology.  
The pre-defined aim of the research was to determine whether PET/CT is cost-
effective as an add-on test in comparison to routine imaging modalities; for 
pre-operative staging in patients with colorectal cancer.  Given this aim of the 
research problem, identified by the funding body, probabilistic decision 
analytic modelling was undertaken using Monte Carlo simulation to address the 
following questions: 
• Is PET/CT likely to be cost-effective as an addition to routine tests for 
pre-operative staging in CRC compared to current routine methods of 
diagnosis and staging, given current evidence and uncertainty?  
• In which patients groups (i.e. primary, recurrent, metastatic disease)? 
A value of information analysis was also undertaken to help inform whether 
there was potential worth in undertaking further research.   
This chapter outlines the development of the economic component of the 
research, i.e. synthesising current evidence and clinical expertise to develop 
and populate the decision models.  The next section provides an overview of 
the methods employed.  Following this the design and development of each of 
the three models is detailed in turn.  Subsequently, the evidence base and 
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data used to parameterise and populate the models is discussed for each model 
in turn and finally the deterministic results presented.  The subsequent 
chapter (Chapter 4) explores the use of early decision analytic modelling to 
help inform the design of future research; presenting the probabilistic analysis 
results from the three models developed in this chapter and exploring 
uncertainty to assess whether there is any value in further research through 
value of information analyses.   
 
3.2 Methods 
3.2.1 Overview 
The economic evaluation utilised existing evidence, incorporating decision 
modelling techniques to synthesise data from numerous sources (31;66). The 
evaluation was undertaken from the perspective of the UK NHS, reporting short 
term outcomes in terms of the incremental cost per correct diagnosis, and 
longer term outcomes in terms of the incremental cost per quality adjusted life 
year (QALY) gained.  Reporting QALY outcomes enabled the analysis to 
incorporate the potential patient management implications of accurate and 
inaccurate diagnoses, particularly the implications for the patients’ quality of 
life.   
PET/CT and conventional imaging devices have different diagnostic test 
accuracies (DTA) for staging primary, recurrent and metastatic colorectal 
cancer, as such, in order to address the questions outlined in the aims, three 
separate economic models were designed.  Patient management routes also 
differ between colon and rectal cancer, and therefore the primary and 
recurrent models were adapted to incorporate the specifics of rectal and colon 
cancer separately.  The economic evaluation therefore involved five analyses, 
based on the three models, as detailed in Table 3-2.  
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Table 3-2: Model type and analysis undertaken 
  
 
Model Analysis 
1 Primary rectal cancer 
    colon cancer 
   
2 Recurrent rectal cancer 
    colon cancer 
   
3 Metastatic metastatic disease 
      
 
The cost-effectiveness of PET/CT as an add-on imaging device in pre-operative 
staging was assessed for: (i) primary rectal cancer, (ii) primary colon cancer, 
(iii) recurrent rectal cancer, (iv) recurrent colon cancer and (v) metastatic 
disease. 
Each model was analysed probabilistically, using Monte Carlo simulation, to 
determine the expected cost, expected outcomes (correct diagnoses and 
QALYs) and the expected cost-effectiveness (cost per correct diagnosis and 
cost per QALY gained).  The Monte Carlo simulations involved 2000 iterations 
for each model. Using any number of iterations greater than 1000 is generally 
considered acceptable (4), however to ensure a robust approach, the stability 
of the results was tested at 1000 iterations and 10,000 iterations for two of the 
analyses and found to be within reasonable bounds; i.e. there was only very 
slight changes to the incremental cost-effectiveness outcomes between 1000, 
2000 and 10,000 iterations and therefore 2000 iterations was deemed 
acceptable.  
3.2.2 Existing evidence  
The economic models were designed, developed and populated based on a 
variety of information sources, in particular, from published data sources, 
literature and in consultation with clinical experts. 
Previous economic evaluations of imaging devices for CRC were used to aid the 
design of the models, while the systematic review component of the research 
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project derived diagnostic test accuracy evidence for PET/CT and alternative 
imaging modalities.  Economic and non-economic literature was required to 
inform specific model parameters, such as resource use, implications of 
diagnosis on patient management and therapeutic impact, quality of life and 
survival.  Costing and resource use information was obtained from both the 
literature and UK NHS cost information sources such as the British National 
Formulary (100), Department of Health Reference Costs (101) and the Personal 
Social Services Research Unit (102).   
Papers which were considered to be potentially relevant for the health 
economic evaluation were identified by the systematic reviewers during their 
screening process and passed on to the health economists as first-line 
literature to inform the development of the economic model.  These initial 
papers provided an indication of the types of literature that were available and 
helped inform the design of the economic evaluations.  Having established 
some first-line literature, a separate non-systematic literature search was 
undertaken in November 2009 to provide further information on the various 
parameters for the economic models. The objective was to search for and 
utilise information from economic evaluations and non-economic papers to 
develop and populate the economic models. Specifically, the search considered 
what evidence was available regarding the costs, treatment outcomes, 
management pathways, overall survival, quality of life and adverse events 
experienced by CRC patients undergoing pre-operative screening for primary, 
recurrent or metastatic colorectal cancer. 
The following electronic databases were searched from beginning until 
November 2009: Medline, Embase, Web of Science, CINAHL Plus, Cochrane 
Library (NHSEED, HTA, CENTRAL, DARE), the Health Management Information 
Consortium (HMIC) and the CEA Registry.  Specific searches were constructed 
for four main areas (PET/CT imaging for colorectal cancer, economics, adverse 
events or quality of life, and decision analysis) for each of the databases, as 
detailed in Appendix 1.   Inclusion criteria were applied to include relevant 
publications in any language that provided information on the diagnostic 
imaging devices PET/CT, contrast enhanced CT (ceCT) or MRI for detecting 
colorectal cancer, with regards to the topic areas of economic evaluation, 
Chapter 3   74 
costing, patient management and therapeutic impact, quality of life and 
overall survival.  Papers that only provided details on diagnostic test accuracy 
(DTA) were excluded, as this detail was being gathered by the systematic 
review team.  Literature that was only detailed in conference proceedings or 
abstracts was also excluded.  The search outputs are detailed in Table 3-3 
below, resulting in a total 51 papers identified from the search which were 
deemed to be of relevance, plus an additional four quality of life papers 
identified through hand searching.   
Table 3-3: Economics literature search 
Search Stage Search Strategy / Specified Criteria No. of 
papers  
 
Initial search 
 
Identified 902 papers after de-duplication.  
Appendix 1 details the search for each database 
 
902 
 
Check titles & 
abstracts 
  
 Rejected 802 papers: All deemed irrelevant at 
title and abstract 
 
100 
 
Check full paper, apply 
inclusion criteria  
  
Rejected 49 papers: Irrelevant / unavailable / 
abstract only / conference proceeding (21);  
Irrelevant / efficacy data alone (28) 
 
 
51 
 
 
Final papers 
 
Costing studies (7)  
Economic evaluations (10)  
Quality of life (2) 
Survival (4) 
Management (28) 
Hand searched quality of life papers (4) 
 
 
55 
 
Information from this literature was used in consultation with the clinical 
experts involved with the project in order to design the models, in particular 
to identify appropriate comparators, management pathways and parameter 
estimates for each model. 
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3.3 Model design and development 
Each of the three models was developed to incorporate the short term 
diagnostic pathway for the patient, the resultant treatment options and longer 
term outcomes such as patient survival and quality of life.  Each model initially 
adopted a decision tree design to illustrate the patient pathway from 
suspected disease through to test outcome to distinguish between accurate and 
inaccurate disease staging. The costs and diagnostic test accuracy of the 
imaging devices were attributed to the appropriate branches in the trees.  
Following this, optimal treatment strategies with their associated costs and 
utilities were assigned dependent on the diagnosis from the decision tree, in 
order to account for treatment under both accurate and inaccurate staging.  A 
longer term survival simulation was then undertaken to account for the costs, 
quality of life and survival impact of optimal versus received treatment.  The 
diagnostic pathway for ‘add-on’ technologies will next be explored followed by 
details of the development of the Primary, Recurrent and Metastatic models 
respectively.  
3.3.1 The diagnostic pathway 
An economic evaluation for an intervention that is utilised as an add-on 
technology can be more complex than for a typical evaluation where cost-
effectiveness is determined as a replacement technology.  In this case, the 
evaluation involves the combination of two or more diagnostic tests and 
therefore presents some issues for mapping the diagnostic pathway and 
interpretation of test results, particularly if the second test refutes the 
outcomes from the first test.  Therefore, prior to developing the decision 
models, the diagnostic pathway with a combination of two diagnostic tests 
needs to be explored.   
In mapping the patient pathway for a diagnostic technology, decision trees are 
an ideal tool and typically follow the chronological order of the patient 
experience, for example, from a patient’s initial examination, through to any 
tests, diagnosis and treatment, with the terminal node representing the true 
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patient disease status in order to distinguish between correct and incorrect 
diagnoses. However, in the case of diagnostic interventions, it may be more 
appropriate to structure the tree with disease prevalence at the beginning of 
the tree, prior to any diagnostic tests, in order to present a clearer, logical 
pathway.  Phelps et al.(103) use such a strategy and portray a standard 
decision tree for a diagnostic test with disease prevalence at the first chance 
node, prior to the diagnostic test outcomes.  Snider et al. (page 48) (61) also 
recommend this approach where appropriate. 
“Often the first chance node on a decision branch incorporates the 
characteristics of the population relevant to the prevention problem.  
The characteristics of the relevant population may be demographic, may 
be related to the prevalence of a disease or injury…” 
Classifying the disease prevalence at the outset helps build a clear and logical 
structure in which the diagnostic test and its accuracy can then be identified, 
finishing up with correct or incorrect diagnosis at the terminal node.  Fenwick 
(104) also prefers this approach for diagnostic interventions, noting that 
regardless of whether true disease status is mapped at the beginning or 
terminal nodes of the tree, the information and the probabilities associated 
with each pathway are the same.  Therefore, in developing the decision tree a 
structure with disease prevalence at the outset was considered to be an 
appropriate approach.  
Diagnostic testing is undertaken to aid in the diagnosis or detection of a 
disease, and the accuracy of the test depends on how well the technology or 
test correctly identifies or diagnoses the disease. The standard approach for 
measuring correct and incorrect diagnosis is the Diagnostic test accuracy 
(DTA), which is expressed through the test characteristics sensitivity and 
specificity. The sensitivity of a test is the probability that it can identify true 
positives, i.e. the proportion of patients who have the disease and are 
identified positively by the test (105).   The specificity of the test is the 
probability that the test correctly identifies true negatives, i.e. the proportion 
of patients without the disease who correctly receive a negative test result.  
These test characteristics are outlined in Table 3-4 for clarity.   
Chapter 3   77 
Table 3-4: Diagnostic test accuracy 
 
Disease Prevalence 
Test outcomes Disease +  Disease - 
Test + True Positive False Positive 
  (sensitivity) (1-specificity) 
Test - False Negative True Negative 
  (1 – sensitivity) (specificity) 
 
As detailed in Table 3-4, incorrect diagnoses can fall into two categories: false 
positives or false negatives.  When a patient has the disease but the diagnostic 
test (incorrectly) identifies no disease, this is known as a false negative, and 
the probability is equivalent to 1 minus the sensitivity of the test.  When a 
patient does not have the disease, but a diagnostic device incorrectly identifies 
the patient as disease positive, this is known as a false positive, and the 
probability of occurring is equivalent to 1 minus the specificity.   As all 
diagnostic devices classify patients with some error, a clinician must select 
amongst various ways to interpret the diagnostic test results, trading-off the 
risks of false positives and false negatives (103).  Therefore in an economic 
model it is important to analyse the longer term impact of diagnostic test 
accuracy, and specifically the impact on patient management in terms of false 
positives (where the patient may subsequently receive treatment for a disease 
they do not have) and false negatives (where patient may not receive 
treatment or experience a delay in treatment for their disease which was not 
identified).   
If there is more than one diagnostic device used in the detection or diagnosis 
of a disease, such as in the case of add-on technologies, clinicians must deal 
with test error (false negatives and false positives) from both tests, and will 
require a strategy for dealing with conflicting test results (106;107).  Figure 3-1 
provides an example of a two test intervention, illustrating one branch from a 
decision tree for intervention (A) that involves two tests.   
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Test 2 +ive + +
sensitivity 2
Test 1 +ive
sensitivity 1
Test 2 -ive + -
Disease +ive 1-sensitivity 2
prevalence
Test 2 +ive + -
sensitivity 2
Intervention A Test 1 -ive
1-sensitivity 1
Test 2 -ive - -
1-sensitivity 2
Test 2 +ive + +
1-specificity 2
Test 1 +ive
1-specificity 1
Test 2 -ive + -
Disease -ive specificity 2
1-prevalence
Test 2 +ive + -
1-specificity 2
Test 1 -ive
specificity 1 Test 2 -ive - -
specificity 2  
Figure 3-1: Diagnostic pathway for a two test intervention 
This is an example with only 1 branch of a decision tree for an Intervention A, and does not include the comparator arm at the initial decision node  
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The branch for intervention A initially splits the patient population according 
to their true disease status, Disease positive (prevalence) or Disease negative 
(1 minus prevalence), and then incorporates the first diagnostic test, so that 
accurate (true positives and true negatives) and inaccurate (false positive and 
false negative) scan diagnoses can be identified from Test 1.  The diagnostic 
test accuracy (sensitivity and specificity) for Test 1 is initially applied 
identifying true positives (sensitivity1) and true negatives (specificity1) for 
accurate diagnoses; and false negatives (1-sensitivity1) and false positives (1- 
specificity1) for inaccurate diagnoses.  Following this, the second test is 
incorporated into the respective branches and the diagnostic test accuracy for 
Test 2 is applied (sensitivity2, 1-sensitivity2, specificity2, 1-specificity2).  As 
can be seen in Figure 3-1, Test 2 either confirms or refutes the diagnoses from 
Test 1 depending on the diagnostic test accuracy of Test 2.  In order to deal 
with the combined diagnostic test accuracy outcomes from the two tests, it is 
necessary to adopt a strategy to deal with conflicting results. 
In the upper most layer of the branch in Figure 3-1, both Test 1 and Test 2 give 
positive disease confirmation, however, in the lower section of this upper 
branch, Test 2 is negative, refuting the positive Test 1 outcome.  In this 
situation which test diagnosis should be accepted?  If Test 2 outcomes always 
override Test 1 outcomes, then there is no need for Test 1 and the situation is 
no longer an add-on scenario but a replacement, and likewise if Test 1 
outcomes are always chosen, there is no need for the add-on Test 2.  
Therefore, in a situation where the two tests are combined, there are two 
alternative strategies that can be adopted: confirmatory positive or 
confirmatory negative, as illustrated after the terminal node in Figure 3-1.   
A confirmatory positive strategy would accept positive outcomes over negative 
results, i.e. where Test 2 is positive but Test 1 was negative the positive 
diagnosis from Test 2 would be accepted. Likewise where Test 1 is positive and 
Test 2 is negative, the positive result from Test 1 is accepted.  This will have 
implications in terms of the proportion of false positives and false negatives 
identified from the tree.  A confirmatory positive strategy benefits from the 
sensitivity of both tests, and may help identify a greater proportion of true 
positives than either test alone because false negatives from Test 1 would be 
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refuted by positive results from Test 2 in this strategy.  However, this is at the 
expense of identifying fewer true negatives and also incurring a greater 
proportion of false positives i.e. trading-off specificity for improved sensitivity.  
The alternative strategies after the terminal node in Figure 3-1 shows that a 
confirmatory positive strategy results in mostly positive diagnoses from the 
tree, with a greater proportion of both true and false positives.  In terms of 
patient management, the impact of additional false positives in this strategy 
must be considered, which is likely to lead to (over)treatment of patients for a 
disease that they don’t actually have. 
Alternatively, a confirmatory negative approach can be taken, whereby 
negative results overrule positive results, and in situations where the two tests 
contradict each other, the negative outcome is accepted.  This is the second 
strategy illustrated at the terminal node in Figure 3-1, resulting in a greater 
proportion of negative outcomes.  With this strategy more true negative cases 
will be identified, however, there will also be a greater proportion of false 
negatives identified.  Therefore, this strategy benefits from the specificity of 
both tests, at the expense of lower overall sensitivity, and a greater proportion 
of false negative identifications.  In terms of patient management, the impact 
of additional false negatives in this strategy must be considered, which is likely 
to lead to missed treatment (or at least delayed treatment) for patients with a 
disease, who were not identified correctly. 
It is also important to note that if a confirmatory positive strategy is taken, 
then theoretically it would be more efficient to only incorporate Test 2 when 
Test 1 gives negative results.  This strategy would give identical results as the 
confirmatory positive strategy but would only incur the cost of Test 2 in some 
rather than all cases.  Likewise, if a confirmatory negative strategy is adopted, 
it would be more efficient and cost saving to only use Test 2 where Test 1 gives 
a positive result.  While this is theoretically more efficient, in practice this 
approach may be less well accepted, and in the case of PET/CT, clinicians 
advised that all patients would be given a scan regardless of the conventional 
test outcomes.   
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In developing the model for the PET/CT as an add-on device in colorectal 
cancer staging, clinicians advised that in practice they adopt a confirmatory 
positive strategy for add-on PET/CT, i.e. positive results overrule negative 
results, and therefore results are only treated as negative when both the 
conventional and PET/CT test outcomes are negative.  This strategy takes 
advantage of improved sensitivity from an add-on device, however this is at 
the risk of some over-staging (and subsequent unnecessary treatment) through 
false positives.  By adopting a confirmatory positive strategy the clinicians 
indicate the importance of the benefit from improved sensitivity and are 
willing to accept the risk of incurring some additional false positives which may 
result in some patients receiving treatment unnecessarily, rather than adopt a 
strategy which would favour specificity and result in false negative 
identifications where patient would be untreated (or delayed treatment).   
Therefore the baseline models adopted a confirmatory positive strategy, based 
on clinician advice, assuming that any positive test outcome overrides negative 
results.  Negative results from the conventional imaging tests which are 
refuted by the PET/CT test are treated as positive, and likewise negative 
results from a PET/CT scan which conflict with prior positive results, are still 
treated as positive.   In situations where one of the tests is found to be 
superior to the other (in terms of both sensitivity and specificity) then the 
superior test can be taken to represent the combined DTA (108), therefore, in 
the PET/CT model a confirmatory positive strategy was adopted where there 
was no test superiority, and where one diagnostic test was found to be superior 
over the other, then this was taken to represent joint DTA in the add-on arm.    
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3.3.2 Model 1: Primary rectal & colon cancer 
Diagnostic Pathway 
The cost-effectiveness of PET/CT as an add-on device in primary (rectal and 
colon) cancer relates to the initial, pre-operative staging of primary patients.  
The value of incorporating a PET/CT scan in addition to conventional imaging 
in the primary disease stage is potentially greater sensitivity for the 
identification of nodal and metastatic disease (109-111); i.e. the N and M 
classifications in the TNM staging system, as detailed earlier in Table 3-2.  The 
only diagnostic test accuracy evidence available for PET/CT in this context 
relates to the identification of lymph node involvement (109;110) and 
therefore the primary models were designed to evaluate PET/CT as an add-on 
device in nodal staging.  In the AJCC staging system (detailed in Table 3-2), 
stages 1 and 2 have no nodal involvement, while both AJCC stages 3 and 4 can 
have some nodal involvement, and therefore the AJCC stages were considered 
to be an appropriate classification for distinguishing between nodal 
involvement in the primary model.   
Figure 3-2 depicts the decision tree structure used for mapping the diagnostic 
pathway in the primary model. Due to the absence of economic models of 
PET/CT in primary CRC in the literature (none were identified from the 
systematic review or economics literature search), this model structure was 
informed primarily through consultation with clinical experts from the research 
team in order to accurately reflect the clinical pathway for nodal staging.  The 
model was altered to include the disease specific criterion for rectal and colon 
cancers separately.   
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Disease Prevalence Diagnostic Test Accuracy AJCC stage identified
Test +ive AJCC 3 as AJCC 3 (accurate)
sensitivity AJCC 4 as AJCC 4 (accurate)
Nodal Spread (+)
AJCC 3 + 4
AJCC 3 as AJCC1 (inaccurate)
Test -ive AJCC 3 as AJCC 2 (inaccurate)
1-sensitivity AJCC 4 as AJCC 1 (inaccurate)
AJCC 4 as AJCC 2 (inaccurate)
Conventional strategy
AJCC 1 as AJCC 3 (inaccurate)
Test +ive AJCC 1 as AJCC 4 (inaccurate)
1-specificity AJCC 2 as AJCC 3 (inaccurate)
AJCC 2 as AJCC 4 (inaccurate)
Initial Assessment: suspected No nodal spread (-)
primary colon / rectal cancer AJCC 1 + 2
Test -ive AJCC 1 as AJCC1 (accurate)
specificity AJCC 2 as AJCC 2(accurate)
PET/CT +ive AJCC 3 as AJCC 3 (accurate)
sensitivity 2 AJCC 4 as AJCC 4 (accurate)
Test +ive
sensitivity 1
PET/CT -ive AJCC 3 as AJCC 3 (accurate)
Nodal spread (+) 1-sensitivity 2 AJCC 4 as AJCC 4 (accurate)
AJCC 3 + 4
PET/CT +ive AJCC 3 as AJCC 3 (accurate)
sensitivity 2 AJCC 4 as AJCC 4 (accurate)
Conventional then Test -ive
add-on PET/CT 1-sensitivity 1
AJCC 3 as AJCC1 (inaccurate)
PET/CT -ive AJCC 3 as AJCC 2 (inaccurate)
1-sensitivity 2 AJCC 4 as AJCC 1 (inaccurate)
AJCC 4 as AJCC 2 (inaccurate)
AJCC 1 as AJCC 3 (inaccurate)
PET/CT +ive AJCC 1 as AJCC 4 (inaccurate)
1-specificity 2 AJCC 2 as AJCC 3 (inaccurate)
Test +ive AJCC 2 as AJCC 4 (inaccurate)
1-specificity 1
AJCC 1 as AJCC 3 (inaccurate)
PET/CT -ive AJCC 1 as AJCC 4 (inaccurate)
No nodal spread (-) specificity 2 AJCC 2 as AJCC 3 (inaccurate)
AJCC 1 + 2 AJCC 2 as AJCC 4 (inaccurate)
AJCC 1 as AJCC 3 (inaccurate)
PET/CT +ive AJCC 1 as AJCC 4 (inaccurate)
1-specificity 2 AJCC 2 as AJCC 3 (inaccurate)
Test -ive AJCC 2 as AJCC 4 (inaccurate)
specificity 1
PET/CT -ive AJCC 1 as AJCC1 (accurate)
specificity 2 AJCC 2 as AJCC 2(accurate)
 
Figure 3-2: Decision tree for staging primary colorectal cancer 
 
The decision tree model begins with patients who have had an initial 
assessment (involving a clinical examination, colonoscopy or sigmoidoscopy and 
a biopsy), which identified them as having primary (rectal or colon) cancer.  
The decision node in the tree represents the decision between the 
conventional strategy, where patients receive the standard imaging 
procedures, or the intervention strategy where PET/CT is added on.  The 
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standard procedure for patients suspected of primary colon cancer is a contrast 
enhance computerised tomography (ceCT) scan of the chest, abdomen and 
pelvis to diagnose and/or stage the extent of the disease.  In the case of 
primary rectal cancer, the conventional procedure involves a ceCT scan of the 
chest, abdomen and pelvis followed by an MRI scan of the pelvis2.  This 
conventional pathway is represented in the top half of the tree in Figure 3-2. 
The intervention arm involves the conventional work up (ceCT for colon cancer 
or ceCT and an MRI for rectal cancer) followed by a PET/CT scan, which is 
depicted in the bottom half of the tree.   
The primary decision tree model has been designed using actual CRC disease 
status at the outset, splitting the patient population according to the disease 
prevalence prior to the imaging scans, so that accurate and inaccurate scan 
diagnoses can be clearly identified.  The objective of the scan in this model is 
to assess whether there is any nodal spread and therefore, after the initial 
decision node depicting the choice between the conventional or add-on 
PET/CT intervention, the tree divides the population according to actual nodal 
spread disease status using the AJCC colorectal cancer staging system (95) as 
detailed in Table 3-2.  In the AJCC system, stages 1 and 2 have no nodal 
involvement, while both AJCC stages 3 and 4 can have some nodal 
involvement.  
After dividing patients according to their true nodal spread disease status, the 
work-up of diagnostic tests are undertaken which will either identify nodal 
involvement (test positive), or no nodal involvement (test negative), depending 
on the sensitivity and specificity of the test.  Having previously specified actual 
disease status, the top branch represents primary (rectal or colon) cancer with 
nodal spread (AJCC stages 3 and 4), and therefore at the test chance node the 
tree branch splits depending on whether the test was positive (accurately 
identified nodal involvement) or negative (inaccurately identifying no nodal 
involvement).  The true positive outcomes correctly identify AJCC 3 as AJCC 3 
and AJCC 4 as AJCC 4, however, the false negative outcomes lead to 
                                         
2
 For simplification the conventional strategy is illustrated as one test and the intervention as two 
tests, however, in the case of primary rectal cancer the conventional strategy involves two 
tests and the intervention three tests.  
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inaccurate under-staging, identifying no nodal involvement (AJCC 1 and 2) 
when the patients do have nodal involvement (AJCC 3 and 4).  The outcomes 
identified are detailed at the terminal node in Figure 3-2, where AJCC3 is 
identified as AJCC1 or AJCC2, and AJCC 4 is identified as AJCC 1 or AJCC2.  
The model does not allow for inaccuracies in staging between stages AJCC 3 
and 4 or between AJCC1 and 2, as the purpose of the imaging scans (and 
therefore the model) is to identify spread to the lymph nodes.  Therefore the 
model assumes that once lymph node spread has been identified as either 
positive or negative, the corresponding AJCC classifications (AJCC 1 & 2 for no 
nodal involvement or AJCC 3 & 4 for nodal involvement) are applied based on 
the AJCC stage specific prevalence.   
The bottom half of the top branch, which split at the disease prevalence 
chance node, represents primary cancer with no nodal spread (AJCC 1 and 2).  
The tree depicts the negative test outcomes that were accurate (true 
negatives), i.e. patients who are staged as AJCC1 or 2 accurately, and also 
positive test outcomes which were inaccurate (false positives), again 
depending on the sensitivity and specificity of the test.  These false positive 
outcomes diagnose nodal involvement, over-staging the extent of the disease 
which is actually no nodal involvement (inaccurately diagnosing AJCC 1 as AJCC 
3 or AJCC 4, and AJCC2 as AJCC 3 or AJCC 4).  In this way the decision tree 
separates out accurate and inaccurate diagnosis of nodal involvement. 
Patients in the conventional arm of the model will be staged using the standard 
diagnostic test work-up described above (ceCT of the chest, abdomen and 
pelvis in colon cancer, and ceCT followed by a pelvic MRI in rectal cancer), 
represented by ‘Test’ in the top half of the tree in Figure 3-2.  Patients in the 
intervention arm of the model are also given these conventional imaging tests 
represented by ‘Test’, followed by the addition of a PET/CT scan, represented 
as ‘PET/CT’ in the bottom half of Figure 3-2.  In the intervention arm, the 
PET/CT test is given regardless of the outcomes from the initial test, and 
therefore the diagnostic test accuracies from both tests are combined.  As 
PET/CT is an add-on test after the conventional test, a strategy is required to 
deal with the combined diagnostic test accuracy outcomes, particularly when 
one of the tests refutes the other (as discussed in section 3.3.1). The clinicians 
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advised that a confirmatory positive strategy is adopted in practice, and 
therefore the baseline model adopts such a strategy, whereby positive test 
results override negative results.  Negative results from the conventional 
imaging tests which are refuted by the PET/CT test are treated as positive and 
vice versus, so that results are only treated as negative when both the 
conventional and PET/CT test outcomes are negative.   
In the intervention arm of the tree, the outcomes are different from the top 
half of the tree, due to the combined DTA and the confirmatory positive 
strategy adopted.  In Figure 3-2 the top branch in the intervention arm 
represents primary cancer with nodal spread (AJCC 3 and 4).  The tree depicts 
the conventional test outcomes which are either positive (sensitivity 1) or 
negative (1-sensitivity 1) and is then directly followed by the PET/CT test, 
regardless of the outcomes from the conventional test.  The DTA of the PET/CT 
test is then applied in the tree, distinguishing between positives (sensitivity 2) 
and negatives (1-sensitivity 2). In the top layer of this branch both tests were 
positive and therefore stages AJCC 3 and AJCC 4 are identified accurately. At 
the lower level of this branch, where the PET/CT chance node is negative, it 
conflicts with the conventional tests positive result, however, the positive 
outcome takes precedence due to the strategy adopted, and therefore this 
branch also identifies AJCC 3 and 4 accurately. Only when both the 
conventional and PET/CT tests report negative outcomes are the results 
treated as such.  Figure 3-2 reports the AJCC stages identified, and whether 
these are accurate or inaccurate at the terminal node.  
The proportion of accurate and inaccurate nodal staging outcomes at the end 
of the decision tree branches for the conventional arm of the model are 
compared against the intervention arm of the model and short-term cost-
effectiveness can be assessed in terms of the incremental cost per accurate 
diagnosis.  These interim decision model outcomes of accurate and inaccurate 
diagnosis for the four AJCC stages were then used to incorporate patient 
management in the model, as discussed next. 
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Treatment options 
Following the development of a decision tree to map the diagnostic pathway 
for primary (rectal and colon) cancer, the economic model was adapted to 
incorporate the treatment impacts of accurate and inaccurate staging in 
primary colorectal cancer. The optimal treatment strategies for each AJCC 
stage were identified, along with their associated costs and utilities and 
applied in the model depending on the stage identified (diagnosis) from the 
decision tree.   
Optimal treatment combinations for the four AJCC stages were determined 
through consideration of the literature (112-118) and in consultation with 
clinical experts. The various treatment options vary slightly between colon and 
rectal cancer, with the main difference being that radiotherapy is only 
appropriate for rectal cancer patients. Therefore the treatment combinations 
for both types of cancer were ascertained. Figure 3-3 details the optimal 
treatment options as decision tree branches, which were applied to each AJCC 
stage identified in the model for both rectal and colon cancer.   
For primary colorectal cancer the model assumed that all AJCC 1 patients 
receive primary surgery; this is the only treatment option for patients with 
stage AJCC1.  In the case of primary rectal cancer surgery entails rectal 
excision with lymphadenectomy, and for colon cancer a colonic resection with 
lymphadenectomy.   
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AJCC stage identified Primary Rectal treatment options AJCC stage identified Primary Colon treatment options
AJCC 1 Surgery (rectal excision with lymphadenectomy) AJCC 1 Surgery (colonic resection with lymphadenectomy)
Surgery
Surgery
AJCC 2  Longcourse chemo-radiotherapy then surgery AJCC 2 
Surgery followed by adjuvant chemotherapy
Surgery followed by adjuvant chemotherapy
Surgery
Surgery
AJCC 3  Longcourse chemo-radiotherapy then surgery AJCC 3
Surgery followed by adjuvant chemotherapy
Surgery followed by adjuvant chemotherapy
Surgery Surgery
 Longcourse chemo-radiotherapy then surgery Surgery followed by metastatic surgery
AJCC 4
AJCC 4 Surgery followed by metastatic surgery Surgery followed by palliative care 
Surgery followed by palliative care Palliative care 
Palliative care 
 
Figure 3-3: Treatment pathways for primary rectal & colon cancers 
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For patients with primary rectal cancer identified as stage AJCC2 or AJCC 3, 
there are three treatment options: surgery alone, long course chemo-
radiotherapy prior to surgery or surgery followed by adjuvant chemotherapy.  
Surgery refers to a rectal excision with lymphadenectomy, long course chemo-
radiotherapy refers to 5 weeks of radiotherapy (45Gy in 25 fractions over 5 
weeks) followed by a 12 week course of chemotherapy of 5 Fluorouracil (5FU) 
(119;119), and adjuvant chemotherapy involves a 6 months course post surgery 
of intravenous 5FU and Oxaliplatin (100;120).   Primary colon cancer patients 
identified as stage AJCC2 or AJCC 3, have two treatment options: surgery 
alone, or surgery followed by adjuvant chemotherapy.  Surgery refers to a 
colonic resection with lymphadenectomy, and adjuvant chemotherapy involves 
a 6 months course post surgery of intravenous 5FU and Oxaliplatin (100;120).    
AJCC4 rectal cancer patients can receive one of five treatment options: 
primary surgery alone, long course chemo-radiotherapy prior to primary 
surgery, primary surgery followed by metastatic surgery, primary surgery 
followed by palliative care or palliative care alone.  Surgery refers to a rectal 
excision with lymphadenectomy, long course chemo-radiotherapy refers to 5 
weeks of radiotherapy (45Gy in 25 fractions over 5 weeks) followed by a 12 
week course of chemotherapy of 5 Fluorouracil (5FU) (97;119), and adjuvant 
chemotherapy refers to a 6 months course post surgery of intravenous 5FU and 
Oxaliplatin (100;120).  Metastatic surgery refers to surgery at the metastatic 
site and palliative care, which is treatment designed to relieve symptoms and 
improve quality of life (as opposed to having a curative intent), represents an 
array of palliative treatments which may include chemotherapy or chemo-
radiotherapy for rectal cancer patients.  In the case of colon cancer AJCC 4 
patients have four treatment options: primary surgery alone3 (colonic resection 
with lymphadenectomy), primary surgery followed by metastatic surgery, 
primary surgery followed by palliative care or palliative care alone. 
                                         
3
 There is typically a fifth treatment option of primary surgery combined with contemporaneous 
resection of metastases, however, after consultation with clinical experts it was decided this 
additional treatment option would only result in an unquantifiable and likely marginal effect on 
overall cost compared to primary surgery alone, hence these are considered together. 
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Assigning these optimal treatment options for each AJCC stage in the model 
means that patients in the decision tree who are accurately diagnosed will 
receive optimal treatment while patients who are inaccurately diagnosed 
(through false positive or false negative test outcomes) will receive suboptimal 
treatment, i.e. patients with no nodal involvement (AJCC1 or AJCC2 patients) 
who are inaccurately diagnosed as having nodal involvement (over-staged to 
either AJCC3 or 4) will receive unnecessary AJCC3 or AJCC4 treatments.  In the 
case of inaccurate staging, the model assumes patients will receive the 
treatments for their (mis)diagnosed stage, but within a year their true 
diagnosis will be correctly identified and optimal treatment will then be given. 
This assumption was made in consultation with clinical experts and was 
considered to be valid with one year as an appropriate time scale for 
encompassing most cases of under-staging.  In this way the model accounts for 
the cost and quality of life of optimal treatment and in the treatments which 
are received unnecessarily or initially failed to be received, due to over or 
under-staging.  No transitions between nodal states are allowed during the 
year. The treatment profiles were assigned costs and utility weights in the 
model, which will be discussed later in section 3.4.1.   
Survival 
Following treatment for the diagnosed AJCC stage, the model incorporated a 
survival analysis in order to capture the mortality and quality of life impacts 
for the patients in each intervention.  The survival analysis utilised a basic 
two-state Markov format for each of the four AJCC stages to calculate the 
average life expectancy and average quality adjusted life years (QALYs) in each 
AJCC stage.  Figure 3-4 illustrates the model for the four AJCC colorectal 
cancer stages.   The first state represents the patients AJCC colorectal cancer 
stage, and the patient can either remain in this state or die moving into the 
death state. 
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AJCC 2
Death
AJCC 4
Death
AJCC 3
Death
utility weight
mortality rate
AJCC 1
Death
 
Figure 3-4: Two-state survival model for each AJCC colorectal cancer stage 
 
The survival analysis assumed four patient cohorts, one for each AJCC stage, 
starting with the sample of patients in each stage in the Scottish CRC dataset 
(121). The model used annual cycles and assumed a starting age of 50 years4.  
A utility weight is applied to the AJCC state to reflect that state’s average 
utility for five years post diagnosis; each of the four AJCC states has a different 
mean utility weight (122).  Studies have shown (122;123) that five years post-
diagnosis quality of life in colorectal cancer patients is on par with age specific 
general population utility weights, and therefore after five years in the AJCC 
state, it was assumed that patients who are still alive will have age specific 
population utility weights for the remainder of time in that state (124). 
Transition from the AJCC state to death was represented by the colorectal 
cancer AJCC stage specific morality rates for the first 10 years of the model 
(based on Scottish colorectal cancer five year overall survival estimates for 
each AJCC stage (121)).  Returning to age specific population mortality rates 
five years post diagnosis was considered lenient as there is evidence of disease 
related death beyond five years (94), and therefore a more conservative 
approach was adopted whereby patients were considered to be cured 10 years 
post diagnosis.  Beyond 10 years patients were assumed to have survived their 
                                         
4
 The starting age of 50 years was used in the model as the dataset is based on the Scottish 
CRC population aged 50yrs and over (mean age 61 yrs). The models were also run using an 
older population (starting at age 70yrs), with the resultant effect of lowering life expectancy 
and quality adjusted life expectancy for patients in each AJCC stage, but no overall change to 
the incremental cost-effectiveness outcomes. 
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cancer and were assigned the age specific population level mortality rates 
(which were derived from routine data, and included all mortality including 
that from cancers)(125).  
Figure 3-5 demonstrates the survival curves for each of the AJCC stages in 
patients suspected of primary rectal cancer. The population in each AJCC stage 
group was taken from the Scottish CRC dataset (121); however as the survival 
analysis is used to calculate average life expectancy in each group, the sample 
size at diagnosis (time zero) for each group in Figure 3-5 was assumed to be 
the same (n=1000) in order to clearly illustrate the difference in survival curves 
between the different AJCC groups.   
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Figure 3-5: Overall survival for primary rectal cancer for each AJCC stage  
 
As would be expected from AJCC 3 and AJCC4 patients, who have lymph node 
involvement in their primary cancer (and metastases to other sites in the body 
for AJCC 4), survival falls sharply in the first few years post-diagnosis, with 
only a small number of AJCC 4 patients surviving beyond ten years. The model 
starting age was set at 50 years for each AJCC group, based on the information 
from the Scottish dataset (121).  The AJCC4 population have been diagnosed 
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with metastatic disease at their first (primary) diagnosis.  This population have 
a very low life expectancy, and at 5 years post-diagnosis only 13% remain alive, 
and 10 years post diagnosis only 1.8% remain alive.  
Note how AJCC stages 1 through to 3 survival curves all flatten out after 10 
years; this is due to the change to population mortality rates.  If they have 
survived this long, they are considered to be cured from their cancer and 
subject to same life expectancy as the general population, for their age.  Ten 
years post diagnosis, the age specific population mortality rates kick in, and 
after 25 years the survival curves begin to decline more rapidly (population age 
75 years).  A very small percentage of the AJJC 1 & 2 populations live until 
approximately 100 years old.  This is based purely on UK age specific 
population mortality rates, which incorporate all causes of death, including 
cancer 
This survival analysis generated average life expectancies and average quality 
adjusted life years (QALYs) for each of the AJCC stages.  These represent the 
average life expectancy and QALYs for patients who were accurately staged.  It 
was assumed that patients who were inaccurately staged would be re-
diagnosed within one year to their accurate diagnosis; however they would 
suffer negative impacts on their mortality and quality of life where 
appropriate. Publications (112;114;126-128) indicate that in comparison to 
conventional imaging modalities PET/CT scanning has no impact on overall 
survival; however, consultation with clinical experts highlighted that patients 
with AJCC 3 stage cancer (nodal involvement but no metastases) who fail to 
receive adjuvant chemotherapy due to inaccurate staging, may suffer a 
reduction in overall survival.  This was incorporated into the model for AJCC 3 
patients who were inaccurately under-staged as AJCC1 or 2, as a 25% reduction 
in overall survival.  No other survival deductions were applied for inaccurate 
diagnoses; given the evidence form the literature and consultation with clinical 
experts.   
With regards to adverse impacts on quality of life, a deduction was applied to 
utility to account for the impact of misdiagnosis where patients failed to 
receive treatment (due to false negative diagnoses) or received unnecessary 
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treatment (due to false positive diagnoses).    With regards to the disutility 
applied, this was used to account for the negative health impacts of delayed 
(or no) treatment, where it would have been optimal if given. Utility values 
are applied to the various (true disease) states to reflect quality of life in that 
state, given optimal treatment.  A 6 month or 1 year disutility was added to 
cases that were inaccurately diagnosed, to reflect the negative impact on their 
health of failing to receive treatment.  While in the short term invasive 
treatments may reduce quality of life (and is accounted for in the model), 
ultimately these treatments are used to improve the health of the patient.  By 
failing to receive necessary treatment, it was felt that a reduction in quality of 
life was required to reflect the intermediate (up to 1 year) impact of this on 
the patients overall health state.   
Table 3-5 details the sub-optimal treatments received due to inaccurate 
staging, through false positive and false negative diagnoses, and the duration 
of negative impact this has on quality of life in the model.  
 
 
 
 
 
 
 
 
 
Chapter 3   95 
Table 3-5: Inappropriate treatments for inaccurate staging 
Inaccurate 
staging Inappropriate treatment Impact on quality of life 
AJCC 3 as 1  Fail to receive long course chemo-radiotherapy 6 months disutility 
  Fail to receive adjuvant chemotherapy 6 months disutility 
        
AJCC 3 as 2 Fail to receive adjuvant chemotherapy 6 months disutility 
  
Receive unnecessary long course chemo-
radiotherapy 
6 months alternative utility 
 
        
AJCC4 as 1 Fail to receive long course chemo-radiotherapy 6 months disutility 
  
Fail to receive metastatic surgery and/or palliative 
care 
1 year disutility 
 
        
AJCC 4 as 2 
Fail to receive metastatic surgery and/or palliative 
care 
1 year disutility 
 
        
AJCC 1 as 3 
Receive unnecessary long course chemo-
radiotherapy 
6 months alternative utility 
 
  Receive unnecessary adjuvant chemotherapy 6 months alternative utility 
        
AJCC1 as 4 
Receive unnecessary long course chemo-
radiotherapy 
6 months alternative utility 
 
  
Receive unnecessary metastatic surgery and/or 
palliative care 
1 year alternative utility 
 
        
        
AJCC 2 as 3 Fail to receive long course chemo-radiotherapy 6 months disutility 
  Receive unnecessary adjuvant chemotherapy 6 months alternative utility 
        
AJCC 2 as 4 
Receive unnecessary metastatic surgery and/or 
palliative care 1 year alternative utility 
  Fail to receive long course chemo-radiotherapy 6 months disutility 
  Fail to receive adjuvant chemotherapy 6 months disutility 
        
 
These inappropriate treatments correspond to the inaccurate diagnoses 
detailed in Figure 3-2, whereby false negative diagnoses lead to stage AJCC 3 
being identified as AJCC 1 and AJCC 2, and stage AJCC 4 being identified as 
AJCC 1 and AJCC 2; while false positive diagnoses lead to stage AJCC 1 being 
identified as AJCC 3 and AJCC 4, and stage AJC C2 being identified as AJCC 3 
and AJCC 4. The parameter values and references are detailed in section 3.4 
The utility estimates were combined in the survival analysis and discounted at 
3.5% (24) to derive discounted quality adjusted life expectancies for each AJCC 
stage. 
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3.3.3 Model 2: Recurrent colorectal cancer 
The model developed for recurrent colorectal cancer follows a similar 
structure to the primary colorectal cancer model, incorporating the short term 
diagnostic pathway for the patient, the resultant treatment options and longer 
term outcomes such as patient survival and quality of life.  Development of the 
recurrent model is now discussed. 
Diagnostic Pathway 
The recurrent model was developed to assess the cost-effectiveness of PET/CT 
as an add-on technology in detecting recurrent rectal and colon cancer.  The 
additional value of incorporating a PET/CT scan to conventional imaging in this 
disease stage is through the ability to confirm or refute local recurrence and 
potentially identify metastatic recurrence.  
Figure 3-6 depicts the decision tree structure used for the recurrent model.  
This was altered to include the disease specific criterion for rectal and colon 
cancer separately.  The model structure was informed by the available 
literature (129;130) and based on consultation with clinical experts.   
The recurrent decision tree model begins with patients who have previously 
had surgical treatment for primary rectal or colon cancer and in a routine 
follow-up assessment (involving clinical examination, routine imaging and CEA 
testing) were found to have rising CEA levels, which identified them as 
potentially having recurrent rectal or colon cancer.  The decision tree then 
outlines the choice between conventional diagnostic testing and the add-on 
PET/CT strategy.  The standard procedure for patients suspected of recurrent 
colon cancer involves a ceCT scan of the chest, abdomen and pelvis, while in 
recurrent rectal patients it involves a ceCT scans of the chest, abdomen and 
pelvis and an MRI scan of the pelvis, to confirm or refute local recurrence and 
assess whether this is an isolated recurrence or associated with distant 
metastases.  The intervention arm also involves the conventional test, followed 
by a PET/CT test regardless of the conventional test outcomes.  
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Disease Prevalence Diagnostic Test Accuracy Recurrence status identified
Curable (accurate)
Test +ive
sensitivity
Non-curable (accurate)
Recurrence (+)
prevalence
Test -ive No recurrence (inaccurate)
1-sensitivity
Conventional Strategy
Curable (inaccurate)
Test + 
1-specificity
Non-curable (inaccurate)
No recurrence (-)
1-prevalence
Test - No recurrence (accurate)
specificity
Curable (accurate)
PET/CT +ive
sensitivity 2
Clinical Assessment: suspected Non-curable (accurate)
recurrent rectal / colon cancer Test +ive
sensitivity 1 Curable (accurate)
PET/CT -ive
1-sensitivity 2
Non-curable (accurate)
Recurrence (+)
prevalence
Curable (accurate)
PET/CT +ive
sensitivity 2
Test -ive Non-curable (accurate)
1-sensitivity 1
PET/CT -ive No recurrence (accurate)
Conventional plus add-on 
PET/CT 1-sensitivity 2
Curable (inaccurate)
PET/CT +ive
1-specificity 2
Non-curable (inaccurate)
Test +ive
1-specificity 1
Curable (inaccurate)
PET/CT -ive
No recurrence (-) specificity 2
1-prevalence Non-curable (inaccurate)
Curable (inaccurate)
PET/CT +ive
1-specificity 2
Test -ive Non-curable (inaccurate)
specificity 1
PET/CT -ive No recurrence (accurate)
specificity 2
 
Figure 3-6: Decision tree for staging recurrent colorectal cancer 
 
In Figure 3-6 the conventional pathway is represented in the top half of the 
tree, while the intervention pathway is represented in the bottom half.   
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Similar to the structure used in the primary models, this decision tree model 
has been designed using actual disease status, and therefore after the decision 
node depicting the choice between the conventional and intervention 
strategies, the tree splits the patient population according to their true disease 
status, so that accurate and inaccurate diagnoses can be identified.  The 
objective of the scan in this model is to assess whether there has been any 
recurrence of disease and therefore the tree divides disease prevalence into 
recurrence (isolated local or local combined with distant metastases) and no 
recurrence populations. The standard work-up of diagnostic tests are then 
undertaken, represented by ‘Test’ in Figure 3-6, which will either identify 
recurrence (test positive), or no recurrence (test negative).  Having previously 
specified actual recurrence status, the top branch for the conventional 
strategy represents recurrent cancer, and therefore the tree branch splits 
depending on whether the test was positive (accurately identified recurrence) 
or negative (inaccurately identifying no recurrence).  Positively identified 
recurrence is then further separated into curable and non-curable recurrence 
which will involve different treatment options. In the top half of this branch, 
negative test outcomes represent false negatives, which lead to patients being 
inaccurately diagnosed as having no recurrence. The objective of the scan in 
this model is to assess whether or not there has been any recurrence of disease 
and therefore the model assumes that there is no inaccurate diagnoses 
between recurrence curable and recurrence incurable. Inaccurate diagnoses 
are dependent on the DTA for the test in identifying recurrence or nor 
recurrence.  
The bottom branch in the top half of the tree represents the disease status of 
no recurrence, so negative test outcomes accurately indicate no recurrence. 
Positive test outcomes in this branch of the tree are false positives which 
inaccurately diagnose recurrence when there is no recurrence.  This population 
is further divided into curable and non-curable recurrence in order to 
determine inaccurate treatment in the next stage of the model.  
In the intervention arm of the tree, the conventional ‘Test’ is followed by the 
‘PET/CT’ scan in Figure 3-6, and therefore the test outcomes must be 
combined, and a strategy adopted for dealing with conflicting results. As with 
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the primary model a confirmatory positive strategy was the baseline approach, 
however, if one test was found to have superior test performance 
characteristics over the other, i.e. superior in terms of both sensitivity and 
specificity, then the test with superior DTA can be used to represent the joint 
DTA.  This approach of using superior test performance to represent joint 
imaging modalities has been used previously for in add-on PET/CT screening for 
cervical cancer (108).  
The accurate and inaccurate identification of recurrence at the end of the 
decision tree branches for the conventional arm of the model can be compared 
against the intervention arm and assessed in terms of the incremental cost per 
accurate diagnosis. These interim outcomes of accurate and inaccurate 
diagnosis were then used to assess the impact on patient management in the 
model, incorporating optimal treatments for curable recurrence, non-curable 
recurrence and no recurrence, as discussed next. 
Treatment Options 
Following the diagnostic pathway for recurrent rectal and colon cancer, the 
model incorporates the treatment impacts of accurate and inaccurate 
diagnoses of recurrent colorectal cancer.  Optimal treatment combinations for 
curable and non-curable recurrence were determined through the literature 
(115-118;131) and in consultation with clinical experts.  The treatment options 
vary slightly between recurrent rectal and colon cancer and therefore 
treatment combinations for each type of cancer were ascertained. Figure 3-7 
details the optimal treatment options as decision tree branches, which were 
applied to the diagnoses from the decision tree (Figure 3-6) for both recurrent 
rectal and colon cancer.  
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Diagnosis Recurrent Rectal treatment options Diagnosis Recurrent Colon treatment options
Local surgery
Local surgery
 Local surgery followed by adjuvant chemotherapy
 Long course chemo-radiotherapy then surgery  Local surgery followed by adjuvant chemotherapy
Recurrence Curable  Local surgery followed by metastatic surgery Recurrence Curable
 Local surgery followed by metastatic surgery
 Local surgery followed by adjuvant chemotherapy then 
metastatic surgery
 Local surgery followed by adjuvant chemotherapy then 
metastatic surgery
 Long course chemo-radiotherapy followed by local 
surgery then metastatic surgery
Metastatic surgery followed by palliative care
Metastatic surgery followed by palliative care
Recurrence Incurable Recurrence Incurable
Palliative care alone Palliative care alone
No recurrence Wait and watch with an annual follow-up No recurrence Wait and watch with an annual follow-up
 
Figure 3-7: Treatment pathways for recurrent rectal & colon cancers 
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Based on clinicians advice the model assumed that 40% of recurrent rectal 
cancer patients would have received radiotherapy as part of their treatment 
for primary cancer and therefore would not receive further radiotherapy, while 
the remaining 60% of those patients who subsequently developed local 
recurrence but who did not receive radiotherapy for their primary cancer, 
would receive long course chemo-radiotherapy prior to surgery for recurrent 
disease.  Patients with curable rectal recurrence had one of six treatment 
options: local surgery alone, local surgery followed by adjuvant chemotherapy, 
long course chemo-radiotherapy prior to local surgery, local surgery followed 
by metastatic surgery, local surgery and adjuvant chemotherapy followed by 
metastatic surgery or long course chemo-radiotherapy prior to local surgery 
followed by metastatic surgery.  As with the primary colon model, radiotherapy 
is not included as a treatment option for recurrent colon cancer.  Therefore, 
patients with curable colon recurrence had one of four treatment options: 
local surgery alone, local surgery followed by adjuvant chemotherapy, local 
surgery followed by metastatic surgery or local surgery and adjuvant 
chemotherapy followed by metastatic surgery.   
Local surgery refers to a rectal excision with lymphadenectomy for recurrent 
rectal cancer patients and a colonic resection with lymphadenectomy for 
recurrent colon cancer.  Long course chemo-radiotherapy refers to 5 weeks of 
radiotherapy (45Gy in 25 fractions over 5 weeks) followed by a 12 week course 
of chemotherapy of 5 Fluorouracil (5FU) (97;119), and adjuvant chemotherapy 
involves a 6 months course post surgery of intravenous 5FU and Oxaliplatin 
(100;120).  Metastatic surgery refers to surgery at the metastatic site.   
Patients with incurable recurrence had one of two treatment options: 
metastatic surgery followed by palliative care, or palliative care alone.  This is 
the same for both rectal and colon recurrence.  Palliative care, involves 
treatments designed to relieve symptoms and improve quality of life (as 
opposed to having a curative intent), and therefore represents an array of 
palliative treatments which may include chemotherapy or chemo-radiotherapy 
for rectal cancer patients.  Patients diagnosed with no recurrence are treated 
with a wait and watch strategy in which they have an annual oncology follow-
up. 
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Assigning these optimal treatment options for each diagnoses (curable 
recurrence, incurable recurrence and no recurrence) in the model means that 
patients in the decision tree who are accurately diagnosed will receive optimal 
treatment while patients who are inaccurately staged (through false positive or 
false negative test outcomes) will receive suboptimal treatment i.e. patients 
with no recurrence who are inaccurately diagnosed as having curable 
recurrence will receive one of the curable treatment options unnecessarily.  In 
the case of inaccurate diagnosis, the model assumes patients will receive the 
treatments for their (mis)diagnosed stage, but within a year their true 
diagnosis will be correctly identified and optimal treatment will then be given. 
This assumption was made in consultation with clinical experts and was 
considered to be valid with one year as an appropriate time scale for 
encompassing most cases of misdiagnosis.  In this way the model accounts for 
the appropriate treatments and the treatments which are received 
unnecessarily or initially failed to be received, due to over or under-staging.  
The treatment profiles were assigned costs and utility weights in the model, 
and will be discussed in section 3.4.2. 
Survival 
Following treatment for diagnosis and misdiagnosis (recurrence curable, 
recurrence incurable, no recurrence), the model incorporated a lifetime 
analysis in order to capture the mortality and quality of life impacts for the 
patients in each intervention.   
The lifetime analysis was implemented using an approach similar to that used 
in the primary model.  A basic two-state Markov format was used for each of 
the three recurrence statuses, as depicted in Figure 3-8, to calculate average 
life expectancy and average quality adjusted life years in each status.   The 
first state represents the patients’ true diagnosis (no recurrence, recurrence 
curable, or recurrence incurable), and the patient can either remain in this 
state or die, moving into the death state. The model uses annual cycles and 
assumed a starting age of 50 years.   
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utility weight
mortality rate
Recurrence 
curable
Death
Recurrence 
incurable
Death
No recurrence
Death
 
Figure 3-8: Two-state survival model for each recurrence status 
 
A utility weight is applied to each of the disease states to reflect that states 
average utility for 5 years post diagnosis; each state has a different mean 
utility weight (122;132).  After five years in the disease state, it was assumed 
that patients who are still alive will have age specific population utility weights 
for the remainder of time in that state.  Five year overall survival estimates 
were determined from the literature for patients with no recurrence, 
recurrence that is curable and for non-curable recurrence (133). This 5 year 
overall survival data was used to determine an annual mortality rate under the 
assumption of an exponential survivor function, and was used to represent 
transitions from the recurrence state to death for the first 10 years of the 
model.  Beyond ten years patients were assumed to have survived their cancer 
and were assigned the age specific population level mortality rates (125). The 
disease state utility weights were applied for five years post diagnosis, based 
on available evidence (122;123), however, disease state mortality rates were 
applied for 10 years post diagnosis, adopting a conservative approach which 
incorporates evidence of disease related death beyond five years (94). The 
model did not account for transitions between the various states as this 
analysis was used to determine the average life expectancy and QALYs for each 
state.  
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Figure 3-9 demonstrates the survival curves for each of the recurrence 
categories (no recurrence, recurrence curable, recurrence incurable) in 
patients suspected of recurrent rectal cancer.  The Scottish network CRC 
dataset (121) was used to represent a cohort of AJCC1-3 patients who would be 
susceptible to colorectal recurrence (n=2409), and used disease prevalence 
estimates to determine no recurrence (n=723) and recurrence colorectal 
cancer (n=1686) samples, a subset of which was deemed to have curable 
recurrence (n=506), while the rest have incurable recurrence (n=1180). As the 
survival analysis is used to calculate average life expectancy in each group, the 
sample size at diagnosis (time zero) for each group in Figure 3-9 was assumed 
to be the same (n=1000) in order to clearly illustrate the difference in survival 
curves.   
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Figure 3-9: Overall survival for patients suspected of recurrent rectal cancer  
Note: FTT= fail to treat, Recurr= recurrence  
As would be expected the population with incurable recurrence have a drastic 
fall in their survival curve in the first few years post-diagnosis.  The recurrence 
curable population see a steep decline in survival, while the no recurrence 
population have a steady decline, which flattens out for patients surviving 
beyond ten years, who then have mortality rates on par with the age specific 
general population.   
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This survival analysis generated average life expectancies and average quality 
adjusted life years (QALYs) for the no recurrence, recurrence curable and 
recurrence incurable states.  These represent the average life expectancy and 
QALYs for patients who were accurately staged.  It was assumed that patients 
who were inaccurately staged would be re-diagnosed within one year to their 
accurate diagnosis; however they would suffer negative impacts on their 
mortality and quality of life where appropriate.  
Based on clinical advice, it was assumed that patients in the model who had 
curable recurrence but were inaccurately diagnosed as no recurrence (false 
negatives) and failed to receive treatment in the first year would have a 
negative impact on their mortality.  Therefore five year mortality rates for 
these patients were determined to be midway between curable and non-
curable mortality rates, and a fourth category was included in the survival 
analysis (and in Figure 3-9) to calculate the average life expectancy of patients 
with curable recurrences who initially fail to receive adjuvant chemotherapy 
negative diagnoses. As can be seen in Figure 3-9, using the same cohort 
population for curable recurrence, those who initially fail to receive treatment 
have a lower survival than those who are accurately staged and receive timely, 
optimal treatment. No other survival deductions were applied for inaccurate 
diagnoses; however there were implications in terms of patient quality of life.   
With regards to adverse impacts on quality of life, a deduction was applied to 
utility to account for the impact of misdiagnosis where patients failed to 
receive treatment (due to false negative diagnoses) or received unnecessary 
treatment (due to false positive diagnoses).  Table 3-6 details the sub-optimal 
treatments received due to inaccurate diagnoses, through false positive and 
false negative diagnoses, and the duration of negative impact this has on 
quality of life.  
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Table 3-6: Inappropriate treatments for inaccurate diagnosis 
 
Inaccurate diagnosis Inappropriate treatment 
Impact on  
quality of life 
Recurrence curable Fail to receive local surgery 1 year disutility 
as No recurrence Fail to receive adjuvant chemotherapy   
  
Fail to receive long course chemo-
radiotherapy   
  Fail to receive metastatic surgery   
  Fail to receive palliative care   
      
Recurrence incurable Fail to receive metastatic surgery 1 year disutility 
as No recurrence Fail to receive palliative care   
      
No recurrence as Receive unnecessary local surgery 1 year alternative utility  
Recurrence curable 
Receive unnecessary adjuvant 
chemotherapy   
  Receive unnecessary long course chemo-radiotherapy 
  Receive unnecessary metastatic surgery    
  Receive unnecessary palliative care   
      
No recurrence as Receive unnecessary metastatic surgery 1 year alternative utility 
Recurrence incurable Receive unnecessary palliative care   
      
 
These inappropriate treatments correspond to the inaccurate diagnoses 
detailed in Figure 3-6, whereby false negative diagnoses lead to Recurrence 
(curable and incurable) being misdiagnosed as No recurrence, and false 
positive diagnoses lead to No recurrence being misdiagnosed as Recurrence 
curable and incurable. The parameter values and references for this model are 
detailed in section 3.4.2. 
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3.3.4 Model 3: Metastatic cancer 
The model developed for metastatic colorectal cancer follows the same 
structure as the first two models, incorporating the short term diagnostic 
pathway, the resultant treatment options and longer term outcomes such as 
patient survival and quality of life.  The structure of the metastatic model is 
now discussed. 
Diagnostic pathway 
The metastatic model was undertaken to assess the cost-effectiveness of 
PET/CT as an add-on device in detecting metastatic cancer.  The additional 
value of incorporating a PET/CT scan to conventional imaging in this disease 
stage is through its ability to detect unsuspected, metastatic disease and 
potentially identify unsalvageable extra metastases not detected by 
conventional imaging devices.  
Figure 3-10 depicts the decision tree structure used for the metastatic model, 
informed by the literature (134-136) and based on consultation with clinical 
experts.  
 
Chapter 3   108 
Disease Prevalence Diagnostic Test Accuracy Metastases identified
Metastases at one site (accurate)
Test +ive
sensitivity
Extra metastases (accurate)
Metastases (+)
prevalence
Test -ive No metastases (inaccurate)
Conventional Strategy 1-sensitivity
Metastases at one site (inaccurate)
Test +ive
1-specificity
No metastases (-) Extra metastases (inaccurate)
1-prevalence
Test -ive No Metastases (accurate)
Clinical Assessment: suspected specificity
metastatic recurrence
Metastases at one site (accurate)
PET/CT +ive
sensitivity 2 Extra metastases (accurate)
Test +ive
sensitivity 1 Metastases at one site (accurate)
Metastases (+) PET/CT -ive
prevalence 1-sensitivity 2
Extra metastases (accurate)
Metastases at one site (accurate)
PET/CT +ive
sensitivity 2 Extra metastases (accurate)
Test -ive
1-sensitivity 1
PET/CT -ive No metastases (inaccurate)
Conventional plus      1-sensitivity 2
 add-on PET/CT Strategy
Metastases at one site (inaccurate)
PET/CT +ive
1-specificity 2 Extra metastases (inaccurate)
Test +ive
1-specificity 1 Metastases at one site (inaccurate)
PET/CT -ive
specificity 2
Extra metastases (inaccurate)
No metastases (-)
1-prevalence
Metastases at one site (inaccurate)
PET/CT +ive
1-specificity 2 Extra metastases (inaccurate)
Test -ive
specificity 1
PET/CT -ive No metastases (accurate)
specificity 2
 
Figure 3-10: Decision tree for staging metastatic colorectal cancer 
 
The metastatic decision tree begins with patients who have previously had 
surgical treatment for primary CRC and in a routine follow-up assessment 
(involving a clinical examination and CEA testing) were found to have rising 
CEA levels, and were identified as potentially having a metastatic recurrence.  
The decision node depicts the choice between the conventional or add-on 
PET/CT strategies.  Similar to the structure used in the previous models, this 
decision tree has been designed using actual disease status, and therefore the 
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decision tree has split the patient population according to their true disease 
status (metastatic recurrence or no metastatic recurrence) prior to applying 
the DTA estimates for the tests, so that accurate and inaccurate diagnosis can 
be identified. 
The conventional procedure for patients suspected of metastatic recurrence is 
to undertake a ceCT scan of the chest, abdomen and pelvis to confirm or 
refute metastatic recurrence and potentially identify additional sites of 
metastases. This is depicted as ‘Test’ in the upper branch of Figure 3-10, and 
will either identify metastases (test positive), or no metastases (test negative).  
In the conventional arm, having specified actual disease status, the top half of 
this branch represents metastatic recurrence, and therefore the tree branch 
splits depending on whether the test was positive (accurately identified 
metastatic recurrence) or negative (inaccurately identifying no metastatic 
recurrence).  Positive identification of metastatic recurrence is further 
separated in this model to distinguish between metastases at one site or extra 
metastases at numerous sites, as the extent of the metastatic recurrence will 
impact on the treatment options in the longer-term model.  The negative test 
outcomes in the top branch of the decision tree indicate a misdiagnosis of no 
metastatic recurrence (false negative).  
The bottom half of the conventional tree branch represents the status of no 
metastatic recurrence, so negative test outcomes accurately indicate no 
metastases.  Positive test outcomes in the bottom half of the tree are false 
positives which inaccurately diagnose metastatic recurrence when there is no 
recurrence.  This population is then further divided to distinguish between 
inaccurate diagnosis of metastases at one site and inaccurate diagnosis of extra 
metastases at numerous sites.  In this way the decision tree separates out 
accurate and inaccurate diagnoses of metastatic recurrence. 
Patients in the ‘conventional arm’ of the model will be staged using the 
standard diagnostic test (ceCT chest, abdomen and pelvis), represented by 
‘Test’ in the top half of Figure 3-10.  Patients in the ‘intervention arm’ of the 
model will also be given the ceCT scan, followed by the addition of a PET/CT 
scan.  This is represented in the bottom half of the tree, with the second ‘PET-
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CT’ test added-on regardless of the conventional ‘Test’ outcomes.  As this is an 
add-on strategy the test outcomes must be combined, and a strategy adopted 
for dealing with conflicting results. As with the primary and recurrent models a 
confirmatory positive strategy was the baseline approach and is depicted in the 
intervention arm in Figure 3-10.  In the add-on strategy, if one test was found 
to have superior test performance characteristics over the other, i.e. superior 
in terms of both sensitivity and specificity, then the confirmatory positive 
strategy can be dropped and the test with superior DTA can be used to 
represent the joint DTA.  This approach of using superior test performance to 
represent joint imaging modalities has been used previously in add-on PET/CT 
screening for cervical cancer (108).  
The accurate and inaccurate identification of metastases at the end of the 
decision tree branches for the conventional arm of the model are compared 
against the intervention arm and assessed in terms of the incremental cost per 
accurate diagnosis.  These interim outcomes of accurate and inaccurate 
diagnosis were then used to assess the impact on patient management in the 
model, incorporating optimal treatments for metastases at one site, extra 
metastases and no metastatic recurrence.   
Treatment Options 
Following the development of a diagnostic pathway for metastatic colorectal 
cancer, the model incorporates the treatment impacts of accurate and 
inaccurate diagnoses of metastatic recurrence.  Optimal treatment 
combinations for metastatic recurrence at one site, extra metastases (at more 
than one site) and no metastatic recurrence were determined from the 
literature and in consultation with clinical experts.  Figure 3-11 details the 
optimal treatment options as decision tree branches, which were applied to 
the diagnoses from the decision tree in Figure 3-10.  
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Diagnosis Metastatic treatment options
Metastases at one site Pre-operative chemotherapy followed by metastatic surgery
Pre-operative chemotherapy followed by metastatic surgery and palliative care
Extra metastases
Chemotherapy followed by palliative care
No metastases Wait and watch with an annual follow-up
 
Figure 3-11: Treatment pathways for metastatic colorectal cancer 
 
The model assumes that all patients with metastases at a single site will 
receive pre-operative chemotherapy and metastatic surgery.  Pre-operative 
chemotherapy involves a 6 months course of intravenous 5FU and Oxaliplatin 
(100;120), and metastatic surgery refers to surgery at the metastatic site.   
Patients with extra metastases are assumed to be non-curable and will receive 
one of two treatment options: pre-operative chemotherapy followed by 
metastatic surgery and palliative care, or chemotherapy and palliative care.  
Palliative care, involves treatments designed to relieve symptoms and improve 
quality of life, and therefore represents an array of palliative treatments.   
It was assumed that all patients identified as having no metastatic recurrence 
would be treated with a wait and watch strategy in which they would be 
followed-up annually. 
Assigning these optimal treatment options for each of the diagnoses means 
that patients in the decision tree who are accurately diagnosed will receive 
optimal treatment while patients who are inaccurately staged (through false 
positive or false negative test outcomes) will receive suboptimal treatment i.e. 
patients with no metastatic recurrence who are inaccurately diagnosed as 
having metastases will receive treatment for either metastases or extra 
metastases unnecessarily.  In the case of inaccurate diagnosis, the model 
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assumes patients will receive the treatments for their (mis)diagnosed stage, 
but within a year their true diagnosis will be correctly identified and optimal 
treatment will then be given. This assumption was made in consultation with 
clinical experts and was considered to be valid with one year as an appropriate 
time scale for encompassing most cases of misdiagnosis.  In this way the model 
accounts for the appropriate treatments and the treatments which are 
received unnecessarily or initially failed to be received, false positive and false 
negative diagnoses.  The treatment profiles were assigned costs and utility 
weights in the model, which are discussed in section 3.4.3. 
Survival 
The survival analysis was implemented employing an approach similar to that 
used in the primary and recurrent models.  Following treatment for diagnosis 
and misdiagnosis (no metastases, metastases at one site, extra metastases), 
the model incorporated a lifetime analysis in order to capture the mortality 
and quality of life impacts for the patients in each intervention.  A basic two-
state Markov format was used for each of the three disease states, as depicted 
in Figure 3-12, to calculate average life expectancy and average quality 
adjusted life years in each status.   The first state represents the patients’ true 
diagnosis (no metastases, metastases at one site, or extra metastases), and the 
patient can either remain in this state or die, moving into the death state. The 
model uses annual cycles and assumed a starting age of 50 years.   
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Utility weight
mortality rate
No metastases
Death
Metastases 
at one site
Death
Extra 
Metastases 
Death
 
Figure 3-12: Two-stage survival model for metastatic disease status 
 
A utility weight is applied to each disease state to reflect that states average 
utility for five years post diagnosis (122;132;137).  After five years in each 
state it was assumed that patients who are still alive will have a quality of life 
similar to the general population and therefore age specific population utility 
weights were applied for the remainder of time in that state.  
Transition from the disease state to death is represented by mortality rates. 
Five year overall survival estimates were determined from the literature for 
the no metastases and metastases at one site states (133;138).  The extra 
metastases state was split between the two different treatment options for 
this state (surgery or palliative care alone), assigning a different five year 
overall survival estimates dependent on the treatment.  This is because 
patients with extra metastases who receive metastatic surgery with palliative 
intent will have a greater five year survival estimate than patients with extra 
metastases who receive palliative care alone (133;138).  The five year overall 
survival estimates were used to determine annual mortality rates under the 
assumption of an exponential survivor function. The disease state mortality 
rates (for no metastases, metastases at one site, extra metastases with 
surgery, and extra metastases palliative care only) were applied for the first 10 
years in each state, and following this age specific population mortality rates 
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(125) were assigned for the remained of time in that state.  The disease state 
mortality rates were applied for 10 years post diagnosis, adopting a 
conservative approach as in the primary and recurrent models.  
Figure 3-13 demonstrates the resultant survival curves for the three disease 
states in patients suspected of metastatic recurrence, including two survival 
curves for extra metastases (surgery and palliative alone), which were assumed 
to have different five year overall survival estimates.  As the survival analysis is 
used to calculate average life expectancy and QALYs in each group, the same 
sample size (n=600) was assumed for each group in order to clearly illustrate 
the difference in survival curves5. 
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Figure 3-13: Overall survival for patients suspected of metastatic recurrence 
No Mets=no metastases, Mets=metastases at one site 
                                         
5
 Alternatively the Scottish network CRC dataset (121) can be used to represent a cohort of 
AJCC1-3 patients who would be susceptible to metastatic recurrence (n=2409), and use the 
disease prevalence estimates to determine no metastases (n=1445), metastases at one site 
(n=289) and extra metastases (n=675) populations.  The same mean life expectancy would 
be derived regardless of the sample size, as it is the average.   
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As would be expected the no metastases population have a steady declining 
survival curve for the first ten years, which then levels off as the age specific 
general population mortality rates set in, and then begins to decline again 
about 25 years post diagnosis, when the cohort population age is 75. The 
population with extra metastases have the sharpest declining survival cure 
(with palliative intent alone falling sharper than those who receive surgery), 
while the sample with metastases at one site, also have a sharp drop in 
survival, but live longer, and many survive beyond ten years.   
This survival analysis generated average life expectancies and average quality 
adjusted life years (QALYs) for each of the model diagnoses.  These represent 
the average life expectancy and QALYs for patients who were accurately 
staged.  It was assumed that patients who were inaccurately staged would be 
re-diagnosed within one year to their accurate diagnosis; however they would 
suffer negative impacts on their quality of life where appropriate.  No survival 
deductions were applied for inaccurate diagnoses; given the evidence form the 
literature and consultation with clinical experts.  
With regards to adverse impacts on quality of life, a deduction was applied to 
utility to account for the impact of misdiagnosis where patients failed to 
receive treatment (due to false negative diagnoses) or received unnecessary 
treatment (due to false positive diagnoses).  Table 3-7 details the sub-optimal 
treatments received due to inaccurate diagnoses (false positives and false 
negatives) and the duration of negative impact this has on quality of life. 
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Table 3-7: Inappropriate treatments for inaccurate diagnosis 
Inaccurate diagnosis Inappropriate treatment 
Impact on  
quality of life 
Metastases 1 site Fail to receive pre-operative chemotherapy 1 year disutility 
as No metastases and metastatic surgery   
      
Extra metastases Fail to receive pre-operative chemotherapy, 1 year disutility 
as No metastases metastatic surgery and palliative care   
      
  Fail to receive chemo and palliative care 1 year disutility 
     
No metastases as  Receive unnecessary pre-operative 1 year alternative utility 
Metastases at 1 site chemotherapy and metastatic surgery  
     
No metastases as  Receive unnecessary pre-operative chemo, 1 year disutility 
Extra metastases metastatic surgery and palliative care   
      
  Receive unnecessary chemo & palliative care 1 year disutility 
      
 
These inappropriate treatments correspond to the inaccurate diagnoses 
detailed in the metastatic decision tree in Figure 3-10, whereby false negative 
diagnoses lead to Metastases (at one site and extra metastases) being 
misdiagnosed as No metastases, and false positive diagnoses lead to No 
metastases being misdiagnosed as Metastases at one site and extra metastases.  
Having outlined the design and development of the three models (for primary, 
recurrent and metastatic colorectal cancer), the following section discusses 
the parameterisation and population for each of the models.   
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3.4 Model Parameterisation and population 
3.4.1 Model 1: Primary rectal and colon 
The model for primary colorectal cancer was populated with parameters 
representing the prevalence of AJCC disease status, the diagnostic test 
accuracy of the conventional and intervention imaging devices, the various 
treatment options, survival estimates and quality of life.  Each of these is 
discussed in turn, followed by details of the associated costs. 
Disease Prevalence 
In the primary colorectal cancer model disease prevalence was defined as the 
spread of the primary cancer into the lymph nodes (nodal involvement) and 
therefore the AJCC stages were used to distinguish between nodal involvement 
(AJCC stages 3 & 4) and no nodal involvement (AJCC stages 1 & 2).   
Prevalence data for the four AJCC stages was derived from a Scottish network 
dataset (121) provided by the clinical experts in the research team.  The data 
comprises detailed clinico-pathological and imaging staging from an on-going 
study involving 2,383 Scottish CRC patients (average age 61 yrs).  The dataset 
is a prospective series which identifies all cases of CRC in Scotland by direct 
clinical and nurse contact, through pathology department returns, managed 
clinical networks, cancer registration and death registrations.  This series is 
considered to represent the generality of CRC in the UK as any differences in 
the epidemiology of CRC between Scotland and the rest of the UK will be 
marginal. The dataset provided information on CRC disease status using the 
AJCC colorectal cancer staging system along with five year overall survival data 
for each of the four AJCC stages.  This dataset is discussed in full in a recent 
publication detailing the population background characteristics and survival 
analysis outcomes (121). A previous analysis of a subset of the dataset was 
published in 2006 (139).  Table 3-8 presents the AJCC stage cancer prevalence 
point estimates, derived from this dataset.   
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Table 3-8: Primary CRC model prevalence parameter estimates 
  
Estimates for Primary colon & rectal cancer 
Parameter 
Point 
estimate 
N 
patients 
Probabilistic 
distribution Data Source 
Cancer Prevalence   
      
Clinical experts 
2010 
AJCC stage 1  
(T1,T2, no nodes, no 
metastases) 0.19 n = 541* Dirichlet (121) 
     
AJCC stage 2  
(T3,T4, no nodes, no 
metastases) 0.34 n = 977* Dirichlet (121) 
     
AJCC stage 3  
(T, nodal spread, no metastases) 0.31 n = 891* Dirichlet (121)  
     
AJCC stage 4  
(T, nodal spread, metastases) 0.15 n = 429* Dirichlet (121)  
          
* Number of patients in each AJCC stage, derived from the Scottish dataset (121) 
The AJCC stage prevalence data was incorporated into the model under the 
assumption that AJCC stages 1 and 2 represent patients with no nodal 
involvement (1518, 53%), and AJCC 3 and 4 represent patients with nodal 
involvement (n = 1320, 47%).  The prevalence and number of patients in each 
AJCC stage in the dataset is detailed in Table 3-8.  Having merged the AJCC 
data to distinguish disease in terms of nodal involvement to synchronise with 
the diagnostic test outcomes, the decision tree then separates the data back 
into the individual AJCC stages in the final branches, using the prevalence 
point estimates for each stage, in order to assign treatment strategies for each 
AJCC stage.  Therefore, patients who are inaccurately staged are done so 
according to that disease stage prevalence, i.e. patients who have nodal 
involvement (AJCC 3 and 4) but have false negative test results, are 
inaccurately staged as either AJCC1 or AJCC2 based on the prevalence of AJCC 
1 and 2.  AJCC2 is more prevalent than AJCC1, as such this assumption ensures 
that when false negatives inaccurately under-stage patients as AJCC 2 and 
AJCC1 (instead of AJCC3 and 4), a greater proportion of patients will be 
inaccurately staged as AJCC2 than inaccurately staged as AJCC1.   It is also 
more likely that an AJCC3 patient would be under-staged to AJCC2 than to 
AJCC1.  In the case of false positives which lead to over-staging, as the 
prevalence of AJCC3 is greater than that of AJCC 4, a greater proportion of 
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inaccurate over-staging will be attributed to AJCC 3 than AJCC4 due to greater 
prevalence.   
For the probabilistic analysis, Dirichlet distributions (4;75) were deemed to be 
appropriate due to the nature of the prevalence data. The point estimates 
were derived from a cohort of 2838 patients in the Scottish colorectal cancer 
dataset (121), within which the sample of patients was split into four 
categories representing the four AJCC stages.  When dealing with multinomial 
data such as this, the Dirichlet distribution which is a multinomial version of 
the Beta distribution, is recommended (4).  Applying the Dirichlet distribution 
interprets the prevalence parameters as sample sizes, allowing the sample size 
within each AJCC stage to vary, but in relation to each other so that the total 
sample size remains constant.   
Diagnostic Test Accuracy 
The systematic review undertaken by the research team was intended to yield 
data on diagnostic test accuracy (DTA) for the various imaging technologies, 
which would be pooled in a meta-analysis to inform the main parameters for 
the economic models.  However, the systematic review found limited evidence 
and inadequacies and reporting bias in published papers for all stages of CRC 
disease.   
For primary colorectal cancer, evidence was required regarding the diagnostic 
test accuracy of ceCT, MRI and PET/CT scanning for staging primary colorectal 
cancer.   Only two papers were identified which evaluated the DTA of PET/CT 
for the detection of primary colorectal cancer (109;110); however one of the 
papers (110) did not include a comparator and the other (109) compared 
PET/CT against contrast enhanced PET/CT (cePET/CT) which is not available in 
the UK.  Both studies were conducted in Japan in cancer research centres, and 
therefore neither study included ceCT or MRI which are the conventional 
imaging technologies used for staging colorectal cancer in the UK.  Neither 
study reported including a consecutive series of patients or a random sample 
and therefore the studies may be unrepresentative of the test in clinical 
practice.  In both studies the assessors were blind to the clinical information 
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and results of other studies, however there was no mention of whether the 
individuals reviewing the scans were blinded. 
Due to the lack of papers it was deemed inappropriate to undertake a meta-
analysis in primary colorectal cancer.  Therefore, the two papers were 
considered one by one, along with other literature identified through the 
economic search and considerable input from the clinical experts, in order to 
decide which data to incorporate in the economic models. One of the studies 
(110) only reported DTA data at a lesion level and was therefore not useful to 
the model; however, the other study by Tateishi et al. (109) (which compared 
PET/CT to cePET/CT) reported patient level data on the sensitivity and 
specificity of PET/CT for staging nodal involvement and provided confidence 
intervals.  No distinction was made between colon and rectal cancer in either 
paper, and due to this and the lack of alternative information, the Tateishi 
paper PET/CT estimates were used in both the colon and rectal analyses.   
Table 3-9 details the DTA parameter estimates for the ceCT, MRI and PET/CT 
imaging technologies used in the primary colon and rectal analyses. 
Table 3-9: Primary colon & rectal cancer DTA parameter estimates 
  
Primary Rectal Model  Primary Colon Model 
  
DTA Parameter 
Point 
estimate se 
Prob 
dist 
Point 
estimate se 
Prob 
dist 
Data 
Source 
 
             
ceCT sensitivity 0.55 0.06 Beta 0.55 0.06 Beta (140) 
ceCT specificity 0.74 0.04 Beta 0.74 0.04 Beta (140) 
MRI sensitivity 0.66 0.06 Beta  -   -   -  (140) 
MRI specificity 0.76 0.09 Beta  -   -   -  (140) 
PET/CT sensitivity 0.85 0.08 Beta 0.85 0.08 Beta (109) 
PET/CT specificity 0.42 0.10 Beta 0.42 0.10 Beta (109) 
                
Note: se=standard error, Prob dist = probability distribution 
The MRI scan is not used in the assessment of primary colon cancer and 
therefore the primary colon analysis incorporates only ceCT as the 
conventional imaging modality.  As previously discussed, the DTA literature 
made few distinctions between colon and rectal cancer, and therefore due to 
this and the lack of alternative information, the PET/CT and ceCT estimates 
were used to represent DTA for both colon and rectal cancer.   
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Sensitivity and specificity are probability parameters and therefore as the data 
is binomial, Beta distributions were used for the probabilistic analysis.  The 
Tateishi paper (109) reported the mean DTA value with the associated 
confidence intervals (CI) for sensitivity: 0.85 (95% CI 0.69, 0.936) and 
specificity: 0.42 (95% CI 0.23, 0.637).  Therefore the Method of Moments was 
used to fit the Beta distributions (4), utilising the mean DTA estimates and the 
corresponding standard errors, which were calculated using the lower 
confidence limit6.  An independent probability distribution was assumed for the 
sensitivity and specificity estimates.   
DTA data for ceCT and MRI was taken from a study (140) that undertook a 
meta-analysis in primary CRC and reported DTA estimates with confidence 
intervals for these imaging modalities for staging nodal involvement.  This was 
the only study which provided patient level DTA estimates for identifying 
lymph node involvement.  Beta distributions were applied in the probabilistic 
analysis, and therefore the lower confidence interval was used to calculate a 
standard error for use in the Method of Moments for fitting the Beta 
distributions.  PET/CT was not included in this meta-analysis, however, as the 
study detailed the sensitivity and specificity of ceCT and MRI specifically for 
nodal involvement, it is reasonable to enter these estimates into the primary 
models, to compare with the addition of PET/CT using the Tateishi (109) 
estimates specifically for staging nodal involvement.  
In the primary colon cancer analysis, there is only one test (ceCT) in the 
conventional arm and therefore the DTA and corresponding standard error 
reported in Table 3-9 were used to represent this.  The primary rectal analysis 
(which involves a ceCT scan and an MRI scan in the conventional arm) used the 
DTA estimates for MRI to represent the joint (ceCT + MRI) DTA, as overall it has 
superior test performance characteristics for lymph node involvement, i.e. 
both sensitivity and specificity of MRI is superior to ceCT (140).  This approach 
of using superior test performance to represent joint imaging modalities has 
been used by others (108) and is also reasonable given the evidence identified 
                                         
6
 Both the lower and upper confidence limits were used to determine the standard error, however 
the lower confidence limit generated a larger standard error than the upper limit, and therefore 
the standard error from the lower limit was used to represent the widest range of uncertainty.  
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in the systematic review which favoured MRI in the identification of nodal 
involvement (141;142).  By adopting the superior tests’ DTA to represent joint 
DTA, conflicting test outcomes are avoided and a confirmatory positive (or 
negative) strategy, as discussed in section 3.3.1, is not required in the 
conventional arm for rectal cancer. In the intervention arm, the DTA for 
PET/CT is added-on after the conventional test, and a confirmatory positive 
strategy was adopted whereby the model assumes that positive test outcomes 
override negative test outcomes.  Therefore, negative results from the 
conventional test which are refuted by the PET/CT test are treated as positive.  
Results are only treated as negative when both the conventional and PET/CT 
tests result are negative.   
Treatments 
The systematic review and the non-systematic economics search identified 
some literature on therapeutic impact and patient management in primary 
colorectal cancer.  This literature found that while PET/CT impacts in terms of 
more accurate staging of primary colorectal cancers, it had only a minor 
impact on changing patient management (112-114;143), and none of the 
studies reported the impact that a change in management had in terms of 
patient outcomes. 
Optimal treatment combinations for the four AJCC stages were determined 
through consideration of the literature (112-118) and in consultation with 
clinical experts, and are detailed earlier in section 3.3.2.  The proportions of 
patients receiving each treatment within each AJCC stage were informed by 
publications reporting treatment and therapeutic impacts for primary rectal 
and primary colon cancer (112;113;118;134;144) however the point estimates 
were assigned based on judgement from the clinical experts on the research 
team. Table 3-10 details the point estimates for the probability of receiving 
the treatment options within each AJCC stage, for rectal and colon cancer.   
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Table 3-10: Primary colon & rectal cancer Treatment parameter estimates 
  
Primary Rectal Model  Primary Colon Model 
Treatment Parameters 
Point 
estimate 
N 
patients 
Prob 
dist 
Point 
estimate 
N 
patients 
Prob 
dist 
  
            
AJCC1             
Surgery 1.00   -  1.00   -  
              
AJCC2 
            
Surgery alone 0.38 n=977 Dirichlet 0.80 n=977 Dirichlet 
LCR plus surgery 0.46   Dirichlet  -     -  
Surgery & adjuvant chemo 0.15   Dirichlet 0.20   Dirichlet 
              
AJCC 3 
            
Surgery alone 0.34 n=891 Dirichlet 0.34 n=891 Dirichlet 
LCR & surgery 0.37   Dirichlet  -   -   -  
Surgery & adjuvant chemo 0.29   Dirichlet 0.66   Dirichlet 
              
AJCC 4 
            
Surgery alone 0.08 n=429 Dirichlet 0.09 n=429 Dirichlet 
LCR & surgery 0.11   Dirichlet  -   -   -  
Surgery & metastatic surgery 0.16   Dirichlet 0.19   Dirichlet 
Surgery & palliative care 0.53   Dirichlet 0.63   Dirichlet 
Palliative care alone 0.13   Dirichlet 0.09   Dirichlet 
Data sources: Clinician advice for point estimates supported by publications (113); Dirichlet 
distributions & N patients derived from Scottish CRC dataset (121) Prob dist = probability 
distribution, LCR = long course chemo-radiotherapy, chemo = chemotherapy   
For patients diagnosed with AJCC1 colon and rectal cancer, the only treatment 
option is local surgery, with a probability of 1.  There is no uncertainty in this 
parameter, everyone diagnosed with AJCC 1 will receive this treatment, and 
therefore this was held constant in the probabilistic analysis.  With regards to 
stages AJCC 2, 3 and 4, the various treatment options were assigned as 
probabilities, summing to 1 within each stage.  These are multinomial 
parameters and therefore it is appropriate to consider the Dirichlet distribution 
to represent uncertainty in the probabilistic analysis.  The sample of patients 
from the Scottish CRC dataset (121) was utilised to represent a cohort of 
patients for each AJCC stage, so that a series of Dirichlet distributions within 
each AJCC stage could be used to incorporate uncertainty.  
Survival  
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The Scottish CRC network dataset (121) (2,328 CRC patients average age 61 
yrs) detailed the five year overall survival of patients for each AJCC stage.  
This data was used to determine annual mortality rates under the assumption 
of an exponential survivor function, for use in the survival analysis, as detailed 
in section 3.3.2. The five year survival data was derived from both rectal and 
colon patients in the colorectal cancer dataset, and therefore the same 
survival estimates were used for both the colon and rectal analyses. Table 3-11 
details the survival parameters for each of the AJCC stages. 
Table 3-11: Primary colorectal cancer Survival parameter estimates 
  
Estimates for Primary colon & rectal cancer 
Survival Parameters 
Point 
estimate 
Std 
error 
Prob 
dist Data Source   
  
  
  
      
5 year overall survival AJCC 1 0.95 0.01 Beta Data provided by 
5 year overall survival AJCC 2 0.86 0.01 Beta 
clinical experts Feb 
2010 
 
5 year overall survival AJCC 3 0.69 0.02 Beta    
 
5 year overall survival AJCC 4 0.13 0.02 Beta     
 
Reduction 5yr overall survival  0.25 0.05 Beta Author Assumption    
For fail to receive AJCC 3 chemo 
 
          
Data source: Scottish CRC overall survival data provided by clinical experts Feb 2010. 
Published reference (121) 
The data was binomial, in the form of the probability of survival 5 years post-
diagnosis, and therefore Beta distributions were deemed appropriate to 
represent uncertainty in the probabilistic analysis. The dataset provided the 
sample size for each AJCC stage and the number of events (deaths) in each, 
and therefore the Beta distribution was fitted in the standard way whereby the 
number of events represents alpha and the sample size minus the events is 
equivalent to beta.  Given the sample size and the number of events, the 
standard error was calculated using the moments of the Beta distribution (4). 
The point estimates and standard errors are presented in Table 3-11.  
Publications (126-128) indicate that in comparison to conventional imaging 
modalities PET/CT scanning has no impact on overall survival; however, 
consultation with clinical experts highlighted that patients with AJCC3 stage 
cancer (nodal involvement but no metastases) who fail to receive adjuvant 
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chemotherapy due to inaccurate staging, may suffer a reduction in overall 
survival.  This was incorporated into the model for AJCC3 patients who were 
inaccurately under-staged as AJCC1 or 2, as a 25% reduction in overall survival.  
The 25% reduction in five year overall survival was an author assumption based 
on advice from the clinical experts.  A corresponding standard error of 0.05 
was assumed, which was greater than the standard errors for the survival data, 
in order to represent the greater uncertainty in this parameter estimate.  
Quality of life / Utility 
Average utility estimates were used to represent quality of life for each of the 
four AJCC stages, while adjustments were made for inaccurate staging, which 
resulted in failing to receive treatment (disutility for 1 year), or receiving 
unnecessary treatment (alternative utility for duration of treatment). Table 3-
12 details the utility and disutility values used for the rectal and colon 
analyses.  
Ramsey et al. (122) report utility values for different stages of CRC at various 
time points’ post-diagnosis.  The mean 5 year utility values and corresponding 
standard errors were used to represent quality of life for each AJCC stage.   
Patients who were correctly diagnosed in the model received the average 
utility for their state for the first 5 years, followed by age adjusted population 
utility weights (124).  
Patients incorrectly diagnosed received their true disease stage utility, but 
with a disutility relating to the inappropriate treatment they received for a 
specified duration as detailed previously in Table 3-5.  It was assumed that 
patients who were inaccurately staged and failed to receive either long course 
chemo-radiotherapy or adjuvant chemotherapy post surgery received a 
disutility of 0.20 for a 6 month duration, while patients who were inaccurately 
diagnosed and failed to receive metastatic surgery or palliative care were 
assumed to receive a disutility of 0.3 for a year, reflecting the large impact on 
quality of life for delayed treatment.  The disutility values and standard errors 
were assigned at the authors discretion, based on advice from clinicians and 
related utility information provided in various papers (122;132;137).   
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Table 3-12: Primary colon & rectal cancer Utility parameter estimates 
  
Primary Rectal Cancer   Primary Colon Cancer 
  
Utility 
Parameters 
Point 
est 
se Prob dist Point 
est 
se Prob dist Data 
Source 
AJCC1 
              
Mean  5 year 
utility 
0.84 0.17 Gamma on 
disutility 
0.84 0.17 Gamma on 
disutility 
(122) 
AJCC2 
              
Mean  5 year 
utility 
0.86 0.14 Gamma on 
disutility 
0.86 0.14 Gamma on 
disutility 
(122) 
AJCC 3 
              
Mean  5 year 
utility 
0.85 0.14 Gamma on 
disutility 
0.85 0.14 Gamma on 
disutility 
(122) 
AJCC4 
              
Mean  5 year 
utility 
0.84 0.12 Gamma on 
disutility 
0.84 0.12 Gamma on 
disutility 
(122) 
Fail to receive 
              
LCR or adjuvant 
chemotherapy 
0.20 0.08 Gamma   0.20 0.08 Gamma   AA based 
on (132) 
        
metastatic 
surgery / 
palliative care 
0.30 0.08 Gamma 0.30 0.08 Gamma AA based 
on (132) 
                
Receive unnecessary 
            
LCR 0.74 0.14 Gamma on 
disutility 
 -   -   -  (122;132) 
adjuvant chemo 0.80 0.14 Gamma on 
disutility 
0.80 0.14 Gamma on 
disutility 
(122) 
metastatic surgery 0.74 0.21 Gamma on 
disutility 
0.74 0.21 Gamma on 
disutility 
(137) 
 
                
LCR = long course chemo-radiotherapy, chemo = chemotherapy, AA = authors assumption, 
se=standard error, est=estimate, prob=probability 
Patients who received unnecessary long course chemo-radiotherapy or 
unnecessary adjuvant chemotherapy received an alternative, lower utility 
value (122;132) for six months to reflect the impact on their quality of life 
during their unnecessary treatment.  Patients who received unnecessary 
metastatic surgery or palliative care had a lower, alternative utility value (137) 
for one year.  
For probabilistic analysis of utilities it is common to assume that zero is the 
worst possible health state (no negatives) and fit Beta distributions, however, 
due to the nature of the utility values for cancer, where quality of life can be 
very low (and even negative) during treatment or in advanced stages of cancer, 
the Gamma distribution was considered to be more appropriate.  The 
transformation method was used whereby the Gamma distribution was set on 
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disutility (Disutility= 1-Utility) (4), so that the distribution was constrained on 
the interval zero to infinity, allowing for a right skew of the data which 
represents very low and even negative utility values.  The mean utility values 
and corresponding standard errors were reported in the literature, and 
therefore the method of moments for gamma was used to calculate the shape 
(alpha) and scale (beta) parameters to fit the gamma distributions.  
Costs  
The costs for the economic model are attributed to the cost of the alternative 
imaging devices as a cost per scan and the cost of the various treatments for 
each AJCC stage.  NHS reference costs data was used (101;145) along with 
various other data sources for the AJCC stage treatment options 
(97;100;102;119).  The various cost items are detailed in Table 3-13. 
The cost of the imaging devices was incorporated as a cost per scan, 
representing staff time, and use of the imaging machinery.  Cost details 
regarding ceCT and MRI scans were available in NHS reference costs, however, 
no details were provided for the cost of PET/CT scanning in either the 
Department of Health or the Scottish ISD reference costs.  Various literature 
reports the cost of a PET/CT scan in the UK as between £750 and £1000 per 
scan (120;146-148).  It is also widely reported that PET/CT scans generally 
have a duration of 20-40 minutes on equipment costing 2-3 times that of CT 
scanners, which can perform scans on a patient every 5-10mins (99) therefore, 
assigning a cost of £800 per PET/CT scan seemed appropriate.  A standard 
error for this baseline cost was derived using the upper and lower price range 
reported for an PET/CT scan (148).    
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Table 3-13: Primary CRC model costs 
  
Primary Rectal Cancer Primary Colon Cancer   
Item 
Unit Cost 
(£) se 
Prob 
dist 
Unit cost 
(£) se 
Prob 
dist 
Data 
Source 
Imaging Devices 
              
ce CT scan  143 22 Normal 143 22 Normal (101) 
(chest abdomen & pelvis)               
MRI scan (pelvis) 179 24 Normal  -   -    (101) 
PET/CT scan 800 100 Normal 800 100 Normal (101) 
Treatments 
              
Primary surgery (rectal 
excision with 
lymphadenectomy):  5637 677 Normal - - - (51;145)   
Primary surgery (colonic 
resection with 
lymphadenectomy) 
 -   -   -  5893 746 Normal (51;145)   
LCR 13721  -   -   -   -   -  
(97;100;119
;120;145) 
Adjuvant chemotherapy 11532  -   -  11532  -   -  (100;120;145) 
Palliative Care 2468 494 Normal 2468 494 Normal (149) 
Metastatic surgery 9134 1827 Normal 9134 1827 Normal (145) 
                
Prob dist=probabilistic distribution, se=standard error, LCR=long course chemo-
radiotherapy 
The cost of primary rectal surgery (rectal excision with lymphadenectomy) 
involves the cost of a distal colon procedure (including surgical consultation, 
theatre time and staff costs), an average hospital inpatient stay of 6 days and a 
CRC surgery consultant follow-up. Primary colon surgery (colonic resection with 
lymphadenectomy) involves the cost of a proximal procedure (including 
surgical consultation, theatre time and staff costs), an average hospital 
inpatient stay of 6 days and a CRC surgery consultant follow-up.  
The cost of long course chemo-radiotherapy treatment includes the 
radiotherapy drugs (45Gy in 25 fractions given over five weeks),12 weeks of 
intravenous 5-fluorouracil (5FU) for chemotherapy and the associated 
administration and hospital stay costs (97;120).  The cost of adjuvant 
chemotherapy treatment incorporated a six month course of intravenous 5FU 
plus Oxilaplatin for 24 weeks (100;120) and the associated administration and 
hospital costs.  The cost of metastatic surgery was represented by the 
Information Services Division reference cost of surgical specialities in medical 
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oncology (145), which includes the cost of surgery including theatre time, 
surgical consultation and follow-up, and an average inpatient stay in hospital 
of 10 days.  Resource use and costs for palliative care were taken from a study 
which assessed the cost to the NHS of palliative care in colorectal cancer 
(149).  The costs of palliative care were reported at price year 2000/01, and 
therefore the HCHS pay and price index was used to adjust this to price year 
2009 (102).  
The unit costs, standard errors and distributions used in the probabilistic 
analysis are reported in Table 3-13.  In the probabilistic analysis normal 
distributions were considered to be appropriate for representing the unit cost 
parameters, as the point estimates were derived from UK and Scottish 
reference costs sources, and as these are very large data sources they can be 
considered to have sufficient sample sizes for the central limit theorem to 
apply.  The unit costs for long course chemo-radiotherapy and chemotherapy 
remained constant in the probabilistic analysis.     
The average cost per AJCC stage was calculated using the proportion of 
patients receiving each treatment option within each AJCC stage.  In the 
model, if a patient was staged accurately they would receive their optimal 
treatment option and be assigned the average cost of treatment for that stage.  
The model also incorporates the extra costs incurred through inaccurate 
staging.  If a patient is inaccurately diagnosed they incur the cost of the 
misdiagnosed treatment, followed by the discounted cost of treatment for 
their true stage the following year (i.e. it is assumed that the true disease 
stage will be identified within a year).  Costs were discounted at 3.5% (24).   
Scenario analysis: cePET/CT as a lone technology 
The systematic literature review of PET/CT found suggestions within the 
literature that as PET/CT technology improves with the development and 
introduction of contrast enhanced PET/CT (cePET/CT) scanners (109), it may 
be possible to use this higher quality technology as an alternative to CT or 
ceCT in primary CRC rather than using PET/CT as an add-on imaging device.   
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While the scope of the research undertaken was focussed on PET/CT as an add-
on device, a scenario analysis was undertaken for the primary colorectal model 
in which PET/CT was considered to be a replacement for conventional ceCT, 
rather than as an add-on device.  The Tateishi paper (109) which provided DTA 
evidence for PET/CT also provided patient level DTA estimates for cePET/CT in 
nodal staging (with equivalent sensitivity to PET/CT but improved specificity).  
These contrast enhanced DTA estimates and confidence intervals were used in 
the scenario analysis to portray the future potential of improved PET/CT 
imaging.  For the primary rectal scenario, the conventional strategy (ceCT 
followed by MRI) was compared against a cePET/CT replacement strategy 
(cePET/CT followed by MRI); and for the primary colon scenario, the 
conventional ceCT was compared with cePET/CT alone.  All model parameters 
remain as detailed in Tables 3-8 to 3-13 with the exception of the DTA 
estimates and the cost of cePET/CT.  The cePET/CT DTA estimates and 95% 
confidence intervals for sensitivity: 0.85 (0.69, 0.93) and specificity: 0.68 
(0.46, 0.85) were used (109) and a cost for the cePET/CT scan was 
incorporated, assuming an increase of 20% to the PET/CT scan cost to reflect 
the cost of this more expensive technology. 
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3.4.2 Model 2: Recurrent disease  
The model for recurrent colorectal cancer was populated with parameters 
representing the prevalence of recurrent colorectal cancer, the diagnostic test 
accuracy of the conventional and intervention imaging technologies for 
diagnosing recurrent rectal and colon cancer, and the various treatment 
options, survival estimates and quality of life.  Each of these is discussed in 
turn, followed by details of the associated costs. The parameter tables 
distinguish the estimates for rectal and colon cancer separately where the 
details are different, and jointly as colorectal cancer where the same 
estimates were used for both analyses.   
Disease Prevalence 
Some publications indicate that local recurrence in rectal cancer is more 
common than local recurrence in colon cancer, however, data for the UK 
indicate only a very small difference in local recurrence for rectal and colon 
cancers (120).  Therefore, the recurrent model assumed the same probability 
of recurrence for both the rectal and colon analyses. 
The literature identified in the economics search and the systematic review 
was used to provide disease prevalence evidence for the recurrent model. 
Disease prevalence data on recurrence in CRC (150) determined a 30% 
probability of local recurrence and a 40% probability of metastatic recurrence 
for patients previously treated for primary colorectal cancer.  These point 
estimates were used and therefore the probability of no recurrence is 30%, as 
detailed in Table 3-14.   
 
 
 
 
Chapter 3   132 
Table 3-14: Recurrent CRC model prevalence parameter estimates 
  
Recurrent Rectal and Colon Cancer 
  
Prevalence Parameters 
Point 
estimate 
Standard 
error 
Probabilistic 
distribution Data source 
   
    
  
Local recurrence 0.3 n=723  Dirichlet (150) 
Metastatic recurrence 0.4 n=964  Dirichlet (150) 
No recurrence 0.3 n=723  Dirichlet 
  
 
Recurrence curable 0.3 0.1 Beta (135) 
Recurrence non-curable 0.7   1- above 
  
          
* These are not standard errors; they are the mean number of patients in each sample for 
the Dirichlet distributions 
 
It was assumed that a cohort of patients who were diagnosed as AJCC1, AJCC2 
or AJCC3 for primary CRC would be susceptible to recurrence.  The Scottish 
network CRC dataset (121) of patients (n=2838) was used to determine a 
sample of patients diagnosed with stages AJCC 1, 2 & 3 (n=2409).  This sample 
was then used to represent a cohort susceptible to recurrence, and the point 
estimate probabilities of recurrence (150) were applied; so that 30% of the 
n=2409 patients would have local recurrence, 40% would have metastatic 
recurrence, and the remaining 30% no recurrence.  Uncertainty in these 
prevalence point estimates was incorporated by applying a Dirichlet 
distribution to the cohort, so that uncertainty between the three prevalence 
categories: no recurrence, local recurrence, or metastatic recurrence was 
accounted for.  As recurrence falls into three categories in this model, it is 
appropriate to use the Dirichlet distribution, so that the prevalence 
parameters are interpreted as sample sizes, allowing the sample size within 
each recurrence category to vary, but in relation to each other so that the 
total sample size remains constant.   
Once the prevalence of recurrence had been established, the model splits 
recurrence in to curable and non-curable recurrence in order to incorporate 
appropriate treatment options.  This model structure is similar to the structure 
used in two other economic evaluations which assessed the value of using PET 
in the identification of recurrent colorectal cancer (129;130).  These two 
models also incorporated patient management and quality of life impacts to 
their models by including a probability of curable and non-curable recurrence 
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to the recurrent population (129;130).  Table 3-14 details the point estimates 
used to identify curable and non-curable recurrence (135). The probabilistic 
analysis accounted for the uncertainty in the parameter estimate by fitting a 
Beta distribution.  As there are two categories, summing to a probability of 1, 
Beta distributions were fitted, using the method of moments to find alpha and 
beta, given the reported mean value and confidence intervals (135).   
Diagnostic Test Accuracy 
The systematic review undertaken by the research team was intended to yield 
data on diagnostic test accuracy (DTA) for the various imaging technologies, 
which would be pooled in a meta-analysis to inform the main parameters for 
the economic models.  The meta-analysis was undertaken by the systematic 
review team in order to elicit pooled diagnostic test accuracy estimates of 
PET/CT for recurrent colorectal cancer (151).  The quality of evidence from 
literature identified in the systematic review was poor and subject to reporting 
bias and only five studies were considered to be eligible for meta-analysis (152-
156).  All of the studies were retrospective, patient populations were not well 
described in terms of disease classification or primary diagnosis, and all 
included only a small number of patients.  Figure 3-14 details the forest plot 
presenting the accuracy data of PET/CT in identifying recurrent disease in 276 
patients from the five studies.   
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Figure 3-14: Accuracy data of PET/CT in the detection of recurrent CRC 
 
There was little evidence of heterogeneity in the sensitivity estimates, and 
therefore a fixed effects meta-analysis was undertaken, resulting in an overall 
estimate of sensitivity of 0.91 (95% CI 0.87 to 0.95). There was some evidence 
of heterogeneity in the specificity estimates from these papers and therefore 
the random effects Bivariate/HSROC method was intended to be used, but the 
data were not adequate to fit the Bivariate/HSROC model and therefore two 
separate univariate meta-analyses were used. The overall estimate of 
specificity is 0.91 (95% CI 0.85 to 0.95).  
These pooled estimates for PET/CT may not be an accurate reflection of 
diagnostic test accuracy due to the inadequacies and reporting bias in the 
identified papers.  The pooled estimates also give tight confidence intervals 
which do not fully represent the wide uncertainty in the mean estimates. 
Therefore, it was decided that the pooled DTA estimates were not adequate 
for use in the baseline economic model.  The papers identified by the 
systematic review were considered one by one, along with other papers 
identified through the economic search and considerable input from the 
clinical experts, in order to decide which data to incorporate in the economic 
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models and to find reasonable estimates of DTA for the economic models with 
wide uncertainty intervals. 
Three papers provided DTA evidence of PET/CT as an add-on device for 
diagnosis of recurrent colorectal cancer.  One paper (156) compared PET/CT 
with whole body MRI, but reporting bias was evident in this study.  In addition, 
the DTA for whole body MRI was inappropriate for the model which 
incorporates pelvic MRI rather than whole body MRI.  A second paper (157) 
provided evidence for ceCT in comparison to PET/CT, but the point estimates 
assigned appeared to be biased in favour of PET/CT (reporting a sensitivity of 
zero for ceCT, but with a confidence interval range up to 0.65).  The final 
paper (158) provided DTA evidence for ceCT in comparison to PET/CT; however 
they did not report any confidence intervals or other measures of uncertainty.  
The point estimates from this paper (158) were deemed to be the best 
reflection of mean DTA and were therefore used in the model along with the 
wide confidence intervals from Ramos et al. (157) to ensure a suitably wide 
range to reflect the considerable uncertainty surrounding the mean DTA 
estimates. The pooled meta-analysis DTA estimates had more restrictive 
confidence limits, and were therefore deemed inappropriate to accurately 
reflect uncertainty in the economic models.  There were no reliable estimates 
of pelvic MRI diagnostic test accuracy for recurrent rectal cancer reported, as 
such an estimate was taken from the DTA of MRI used in another (134) 
economic evaluation.  DTA estimates, their standard errors and the 
distributions used in the probabilistic model are detailed in Table 3-15. 
Table 3-15: Recurrent CRC model Diagnostic Test Accuracy estimates 
  
Recurrent Rectal Cancer Recurrent Colon Cancer 
  
DTA Parameters 
Point 
estimate se 
Prob 
dist 
Point 
estimate se 
Prob 
dist Data source 
  
              
ceCT sensitivity 0.53 0.06 Beta  0.53 0.06 Beta  (157;158) 
ceCT specificity 0.98 0.015 Beta  0.98 0.015 Beta  (157;158) 
                
MRI sensitivity 0.85 0.03 Beta   -   -   -  (134) 
MRI specificity 0.95 0.08 Beta   -   -   -  (134) 
                
PET/CT sensitivity 0.93 0.069 Beta  0.93 0.069 Beta  (157;158) 
PET/CT specificity 0.98 0.025 Beta  0.98 0.025 Beta  (157;158) 
    
  
    
  
  
  
Prob dist=probability distribution, se=standard error  
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As the diagnostic test accuracy parameters are binomial in nature, Beta 
distributions were fit using the Method of Moments (4) with the mean 
estimates and standard errors derived from the reported confidence intervals.   
With regards to dealing with joint test outcomes (for the intervention arm of 
the model and in the conventional arm for the rectal cancer analysis), where 
there was superiority in one test, this was taken to represent combined DTA 
(108), and where there was no test superiority, a confirmatory positive 
approach was adopted.  
Treatments 
The optimal treatment combinations for patients with curable and incurable 
recurrent colorectal cancer were determined through consideration of the 
literature, and in consultation with clinical experts and are reported earlier in 
Figure 3.7.   
The proportions of patients receiving each treatment for curable recurrence 
were assigned based on consultations with clinical experts and the publications 
reporting treatment and therapeutic impacts for recurrent colorectal cancer 
(117;118;131). As patients with recurrent colon cancer do not receive long 
course chemo-radiotherapy, the treatments and probabilities of receiving the 
treatments vary from the rectal analysis.  The proportions of patients receiving 
each treatment for incurable recurrence were informed by literature and 
previous economic models for recurrent colorectal cancer (129;159).  No 
recurrence had only one treatment option and was therefore assigned a 
probability of 1. Table 3-16 details the parameter estimates for the recurrent 
colon and rectal cancer treatment options. 
 
 
 
Chapter 3   137 
Table 3-16: Recurrent CRC model Optimal Treatment estimates 
  
Recurrent Rectal Cancer Recurrent Colon Cancer 
Treatment Parameters 
Point 
estimate se 
Prob 
dist 
Point 
estimate se 
Prob 
dist 
  
        
  
  
Recurrence Curable  
            
Surgery alone  0.05   Dirichlet 0.05   Dirichlet 
Surgery & adjuvant chemo 0.1   Dirichlet 0.35   Dirichlet 
LCR then surgery 0.25   Dirichlet  -     -  
Surgery (local) & metastatic 
surgery 0.1   Dirichlet 0.1   Dirichlet 
Surgery (local), adjuvant chemo 
& metastatic surgery 0.15   Dirichlet 0.50   Dirichlet 
LCR, surgery & metastatic 
surgery 0.35   Dirichlet  -   -   -  
              
Recurrence Incurable  
            
Metastatic surgery & palliative 
care 0.2 0.04 Beta 0.2 0.04 Beta 
Palliative care alone 0.8   1- above 0.8   1- above 
              
No recurrence 
            
Wait & watch 1 - - 1 - - 
              
Data Sources: Recurrence Curable clinician advice & various refs (112;113;118), 
Recurrence Incurable (129), No recurrence: author assumption.  Chemo=chemotherapy, 
LCR=long course chemo-radiotherapy, se=standard error, Prob dist=probability distribution 
With regards to uncertainty in the treatment options for curable recurrence, 
Dirichlet distributions were considered to be appropriate given the categorical 
nature of the parameters.  Therefore, the Scottish network CRC dataset (121) 
was used to derive a cohort of patients with AJCC stages 1-3 (n=2409) who 
would be susceptible to colorectal recurrence.  The recurrent colorectal 
cancer sample was then derived using the probabilities of local and metastatic 
recurrence from Table 3.14 (n=1686), and a subset of this population was 
deemed to have curable recurrence (n=505), again using the prevalence 
probabilities assigned in the model (detailed in Table 3-14). A Dirichlet 
distribution was applied to this subset, in order to capture the uncertainty 
surrounding the treatment allocations.  
With regards to incurable recurrence, there were only two treatment options, 
making this a binomial parameter and therefore a Beta distribution was fitted 
using the mean and standard error reported in the literature (129).  
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Survival 
Five year survival estimates for recurrent and non recurrent colorectal cancer 
patients are reported by the American Cancer Society (133).  This data was 
used to determine annual mortality rates under the assumption of an 
exponential survivor function, for use in the survival analysis, as detailed in 
section 3.3.3.  As the survival data represents colorectal cancer, not 
distinguishing between colon and rectal patients, the same survival estimates 
were used for both the colon and rectal analyses. Table 3-17 details the 
survival parameters for the recurrent colorectal cancer model.  
Table 3-17: Recurrent CRC model Survival estimates 
  
Recurrent Rectal and Colon   
Survival Parameters 
Point 
estimate Std error 
Probability 
distribution Data source 
          
5 year overall Survival 
        
No recurrence 0.85 0.01 Beta (133) 
Recurrence curable 0.3 0.02 Beta (133) 
Recurrence non-curable 0.1 0.01 Beta (133) 
 
Recurrence curable (fail to treat) 0.2    Author Assumption 
    
  
   
Std = standard 
 
The data was binomial, in the form of the probability of survival 5 years post-
diagnosis, and therefore Beta distributions were deemed appropriate to 
represent uncertainty in the probabilistic analysis. The Scottish network CRC 
dataset (121) was used to represent a cohort of AJCC1-3 patients who would be 
susceptible to colorectal recurrence (n=2409). The prevalence estimates 
(detailed in Table 3-14) were then applied to derive a population for no 
recurrence (n=723) and recurrence (n=1686), within which there would be 
curable patients (n=506) and incurable patients (n=1180).  These populations 
were taken to represent sample sizes for the three recurrence categories, and 
the number of events (deaths) within each sample was determined from the 5 
years survival estimates (133).  Beta distributions were then fit to this data 
employing the Method of Moments (4) and using the number of deaths within 
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each recurrence category to represent the alpha parameter, and the sample 
size minus the events to represent the Beta parameter.  
Patients who had curable recurrence but were inaccurately diagnosed as no 
recurrence (false negatives) and failed to receive treatment in the first year 
would have a negative impact on their mortality, as detailed in section 3.3.3.  
This was based on clinical advice, and as there was no survival estimates for 
such a scenario in the available literature, it was assumed that five year 
survival for these patients would be midway between the curable and non-
curable survival estimates (0.2), as detailed in Table 3-17.   
Quality of life / Utility 
Average utility estimates were used to represent quality of life in the no 
recurrence, curable recurrence and incurable recurrence groups.  Adjustments 
were made for inaccurate diagnoses, which resulted in failing to receive 
treatment (disutility for that year to account for the negative impact on the 
patients’ quality of life), or receiving unnecessary curative or non-curative 
treatments (an alternative, lower utility for 1 year). Table 3-18 details the 
utility and disutility values which were used for the rectal and colon analyses.     
Table 3-18: Recurrent CRC Utility parameter estimates 
  
Recurrent Rectal and Colon   
Utility Parameters 
Point 
estimate 
Standard 
error 
Probability 
distribution Data source 
  
        
No Recurrence 0.91 0.11 Gamma (disutility) (122) 
mean 5 year utility       
  
        
  
Curable Recurrence 0.84 0.12 Gamma (disutility) (122) 
mean 5 year utility       
  
        
  
Incurable Recurrence 0.52 0.08 Gamma (disutility) (132) 
mean 5 year utility       
  
          
Fail to receive  
        
Curable treatment 0.3 0.08 Gamma   AA based on (132) 
Incurable treatment 0.2 0.08 Gamma   AA based on (132) 
        
  
Receive unnecessary 
      
  
Curable treatment 0.74 0.14 Gamma (disutility) AA based on (132) 
Incurable treatment 0.61 0.2 Gamma (disutility) (137) 
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Utility estimates and standard errors reported in Ramsey et al. (122) were used 
to represent mean quality of life for patients with no recurrence and curable 
recurrence, for five years post-diagnosis.  A utility estimate reported in Tengs 
& Wallace (132) for colorectal patients who receive best palliative/supportive 
care was taken to represent mean quality of life for patients with incurable 
recurrence, for five years post-diagnosis.   No standard error or confidence 
intervals were given to support this point estimate, and therefore the authors 
assumed a standard error of 0.08. Following the first 5 years in the survival 
analysis, UK age adjusted population utility weights were applied (124).  
Patients incorrectly diagnosed received their true disease stage utility, but 
with a disutility relating to the inappropriate treatment they received for a 
specified duration as detailed previously in Table 3-6.  It was assumed that 
patients who were inaccurately diagnosed and failed to receive curable 
treatments (such as surgery, adjuvant chemotherapy, long course chemo-
radiotherapy, metastatic surgery and palliative care) were assumed to receive 
a disutility of 0.2 for a year, and patients who failed to receive incurable 
treatments (metastatic surgery and palliative care) received a disutility of 0.3 
for a year, reflecting the large impact on quality of life for delayed treatment.  
The disutility values and standard errors were assigned at the authors’ 
discretion, based on advice from clinicians and related utility information 
provided in various papers (132).  The authors assumed a corresponding 
standard error of 0.08. 
Patients who received unnecessary curative treatment (local surgery, adjuvant 
chemotherapy, long course chemo-radiotherapy, metastatic surgery) received 
an alternative, lower utility value of 0.74 (132) for one year to reflect the 
impact on their quality of life during their unnecessary treatment.  No standard 
error or confidence intervals were given to support this point estimate, and 
therefore the authors assumed a standard error of 0.14 to represent 
uncertainty in the point estimate.  Patients who received unnecessary 
incurable treatments were assigned an even lower alternative utility value 
(0.61 with a corresponding standard error 0.2 (137) for one year, to reflect the 
considerable impact on quality of life of receiving unnecessary treatment for 
misdiagnosed incurable disease.  
Chapter 3   141 
Similar to the approach adopted for the primary CRC model, Gamma 
distributions were considered to be appropriate for the probabilistic analysis of 
utilities. The transformation method was used whereby the Gamma distribution 
was set on disutility (Disutility= 1-Utility) (4), so that the distribution was 
constrained on the interval zero to infinity, allowing for a right skew of the 
data which represents very low and even negative utility values.  The mean 
utility values and corresponding standard errors were reported in the literature 
(or derived based on author assumption where appropriate), and therefore the 
Method of Moments for gamma was used to calculate the shape (alpha) and 
scale (beta) parameters to fit the gamma distributions.  
Costs 
The costs for the recurrent model are attributed to the alternative imaging 
devices and the treatment options for diagnoses of no recurrence, recurrence 
curable and recurrence incurable, as detailed in Table 3-19. 
Table 3-19: Recurrent CRC model costs 
  
Rectal Cancer Colon Cancer   
Item 
Unit 
cost £ se 
Prob 
dist 
Unit 
cost £ se 
Prob 
dist Data Source 
Imaging Devices 
              
ce CT scan  143 22 Normal 143 22 Normal (101) 
(chest abdomen & 
pelvis)               
MRI scan (pelvis) 179 24 Normal  -   -    (101) 
PET/CT scan 800 100 Normal 800 100 Normal (148) 
                
Treatments 
              
Local surgery (rectal 
excision with 
lymphadenectomy) 5637 677 Normal  -   -   -  (101;145)   
Local surgery (colonic 
resection with 
lymphadenectomy)  -   -   -  5893 746 Normal (101;145)   
LCR 13721  -   -   -   -   -  
(97;100;119;120;
145) 
Adjuvant chemotherapy 11532  -   -  11532  -   -  (100;120;145) 
Palliative care 2468 494 Normal 2468 494 Normal (149) 
Metastatic surgery 9134 1827 Normal 9134 1827 Normal (145) 
                
Prob dist=probabilistic distribution, se=standard error, LCR=long course chemo-
radiotherapy 
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Table 3-19 details the various cost items, unit costs and standard errors.  NHS 
reference costs data was used (101;145) along with other data sources for the 
various treatment options (97;100;102;119;120).   
The costs of imaging devices are the same as those used in the primary model.  
The treatment option combinations for the recurrent rectal model are 
different to those in the primary model; however the cost of the component 
treatments were assigned in the same way. For example, the cost of local 
recurrent surgery involves the cost of the procedure (including surgical 
consultation, theatre time and staff costs), an average hospital inpatient stay 
of 6 days and a CRC surgery consultant follow-up. The cost of long course 
chemo-radiotherapy treatment, adjuvant chemotherapy treatment, metastatic 
surgery and palliative care were also determined by the same means as in the 
primary model.  
In the probabilistic analysis normal distributions were considered to be 
appropriate for representing the unit cost parameters, as in the primary CRC 
model.  The point estimates were derived from UK and Scottish reference costs 
sources, and as these are very large data sources they can be considered to 
have sufficient sample sizes for the central limit theorem to apply.   
The expected costs in the no recurrence, recurrence curable and recurrence 
incurable groups were calculated using the proportion of patients receiving 
each treatment option within each different group.  In the model, if a patient 
was diagnosed accurately they would receive their optimal treatment option 
and the associated costs of that treatment.  If a patient is inaccurately 
diagnosed they incur the cost of the diagnosed group treatment, followed by 
the discounted cost of treatment for their true diagnosis the following year 
(i.e. it is assumed that the true diagnosis would be identified within a year). 
Costs were discounted at 3.5% (24).  
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3.4.3 Model 3: Metastatic disease 
The model for metastatic colorectal cancer was populated with parameters 
representing the prevalence of metastatic colorectal cancer, the diagnostic 
test accuracy of the conventional and intervention imaging technologies for 
diagnosing metastases, and the various treatment options, survival estimates 
and quality of life.  Each of these is discussed in turn, followed by details of 
the associated costs.  
Disease Prevalence 
The literature identified in the economics search and the systematic review 
was used to provide disease prevalence evidence for the metastatic model. 
Estimates provided by Saunders et al (150) were used for the prevalence point 
estimates of metastatic recurrence for patients previously treated for primary 
colorectal cancer.  The point estimates and probabilistic distributions are 
detailed in Table 3-20. 
Table 3-20: Metastatic CRC model Prevalence parameters 
 
 
Prevalence 
Parameters Point estimate 
Standard 
error 
Probabilistic 
distribution 
Data 
Source 
  
     
  
No metastases 0.6 n=1445* Dirichlet (150) 
Metastases 0.4 n=964* Dirichlet (150) 
         
Metastases at one site 0.3 0.1 Beta  (135) 
Extra metastases 0.7   1 - above 
 
        
  
* These are not standard errors; they are mean number of patients assumed in each sample 
for Dirichlet distributions 
 
It was assumed that a cohort of patients who were diagnosed as AJCC1, AJCC2 
or AJCC3 for primary CRC would be susceptible to metastatic recurrence.  
Using the Scottish network CRC dataset (121) to represent this cohort (n=2409) 
and assigning the probability of metastatic recurrence (150), a cohort of 
patients with no metastases (n=1445) and metastases (n=964) was generated.  
In the probabilistic analysis, uncertainty was incorporated by applying a 
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Dirichlet distribution to the cohort, to represent the uncertainty in the mean 
sample sizes for no metastases and metastases which in turn reflects 
uncertainty in the prevalence point estimates.  As there are two categories the 
point estimates are binomial in nature, and therefore a Beta distribution would 
typically be used to represent uncertainty, however, there was no standard 
error and as Dirichlet distribution had been used to represent uncertainty in 
the prevalence parameters for the primary and recurrent CRC models, a 
consistent approach was adopted. 
Once the prevalence of metastases had been established, the model splits 
metastases in to metastases at one site and extra metastases (at more than 
one site), in order to incorporate appropriate treatment options. This model 
structure is similar to that used by previous economic evaluations assessing the 
cost-effectiveness of using add-on PET/CT in the identification of metastatic 
disease (134;135).  Previous models have attempted to incorporate patient 
management and quality of life impacts by distinguishing between resectable 
and unresectable metastases (135) or by distinguishing between hepatic 
metastases and extra metastases (134).  Our evaluation distinguished between 
metastases at one site and at multiple sites (extra metastases), assigning a 
probability for each in the overall metastatic recurrence population (135).   In 
this way the model could distinguish between metastatic and extra metastatic 
disease, even though the DTA estimates referred only to identification of 
metastases.   
The probabilistic analysis accounted for uncertainty in these parameter 
estimates by fitting a Beta distribution.  As there are two categories, summing 
to a probability of 1, Beta distributions were fitted, using the method of 
moments to find alpha and beta, given the reported mean value and 
confidence intervals (135).
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Diagnostic Test Accuracy 
The systematic review undertaken by the research team was intended to yield 
data on diagnostic test accuracy (DTA) for the various imaging technologies, 
which would be pooled in a meta-analysis to inform the main parameters for 
the economic models.  The meta-analysis was undertaken by the systematic 
review team in order to elicit pooled diagnostic test accuracy estimates of 
PET/CT for metastatic colorectal cancer.  The quality of evidence from 
literature identified in the systematic review was poor and out of 16 studies 
identified only seven studies were considered to be eligible for meta-analysis 
(158;160-165).  The majority of papers did not reveal how sample patients 
were recruited, but three did report taking a consecutive approach 
(158;163;164).  Figure 3-15 details the forest plot presenting the accuracy data 
of PET/CT in identifying metastatic CRC in n=281 patients from the seven 
studies. 
 
Figure 3-15: Accuracy of PET/CT in detecting hepatic metastases 
 
The systematic review team undertook two univariate meta-analyses for 
sensitivity and specificity separately.  There was little evidence of 
heterogeneity in sensitivity estimates, and therefore a fixed effects model was 
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used, giving an overall estimate of sensitivity of 0.91 (95% CI 0.87 to 0.94).  
There was evidence of some heterogeneity in the specificity estimates, so a 
random effects model was used and the overall estimate of specificity was 
found to be 0.76 (95% CI 0.58 to 0.88).  The validity of these pooled estimated 
is compromised due to the retrospective study designs (case series, audits), the 
variation in the types of reference standard used (differential verification bias) 
which undermines the estimates and several other types of bias including 
review bias. 
Due to the inadequacies and reporting bias in the identified papers, the pooled 
estimates for PET/CT were considered unlikely to be an accurate reflection of 
the mean diagnostic test accuracy.  The confidence intervals for the pooled 
estimates were also tight around the pooled mean, restricting the level of 
uncertainty represented.  Therefore, the meta-analysis of DTA data was 
deemed to be inappropriate for use in the baseline economic model and papers 
identified by the systematic review were considered along with papers 
previously identified through the economic search, to find reasonable 
estimates of DTA for the economic models.  
Four papers provided DTA evidence of PET/CT at the patient level for 
diagnosing metastatic recurrence in comparison to ceCT (158;161-163).  These 
papers were all deemed to be of variable quality. The DTA evidence reported 
by Chau et al. (161) compared ceCT and PET/CT in identifying hepatic 
metastases and appeared to provide reasonable point estimates and confidence 
intervals for PET/CT, however, the point estimate of specificity for ceCT was 
very low (0.25) compared with that reported in other studies, and appeared to 
bias the results in favour of PET/CT. Therefore, the point estimates and 
confidence intervals for PET/CT and the sensitivity for ceCT were taken from 
Chau et al. (161), with the point estimate for ceCT specificity and 
accompanying wide confidence interval from Selzner et al. (158). The DTA 
estimates, their standard errors and the distributions used in the probabilistic 
model are detailed in Table 3-21. 
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Table 3-21: Metastatic CRC model Diagnostic Test Accuracy parameters 
  
 
Diagnostic Parameters 
Point 
estimate 
Standard 
error 
Probabilistic 
distribution Data Source 
  
      
  
ceCT sensitivity 0.91 0.05 Beta (161) 
ceCT specificity 0.7 0.15 Beta (158) 
PET/CT sensitivity 0.94 0.04 Beta (161) 
PET/CT specificity 0.75 0.17 Beta (161) 
    
  
  
  
 
As the diagnostic test accuracy parameters are binomial in nature, Beta 
distributions were fit using the Method of Moments (4) with the mean 
estimates and standard errors derived from the reported confidence intervals.   
With regards to dealing with joint test outcomes for the intervention arm of 
the model where PET/CT is an add-on after the conventional ceCT test; the 
PET/CT test characteristics were superior to the conventional test, and this 
was taken to represent combined DTA, as adopted in other studies involving 
combined tests (108).  
Treatments 
The treatment combinations for metastatic diagnosis (metastatic recurrence at 
one site, extra metastases and no metastatic recurrence) were determined 
from the literature and in consultation with clinical experts, as detailed 
previously in Figure 3-11.  For a diagnosis of metastases (at one site) there is 
only one treatment option (pre-operative chemotherapy followed by 
metastatic surgery) and therefore this treatment is assigned a probability of 1.  
Likewise, patients with no metastatic recurrence are treated as wait and 
watch with an annual follow-up, and this treatment option was also assigned a 
probability of 1. The proportion of patients receiving each of the two 
treatment options for extra metastases was determined from previous 
economic evaluations (129;130). Table 3-22 details these treatment options. 
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Table 3-22: Metastatic CRC model Treatment Parameters 
  
 
Treatment Parameters 
Point 
estimate 
Standard 
error 
Probabilistic 
distribution 
Data 
Source 
          
Metastases (1 site) 
       
Pre-op chemo & metastatic surgery 1     
Author 
assumption 
         
Extra metastases 
       
Pre-op chemo & metastatic surgery 0.2 0.04 Beta (129) 
Palliative care & chemotherapy 0.8   1 - above (129) 
         
No metastases 
       
Wait Watch; annual follow up 1     
Author 
assumption 
          
Pre-op=pre-operative, chemo=chemotherapy 
The treatment parameter estimates for metastases and no metastases were 
kept constant in the probabilistic analysis, as everyone diagnosed as such will 
receive these respective treatments. Uncertainty in the extra metastases 
parameter estimates was accounted for by fitting a Beta distribution.  As there 
are two treatment options summing to a probability of 1, Beta distributions 
were fitted, using the method of moments to find alpha and beta, given the 
reported mean value and standard error (129). 
Survival 
Five year survival estimates for CRC patients who do not experience 
metastases were reported by the American Cancer Society (133); this estimate 
is the same as that used for no recurrence in the recurrent CRC model.  
Survival estimates for metastases at one site and extra metastases (for surgery 
with palliative intent and palliative care alone) were taken from the American 
Joint Committee on Cancer staging manual (138). These estimates were used 
to determine annual mortality rates under the assumption of an exponential 
survivor function, for use in the survival analysis, as detailed in section 3.3.4.  
Table 3-23 details the survival parameters for the metastatic colorectal cancer 
model.  
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Table 3-23: Metastatic CRC model Survival Parameters 
5 year Survival Parameters 
Point 
estimate 
Standard 
error 
Probabilistic 
distribution Data Source 
        
 
Metastases 0.24 0.03 Beta (138) 
Extra metastases (surgery) 0.12 0.04 Beta (138) 
Extra metastases (palliative) 0.06 0.04 Beta (138) 
No Metastases 0.85 0.01 Beta (133) 
        
  
 
The data was binomial, in the form of the probability of survival 5 years post-
diagnosis, and therefore Beta distributions were applied for the probabilistic 
analysis. The Method of Moments was used to fit the distributions, using the 
mean survival estimate and standard errors reported for Metastases and Extra 
metastases (surgery with palliative intent).  No standard error was given for 
the Extra metastases - palliative alone estimate, so the standard error was 
assumed to be the same as that for Extra metastases - surgery. No standard 
error was provided with the 5 yr survival estimate for patients who have No 
metastases (133) and therefore, a sample size was derived from the Scottish 
network CRC dataset (121).  This data was used to represent a cohort of 
AJCC1-3 CRC patients who would be susceptible to metastases (n=2409). The 
prevalence estimates (detailed in Table 3-17) were then applied to derive a 
population for no metastases (n=1445), and the number of events (deaths) was 
determined from the 5 years survival estimate (133).  Beta distributions were 
then fit to this data employing the Method of Moments (4) using the number of 
deaths to represent the alpha parameter, and the sample size minus the events 
to represent the Beta parameter.  
Quality of life / Utility 
Utility estimates were incorporated into the model, representing the average 
quality of life for patients in the no metastatic recurrence, metastases at one 
site and extra metastases groups.  Patients who were inaccurately diagnosed as 
no metastatic recurrence (false negatives) and therefore failed to receive 
treatment for either metastases or extra metastases in the first year were 
assigned a disutility for that year to account for the negative impact on the 
patients’ quality of life.  Likewise, patients who were inaccurately diagnosed 
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as metastatic (false positives) and received unnecessary metastatic surgery or 
treatments for extra metastases were assigned a lower utility status for that 
year to account for the negative impact of unnecessary treatment on quality of 
life.   Table 3-24 details the utility parameter estimates, standard errors and 
distributions used in the probabilistic model.  
Table 3-24: Metastatic CRC model Utility Parameters 
Utility Parameters 
Point 
estimate 
Standard 
error 
Probabilistic 
distribution Data Source 
        
  
No Metastases 0.91 0.11 Gamma (disutility) (122) 
        
  
Metastases 0.84 0.12 Gamma (disutility) (122) 
        
  
Extra Metastases 
      
  
Palliative care alone 0.52 0.08 Gamma (disutility) (132) 
Metastatic surgery & palliative 0.74 0.21 Gamma (disutility) (137)  
          
Fail to receive 
        
Metastases treatment 0.3 0.08 Gamma   Assumption (132) 
Extra metastases treatment 0.2 0.08 Gamma   Assumption (132) 
        
  
Receive unnecessarily 
      
  
Metastases treatment 0.74 0.14 Gamma (disutility) (137)  
Extra metastases treatment 0.61 0.2 Gamma (disutility) (132) 
          
 
Utility estimates and standard errors reported in Ramsey et al. (122) were used 
to represent the mean quality of life for patients with no metastases and 
metastases at one site, for five years post-diagnosis.  A utility estimate 
reported in Tengs & Wallace (132) for colorectal patients who receive best 
palliative/supportive care was taken to represent mean quality of life for 
patients with extra metastases who receive palliative care alone. Patient with 
extra metastases who receive surgery with palliative intent are assigned a 
slightly higher utility value (137) to represent their slightly better scenario, as 
recommended by clinical experts.  These were applied in the model for five 
years post-diagnosis, followed by UK age adjusted population utility weights for 
the remainder of time alive in the model (124). 
Patients incorrectly diagnosed received their true disease stage utility, but 
with a disutility relating to the inappropriate treatment they received for a 
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specified duration as detailed previously in Table 3-7. Patients who were 
inaccurately diagnosed and failed to receive treatment for metastases at one 
site (pre-operative chemotherapy and metastatic surgery) were assumed to 
receive a disutility of 0.3 for a year, and patients who failed to receive 
treatment for Extra metastases received a disutility of 0.2 for a year, 
reflecting the impact on quality of life for delayed treatment.  The disutility 
values and standard errors were assigned at the authors discretion, based on 
advice from clinicians and related utility information provided in various 
papers (132).  The authors assumed a corresponding standard error of 0.08. 
Patients who received unnecessary metastatic treatment received an 
alternative, lower utility value of 0.74 (132) for one year to reflect the impact 
on their quality of life during their unnecessary treatment, a standard error of 
0.14 was assumed to represent uncertainty in the point estimate.  Patients who 
received unnecessary extra metastases treatments were assigned an even 
lower alternative utility value (0.61 with a corresponding standard error 0.2 
(137)) for one year, to reflect the considerable impact on quality of life of 
receiving unnecessary treatment for misdiagnosed extra metastases.  
Similar to the approach adopted for the primary and recurrent models, Gamma 
distributions were set on disutility (Disutility= 1-Utility) so that the distribution 
was constrained on the interval zero to infinity, allowing very low and even 
negative utility values.  The mean utility values and corresponding standard 
errors were reported in the literature (or derived based on author assumption 
where appropriate), and therefore the Method of Moments for gamma was used 
to calculate the shape (alpha) and scale (beta) parameters to fit the gamma 
distributions.  
Costs 
As in the previous models, the costs for the metastatic model are attributed to 
the alternative imaging devices (as a cost per scan) and the various treatment 
options for diagnoses of no metastases, metastases at one site, extra 
metastases. NHS reference costs data was used (101;145) along with other data 
sources for the various treatment options (100;120;149). The various unit costs 
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point estimates, standard errors and the distributions used in the probabilistic 
analysis are detailed in Table 3-25.   
Table 3-25: Metastatic CRC model costs 
Item 
Unit 
Cost (£) 
Standard 
error (£) 
Probabilistic 
distribution Data Source 
          
Imaging Devices 
       
ce CT scan  143 22 Normal (101)  
(chest, abdomen, pelvis)        
MRI scan (pelvis) 179 24 Normal (101)  
PET/CT scan 800 100 Normal (146;148) 
     
Treatments 
       
Chemotherapy 11532  -  - (100;120;145) 
Palliative Care 2468 494 Normal (149) 
Metastatic surgery 9134 1827 Normal (145)  
Wait & watch: annual follow-up 60 13 Normal (101)  
          
 
The cost of the imaging devices are the same as those used in the previous 
models.  The treatment option combinations for the metastatic model are 
different to those in the primary and recurrent models; however the cost of 
the component treatments were assigned in the same way. For example, the 
cost of metastatic surgery includes surgical consultation, theatre time, staff 
costs and an average inpatient stay of 10 days; pre-operative chemotherapy 
includes six months treatment with 5-FU and Oxilaplatin, and the wait and 
watch treatment involves an annual oncology consultation.  
For the probabilistic analysis normal distributions were considered to be 
appropriate for representing the unit cost parameters, as in the previous two 
models.  The point estimates were derived from UK and Scottish reference 
costs sources, and as these are very large data sources they can be considered 
to have sufficient sample sizes for the central limit theorem to apply.   
The expected costs of treatment for the groups were calculated using the 
proportion of patients receiving each treatment option within each different 
group.  In the model, if a patient was diagnosed accurately they would receive 
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their optimal treatment option and the associated costs of that treatment.  If a 
patient is inaccurately diagnosed they incur the cost of the treatment for the 
(mis)diagnosed group, followed by the discounted cost of treatment for their 
true diagnosis the following year (i.e. it is assumed that the true diagnosis 
would be identified within a year if the patient were still alive).  Costs were 
discounted at 3.5% (24).    
Chapter 3   154 
3.5 Deterministic Results 
Having detailed the development of the three models and how they were 
parameterised, this section now reports the deterministic results for each 
model reporting the incremental cost per correct diagnosis and incremental 
cost per QALY.  The exploration of uncertainty through probabilistic sensitivity 
analysis and value of information analysis is reported in Chapter 4.  
The evaluations were undertaken from the perspective of the UK NHS, 
reporting short term outcomes in terms of the incremental cost per correct 
diagnosis, and longer term outcomes in terms of the incremental cost per 
quality adjusted life year (QALY) gained.  For the three models, five 
evaluations were undertaken to assess the cost-effectiveness of PET/CT as an 
add-on imaging device in pre-operative staging for (i) primary rectal cancer, 
(ii) primary colon cancer, (iii) recurrent rectal cancer, (iv) recurrent colon 
cancer and (v) metastatic disease.  In the primary colon and rectal models a 
scenario analysis was undertaken to assess the future potential (if and when 
the technology becomes readily available in the UK) for contrast enhanced 
PET/CT (cePET/CT) as a replacement for conventional ceCT, rather than as an 
add-on imaging device.  
3.5.1 Primary colorectal cancer results  
Primary Rectal Cancer  
Table 3-26 details the expected costs of the imaging involved in the 
conventional strategy and the intervention strategy, the expected probability 
of a correct diagnosis under each strategy and the probability of a true positive 
diagnosis.  Cost-effectiveness for these two alternative measures of 
effectiveness is presented as incremental cost-effectiveness ratios (ICER). 
Correct diagnosis embodies the probability of identifying both true positives 
and true negatives in the model, and on this basis, the addition of PET/CT is 
dominated by the conventional strategy.  PET/CT is both more expensive and 
less effective in terms of the probability for correct diagnosis.  
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Table 3-26: Primary rectal cancer – cost per correct diagnosis 
Diagnostic 
Tool 
Mean cost per 
scan £ 
Probability correct 
diagnosis 
Probability true 
positive 
     
CT £322 0.71 0.31 
CT + PET/CT £1,122 0.61 0.44 
     
Difference £800 -0.10 0.13 
     
ICER  CT dominates £5,931 
 
This is due to the add-on nature of the PET/CT intervention, and the 
confirmatory positive strategy adopted, which identifies lots of true positives 
(and false positives) but results in fewer true negatives being identified, and 
overall fewer correct diagnoses.  In using an add-on technology there is a 
trade-off between specificity and sensitivity, and in this case, adopting a 
confirmatory positive strategy resulted in improvements in sensitivity, at the 
expense of a reduction in specificity.   
Reporting the overall result of correct diagnoses (true positives plus true 
negatives) implicitly gives an equal weight to the incorrect diagnoses: false 
positive and false negatives, however, they are not equal.  The confirmatory 
positive strategy recommended by the clinicians confirms that in this case false 
negatives are considered to be worse than false positives; as clinicians would 
rather gain additional true positive cases and over-treat additional cases 
incorrectly (false positives) than risk some cases going undetected (false 
negatives). To understand the correct diagnoses outcome more clearly, it is 
worthwhile looking at the probabilities of each of the DTA characteristics.  
Table 3-27 illustrates the outcomes in terms of the probability of correct 
diagnoses, true positives, false negatives, false positives and true negatives, 
for the conventional, and add-on PET/CT strategy adopted in this model.  The 
table also illustrates outcomes if a confirmatory negative approach had been 
adopted, and if PET/CT had only been implemented when the conventional 
test gave a negative result.   
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Table 3-27: Primary rectal cancer – DTA outcomes under different strategies 
 
Outcomes Conventional add on PET/CT add on PET/CT PET/CT only if 
 
  confirmatory + confirmatory - conventional -ive 
Correct diagnoses 0.71 0.61 0.72 0.61 
          
True positives (TP) 0.31 0.44 0.26 0.44 
False negatives (FN) 0.16 0.02 0.20 0.02 
False positives (FP) 0.13 0.36 0.07 0.36 
True negatives (TN) 0.41 0.17 0.46 0.17 
          
Cost £322 £1,122 £1,122 £774 
          
Cost-effectiveness 
  
ICER ICER ICER 
Correct diagnoses   Dominated £89,695 Dominated 
True positives    £5,931 Dominated £3,349 
          
 
Table 3-27 shows that while the conventional strategy results in a greater 
probability of correct diagnosis than the add-on PET/CT intervention, in terms 
of true positives (TP), PET/CT has the better outcome.  The conventional 
strategy identifies more true negatives (TN) than add-on PET/CT, and once 
they are combined with TP the conventional strategy is the most effective in 
terms of correct diagnosis.  The add-on PET/CT strategy identified more true 
positives, but at the expense of false positives, which have a higher probability 
than in the conventional arm, yet in the conventional arm, many true 
negatives are identified, but at the expense of a greater proportion of false 
negatives. 
Table 3-27 also illustrates the potential outcomes if a confirmatory negative 
strategy had been adopted for add-on PET/CT.  In such a strategy (which 
favours specificity over sensitivity), even fewer true positives are identified 
(0.26) than in the confirmatory positive intervention (0.44), and the 
conventional (0.31), however, more true negatives are identified (0.46) 
resulting in an overall correct diagnosis slightly greater than the conventional 
strategy.  The alternative strategy in which add-on PET/CT is only used when 
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the conventional test is negative, results in the same DTA outcomes as the 
confirmatory positive strategy.  
Table 3-27 also details the cost of each strategy and reports the incremental 
cost-effectiveness ratios (ICER) with effectiveness measured by correct 
diagnoses and by true positives. The confirmatory negative strategy may have 
the best outcome in terms of correct diagnoses, however, it is only marginally 
so and this is reflected in a high ICER of approximately £90,000.  If true 
positives were the measure of effectiveness, then the confirmatory negative 
strategy would be dominated by both the conventional strategy and the 
confirmatory positive strategy.  When a correct diagnosis is the outcome of 
interest, add-on PET/CT with confirmatory positive is dominated by the 
conventional strategy, however under the true positives outcome, it has an 
ICER of approximately £6000. When PET/CT is used only when the conventional 
test is negative, the DTA results are the same as confirmatory positive 
strategy, however cost-effectiveness is improved with an ICER of 
approximately £3000, as the cost of PET/CT would only be incurred in some of 
the patients, those who get a negative result from the conventional test (56%).  
This is a more efficient research design and has been used by others (134) 
however, in practice this approach may be less well accepted and in the case 
of PET/CT, clinicians advised that all patients would be given a scan regardless 
of the conventional test outcomes. 
Given the add-on PET/CT intervention with a confirmatory positive strategy 
compared with the conventional strategy, the cost-effectiveness depends on 
whether the effectiveness outcome of interest is ‘probability of correct 
diagnosis’ (conventional strategy dominates) or ‘probability of true positives’ 
(PET/CT cost-effective at £5,900 per true positive identified).  These interim 
analysis outcomes detailed in Tables 3-26 appear to ignore the impact of false 
positives and false negatives (or implicitly value them as equal), which is not 
the case. They are incorporated in the longer term analysis through the 
treatment given under correct and incorrect diagnosis.  The longer term model 
also captures the resultant life expectancy and quality of life for patients, 
reporting the incremental cost per QALY gained, which incorporates the 
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diagnoses which were true positives, true negatives, false positives and false 
negatives.    
Table 3-28 details the long term cost-effectiveness outcomes.  The expected 
cost per person incorporates the imaging device and the subsequent treatment 
costs associated with the conventional and intervention strategies.  The 
outcomes are reported in terms of QALYs under each strategy and cost-
effectiveness is reported in terms of the incremental cost per QALY gain for 
primary rectal cancer. 
Table 3-28: Primary rectal cancer – cost per QALY gain 
Diagnostic Tool  Cost per person (£) QALY gain 
MRI + CT £15,151 9.42 
MRI + CT + PET/CT £17,418 9.43 
Difference £2,267 0.0053 
ICER £431,691 
 
 
These outcomes reflect the cost and quality of life implications of false 
negative and false positive diagnoses from the model. Tables 3-26 and 3-27 
showed that under an interim effectiveness outcome of correct diagnoses, the 
conventional strategy dominated the add-on PET/CT intervention.  However, 
Table 3-28 illustrates an ICER outcome, in which the intervention arm is no 
longer dominated.  This is due to the superior sensitivity from the PET/CT 
intervention which resulted in a greater probability of true positives than in 
the conventional strategy.  However, the impact of the additional false 
positives and false negative outcomes are also incorporated here. The low 
specificity of PET/CT as an add-on technology (under a confirmatory positive 
strategy) results in a greater number of false positive outcomes, in which 
patients are over-staged and incur additional costs and suffer quality of life 
impacts for unnecessary treatments.  The resultant impact in terms of QALYs is 
marginal, with the PET/CT intervention gaining only 0.005 QALYs per person.  
This is reflected in the extremely high ICER outcome from the primary rectal 
cancer analysis. 
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 The addition of PET/CT to the conventional strategy involves an additional 
cost of approximately £432,000 per QALY gained and therefore would not be 
considered cost-effective in the UK under the usual definition of between 
£20,000 and £30,000 per QALY (£20k/QALY < ICER < £30k/QALY) (24). 
Primary Colon Cancer 
The results from the primary colon cancer analysis are now presented.  Table 
3-29 details the outcomes in terms of both the incremental cost per correct 
diagnosis and the incremental cost per true positive diagnosis. The expected 
costs of the imaging devices involved in each strategy are presented along with 
the expected probability of a correct diagnosis, and probability of a true 
positives diagnosis under each strategy. 
Table 3-29: Primary colon cancer – cost per correct diagnosis 
Diagnostic 
Tool 
Mean cost per 
scan £ 
Probability correct 
diagnosis 
Probability true 
positive 
        
CT £143 0.65 0.26 
CT + PET/CT £943 0.60 0.43 
        
Difference £800 -0.05 0.18 
        
ICER   CT dominates £4,481 
 
The addition of PET/CT is dominated by the conventional strategy in terms of 
correct diagnosis, i.e. PET/CT is both more expensive and less effective than 
CT alone.  The add-on nature of the PET/CT strategy gives rise to a combined 
DTA where more cases of true positives are identified than the conventional 
strategy, but far fewer true negatives and therefore has a lower overall 
probability of correct diagnosis.  However, as with primary rectal cancer, when 
the probability of a true positive diagnosis is used as a measure of 
effectiveness the PET/CT intervention has an ICER, in this case of 
approximately £4000 per true positive diagnosis.  These interim outcomes do 
not reflect the inaccurate diagnoses (FP and FN test outcomes) under either 
strategy and therefore, it is the longer term QALY analysis that is more 
informative.  
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Table 3-30 details the cost per QALY outcomes. The expected costs incorporate 
the cost of the imaging device as well as the subsequent costs of treatment 
following the outcomes of each strategy.  The expected outcomes are reported 
in terms of QALYs under each strategy and the cost-effectiveness in terms of 
incremental cost per QALY gain for primary colon cancer. 
Table 3-30: Primary colon cancer – cost per QALY gain 
Diagnostic Tool  Cost per person (£) QALY gain 
   
CT £12,815 9.41 
CT + PET/CT £15,066 9.42 
Difference £2,253 0.013 
ICER £171,018 
 
 
The impact of the additional false positives and false negative in the model are 
incorporated in these outcomes. The low specificity of PET/CT as an add-on 
technology (under a confirmatory positive strategy) results in a greater number 
of false positive outcomes, in which patients are over-staged and incur 
additional costs and suffer quality of life impacts for unnecessary treatments.  
However, in the conventional arm there are a greater proportion of false 
negative diagnoses where patients fail to receive necessary treatment for a 
year, and incur negative impacts on their survival and quality of life impacts. 
The resultant impact in terms of QALYs is marginal, with the PET/CT 
intervention gaining only 0.01 QALYs per person.  This is reflected in a high 
ICER (£170,000), which is lower than the ICER for PET/CT in the primary rectal 
analysis (£430,000) but still far too high to be considered cost-effective. 
The addition of PET/CT to the conventional strategy involves an additional cost 
of approximately £171,000 per QALY gained and would not be considered cost-
effective under the typical UK definition of £20,000 to £30,000 per QALY (24). 
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Primary Colorectal Cancer Scenario: cePET/CT as a lone technology  
PET/CT technology is rapidly advancing (120;148) and contrast enhanced 
PET/CT (cePET/CT) is already being explored in Japan (109;110).  
Improvements in PET/CT technology may lead to improved accuracy of the CT 
component, so that if and when cePET/CT becomes readily available for use, it 
could potentially be used as a replacement for conventional ceCT, rather than 
as an add-on technology.  
Primary Rectal Cancer Scenario 
The primary rectal scenario explored the potential cost-effectiveness of such 
an advanced cePET/CT technology; replacing standard ceCT test with contrast 
enhanced PET/CT (cePET/CT) in addition to an MRI scan.  The results are 
detailed in Table 3-31, and offer an improvement in cost-effectiveness 
compared to the baseline add-on PET/CT results detailed in Table 3-28.  
Table 3-31: Primary rectal cancer scenario – cost per QALY 
Diagnostic Tool  Cost per person (£) QALY gain 
MRI+ CT £15,120 9.43 
MRI+ cePET/CT £16,095 9.44 
Difference £975 0.009 
ICER £107,652 
 
 
In primary rectal cancer, an advanced cePET/CT technology would be useful 
but would not negate the requirement for an MRI scan, and therefore, the 
additional benefit in terms of QALYs is marginal, while there would be an 
additional cost of the cePET/CT scan.  This scenario results in an ICER of 
£107,600 and therefore this potential future strategy of cePET/CT as a 
replacement for contrast enhanced CT in primary rectal cancer is not 
considered to be cost-effective under the typical willingness to pay threshold 
in the UK, i.e. £20,000 per QALY < ICER < £30,000 per QALY (24). 
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Primary Colon Cancer Scenario 
MRI scans are not used for the detection of colon cancer, and therefore 
cePET/CT could be used as a complete replacement for the conventional 
strategy (ceCT), if and when it becomes available in the UK.  With regards to 
the primary colon scenario, the results indicate that there is potential for this 
strategy to be highly cost-effective.  Table 3-32 details the cost-effectiveness 
results. 
Table 3-32: Primary colon cancer scenario – cost per QALY 
Diagnostic Tool  Cost per person (£) QALY gain 
CT £12,766 9.45 
cePET/CT £12,972 9.47 
Difference £206 0.02 
ICER £12,832 
 
 
The incremental cost of cePET/CT is £200 and the improved diagnostic test 
accuracy of cePET/CT is reflected in a QALY gain of 0.02.  This results in an 
ICER of £12,800 which is considerably below the typical UK willingness to pay 
threshold of £20,000 to £30,000 per QALY (24).  Therefore, using contrast 
enhanced PET/CT as a replacement technology for contrast enhanced CT is 
likely to be cost-effective, given current evidence.   
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3.5.2 Recurrent colorectal cancer results  
Recurrent Rectal Cancer 
The cost-effectiveness results from the recurrent rectal cancer analysis are 
detailed in Table 3-33, in terms of the incremental cost per correct diagnosis 
and the incremental cost per true positive diagnosis.  The expected costs of 
the imaging involved in both the conventional and intervention test strategies 
are detailed along with the expected probabilities. 
Table 3-33: Recurrent rectal cancer – cost per correct diagnosis 
Diagnostic Tool 
Mean cost per 
scan £ 
Probability correct 
diagnosis 
Probability true 
positive 
        
MRI + CT £322 0.88 0.60 
MRI+CT + PET/CT £1,122 0.95 0.65 
        
Difference £800 0.07 0.06 
        
ICER   £11,713 £13,769 
 
The inclusion of a PET/CT scan involves an additional cost of £800 but this also 
leads to an increased probability of correct diagnosis (true positives and true 
negatives), resulting in an ICER of approximately £12,000 per correct diagnosis.  
If the probability of a true positive diagnosis is the outcome of interest, then 
the add-on PET/CT strategy is also more effective than the conventional 
strategy, resulting in an ICER of approximately £14,000 per true diagnosis. The 
PET/CT intervention is superior to the conventional test in terms of both 
sensitivity and specificity and therefore rather than adopting a confirmatory 
positive strategy (as was done in the primary CRC model) the PET/CT 
diagnostic test accuracy was taken to represent joint DTA.  As PET/CT has 
superior DTA characteristics, the interim cost-effectiveness outcomes reflect 
this. Therefore, given current information, the MRI, CT and PET/CT scan 
strategy would be considered cost-effective compared with the conventional 
strategy under the typical UK willingness to pay threshold of £20,000 to 30,000 
per QALY gained (24).  
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These interim outcomes don’t reveal the impact of false positives and false 
negative diagnoses, and therefore the longer term outcomes reporting 
incremental cost per QALY gains are more informative. The lifetime analysis 
results are presented in Table 3-34.  The expected cost per person is presented 
which includes the cost of the imaging devices along with the subsequent costs 
of treatment associated with each of the test strategies.  The QALYs under 
each strategy are presented and cost-effectiveness is reported in terms of cost 
per QALY gain for recurrent rectal cancer.   
Table 3-34: Recurrent rectal cancer – cost per QALY gain 
Diagnostic Tool Cost per person (£) QALY gain 
MRI + CT £7,243 4.56 
MRI + CT + PET/CT £7,955 4.59 
Difference £712 0.03 
ICER £21,409 
 
 
The addition of PET/CT to the conventional strategy involves an additional cost 
of approximately £700, with an increase of 0.03 QALYs.  The ICER is 
approximately £21,500 and would therefore be considered cost-effective under 
the usual UK definition (£20k/QALY < ICER < £30k/QALY) (24). 
Recurrent Colon Cancer 
The results from the recurrent colon model are now presented. Table 3-35 
details the interim analysis outcomes for probability of correct diagnosis and 
probability of true positive diagnosis.  The expected costs of the imaging 
devices for each strategy are presented along with the expected probability of 
a correct diagnosis under each strategy and the cost-effectiveness in terms of 
incremental cost per correct diagnosis for recurrent colon cancer. 
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Table 3-35: Recurrent colon cancer – cost per correct diagnosis 
Diagnostic 
Tool 
Mean cost per 
scan £ 
Probability correct 
diagnosis 
Probability true 
positive 
        
CT £143 0.67 0.37 
CT + PET/CT £943 0.94 0.65 
        
Difference £800 0.27 0.28 
        
ICER   £2,999 £2,857 
 
The PET/CT intervention is superior to the conventional test in terms of both 
sensitivity and specificity and this is reflected in the correct diagnosis and true 
positive outcomes.  The benefit of add-on PET/CT is through improved 
sensitivity, with an increase of 0.28 in the probability of true positive diagnosis 
and resulting in fewer false negative diagnoses than in the conventional arm.  
As the DTA of PET/CT is superior to that of ceCT, PET/CT was taken to 
represent joint DTA in the intervention arm.  Including a PET/CT scan as an 
add-on technology involves an additional cost of £800, but this strategy also 
improves the probability of correct diagnosis by 28%.  The resultant 
incremental cost-effectiveness ratio is approximately £3,000 per correct 
diagnosis and per true positive diagnosis.  This ratio would be considered cost-
effective compared with the conventional strategy under the typical UK 
threshold for cost-effectiveness, i.e. £20,000 to £30,000 per QALY (24). 
The outcomes in terms of incremental cost per QALY gain are presented in 
Table 3-36.  The expected costs incorporate the cost of the imaging devices as 
well as the longer term costs associated with treatment under each strategy.  
The expected outcomes are in terms of QALYs under each strategy. 
Table 3-36: Recurrent colon cancer – cost per QALY gain 
Diagnostic Tool  Cost per person (£) QALY gain 
CT £6,677 4.44 
CT + PET/CT £7,543 4.58 
Difference £866 0.14 
ICER £6,189 
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In the longer term analysis the addition of a PET/CT scan improves QALYs by 
0.14 QALYs at an additional cost of £860. This translates to an ICER of 
approximately £6,000 per QALY gain and would be considered highly cost-
effective under the typical UK definition (£20k/QALY < ICER < £30k/QALY) (24). 
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3.5.3 Metastatic colorectal cancer results  
The deterministic results from the metastatic model are now presented. Table 
3-37 reports the incremental cost per correct diagnosis and per true positive 
diagnosis.  The expected cost represents the cost of the imaging devices 
involved in each strategy and the outcome is the expected probability of a 
correct diagnosis under each strategy. As with the recurrent colorectal cancer 
analyses, DTA for PET/CT was found to be superior to ceCT in terms of both 
sensitivity and specificity and therefore, was used to represent joint DTA in the 
intervention arm. 
Table 3-37: Metastatic cancer – cost per correct diagnosis 
Diagnostic 
Tool 
Mean cost per 
scan £ 
Probability correct 
diagnosis 
Probability true 
positive 
        
CT £143 0.78 0.36 
CT + PET/CT £943 0.83 0.38 
        
Difference £800 0.04 0.01 
        
ICER   £19,048 £66,667 
 
The intervention strategy of PET/CT in additional to contrast enhance CT 
involves an additional cost of £800 and results in an expected improvement in 
correct diagnoses of 4%. The correct diagnosis outcome incorporates both true 
positive and true negative outcomes, and as can be seen the intervention arm 
benefits from improved sensitivity and specificity over the conventional 
strategy.  In terms of true positive outcomes alone, the intervention strategy is 
only marginally more effective, with an improvement in probability of correct 
diagnosis of 0.01, leading to a higher ICER of £66,000 which would not be 
considered cost-effective in the UK.  The correct diagnosis outcome reflects 
the superiority of the PET/CT test in both the sensitivity and specificity 
characteristics, and results in an ICER of approximately £19,000 which would 
be considered cost-effective compared with the conventional strategy under 
the usual definition of cost-effectiveness in the UK (24). 
Chapter 3   168 
The longer term analysis formally incorporates the impact of false negative and 
false positive outcomes, and the results are presented in Table 3-38.  The 
expected costs incorporate the cost of the imaging devices as well as the 
subsequent treatment costs associated with each strategy, while QALYs 
incorporate the quality of life and life expectancy for patients diagnosed 
accurately and inaccurately.  
Table 3-38: Metastatic cancer – cost per QALY gain 
Diagnostic Tool  Cost per person (£) QALY gain 
CT £10,184 7.48 
CT + PET/CT £10,460 7.49 
Difference £276 0.01 
ICER £21,434 
 
 
The addition of PET/CT to the conventional strategy involves an additional cost 
of approximately £300 and results in a gain of 0.01 QALYs.  The lifetime QALY 
impact of the addition of a PET/CT scan is marginal; however impact on cost is 
also small resulting in an incremental cost-effectiveness ratio of £21,000 per 
QALY gained.  This is likely to be considered cost-effective under the usual 
definition of £20,000 to £30,000 per QALY (24). 
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3.6 Summary 
This chapter outlined the development of three economic models using existing 
evidence and clinical opinion as part of an early stage economic evaluation to 
determine the potential cost-effectiveness of PET/CT as an additional to 
routine care for staging colorectal cancer.  This case study demonstrated the 
benefit and ease of synthesising current evidence and clinical expertise to 
develop early stage models, for an explorative economic evaluation, i.e. stage 
2 of the iterative economic approach.  Systematic literature reviewing (166) is 
an efficient, structured technique which ensures all relevant literature has 
been captured, and following this with meta-analysis techniques (167) is an 
ideal means of establishing pooled estimates of key parameters which can be 
used in economic models.   However, decision analytic modelling in itself is a 
mechanism for synthesising information, and this chapter highlighted that even 
when existing evidence is of poor quality and clearly subject to various forms 
of bias (including reporting bias), clinical expertise and research group 
consensus decision making can be used to decide on appropriate mean point 
estimates and wide uncertainty intervals to capture the present uncertainty. 
This is particularly of use when meta-analysis cannot be undertaken due to lack 
of data or (in the case of recurrent and metastatic CRC) where meta-analysis 
results do not credibly represent the wide range of uncertainty.  Early decision 
analytic models may be undertaken prior to the design of large scale trials, and 
require to capture cost-effectiveness based on current (and potentially limited 
or poor quality) evidence.  Just because evidence is poor, does not mean that 
the economic evaluation will be poor quality.  
With regards to the alternative interventions and delivery strategies compared 
in the PET/CT models, it is of interest to consider the extent to which this was 
led by the current clinical context.  One of the key advantages of early DAM is 
that it enables explicit strategy identification through exploring a wide range 
of alternative interventions; however, in practice implicit judgements are 
often made concerning which strategies should be included, based on arbitrary 
judgements.  Recommended good practice for decision modelling (30;37) 
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emphasises that all relevant alternatives and strategies should be incorporated 
into a decision model.   
In the PET/CT assessment, the choice of comparators was led primarily by the 
research question set by the funders and the clinicians involved in the study.  
As such the comparators, structure and boundaries of the decision model were 
potentially constrained by the current clinical context, limiting the range of 
strategies compared in the decision model.  For example, early into the 
research project it became evident that as an add-on technology PET/CT was 
not efficient and would have limited benefit in primary CRC; while an 
advanced cePET/CT technology (which may become available in the UK in the 
near future) has potential value as a replacement technology in primary CRC. 
The original scope of the research question, defined by the funding body, was 
restrictive with regards to specifying PET-CT as an add-on device in primary 
colorectal cancer and therefore limited the baseline analysis.   To counter-act 
this limitation, a scenario analyses was incorporated in the primary CRC 
assessment, to model the potential impact of cePET-CT as a stand alone 
device.   
With regards to clinician led approaches potentially restricting the strategies 
modelled there were two examples. The confirmatory negative strategy for the 
add-on test was not incorporated as an alternative strategy in the baseline 
model as clinicians identified that this would not be considered in practice.  
Additionally, a potentially much more efficient strategy was identified as 
appropriate for the economic evaluation, in which PET-CT is used as an add-on 
test only when the conventional test is negative.  This strategy was dismissed 
by the clinicians due to their concerns over the practicalities and possibly a 
preoccupation with current practice. 
The confirmatory positive strategy recommended by the clinicians confirms 
that false negatives are considered to be worse than false positives; as 
clinicians would rather gain additional true positive cases and over-treat 
additional cases incorrectly (false positives) than risk some cases going 
undetected (false negatives).  This is also of interest when the possibility for 
litigation proceedings to the NHS is considered.  A confirmatory negative 
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approach has a much higher proportion of false negative cases (as detailed in 
Table 3-27) than the other strategies, and therefore may result in a greater 
proportion of unhappy patients attempting to sue the NHS for false negative 
results. The potential importance of litigation costs to the NHS could be 
explored in the model by incorporating an additional scenario analysis.  By 
making an assumption about the proportion of false negative cases that will 
proceed to legal/court proceedings (based on morbidity through failing to 
detect/early treatment of cancer) the potential additional litigation costs can 
be incorporated.   
While the confirmatory positive approach was not considered to be the most 
efficient from an economic standpoint (the ‘PET-CT only if conventional test is 
negative’ was the most efficient approach as demonstrated in Table 3-27), by 
insisting on a confirmatory positive approach, doctors are implicitly 
incorporating an additional source of benefit (through less false negatives, and 
less unhappy patients).  An evaluation may miss this implicit benefit in the 
confirmatory positive approach, which may only become apparent when the 
(importance of) potential costs of litigation proceedings are assessed in the 
economic model.  
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3.6.1  Primary CRC 
Few diagnostic tests have both high sensitivity and specificity and therefore 
combining two tests can help improve DTA, but creates a problem where 
results from two tests conflict with one another. Given the add-on nature of 
the PET/CT intervention, a strategy must be adopted to deal with conflicting 
test results.  A confirmatory positive strategy, also known as the ‘either 
positive’ strategy (106), accepts positive results when either of the tests give a 
positive result; while a confirmatory negative strategy favours negative results 
and therefore a positive result is only accepted when both tests report a 
positive.  Adopting one of these strategies involves a trade-off between 
sensitivity and specificity.  The confirmatory positive strategy results in an 
overall larger number of positive outcomes, both true positives and false 
positives, and a reduction in negative outcomes, while the confirmatory 
negative approach favours specificity and results in a greater proportion of 
both true and false negative outcomes (as demonstrated in Table 3-27).  In the 
PET/CT case study, a confirmatory positive approach was adopted as 
recommended by clinicians.  This implies a preference for improving true 
positive outcomes and that false negative results (in which patients with the 
disease would be undetected or under-staged) are considered to be worse than 
false positive outcomes where patients would be treated for a disease they do 
not have.   
An alternative strategy, in which add-on PET/CT is only used when the 
conventional test is negative, is likely to be a much more efficient research 
design.  As demonstrated in Table 3-27, such a strategy would give the same 
DTA outcomes as a confirmatory positive strategy, however, the cost of a 
PET/CT scan (which is approximately four times that of the conventional scans) 
and the inconvenience to the patient would only be incurred when 
conventional imaging results are negative, reducing the overall cost of the 
strategy.  Table 3-27 illustrated this for primary rectal cancer, showing that 
using PET/CT only when conventional tests gave negative results would 
improve short-term cost-effectiveness (where probability of a true positive 
diagnosis is the effectiveness endpoint of interest) with an ICER of 
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approximately £3,000 per true positive diagnosis rather than £5,900 under a 
test all approach.  This is a more efficient research design and has been used 
by others (134) however, in practice this approach may be less well accepted 
and in the case of PET/CT, clinicians advised that all patients would be given a 
scan regardless of the conventional test outcomes.  The add-on nature of the 
PET/CT technology also causes difficulty for interpreting short term cost-
effectiveness based on DTA.  The cost-effectiveness of the PET/CT intervention 
in primary CRC depends on whether the effectiveness outcome of interest is 
the probability of correct diagnosis, whereby the conventional strategy 
dominates, or probability of a true positive diagnosis, in which case the 
PET/CT intervention is cost-effective at £5,900 per true positive identified.  
The probability of correct diagnosis considers the overall advantage of the 
combined tests, in terms of both true positives and true negatives, whereas 
the probability of a true positive outcome is only interested in the sensitivity 
of the tests.  As a confirmatory positive strategy was adopted, it could be 
argued that identification of true positive cases is the outcome of interest; 
however, it is the longer term outcomes that need to be considered to give a 
more appropriate measure of cost-effectiveness.   The lifetime analysis 
formally incorporates the impact of accurate and inaccurate (false positive and 
false negative) diagnoses, in terms of the costs of the inappropriate and 
appropriate treatments and the resultant impact on quality of life.  
The cost per QALY analyses for primary rectal and colon cancer showed that 
the confirmatory positive strategy and low specificity of PET/CT in primary 
CRC results in a greater number of false positive outcomes, in which patients 
are over-staged and incur additional costs and suffer quality of life impacts for 
unnecessary treatments.  This is reflected in the extremely high incremental 
cost per QALY outcomes.  Further, the therapeutic impact literature identified 
in the systematic review (112-114;143) found that while PET/CT may 
potentially impact on accurate staging of primary colorectal cancer, it had only 
a minor impact on changing patient management.  In the decision analytic 
models developed for this analysis, both the rectal and colon primary models 
identified an incremental QALY gain of only 0.005 and 0.01 for rectal and colon 
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cancer respectively, indicating that PET/CT as an add-on imaging device in 
primary CRC does not have any overall impact on patient outcomes.  
The cost per QALY results for both the primary rectal and primary colon 
evaluations are extremely high, greater than £400,000 per QALY and greater 
than £170,000 per QALY respectively.  As such, PET/CT is not cost-effective in 
either primary rectal or primary colon cancer given the UK recommended QALY 
threshold of £20k-£30k per QALY (24).  
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3.6.2 Recurrent CRC 
The recurrent CRC model found PET/CT as an add-on imaging device to have 
an ICER of £21,409 for rectal cancer and £6,189 for colon cancer.  Considering 
the UK monetary threshold of £20-30,000 per QALY, these can be considered to 
be cost-effective. 
The ICER for the recurrent colon cancer analysis is considerably lower than 
that for recurrent rectal cancer, indicating that PET/CT is more cost-effective 
in the assessment of colon recurrence than in rectal recurrence.  This 
difference is likely to be due to the sensitivity estimate for the CT diagnostic 
test parameter, which has considerably lower sensitivity than the PET/CT 
sensitivity estimate. Uncertainty around these parameter estimates is explored 
in Chapter 4 in the probabilistic sensitivity analysis.  
Meta-analyses were undertaken using relevant papers identified from the 
systematic review to elicit pooled diagnostic test accuracy estimates of 
PET/CT for the recurrent colorectal cancer model.  Due to inadequacies and 
reporting bias in the identified papers, the pooled estimates for PET/CT were 
considered to be an inaccurate reflection of the diagnostic test accuracy and 
the confidence intervals were tight around the pooled means, which was 
considered to be restrictive in terms of capturing the wide range of 
uncertainty.  Therefore, expert judgment was used to determine point 
estimates and wide uncertainty intervals from the literature.  
Most previous economic evaluations undertaken for recurrent CRC have been 
specifically interested in hepatic metastases.  Two papers were identified 
which were interested in assessing recurrence.  A cost-effectiveness analysis 
undertaken in Canada (130)  considered PET/CT in comparison to CT for 
diagnosing colorectal recurrence, and an Australian based study (129) 
undertook a cost-consequence analysis of PET versus no PET for diagnosing 
local recurrence. The decision analytic model developed for this piece of 
research adds to this literature, providing an assessment of the cost-
effectiveness of PET/CT as an add-on imaging device for diagnosing both 
recurrent rectal and recurrent colon cancer.   
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The Canadian CEA (130) reports cost savings with the PET/CT approach through 
avoidance of unnecessary surgeries.  The paper does not report the number of 
unnecessary surgeries avoided in each strategy, just the cost savings.  After 
considering the parameter estimates used in their model, it can be seen that 
the DTA estimates assigned to PET/CT are superior to those in the CT 
comparator arm by a wide margin, so it is no surprise that the PET/CT 
intervention was found to dominate CT.  The recurrent model developed for 
the present analysis utilised DTA estimates from three trials (156-158) and 
based on this evidence adopted a more conservative approach, assigning the 
same specificity values to ceCT and PET/CT.  This resulted in no difference 
between the alternative strategies in terms of the unnecessary surgeries 
outcome in the recurrent colon model; however, the recurrent rectal model 
did indicate reductions in unnecessary surgeries with the PET/CT intervention.  
The Australian publication (129) also report cost savings through the use of PET 
in comparison to a no PET strategy, however, few details are provided as to 
what the no PET strategy entails.    
In comparison to other economic evaluations undertaken in this disease area, 
the model developed for this piece of research appears to have adopted a 
more conservative approach in assigning DTA estimates and through 
incorporating quality of life impacts and overall survival impacts in a cost per 
QALY outcome.  This conservative approach attempted to minimise bias in the 
model to avoid unfairly favouring the intervention arm (add-on PET/CT).   
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3.6.3 Metastatic CRC 
The metastatic model found PET/CT as an add-on device to have an ICER of 
£21,434 per QALY gained.  This ICER value is within the UK monetary threshold 
range of £20-30,000 per QALY for determining cost-effectiveness (24). 
Most of the existing publications which have undertaken economic evaluations 
of PET for CRC have been specifically interested in hepatic metastases.  An 
American study (134) developed a decision model to determine the cost-
effectiveness of PET and CT imaging in comparison to CT alone.  They 
evaluated outcomes in terms of life year gains and report an incremental cost 
per life year gained of $16,437.  This paper is the most similar to our model, 
but does not incorporate quality of life impacts. 
Another economic evaluation in metastatic CRC was undertaken in France from 
the national health insurance perspective (135), reporting cost savings of €2671 
($3213) with no change in life expectancy when PET/CT was compared against 
CT in staging metastatic colorectal cancer.  Another American study (136) 
assessed the cost-effectiveness of PET/CT in comparison to CT for identifying 
the presence of extra hepatic metastases.  They report a cost saving of $5,269, 
due to unnecessary surgeries avoided, however they provide few details of how 
their model was constructed.   Details were not provided of the diagnostic test 
accuracy estimates used in the model or how the impact on patient 
management was incorporated.  None of these metastatic models used 
probabilistic analysis to incorporate uncertainty to each of the model 
parameters. Uncertainty around the parameter estimates in the present 
analysis is explored in Chapter 4 in the probabilistic sensitivity analysis.  
3.6.4 Next steps in the analysis 
The economic models developed in this chapter relied heavily on clinical 
expertise, given the dearth of previous economic evaluations and poor quality, 
biased DTA evidence in this area.  Some reviewers may consider this to be a 
major drawback to this type of decision analytic modelling approach; however, 
this is precisely the point of early stage decision models: attempting to capture 
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what knowledge is available and what is not, in a systematic manner.   Just 
because the existing evidence is poor, does not necessarily mean the outcomes 
of the economic evaluation are poor.  It is entirely appropriate to utilise 
clinical expertise in such situations, however it is important to capture the 
uncertainty in these parameters, and explore what this means for uncertainty 
in terms of the model outputs.   
In the PET-CT models, the parameters for the various treatments at diagnosis, 
probability of receiving those treatments and assumptions regarding the 
negative health impacts of incorrect diagnosis, were informed directly by the 
clinical experts on the team, due to a lack of published evidence.   Ideally 
formal elicitation of clinical opinion would have been undertaken (using Delphi 
techniques); however, due to time constraints on the research project a 
slightly less formal elicitation process was used.  Tables were created for each 
of the treatment parameters and the two senior clinicians on the research 
team completed them with their estimates and surrounding uncertainty 
estimates.  Uncertainty in these model parameters was dealt with in 
probabilistic sensitivity analysis with wide uncertainty intervals.  The structural 
uncertainty regarding these could also potentially have been dealt with 
through scenario analyses.  For example, alternative scenarios for greater and 
lower disutility impacts for receiving unnecessary treatment, or failing to 
receive treatment could have been modelled to explore the impact of this 
structural uncertainty on the model outcomes.  Due to time constraints this 
was not included in the scenario analyses undertaken, however, given the wide 
uncertainty around the mean estimates used in the PSA, it is unlikely that such 
scenario analyses would have changed the conclusions around decision 
uncertainty.   
Chapter 4 reports the outcomes of the probabilistic analyses, explores 
uncertainty in the cost-effectiveness outcomes and undertakes value of 
information analyses to demonstrate the advantage of early stage decision 
modelling in exploring whether further research is worthwhile, and if so, what 
type of research is appropriate.   
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4 Setting research priorities 
4.1 Introduction 
Following on from the preceding chapter where three economic models were 
developed in order to explore the potential cost-effectiveness of PET/CT as an 
add-on staging technology for colorectal cancer; this chapter explores 
uncertainty in the cost-effectiveness outcomes.  Value of information analyses 
are undertaken to explore decision uncertainty further, in terms of whether 
further research is potentially worthwhile, and if so, what type of research is 
appropriate. This chapter uses the case study of PET/CT to demonstrate the 
rationale for funding evidence synthesis and early decision analytic modelling 
prior to primary research by highlighting the importance of this type of 
research in determining future research priorities. 
4.1.1 Identifying the decision problem 
The Health Technology Assessment (HTA) is a programme funded by the 
National Institute for Health Research (NIHR) (52) which produces independent 
research about the effectiveness, cost-effectiveness and broader impacts of 
health care treatments and technologies.  The research generated is intended 
for an NHS audience, particularly those who plan and provide care in the NHS.  
They commission both primary research and evidence synthesis research, and 
the topics are identified and prioritised to meet the needs of the NHS. The HTA 
identify evidence gaps or decision problems for which they commission 
research through various means, such as consultation with key NHS 
stakeholders, extracting research recommendations from various resources, 
direct recommendations and communication with researchers (52).  This 
process is akin to Stage 1 of the iterative approach to economic appraisal (1), 
but rather than the researchers exploring and forming the research question, 
the HTA programme have already defined the decision problem, specifying the 
intervention of interest and the relevant patient groups.  It is commonly the 
case that funding bodies such as the HTA define an overall research question 
and put out a call for bids to undertake the research. Research bodies are, 
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arguably, well placed to do this as they are likely to have formal criteria for 
setting research priorities, as well as the ability to engage with various 
stakeholders, and also may have financing available to review current evidence 
in order to define an appropriate research question. However, a call for 
research from a funding body does not necessarily mean that an appropriate 
research question has been defined.  The call may well be too prescriptive, or 
alternatively too broad to adequately define the problem, or it may well 
require some explorative research to define the appropriate question.  In the 
context of the iterative economic framework, stage 1 in itself may involve an 
iterative process where exploration of the literature leads to updating and re-
defining of the research question for evidence synthesis and modelling in stage 
2.   
In the context of the PET/CT case study, the HTA identified a decision problem 
for PET/CT in colorectal cancer and commissioned a research brief to answer 
the question: “In which groups of patients with colorectal cancer does the 
addition of PET/CT to preoperative staging add most value?” 
In the United Kingdom colorectal cancer is the third commonest malignancy 
behind lung and breast cancer with 37,514 new cases registered in 2006 (94).  
For patients with colorectal cancer there are a wide range of clinical scenarios 
and various treatment options with different timings, dependent on the stage 
of the cancer and also the extent of the cancer growth within each stage.  
Over the past two decades, a number of diagnostic tools (such as ultrasound, 
CT, ceCT, MRI, and PET/CT) have entered clinical practice and now facilitate 
the process of pre-operative staging for CRC.  Largely due to its wider 
availability and relatively low cost, ceCT is the technique most commonly used 
for staging colorectal cancer, however, supplementary imaging is often needed 
to provide sufficient information to inform surgical decisions, such as MRI 
imaging in rectal cancer. PET/CT is recommended for use in some cancers, but 
its advantages in staging for CRC are less clear.  Several studies have shown 
PET/CT to be more accurate than diagnostic ceCT for staging colorectal cancer 
(98;99), however, PET/CT scanning is considerably more time consuming than 
either imaging device alone, and for CRC it is recommended as an addition to 
routine imaging devices (97), and therefore as an ‘add-on’ technology it carries 
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a heavy cost burden.  Additionally, the diagnostic accuracy and therapeutic 
impacts of PET/CT in colorectal cancer are varied and unclear.   
Given the unclear evidence as to the effectiveness and cost of PET/CT in 
colorectal cancer the HTA programme commissioned research to explore and 
synthesise the existing evidence.  The brief specified a systematic review with 
the requirement for an economic component which incorporated patient 
management and quality of life, to explore potential cost-effectiveness of 
PET/CT as an addition to current practice in the UK.  Clearly the HTA 
recognised the importance of exploring the current evidence (regarding 
effectiveness with an accompanying economic model to determine cost-
effectiveness given the current evidence) before commissioning primary 
research for PET/CT in colorectal cancer.   
In response to this call, a multi-disciplinary research team consisting of clinical 
experts (CRC surgeons, radiographers etc), systematic reviewers, statisticians 
and health economists was formed.  A proposal was developed to undertake a 
systematic review and meta-analysis, which would be used to inform and build 
a DAM to assess potential cost-effectiveness.  Probabilistic modelling was 
specified in the economic analysis to enable the research to explore 
uncertainty in the model parameter estimates.  The proposal also included a 
value of information analysis component for the DAM in order to adequately 
answer the research questions.  If the purpose of the research is a precursor to 
commissioning primary research, what we want to know from reviewing the 
evidence is “should more research be commissioned?”  The research brief only 
specified a requirement for a cost-effectiveness decision model, not any VOI 
analyses, however, VOI techniques are necessary to help explore whether 
research is potentially worthwhile, and if so EVPPI can be undertaken to help 
define the type of research that is required.  Rather than using lack of 
evidence as a justification for further research, VOI allows the potential value 
of further research to be formally assessed and understood through exploring 
uncertainty.  
Chapter 3 detailed the development of the economic models and reported 
deterministic outcomes.  The probabilistic outcomes are now reported, 
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exploring uncertainty in the parameter estimates through the cost-
effectiveness planes, and then uncertainty in the decision using cost-
effectiveness acceptability curves.   
 
4.2 Probabilistic results 
The three economic models (primary, recurrent and metastatic) were analysed 
probabilistically, using Monte Carlo simulation (2000 iterations) to determine 
the expected cost, expected outcomes and the expected cost-effectiveness.  
The costs represent the cost of the imaging scans in each strategy and the 
resultant (accurate and inaccurate) treatments received; while outcomes are 
represented in terms of QALYs gained.  The cost-effectiveness of PET/CT as an 
add-on imaging device in pre-operative staging was assessed for: (i) primary 
rectal cancer, (ii) primary colon cancer, (iii) recurrent rectal cancer, (iv) 
recurrent colon cancer and (v) metastatic disease. The incremental costs and 
QALYs with their 95% confidence intervals are now reported and illustrated on 
cost-effectiveness planes to demonstrate the impact of parameter uncertainty 
on the cost and QALY outcomes for each of the analyses.   
4.2.1 Primary CRC results 
Primary rectal cancer  
In primary rectal cancer the intervention strategy (ceCT, MRI and PET/CT) cost 
an additional £2,267 (95% CI £932 to £3602) per person with a QALY gain of 
0.005 (95% CI -0.02 to 0.03) in comparison to the conventional strategy. This 
represents an incremental cost-effectiveness ratio of £431,691 per QALY 
gained and would not be considered cost-effective in the UK, given the NICE 
threshold of £20,000 to £30,000 per QALY (24). The confidence intervals for 
incremental costs and QALYs were calculated using the percentile method, 
using the 2.5 and 97.5 percentiles (4).   It is important to note that the lower 
95% confidence interval for incremental QALYs is negative, while the mean 
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value and upper confidence interval are positive.  This represents uncertainty 
as to the existence of any QALY gains.  
Figure 4.1 plots the probabilistic outcomes from the Monte Carlo simulation, 
illustrating the uncertainty surrounding the expected incremental costs and 
incremental QALYs for primary rectal cancer.  
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Figure 4-1: The CE plane for PET/CT in primary rectal cancer 
 
The joint distribution of the costs and effects from the Monte Carlo simulation 
are plotted on the cost-effectiveness plane to demonstrate the impact of 
uncertainty in the model parameters on the model outcomes (expected 
incremental cost and effects).  Some guidance exists regarding appropriate 
interpretation of cost-effectiveness results on the cost-effectiveness plane, 
and on the cost-effectiveness acceptability curves (49;70;71). Uncertainty in 
incremental outcomes is demonstrated when the results spread across the y-
axis, representing both QALY gains (in the eastern quadrants) and QALY losses 
(in the western quadrants).  Likewise a spread through the origin passing 
through the horizontal axis represents uncertainty in the incremental cost of 
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the intervention.  The extent of the spread also indicates the extent of 
uncertainty. 
In Figure 4-1 the horizontal plane illustrates the incremental QALYs and shows 
that there is considerable uncertainty regarding the existence of additional 
QALYs, as the spread of points pass through the origin.  Negative QALYs 
represent outcomes in which the conventional strategy had a greater QALY 
gain that the intervention strategy, and therefore we are uncertain as to the 
existence of any QALY gains, and the extent of any gains, represented by the 
wide spread.  The vertical plane represents incremental costs.  Figure 4-1 
illustrates that there is considerable uncertainty about the extent, but not the 
existence, of the additional expected costs.  The additional costs range from 
approximately -£300 to £4500, however, there are only two points below the 
origin representing a negative incremental cost (where the conventional 
strategy is cheaper than the intervention strategy).  Therefore we can be 
confident that the intervention will cost more than the conventional strategy, 
however we are less certain about what the additional cost will be, ranging 
from £900 up to £3,600 within the 95% CI.   
Primary colon cancer  
In primary colon cancer the intervention strategy (ceCT and PET/CT) cost an 
additional £2,253 (95% CI £1195 to £3310) per person with a QALY gain of 0.01 
(95% CI -0.02 to 0.05) in comparison to the conventional strategy. The 95% 
confidence interval for the costs is similar to that in the primary rectal 
analysis, however the 95% CI for incremental QALYs is a little wider and again 
includes negative values in the lower interval, indicating considerable 
uncertainty in both the existence of any QALY gain, and in the extent of gain 
when there is a gain. These probabilistic outcomes are plotted on the cost-
effectiveness plane in Figure 4-2.  
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Figure 4-2: The CE plane for PET/CT in primary colon cancer 
 
Figure 4-2 shows that none of the values for incremental cost fall below zero, 
indicating that we can be certain the intervention strategy will cost more than 
the conventional strategy, however, the extent of additional cost ranges 
between £220 and £4400, with 95% falling within the interval £1195 and £3310.  
The cost-effectiveness plane also illustrates the uncertainty in incremental 
QALYs which was evident from the 95% CI.  The incremental QALY points pass 
through the origin on the horizontal plane and in general are quite spread out, 
illustrating the wide 95% confidence interval and lower negative value.    
The cost-effectiveness plane represents the impact of the uncertainty in the 
model parameters on the incremental cost and QALY outcomes; however it 
does not tell us about uncertainty in the decision regarding cost-effectiveness.  
Figure 4-2 shows that some of the time the conventional strategy will dominate 
the intervention, when the ICER points are in the NW quadrant, however, the 
majority of the points fall into the NE quadrant where cost-effectiveness will 
be dependent on societies’ willingness to pay.  The cost-effectiveness 
acceptability curve can help explore uncertainty in this decision.  
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Primary Rectal Scenario: cePET/CT as a lone technology 
The primary rectal scenario was undertaken to explore the potential cost-
effectiveness of an advanced cePET/CT technology as a replacement for 
standard contrast enhanced CT, in the event that a cePET/CT technology 
becomes available in the UK.  However, in primary rectal cancer an MRI scan 
will still be undertaken and therefore even the cePET/CT would be an add-on 
technology in rectal cancer.   
The probabilistic results indicate an expected incremental cost of £975 (95% CI 
-£322 to £2271) and an incremental QALY gain of 0.01 (95% CI -0.01 to 0.03).  
The lower confidence intervals for both cost and QALYs are negative, while the 
mean value and upper intervals are positive, indicating considerable 
uncertainty in these outcomes.   Figure 4-3 illustrates these probabilistic 
outcomes, showing the spread of ICER outcomes from the Monte Carlo 
simulation. The incremental costs illustrated on the vertical axis have a wide 
range, from -£733 at the lowest value up to £3250 and even the lower 95% 
confidence interval is a negative value indicating uncertainty as to what the 
additional costs, if any, will be.  There is also uncertainty as to the existence 
of additional QALYs, as these values also cross through the origin; however the 
range is narrow and quite tight around the mean value of 0.01.  
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Figure 4-3: The CE plane for cePET/CT in primary rectal cancer scenario 
 
These results indicate uncertainty in the cost and QALY outcomes from the 
primary rectal scenario analysis, which is due to parameter uncertainty in the 
model.    
Primary Colon Scenario: cePET/CT as a lone technology 
The scenario analysis was also undertaken for primary colon cancer where an 
advanced cePET/CT technology could be used as a replacement the 
conventional ceCT scan, in the event that a cePET/CT technology becomes 
available in the UK.  In this scenario the ceCT is the only scan in the 
conventional strategy and therefore cePET/CT would be a replacement 
technology.  Figure 4-4 plots the probabilistic outcomes on the cost-
effectiveness plane.  
The probabilistic results indicate an expected incremental cost of £206 (95% CI 
-£1476 to £1887) and an incremental QALY gain of 0.02 (95% CI -0.0024 to 
0.03).   
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Figure 4-4: The CE plane for cePET/CT in primary colon cancer scenario 
 
There is considerable uncertainty in whether a cePET/CT strategy would cost 
more or less than the conventional ceCT strategy, as shown in Figure 4-4 where 
the incremental cost ranges from -£2300 up to an additional £3400.  The mean 
incremental cost of £206 is therefore a very uncertain expectation.  Likewise 
there is uncertainty as to the existence and extent of any QALY gains, ranging 
from -0.04 to 0.05 QALYs, however, the 95% confidence interval is narrower 
around the mean, but still incorporates negative values, crossing through the 
origin on the horizontal axis in Figure 4-4.  In this scenario, there is 
considerable uncertainty as the ICER values spread into three of the quadrants 
of the cost-effectiveness plane.  The cePET/CT intervention dominates ceCT 
when ICER values fall into the South East quadrant representing a reduction in 
cost and a QALY gain, however, the North West quadrant represent ICER values 
where ceCT dominates PET/CT.  In the North East quadrant of the cost-
effectiveness plane neither technology dominates, therefore societies’ 
willingness to pay will need to be considered to determine whether the ICER 
values are cost-effective in this quadrant.  
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4.2.2 Recurrent CRC results 
Recurrent rectal cancer 
In recurrent rectal cancer the intervention strategy (ceCT, MRI and PET/CT) 
cost an additional £712 (95% CI £185 to £1239) per person with a QALY gain of 
0.03 (95% CI -0.04 to 0.11) in comparison to the conventional strategy. This 
represents an incremental cost-effectiveness ratio of £21,409 per QALY gained 
which would be considered cost-effective in the UK (24).  However, it is of 
interest to consider the impacts of parameter uncertainty on uncertainty in the 
incremental cost and QALY outcomes.  The confidence intervals for 
incremental costs and QALYs were calculated using the 2.5 and 97.5 
percentiles from the Monte Carlo iterations.   The 95% CI for incremental cost 
ranges from approximately £200 to £1200 which is a substantial variation, 
however they are all positive.  Figure 4-5 illustrates that only a few of the 
incremental cost outcomes fall below zero, with a minimum value of -£1150, 
however, these negative incremental costs values are outside the 95% CI.  
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Figure 4-5: The CE plane for PET/CT in recurrent rectal cancer 
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The uncertainty surrounding the existence of additional QALY gains is 
substantial.  There is wide variation around the mean point estimate of 0.03 
and Figure 4-5 shows that the majority of incremental QALY values are 
positive, to the right of the origin on the horizontal axis, however the lower 
95% CI incorporates negative QALY values up to -0.04 QALYs and there are a 
few outlying negative up to -0.17 QALYs. There is considerable uncertainty 
regarding both the existence of and the extent of any expected QALY gains, as 
highlighted by the spread of points along the horizontal plane crossing through 
the origin. 
Recurrent colon  
The results from the recurrent colon probabilistic analysis indicate an expected 
incremental cost of £866 (95% CI £562 to £1170) per person with a QALY gain of 
0.14 (95% CI -0.08 to 0.36) in comparison to the conventional strategy. This 
translates to an ICER of approximately £6,000 per QALY gain and would be 
considered highly cost-effective under the typical UK definition (24).   Figure 
4-6 illustrates the cost-effectiveness plane. 
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Figure 4-6: The CE plane for PET/CT in recurrent colon cancer 
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The expected incremental costs are all greater than zero, and the mean value 
has a reasonably tight 95% CI as illustrated on the vertical axis in Figure 4-6.  
Therefore, we can be confident that the intervention will incur additional costs 
and there is a little uncertainty regarding the extent of the additional costs.  
Figure 4-6 shows that there is greater uncertainty, as to both the existence and 
extent of any additional QALY gains.  The 95% CI for incremental QALYs is very 
wide and the lower interval is negative passing through the origin on the 
horizontal axis, however, the majority of incremental QALYs are positive and 
even though the upper 95% interval is at 0.36 QALY gains, the maximum gain is 
as high as 0.59 QALYs. Given these values we are uncertain as to the existence 
of and extent of any additional QALY gains.   
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4.2.3 Metastatic results 
With regards to the metastatic model, the intervention strategy (ceCT plus 
PET/CT) has an expected additional cost of £276 (95% CI -£4384 to £4937) per 
person with a QALY gain of 0.01 (95% CI -0.08 to 0.10) in comparison to the 
conventional strategy. This represents an incremental cost-effectiveness ratio 
of £21,434 per QALY gained which would be considered cost-effective in the 
UK; however, it is of importance to consider the confidence intervals and note 
that there is considerable uncertainty in both the incremental cost and QALY 
outcomes.   
The results from the probabilistic analysis indicate that we are extremely 
uncertain as to the existence and extent of any additional cost in the 
intervention strategy.  The 95% CI around the incremental cost expectation is 
very wide, crossing through the origin and incorporating negative values as low 
as -£4300, and at the upper level nearly £5000.  Figure 4-7 illustrates these 
outcomes on the vertical axis of the cost-effectiveness plane.  
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Figure 4-7: The CE plane for metastatic cancer 
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It can be seen that at a maximum there would be an additional cost of nearly 
£8000, while at the minimum the intervention strategy is approximately £7000 
cheaper than the conventional strategy. Likewise, the confidence interval for 
QALYs is wide and the spread of values passes through the origin including a 
wide range of both additional and negative QALY gains.   
Looking at the scatter of incremental values, about a third fall in the South 
Eastern quadrant, where the add-on PET/CT intervention is dominant over the 
conventional strategy, but another third of the incremental values fall in the 
North Western quadrant where it is the conventional strategy that dominates. 
The remaining values fall in the North East and South West quadrants, where 
ICERs will be present; therefore, even though the overall ICER can be 
considered cost-effective, the probabilistic results paint a very unclear picture.   
These results illustrate that there must be considerable uncertainty in the 
model parameters, which has impacted on the expected costs and QALY 
outcomes.  
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4.3 Decision Uncertainty 
The incremental costs and QALYs and their 95% confidence intervals (2.5 & 
97.5 percentiles from the distribution of Monte Carlo results) from the 
probabilistic sensitivity analyses were illustrated on cost-effectiveness planes 
to demonstrate the impact of uncertainty in the model parameters on 
uncertainty in the model outcomes (expected incremental cost and QALYs).  
The results showed that in all of the analyses, the spread of incremental QALYs 
passed through the origin on the horizontal axis, representing a situation where 
in some instances there would be a positive ICER value but in other instances 
the conventional strategy would dominated the intervention strategy (in the 
North West quadrant).  If the spread of ICER values had all been contained to 
one quadrant, then a decision regarding cost-effectiveness would be more 
straight forward, yet still dependent on a willingness to pay value (λ) if ICER 
points fall in the North East or South West quadrants.  As the spread of results 
involved two or more quadrants (for all of the analyses), cost-effectiveness is 
more complicated to determine.   
As all of the analyses incorporated instances where the spread of results 
entered two or more quadrants of the cost-effectiveness plane, the 95% 
confidence intervals for the ICERs involve negative values due to some of 
results being dominated by one of the strategies.  In such cases, the 95% CI for 
the ICER may appear back to front with the lower confidence interval 
representing a higher ICER value than the upper confidence interval (40;168).  
Therefore 95% confidence intervals were not presented for the ICER values.  In 
such cases careful consideration must be given to the spread of ICER values and 
the interpretation of the confidence intervals (40); and decision uncertainty 
(as to whether the intervention is cost-effective or not) is better represented 
on cost-effectiveness acceptability curves (CEACs) than in confidence intervals 
(4).   
Having presented the impact of uncertainty in the model parameters on the 
incremental cost and incremental QALY outcomes, cost-effectiveness 
acceptability curves will now be used to present decision uncertainty for each 
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of the analyses, illustrating the probability of each intervention being cost-
effective at different willingness to pay thresholds. 
4.3.1 Primary CRC decision uncertainty 
The aim of calculating a CEAC is to summarise and illustrate graphically the 
probability that a particular intervention is the optimal choice over a wide 
range of values for the ceiling ratio (λ) (7). Fenwick and colleagues (11) 
demonstrate this process and provide a guide to interpreting the CEAC (7;71). 
Primary rectal cancer 
The cost-effectiveness acceptability curve (CEAC) for primary rectal cancer is 
illustrated in Figure 4-8, representing the uncertainty in the cost-effectiveness 
estimate for primary rectal cancer. The CEAC shows the probability that 
PET/CT is cost-effective as an add-on imaging device in comparison to ceCT 
and MRI at different values for the maximum acceptable cost-effectiveness 
ratio (λ).  
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Figure 4-8: The CEAC for primary rectal cancer 
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At a monetary threshold of £100,000 the probability that the PET/CT 
intervention will be cost-effective is less than 20%. Within the usual UK range 
of values for the maximum acceptable cost-effectiveness ratio (λ) (£20,000 to 
£30,000 per QALY) the CEAC illustrates that the conventional strategy (CT and 
MRI) has approximately 100% probability of being cost-effective and the 
PET/CT intervention has a 0% probability of being cost-effective. 
The CEAC illustrates that there is little uncertainty in the cost-effectiveness 
decision.  The cost-effectiveness plane for primary rectal cancer in Figure 4-1 
illustrated considerable uncertainty in the existence and extent of expected 
incremental QALYs and some uncertainty in expected incremental costs, 
however, the CEAC illustrates that this parameter uncertainty does not 
translate into decision uncertainty.  
Primary colon cancer 
The uncertainty in the cost-effectiveness estimate for primary colon cancer is 
illustrated on a cost-effectiveness acceptability curve in Figure 4-9.   
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Figure 4-9: The CEAC for primary colon cancer 
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The CEAC shows that at a monetary threshold of £100,000/QALY the 
probability that the PET/CT intervention will be cost-effective is 
approximately 30%. At a threshold of £30,000 per QALY, the CEAC illustrates 
that the probability that PET/CT will be cost-effective is approximately 1%. At 
this threshold the probability that the conventional ceCT strategy will be cost-
effective is approximately 99%.  
The cost-effectiveness plane for the primary colon cancer PSA results in Figure 
4-2 illustrated considerable uncertainty in the existence and extent of 
expected incremental QALYs and some uncertainty in the extent of additional 
costs; however, this did not translate to decision uncertainty.  At a monetary 
threshold of £30,000 per QALY we can be 99% certain that the conventional 
strategy (ceCT) is cost-effective.  
Primary Rectal Scenario: cePET/CT as a lone technology 
The uncertainty around the cost-effectiveness estimate for the primary rectal 
cancer scenario is illustrated on the CEAC in Figure 4-10.   
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Figure 4-10: The CEAC for primary rectal scenario 
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The CEAC shows that at a monetary threshold of £30,000/QALY the probability 
of cePET/CT and MRI being cost-effective in comparison to ceCT and MRI is less 
than 20%.   As the monetary threshold increases, the probability of the 
intervention strategy (cePET/CT + MRI) being cost-effective increases, however 
even at a threshold of £60,000/QALY which is double the UK recommended 
threshold (24), the probability that the intervention strategy will be cost-
effective is only 35%.  The willingness to pay threshold would need to be 
greater than £100,000 per QALY for the cePET/CT and MRI strategy to be the 
optimal intervention.   
The probabilistic sensitivity analysis for the primary rectal scenario resulted in 
a scatter of ICER vales over three quadrants of the cost-effectiveness plane, 
indicating uncertainty in the existence of both incremental QALYs and 
incremental costs.  This parameter uncertainty translates into some decision 
uncertainty, as we can be reasonably certain (over 80%) that at a monetary 
threshold of £30,000 per QALY the conventional strategy would cost-effective.  
Primary Colon Scenario: cePET/CT as a lone technology 
The cost-effectiveness acceptability curve for the primary colon cancer 
scenario is illustrated in Figure 4-11. The figure shows that at a monetary 
threshold of £30,000/QALY there is a 63% probability of cePET/CT being cost-
effective in comparison to ceCT.  Note that the two curves cross at a 
willingness to pay threshold of approximately £12,800, which corresponds to 
the ICER point estimate value.  If society is willing to pay greater than £12,800 
per QALY then cePET/CT is likely to be the optimal strategy, given current 
information.    
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Figure 4-11: The CEAC for primary colon scenario 
 
The cost-effectiveness plane in Figure 4-4 illustrated uncertainty in the 
existence and extent of both incremental costs and QALYs, with a spread of 
ICER values that crossed three quadrants of the plane.  Some of this 
uncertainty translates into decision uncertainty as can be seen on the CEAC in 
Figure 4-11.  If society is willing to pay greater than £12,800 per QALY then 
cePET/CT is likely to be the optimal strategy, however there is still 
considerable uncertainty surrounding this decision. At £30,000 per QALY the 
probability that the cePET/CT strategy is cost-effectiveness is 63%, and even at 
a threshold of £60,000/QALY the probability is only 75%.  Therefore, there 
remains some decision uncertainty as to whether cePET/CT is the optimal 
strategy in the primary colon scenario. 
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4.3.2 Recurrent CRC decision uncertainty 
Recurrent rectal 
The cost-effectiveness acceptability curve, plotted in Figure 4-12, illustrates 
the uncertainty in the cost-effectiveness estimate for recurrent rectal cancer.  
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
£0 £10,000 £20,000 £30,000 £40,000 £50,000 £60,000 £70,000 £80,000 £90,000 £100,000
Maximum acceptable cost-effectiveness ratio (λ)
Pr
o
ba
bi
lit
y(c
o
st
-
ef
fe
ct
iv
e)
CT+MRI CT+MRI+PET/CT
 
Figure 4-12: The CEAC for recurrent rectal cancer 
 
The figure shows that at a monetary threshold of less than £21,000/QALY there 
is a greater probability that the conventional (ceCT and MRI) strategy is the 
most cost-effective, but at a monetary threshold of greater than £21,000/QALY 
the intervention (add-on PET/CT) strategy has a greater probability of being 
the most cost-effective strategy. The two curves cross at the mean ICER 
estimate of £21,000 per QALY, and therefore, at the £30,000 per QALY 
threshold recommended by NICE (24) the CEAC indicates approximately 70% 
probability that the intervention strategy will be cost-effective in comparison 
to the conventional strategy.  
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The cost-effectiveness plane in figure 4-5 illustrated considerable uncertainty 
regarding both the existence of and the extent of any expected QALY gains, 
and some uncertainty in the extent of additional costs.  This parameter 
uncertainty has translated into some decision uncertainty.   
Recurrent colon 
Uncertainty in the cost-effectiveness estimate at different monetary thresholds 
is illustrated for recurrent colon cancer in Figure 4-13.  
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Figure 4-13: The CEAC for recurrent colon cancer 
 
At a monetary threshold of less than £6,000 per QALY, the conventional 
strategy is the most cost-effective; while at a threshold above £6,000 per QALY 
the PET/CT strategy has the greatest probability of being cost-effective.  At 
the monetary threshold of £30,000/QALY there is an 85% probability that the 
intervention will be cost-effective, versus a 15% probability that the 
conventional strategy will be cost-effective.  Given that the cost-effectiveness 
plane in Figure 4-6 illustrated considerable uncertainty in the incremental 
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QALY estimate and some uncertainty in cost, this parameter uncertainty has 
translated into only a little uncertainty regarding cost-effectiveness.  We can 
be confident that the PET/CT intervention is cost-effective at a monetary 
threshold of £30,000/QALy, but only with a probability of 85%.    
4.3.3 Metastatic decision uncertainty 
With regards to metastatic colorectal cancer, Figure 4-7 illustrated that the 
ICER values from the PSA fall into all four quadrant of the cost-effectiveness 
plane, indicating uncertain as to the existence and extent of any additional 
cost or QALYs in the intervention strategy. The cost-effectiveness acceptability 
curve, in Figure 4-14, can help provide some insight regarding the decision 
uncertainty. 
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Figure 4-14: The CEAC for metastatic cancer 
 
Figure 4-14 illustrates the considerable uncertainty surrounding the cost-
effectiveness of the add-on PET/CT strategy. At a monetary threshold of 
£21,000 per QALY the probability that the PET/CT intervention will be cost-
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effective equals approximately 50% as is the probability that CT will be cost-
effective. Beyond this threshold the probability of cost-effectiveness for the 
intervention strategy increases slightly, but never reaches beyond 57%, even at 
a monetary threshold of £100,000/QALY.  At the £30,000 per QALY threshold 
recommended in the UK (24) the CEAC indicates that the PET/CT intervention 
has a slightly greater probability of being cost-effective (52%) than the 
conventional strategy (48%). This confirms that there is considerable 
uncertainty as to which intervention is cost-effective in the metastatic 
analysis, regardless of societies’ willingness to pay threshold.   
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4.4 Value in further research: EVPI & EVPPI 
Having presented the PSA results and explored the decision uncertainty for 
each of the analyses, illustrating the probability of each intervention being 
cost-effective at different ceiling ratios, it is important to consider two 
questions: given the current evidence and decision uncertainty, should the 
technology be adopted (or not)?, and is further research required to help 
support this decision (4)?  If these questions are not answered, decision makers 
may struggle to interpret the cost-effectiveness results, particularly regarding 
how to make the decision to adopt or reject the add-on PET/CT technology 
given the uncertainty.  In answering these questions the researchers can help 
inform funders and decision makers on how to interpret the results for each 
CRC patient group and the appropriate next steps to take, based on the 
outcomes from the PSA.   
In the PET/CT case study, the results from the probabilistic analysis indicate 
that given current evidence add-on PET/CT is not cost-effective in primary CRC 
and should not be adopted, but it may be cost-effective in recurrent and 
metastatic disease.  This summary does not formally capture the decision 
uncertainty for each of the analyses.  Therefore, value of information analysis 
can be used to formally evaluate whether further research is necessary to 
support the decision to adopt or reject the technology.  
4.4.1 Primary CRC: Value of Information 
Primary Rectal cancer 
The expected value of perfect information (EVPI) was calculated using the 
probabilities of cost-effectiveness for each intervention which were generated 
in the CEAC calculation, over a range of monetary thresholds in increments of 
£500 from zero to £100,000 per QALY gain.  The EVPI results showed that at a 
monetary threshold of £30,000/QALY the expected value of perfect 
information per decision in primary rectal cancer is £1.30.  
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This EVPI is very low; however, when the decision uncertainty demonstrated in 
the CEAC in Figure 4-8 is considered, it is not surprising.  At the monetary 
threshold of £30,000/QALY the probability that PET/CT would be cost-effective 
was only 0.4% and therefore the conventional strategy (CT+MRI) was the 
optimal strategy, with a 99.6% probability.  The EVPI is equivalent to the 
opportunity loss from choosing the optimal (conventional) strategy in the 
instances that the optimal strategy would have been ‘wrong’ given perfect 
information.  Given that there was only a 0.4% probability that the 
conventional strategy is the wrong decision, it makes logical sense that the 
opportunity loss of choosing the conventional strategy is low.  Even at a 
greater ‘willingness to pay’ threshold of £100,000/QALY, the probability that 
PET/CT is cost effective was only 20%.  Therefore at this higher threshold there 
is a 20% probability that choosing the conventional strategy is the wrong 
decision, and this wrong decision resulted in an average opportunity loss, or 
value of perfect information, of £60 per decision.      
It is important to represent what this EVPI per decision represents in terms of 
the relevant patient population who would benefit from the additional 
information.   In order to determine the population value of EVPI, the patient 
population over the lifetime of the technology must be considered.   The 
annual incidence of primary rectal cancer in the UK was estimated to be 
13,315 (94) and a technology timeframe of two years was applied (and 
discounted at 3.5% (24), i.e. PET/CT in its current form will be considered as 
an add-on for imaging for two years. This (relatively short) timeframe was 
been determined in part by the continual development and upgrading of 
PET/CT, such that the estimates that we have for DTA are likely to change 
outside of this timeframe.   Therefore the effective population of primary 
rectal cancer patients who would potentially benefit from additional 
information was estimated to be 26,180. Figure 4-15 details the results from 
the expected value of perfect information analysis (EVPI) at a population level.  
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Figure 4-15: EVPI for primary rectal cancer – population level 
 
At a willingness to pay threshold of £30,000/QALY the expected value of 
perfect information for the population is approximately £34,000. If a monetary 
threshold of £100,000 per QALY were applied, then the population value of 
further research would be £2.3 million, however, the UK recommended 
threshold is £20,000 to £30,000 per QALY (24). This value can be considered to 
be the maximum society should be willing to pay for further research, and 
therefore, it is not worthwhile seeking additional information for PET/CT for 
primary rectal cancer.  The cost of undertaking further research activity, 
would out way this population value of £34,000 and therefore it is not 
worthwhile.    
Primary colon cancer 
Similar to the primary rectal results, the EVPI per decision for primary colon 
cancer was found to be very low. At a willingness to pay threshold of 
£30,000/QALY the expected value of perfect information per decision was 
£1.60. This low EVPI value can be explained by considering the (lack of) 
decision uncertainty demonstrated by the CEAC in Figure 4-9.  The CEAC for 
primary colon cancer showed that at a monetary threshold of £30,000 per 
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QALY, there was only a 1 % probability that the PET/CT intervention would be 
cost-effective, and therefore the conventional strategy was the optimal choice 
with a 99% probability of being cost-effective.   Given that there was only a 1% 
probability that the conventional strategy is the wrong decision, it makes 
logical sense that the opportunity loss of choosing the conventional strategy 
under perfect information is low, and therefore the value of further research is 
low. 
In order to determine the overall population value of EVPI for primary colon 
cancer the annual incidence of primary colon cancer was determined to be 
21,574 (94) and the PET/CT technology timeframe was estimated to be two 
years, discounted at 3.5% (24) to give an effective population of 42,418 
primary colon patients.  As with the primary rectal evaluation, the short 
technology timeframe was determined to reflect the continual development 
and upgrading of PET/CT technology, such that the current estimates for DTA 
are likely to change outside of this timeframe.  Figure 4-16 details the results 
from the expected value of perfect information analysis (EVPI) at a population 
level.   
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Figure 4-16: EVPI for primary colon cancer – population level 
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At a willingness to pay threshold of £30,000/QALY the expected value of 
perfect information for the population is approximately £70,000. Thus, it is 
unlikely that research will cost less than this value, and therefore it is not 
worthwhile seeking additional information for PET/CT for primary colon 
cancer. 
Scenario analysis: cePET/CT in primary rectal cancer 
The scenario analysis for primary rectal cancer was undertaken to explore the 
potential cost-effectiveness of an advanced cePET/CT technology along with 
MRI as an alternative to the conventional contrast enhanced CT and MRI scans.  
The CEAC in Figure 4-10 indicated that while the conventional strategy was the 
cost-effective option, there was some decision uncertainty around this choice.   
The results from the population level expected value of perfect information 
analysis (EVPI) are presented in Figure 4-17, based on the same patient 
population (26,180) and technology timeframe as that specified for the 
baseline primary rectal evaluation.   
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Figure 4-17: EVPI for primary rectal cancer scenario – population level 
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The EVPI results indicate that at a willingness to pay threshold of £30,000 per 
QALY, the expected value of perfect information per decision is £68, which 
translates to a population EVPI of £1.7million.  Therefore it is potentially 
worthwhile undertaking further research to explore whether cePET/CT can 
(and is available to) be used as a replacement for ceCT in primary rectal 
cancer, if the research cost was less than £1.7 million.  
Scenario analysis: cePET/CT in primary colon cancer 
The EVPI analysis for the primary colon cancer scenario was undertaken based 
on the same patient population (42,418) and technology timeframe as that 
specified for the baseline primary colon evaluation.  The results are presented 
in Figure 4-18.    
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Figure 4-18: EVPI for primary colon cancer scenario – population level 
 
The CEAC for the primary colon scenario found that if society is willing to pay 
greater than £12,800 per QALY then cePET/CT is likely to be the optimal 
strategy.  However, there was still considerable uncertainty surrounding this 
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decision, and at £30,000 per QALY the probability that the cePET/CT strategy 
would be cost-effectiveness was 63%.  This decision uncertainty is reflected in 
the value of further research.  The EVPI analysis resulted in an expected value 
of perfect information per decision of £290 at a willingness to pay threshold of 
£30,000 per QALY.  When scaled up to reflected this value to the patient 
population, further research is worth £12.3million as detailed in Figure 4-18.    
Figure 4-18 shows the kink in the EVPI curve, which occurs at the point where 
the ceiling ratio is equivalent to the ICER.  For the primary colon scenario this 
value is £12,800.  Beyond this point the EVPI is still high but diminishing. Given 
the high population EVPI, it can be concluded that it is potentially worthwhile 
undertaking further research to reduce the uncertainty surrounding the 
question of whether cePET/CT can be used as a replacement for ceCT in 
primary colon cancer. 
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4.4.2 Recurrent CRC 
Recurrent Rectal cancer 
As with the Primary model analyses, the EVPI for recurrent CRC was calculated 
using the probabilities of cost-effectiveness for each intervention which were 
generated in the CEAC calculation, over a range of monetary thresholds from 
zero to £100,000 per QALY gain.   
The EVPI results for recurrent rectal cancer report that at a monetary 
threshold of £30,000/QALY the expected value of perfect information per 
decision is £316. To understand this value it is useful to consider the 
probabilistic results and the decision uncertainty presented for recurrent rectal 
cancer in Figure 4-12. The results showed that at a monetary threshold above 
£21,000 per QALY it is most likely that the intervention (PET/CT) strategy will 
be cost-effective, but at a monetary threshold of £30,000/QALY there is only a 
70% probability of cost-effectiveness.  Given that there is a 30% probability 
that the optimal (intervention) strategy will be the wrong decision, the EVPI is 
equivalent to the opportunity loss from choosing the optimal (intervention) 
strategy in the 30% of instances that the optimal strategy would have been 
‘wrong’ given, perfect information.  At a ceiling ratio of £30,000/QALY the 
expected value of further research is £316 per decision. 
It is important to represent the EVPI per decision in terms of the relevant 
patient population who would benefit from the additional information.   In 
order to determine the effective recurrent rectal cancer population an annual 
incidence of recurrent rectal cancer of 9,054 cases was estimated (derived 
using the annual incidence of rectal cancer (94) and applying a 70% probability 
of recurrence (150) and a 2.8% death rate prior to recurrence) along with a 
technology timeframe of two years, to derive an effective population of 
17,802.  As noted previously, the two year timeframe was determined in part 
by the continual development and upgrading of PET/CT, such that the 
estimates for DTA are likely to change outside of this timeframe. The 
population level EVPI results are illustrated in Figure 4-19. 
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Figure 4-19: EVPI for recurrent rectal cancer – population level 
 
The EVPI per decision of £316 translated to population level EVPI of 
approximately £5.6 million, at a monetary threshold of £30,000/QALY.  It is 
likely that further research would cost less than £5million, and therefore, the 
EVPI results indicate that it is potentially worthwhile collecting more 
information about the use of PET/CT for staging in recurrent rectal cancer. 
Having established that further research is likely to be worthwhile in recurrent 
rectal cancer, it is useful to consider what type of research is required.  
‘Further research’ does not necessarily mean that a large scale, randomised 
controlled trial is required.  Rather, the type of research will depend on the 
different parameters that require further information.  For example, utility 
values can be collected alongside a large scale randomised trial, but if they are 
the sole source of uncertainty, then it would be much more efficient (and 
cheaper) to determine utility values from an observational study.  Large scale 
clinical trials are only necessary for clinical information.  Likewise further 
information regarding disease prevalence for a model could be derived by 
accessing and analysing routine data sources rather than undertaking a 
prospective clinical trial.  To define the type, and possibly the scale, of the 
further research that is required (to reduce uncertainty in the cost-
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effectiveness decision), researchers need to consider what is driving the 
uncertainty.  What parameters are driving the uncertainty in the cost-
effectiveness model and would therefore add the most value through further 
information?  Expected value of perfect parameter information (EVPPI) is used 
to identify parameters for which more precise estimates would be most 
valuable.  
In the case of recurrent rectal cancer, EVPPI was undertaken to explore which 
groups of parameters would add most value through further research. The 
various parameter inputs to the model were considered and six parameter 
groups were deemed to be of potential value in gaining further information: 
Prevalence, Diagnostic test accuracy, Five year overall survival, Cost of 
PET/CT, Cost of treating metastases and Utility values for the disease states.   
The parameter groups are summarised in Table 4-1.  With regards to 
prevalence the relevant parameters were those for establishing the probability 
of no recurrence, recurrence (local and metastatic), and for those who have 
recurrence: curable and incurable recurrence.  Likewise the DTA group 
included the sensitivity and specificity parameters for the relevant tests. 
With regards to the cost group, PET/CT is a relatively new technology in 
colorectal cancer and there is no UK reference cost information for PET/CT.  
Additionally there is uncertainty as to the resource use and professional time 
involved and therefore it may well be worthwhile collecting further 
information on the cost of PET/CT in colorectal cancer.  Likewise, the cost of 
metastatic surgery and palliative care were considered to have some 
uncertainty in terms of resource use and were therefore included to explore 
whether or not there is any expected value of perfect information in these 
parameters. 
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Table 4-1: EVPPI parameter groups and parameters 
 
Parameter Groups Parameters 
    
Prevalence no recurrence 
  recurrence 
  recurrence curable 
  recurrence incurable 
    
Diagnostic Test Accuracy ceCT sensitivity & specificity 
  MRI sensitivity & specificity 
  PET/CT sensitivity & specificity 
    
5 year overall survival no recurrence 
  recurrence curable 
  recurrence incurable 
    
Cost PET/CT cost PET/CT 
    
Cost metastases cost metastatic surgery 
  cost palliative care 
    
Utilities (disease state) no recurrence 
  recurrence curable 
  recurrence incurable 
    
Trial information Diagnostic Test Accuracy group 
  cost PET/CT 
  Utilities group 
 
Given these six parameter groups there is only one group which would require 
a randomised trial to gain further information, and that is the DTA group.  If a 
randomised trial was undertaken to determine DTA, the trial could also gather 
information on quality of life for the disease states and the cost of PET/CT 
without requiring additional duration for longer term follow-up.  Therefore, a 
seventh ‘Trial information’ group was established which considered the DTA, 
disease state utilities and cost of PET/CT parameters as a group of their own 
for the EVPPI. The EVPPI was run using 1000 x 1000 iterations for each of the 
seven parameter groups, using a monetary threshold (λ) of £30,000/QALY.   
The EVPPI analysis reports outcomes in terms of the value per decision, but it 
is important to consider the EVPPI in terms of the relevant patient population 
who would benefit from the additional information.  The population EVPPI was 
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based on the same patient population (17,802) and technology timeframe as 
that specified for the recurrent rectal EVPI calculation, and the results are 
presented in Figure 4-20.   
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Figure 4-20: EVPPI for recurrent rectal cancer – population level (λ=£30,000) 
 
The population EVPPI values differed substantially between the seven 
parameter groups, and therefore they are presented on a log scale in Figure 4-
20 so as to adequately illustrate the different values.  The analysis found that 
there was zero value in undertaking further research in the five years overall 
survival and cost of metastases parameter groups.  In the utilities group the 
value of additional information per decision was very low at 1 pence (£0.0144), 
so even when this non-zero value is scaled up by the population to give a 
population EVPPI of £256, the cost of undertaking research would exceed this 
value.   Likewise, the value of further research for the cost PET/CT parameter 
was very low at 25 pence (£0.25) per decision and £4,429 at the population 
level. The value of perfect parameter information for the prevalence group 
was worth £5.64 per decision, translating to £100,000 at the population level. 
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It may or may not be worthwhile undertaking further research on prevalence 
parameters, depending on if the cost of research was lower than £100,000.   
The only parameter groups of any real value in the analysis were the DTA and 
the Trial information groups.  Clearly it is the diagnostic test accuracy 
parameters which are driving uncertainty in the model, leading to uncertainty 
in the cost-effectiveness decision.   
The trial information group (which combined the DTA, utilities and cost of 
PET/CT parameters) had an EVPPI similar to the DTA group, and considering 
the value for the cost and utilities groups, the EVPPI is clearly being driven by 
the DTA parameters in this group.  It is interesting to note that the cost of 
PET/CT and utilities parameters appear to have a reducing impact on the 
value, lowering the combined Trial information EVPPI (£4.9 million) to less 
than that of DTA alone (£5.6 million).  As described by Briggs and colleagues 
(4), individual parameters when considered in isolation do not resolve the same 
way as they do when they are joined as a group.  The EVPPI for the individual 
parameters do not sum to the decision EVPI, and equally, the EVPPI for a group 
of parameters is not the sum of the individual EVPPIs (4). Therefore, there is 
no reason why the various parameter groups should act in an additive fashion 
when combined.  This is evident in the Trial Info group.  There is no particular 
reasoning as to why this group of parameters would have an additive or 
negative effect when combined, however, in this case the utilities and cost of 
PET/CT parameters have an effect of reducing uncertainty, resulting in a lower 
EVPPI value than when the DTA parameters are valued alone.  Also, it is 
perfectly reasonable for EVPPI on all the individual parameters to be zero, but 
as a group they may be substantial. 
In general the EVPPI for the various parameter groups are in line with 
expectation; all being very low with the exception of the DTA parameters.  In 
populating the decision model with DTA evidence from the systematic review, 
the evidence was found to be limited and what did exist was found to be 
inadequate and subject to reporting bias for all stages of CRC disease.   
Therefore, it is unsurprising that it is this set of parameters that is driving 
uncertainty in the model, and driving the expected value in further research to 
help reduce that uncertainty.  Given the results of the EVPPI, the type of 
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further research that would be required is likely to be a trial to evaluate the 
DTA characteristics for both PET/CT and MRI technologies.  Such a trial would 
not necessarily be an RCT; however, the existing DTA studies (identified in the 
systematic review) derived their evidence mostly from retrospective studies in 
university or oncology hospital settings.  Most of the studies used consecutive 
samples and only a few had comparators with no details provided regarding the 
use of blinding.  Therefore an RCT would provide some stronger evidence 
regarding DTA especially if it had an appropriate comparator, was blinded etc. 
Additionally, any further research on DTA would not necessarily require a long-
term duration, as the EVPPI showed that there is little value in further 
research for the survival parameters.  A short enough duration to determine 
unbiased DTA characteristics would suffice, and could possibly also be used to 
derive mean utilities for the disease states.  
Recurrent Colon Cancer 
The EVPI results for recurrent colon cancer are now reported.  The expected 
value of information analysis was undertaken to explore whether it is 
potentially worthwhile collecting more information about the use of PET/CT 
for recurrent colon cancer.  
 At a willingness to pay threshold of £30,000/QALY the expected value of 
perfect information per decision is £178.  The recurrent colon cancer analysis 
determined an ICER of £6000 per QALY, however despite this being 
considerably below the £30,000/QALY ceiling ratio, the CEAC in Figure 4-13 
illustrated that this intervention strategy (ceCT plus PET/CT) was only cost-
effective with an 85% probability.  Therefore, at the £30,000/QALY threshold 
there remains some decision uncertainty, and this is reflected in the EVPI value 
of £178 per decision. Figure 4-21 displays the population level EVPI results.  
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Figure 4-21: EVPI for recurrent colon cancer – population level 
 
The overall population value of EVPI was based on an annual incidence of 
14,670 cases of recurrent colon cancer, derived in the same manner as for the 
recurrent rectal evaluation (using the annual incidence of colon cancer (94) 
and applying a 70% probability of recurrence (150) and a 2.8% death rate prior 
to recurrence).  As with the previous EVPI analyses, a timeframe of two years 
was applied to the PET/CT technology to represent its current lifespan, out 
with which the DTA estimates are likely to change reflecting the continual 
development and upgrading of PET/CT technology.  The effective population of 
recurrent colon patients for which further information may be required, was 
determined to be 28,845.  
Figure 4-21 illustrates that at a willingness to pay threshold of £30,000/QALY 
the expected value of perfect information for the population is approximately 
£5.1 million. It is likely that further research would cost less than £5million, 
and thus it is potentially worthwhile seeking additional information for PET/CT 
in recurrent colon cancer. 
Having established that further research is likely to be worthwhile in recurrent 
colon cancer, EVPPI is undertaken to explore what parameters are driving the 
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uncertainty in the cost-effectiveness analysis.  Establishing what parameter 
information would add the most value will help determine what type of 
‘further research’ is required.    The same parameter groups which were 
determined to be possible sources of uncertainty for the recurrent rectal 
analysis were used for the recurrent colon EVPPI analysis.  The seven 
parameter groups identified were: Prevalence, Diagnostic test accuracy, Five 
year overall survival, Cost of PET/CT, Cost of treating metastases, Utility 
values for the disease states and a Trial Information group.  Table 4-1 details 
the specific parameters within each group, and these are the same for colon 
recurrence, except for the DTA group which only includes ceCT and PET/CT, as 
MRI scans are not used to stage colon patients.   
The EVPPI analysis reported results in terms of the value per decision, and 
these are presented in terms of the relevant patient population who would 
benefit from the additional information.  The population EVPPI was based on 
the same patient population (28,845) and technology timeframe as that 
specified for the recurrent colon EVPI calculation, and the results are 
presented in Figure 4-22.  The results are presented on the log scale, for 
consistency with the recurrent rectal EVPPI results in Figure 4-20.  
The analysis found that there was zero value in undertaking further research in 
the majority of the parameter groups, except for DTA and Trial information.  In 
consideration of the EVPPI results for these parameter groups from the 
recurrent rectal analysis, this is not surprising. The recurrent rectal EVPPI also 
found zero value in cost of treating metastases and overall survival parameter 
groups, and in the Utilities, cost of PET/CT and Prevalence groups the EVPPI 
was extremely low.  It is clear that in the recurrent CRC model, these 
parameters may have some uncertainty surrounding them, but not enough to 
warrant any further information.  The only parameter groups of any value in 
the colon analysis were the DTA and the Trial information groups, with per 
decision values of £155 and £150 respectively.  Clearly it is the diagnostic test 
accuracy parameters which are driving uncertainty in the model, leading to 
uncertainty in the cost-effectiveness decision.   
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Figure 4-22: EVPPI for recurrent colon cancer – population level (λ=£30,000) 
 
As in the rectal analysis, the Trial information group (which combined the DTA, 
utilities and cost of PET/CT parameters) had an EVPPI similar to the DTA 
group, and again the cost of PET/CT and utilities parameters appear to have a 
reducing impact on the EVPPI (even though they had no value in their own 
separate group evaluations), lowering the combined Trial information EVPPI 
(£4.3million) to less than that of DTA alone (£4.4million).  As described by 
Briggs et al. (4), it is perfectly reasonable for EVPPI on all the individual 
parameters to be zero, but as a group they may be substantial.  In the case of 
recurrent (colon and rectal) cancer the utilities and cost of PET/CT parameters 
have zero individual EVPPI, but when combined they have an effect of reducing 
uncertainty, resulting in a lower Trial Info EVPPI value than when the DTA 
parameters are valued alone.  The results of the EVPPI for recurrent colon 
cancer indicate that a short term DTA study could help evaluate the diagnostic 
test characteristics for both PET/CT and ceCT technologies, and could possibly 
also gather information on patient quality of life for the disease states and 
establish the routine cost of PET/CT. 
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4.4.3 Metastatic 
As with the Primary and Recurrent model analyses, the EVPI for metastatic CRC 
was calculated over a range of monetary thresholds from zero to £100,000 per 
QALY gain.   
The EVPI analysis was undertaken to determine whether there is value in 
further research, based on the uncertainty surrounding the cost-effectiveness 
decision.  At the £30,000 per QALY threshold the CEAC in Figure 4-14 indicated 
that even though the PET/CT intervention had an ICER of £21,400 the 
probability of this being cost-effective was only 52%, with the conventional 
strategy having a 48% probability of being the optimal strategy. This confirms 
that there is considerable uncertainty as to which intervention is cost-effective 
in the metastatic analysis, and it is therefore unsurprising that the EVPI results 
for metastatic CRC report that at a monetary threshold of £30,000/QALY the 
expected value of perfect information per decision is £1328.  This is very high 
in comparison to the EVPI values for the primary and recurrent CRC models, 
yet it is unsurprising given that the metastatic model had the most uncertain 
outcomes, as illustrated on the CEAC.  
In order to determine the overall population value of EVPI an annual incidence 
of 4000 cases of metastatic colorectal cancer was assumed (derived from the 
annual incidence of colorectal cancer (94), the probability of metastases (150) 
and the probability of death prior to metastatic diagnoses) and a technology 
timeframe of two years was assumed, in line with the previous EVPI 
calculations. The effective population of metastatic CRC patients who could 
potentially benefit from further evidence was determined to be 7872. The EVPI 
results are presented in Figure 4-23 at the population level.  
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Figure 4-23: EVPI for metastatic colorectal cancer - population 
 
The EVPI results show that it is worthwhile collecting more information about 
the use of PET/CT for recurrent rectal cancer.  At a willingness to pay 
threshold of £30,000/QALY the expected value of perfect information per 
decision is £1,328, which translates to approximately £10.5 million at the 
population level.  Even if societies’ willingness to pay was zero, the value of 
additional information would still be extremely high at £6.3 million. This high 
population EVPI is mostly due to the high degree of uncertainty given current 
information, and therefore it is worthwhile seeking additional information to 
help inform the decision regarding the cost-effectiveness of a PET/CT strategy 
for metastatic colorectal cancer.    
Given that further research is worthwhile in metastatic cancer, the analysis 
can be extended by using EVPPI to establishing what type of further research is 
required.  In this way the model outcomes can be meaningful to decision 
makers. The same parameter groups which were determined to be possible 
sources of uncertainty for the recurrent model were used for the metastatic 
EVPPI analysis: Prevalence, Diagnostic test accuracy (ceCT and PET/CT), Five 
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year overall survival, Cost of PET/CT, Cost of treating metastases, Utility 
values for the disease states and a Trial Information group.  Table 4-2 details 
the seven parameter groups and the parameters specific to the metastatic 
model.  
Table 4-2: EVPPI parameter groups and parameters 
Parameter Groups Parameters 
    
Prevalence no metastases 
  metastases 
  metastases at one site 
  extra metastases 
    
Diagnostic Test Accuracy ceCT sensitivity & specificity 
  PET/CT sensitivity & specificity 
    
5 year overall survival no metastases 
  metastases at one site 
  extra metastases - surgery 
  extra metastases - palliative 
    
Cost PET/CT cost PET/CT 
    
Cost metastases cost metastatic surgery 
  cost palliative care 
    
Utilities - disease state no metastases 
  metastases 
  extra metastases - surgery 
  extra metastases - palliative 
  
Trial information Diagnostic Test Accuracy group 
  cost PET/CT 
  Utilities group 
 
The population EVPPI was based on the same patient population (7,872) and 
technology timeframe as that specified for the metastatic EVPI calculation.  
The EVPPI analysis reported results in terms of the value per decision, and 
these are presented in terms of the relevant patient population who would 
benefit from the additional information in Figure 4-24. The results are 
presented on the log scale, so that the lowest and highest EVPPI values can be 
adequately illustrated and for consistency with the previous EVPPI analyses. 
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Figure 4-24: EVPPI for metastatic CRC – population level (λ=£30,000) 
 
The analysis found that there was value in undertaking further research in all 
of the parameters, but that the DTA and Trial information parameter groups 
were driving the majority of uncertainty in the model.  
The five years overall survival parameter group had an EVPPI per decision of 
£10 which was similar to the cost of metastases parameter groups at £11 per 
decision.  These translated to population values of approximately £80,000.  
Gathering additional evidence on overall survival would not necessarily require 
a trial (if for example a routine CRC data set could be accessed), and therefore 
it may be possible to undertaken research on these parameters at a cost lower 
than £80,000.  The per decision value of further information on the 
prevalence, utilities and cost of PET/CT groups were £14, £22 and £24 
respectively. This translates into population level values of greater than 
£100,000.  These results show that there is a greater uncertainty surrounding 
the cost of PET/CT than there is the cost of metastatic surgery and palliative 
care.  Also, it is likely to be worthwhile collecting information on the cost of 
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PET/CT and the utility parameters.  While the cost of PET/CT and utilities 
information can be collected in a clinical trial, one is not necessary, and 
therefore they could be collected for less than £174,000.  Further information 
on these five parameter groups is of some value; however, the major driver of 
uncertainty is clearly the uncertainty in DTA parameters.  At a per decision 
value of £1339 and a population value of £10.5 million it is clear that further 
information would be beneficial and help reduce uncertainty in the cost-
effectiveness decision. 
Given that these results indicate that a study would be of value to collect 
information on the DTA characteristics for ceCT and PET/CT in metastatic CRC, 
the Trial data group indicates that including data collection on utilities and 
cost of PET/CT would also be worthwhile.  However, the cost of PET/CT and 
utilities parameters appear to have a reducing impact on the overall value, 
lowering the combined Trial information EVPPI (£10.1 million) to less than that 
of DTA alone (£10.5 million).  This effect was also apparent, and in the same 
direction, in the recurrent CRC model. The utilities and cost of PET/CT 
parameters have an effect of reducing uncertainty, resulting in a lower EVPPI 
value than when the DTA parameters are valued alone.  However, it can be 
concluded that at a value of £10.1 million if a trial was undertaken to gather 
evidence on DTA it would also be worthwhile collecting data on utility for the 
different disease groups and the cost of PET/CT. 
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4.5 Discussion 
This chapter used the case study of PET/CT to demonstrate an example of good 
practice where evidence synthesis and early decision analytic modelling was 
funded prior to primary research. The chapter explored uncertainty in the 
results for the each of different CRC patient groups and demonstrated that in 
using value of information techniques the results can be examined in terms of 
decision uncertainty to give meaningful recommendations to funders and 
decision making bodies.   
The results for each of the analyses will now be summarised followed by a 
discussion of using value of information analyses with early decision analytic 
modelling.   
4.5.1 Primary results 
The cost-effectiveness planes in the primary analyses showed that there was a 
lot of uncertainty surrounding both the incremental costs and incremental 
effects associated with PET/CT; however the cost-effectiveness acceptability 
curves show that this parameter uncertainty which impacted on the model 
outcomes does not translate into decision uncertainty. For both the primary 
rectal and primary colon analyses the probability that PET/CT as an add-on 
imaging device is cost-effective, is zero over the recommended QALY threshold 
range of £20k-£30k per QALY.  Therefore, we can be certain (99%) that the 
conventional strategy is cost-effective. In considering the value of further 
research, the EVPI value was very small, reflecting the low decision 
uncertainty.  Therefore, given current evidence we can be certain that the use 
of PET/CT as an add-on imaging device for staging primary colorectal cancers 
is not cost-effective and that there is no value associated with the collection of 
further information.  
As PET/CT technology develops, there will be an increased potential in the 
future for this improved technology to be used as a lone device, replacing 
contrast enhanced CT, as opposed to being utilised as an add-on imaging 
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device.  In primary rectal cancer, cePET/CT could potentially replace ceCT 
with the addition of an MRI scan, and in primary colon cancer, cePET/CT could 
be used alone as a replacement for ceCT.  The two scenario analyses 
undertaken to explore this in primary CRC indicated that such an improved 
cePET/CT device is unlikely to be cost-effective for use in primary rectal 
cancer, but is likely to be very cost-effective for use in colon cancer.    
In primary rectal cancer, an improved cePET/CT technology will not negate the 
necessity for an MRI scan, and therefore the potential incremental value of 
improved cePET/CT is limited by the strong DTA achievable with MRI scanning.  
The primary rectal cancer scenario CEAC indicated that at a monetary 
threshold of £30,000/QALY the probability of cePET/CT technology being cost-
effective in comparison to the conventional ceCT and MRI is less than 20%.  The 
colon cancer scenario analysis indicated substantial improvement in DTA from 
cePET/CT compared to ceCT and improved efficiency through eliminating the 
need for an add-on test, thereby giving a highly cost-effective outcome.  
However, there remains considerable parameter uncertainty and decision 
uncertainty, which is highlighted in the value of information analyses, 
indicating potential value in further research with a population EVPI of £1.7 
million for the primary rectal population, and a value of £12.3 million for the 
primary colon population.    
The scope of the research undertaken was set by the funding body and 
focussed on PET/CT as an add-on device, however, given the information from 
the systematic literature review it was evident that as an add-on technology 
PET/CT was not efficient and would have limited benefit in primary CRC; while 
an advanced cePET/CT technology (which is currently available in Japan and 
may become available in the UK in the near future) could be used as a 
replacement technology for conventional ceCT, rather than as an add-on 
device. The analysis was limited by the pre-specified research question, and 
therefore a scenario analysis was undertaken to demonstrate the potential for 
this alternative to the funders and decision-makers. However, if the funding 
body had undertaken some explorative research in defining the research 
question (at stage 1 of the iterative process) they might have been able to 
specify a more appropriate research question for primary CRC.  By applying the 
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formal process of evidence synthesis and early decision modelling (stage 2 of 
the iterative economic approach) we realise that the decision problem 
identified by the funding body was not quite appropriate.  The original scope 
was not fit for purpose with regards to primary CRC, and if a truly iterative 
process had been adopted, it could have allowed for a re-specification of the 
research question to explore the potential for cePET/CT in primary colorectal 
cancer.  
4.5.2 Recurrent results 
The ICER for the recurrent colon cancer model is considerably lower than that 
for the recurrent rectal cancer model, indicating that PET/CT is more cost-
effective in the assessment of colon recurrence than in rectal recurrence.  This 
difference is likely to be due to the sensitivity estimate for the ceCT diagnostic 
test parameter, which has considerably lower sensitivity than the PET/CT 
sensitivity estimate.  The wide difference favours the accuracy of PET/CT, and 
even though uncertainty around both these estimates was incorporated into 
the model, the strong influence of the DTA parameters on model outcomes is 
evident.  The PET/CT intervention does not have the same DTA sensitivity 
advantage in the recurrent rectal model, as the MRI scan DTA estimates are 
also incorporated.  The MRI DTA was superior to ceCT and therefore in the 
recurrent rectal model, the conventional imaging DTA estimates are closer to 
those of PET/CT, limiting the incremental value of PET/CT.   
At a cost per QALY threshold of £30,000 the probability that the PET/CT 
intervention will be cost-effective for recurrent rectal cancer is 70%, this is 
greater for recurrent colon cancer (85%). Compared with the primary model 
analyses (which showed 99% and 100% certainty that PET/CT was not cost-
effective) the recurrent model exhibits greater levels of decision uncertainty in 
both the rectal and colon analyses leading to non-zero values for the EVPI 
analyses.  At a population level the EVPI is £5.6 million for recurrent rectal 
cancer and £5.1 million for recurrent colon cancer, and therefore there is 
potential worth in collecting further information to inform the decision 
regarding the use of PET/CT in the future.   
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Given that further research is potentially worthwhile, EVPPI analyses were 
then undertaken for rectal and colon cancer to determine what type of 
‘further information’ would add most value.  Seven parameter groups were 
identified as potential sources of uncertainty and these were used in the EVPPI 
to explore whether any or all of them were responsible for driving the decision 
uncertainty. The EVPPI outcomes for the various parameter groups were in line 
with general expectations; all being very low (or zero in the colon analysis) 
with the exception of the DTA parameters which had population values of £5.6 
million and £4.5 million in the rectal and colon analyses respectively.   Given 
the limited and poor-quality DTA evidence found in the systematic review, it is 
unsurprising that it is this set of parameters that is driving uncertainty in the 
model.  For both rectal and colon recurrence the EVPPI for the DTA parameter 
group is very close to the overall EVPI value and therefore it is clear that the 
DTA parameters are driving the expected value in further research to help 
reduce the decision uncertainty.   
As it is the DTA parameters that require additional evidence, the type of 
further research that would be required is a study to evaluate the DTA 
characteristics for the PET/CT, ceCT and MRI technologies. Such a trial would 
not necessarily be an RCT, however, the existing DTA studies (identified in the 
systematic review) derived their evidence mostly from retrospective studies in 
university or oncology hospital settings.  Most of the studies used consecutive 
samples and only a few had comparators with no details provided regarding the 
use of blinding.  Therefore an RCT would provide some stronger evidence 
regarding DTA especially if it had an appropriate comparator, was blinded etc.  
Such a trial would not necessarily be a long term trial (as the EVPPI showed 
that there is little or no value in further research for the survival parameters), 
but of a short enough duration to determine unbiased DTA characteristics, and 
could possibly also be used to derive more accurate data on patients’ quality of 
life in the different disease states and the cost of PET/CT.  
4.5.3 Metastatic results 
The metastatic model found PET/CT as an add-on device to have an ICER of 
£21,434 per QALY gained.  This ICER value is within the UK monetary threshold 
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range of £20-30,000 per QALY (24) and could therefore be considered cost-
effective, however, the probabilistic sensitivity analysis and cost-effectiveness 
acceptability curve highlighted that there is considerable uncertainty regarding 
the cost-effectiveness decision.  The CEAC (in Figure 4-14) illustrated that at 
£30,000 per QALY the probability that the intervention strategy (add-on 
PET/CT) is cost-effective was only 52%.  This level of uncertainty leads to an 
EVPI of £10.5million for the population. Thus there is considerable decision 
uncertainty regarding PET/CT in metastatic CRC and therefore it is potentially 
worthwhile collecting further information to inform the decision regarding the 
cost-effectiveness. 
Having established that further research is worthwhile, it is necessary to 
explore the EVPPI in order to provide more meaningful results and 
recommendations to decision makers; particularly regarding what type (and 
possibly adequate duration) of ‘further research’ is required.  The EVPPI 
analysis found that there was potential value in undertaking research on all 
seven parameter groups identified, but that it is the diagnostic test accuracy 
parameters that drive the decision uncertainty.   With a population value of 
£10.5 million it is clear that further diagnostic information on the ceCT and 
PET/CT parameters would be beneficial and help reduce uncertainty in the 
cost-effectiveness decision. 
The EVPPI results indicate that a study (possibly, but not necessarily an RCT) 
would be of most value to collect unbiased evidence on the DTA characteristics 
for ceCT and PET/CT in metastatic CRC.  If such a trial were being undertaken 
it would be advantageous to also collect data regarding the utility for the 
different disease groups and the cost of PET/CT as indicated in the combined 
Trial information group which had an EVPPI of £10.1million. 
4.5.4 Model conclusions 
The economic literature and DTA systematic review undertaken for this 
research found only a small amount of evidence to support the use of PET/CT 
in the pre-operative staging of primary, recurrent and metastatic CRC and the 
data were generally divergent and the quality of research poor.  The economic 
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models were therefore designed, developed and populated based on a variety 
of information from published data sources, literature and in consultation with 
clinical experts. 
The economic evaluations reveal that given the high degree of uncertainty in 
the models and decision uncertainty in the results, PET/CT as an add-on 
imaging device is cost-effective in recurrent colon, recurrent rectal and 
metastatic colorectal disease.  There is value in undertaking further research 
in these disease areas, particular for generating evidence on diagnostic test 
accuracy.  The evaluations also found that add-on PET/CT is not cost-effective 
in primary colon or rectal cancer and further research is not worthwhile.  
However, the results of a scenario analysis suggest that future developments in 
PET/CT technology to enhance the CT element, making it equivalent to regular 
ceCT, might make cePET/CT cost-effective as a replacement rather than an 
add-on imaging device in primary colon cancer, although not in primary rectal 
cancer. Under this scenario further research is potentially worthwhile for both 
primary rectal and primary colon cancer. 
4.5.5 Early DAM & VOI 
This chapter has demonstrated the advantages of developing early stage 
probabilistic models which can be used to inform future research needs, as 
opposed to a more traditional approach whereby a research problem or lack of 
evidence is identified and used to support a case for primary research, without 
involving any decision analytic modelling.   In this case study, an exploration of 
existing evidence was undertaken, and separate analyses were undertaken for 
each of the appropriate patient groups (primary rectal cancer, primary colon 
cancer, recurrent rectal cancer, recurrent colon cancer, and metastatic 
disease); which each had different outcomes in terms of cost-effectiveness and 
the research needs.   
The decision problem was identified (at stage 1 of the iterative approach to 
economic evaluation) by the funding body and therefore the overall research 
question was pre-specified. This is commonly the case with research funding 
bodies which define an overall research question and put out a call for bids to 
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undertake the research.  Research bodies are, arguably, well placed to do this 
as they are likely to have formal criteria for setting research priorities, as well 
as the ability to engage with various stakeholders, however, a call for research 
from a funding body does not necessarily mean that the research question will 
adequately reflect the correct decision problem.  The call may be too 
prescriptive or alternatively too broad to adequately define the problem and, 
additionally, the research problem itself may not have been sufficiently 
explored, resulting in a sub-optimal research question.   
In this case of the PET/CT study the original research question was broad, 
stipulating an economic model to capture PET/CT as an add-on technology in 
pre-operative staging of colorectal cancer; however, staging pre-operative 
colorectal cancer is complicated. PET/CT and conventional imaging devices 
have different diagnostic test accuracies (DTA) for staging primary, recurrent 
and metastatic colorectal cancer, and as such, in order to address the initial 
research question, three separate economic models were designed.  Patient 
management routes also differ between colon and rectal cancer, and therefore 
the primary and recurrent models were adapted to incorporate the specifics of 
rectal and colon cancer separately.  Therefore, five analyses were undertaken, 
which was considerably more time consuming than originally envisaged.  
Additionally, the original scope of the question was not fit for purpose with 
regards to primary colorectal cancer.  Early into the research project it 
became evident that as an add-on technology PET/CT was not efficient and 
would have limited benefit in primary CRC; while an advanced cePET/CT 
technology (which may become available in the UK in the near future) has 
potential value as a replacement technology in primary CRC.  
It is interesting to consider that had the funding body undertaken some 
explorative research and possibly a DAM in defining the research question (at 
stage 1 of an iterative process) an iterative process could have been applied, 
allowing for a re-specification of the research question.  In the context of the 
iterative approach methodology, Stage 1 in itself may involve an iterative 
process where exploration of the literature leads to updating and re-defining of 
the research question for evidence synthesis and modelling in stage 2. A pre-
prescribed question set by a funding body may have less room for such 
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updating at an early stage and can lead to a research scope that is not fit for 
purpose or an inappropriate research question.  
Having developed a decision analytic model and undertaken probabilistic 
sensitivity analysis, the results can be used to undertake value of information 
analyses.  VOI is a methodological approach which uses the uncertainty 
surrounding the cost-effectiveness decision based on current evidence, the size 
of the patient population, the length of the technology lifespan and societies 
willingness to pay in order to place a monetary value on the worth of further 
research. VOI techniques can be used to make informed decisions as to 
whether a new intervention should be adopted (or rejected) based on current 
evidence, or whether further information is required to help make the 
decision, as opposed to making decisions subjectively.  
In some cases, such as with the primary colorectal evaluations, further 
research is found to be not worthwhile and if undertaken would be a waste of 
resources which could be used elsewhere, i.e. funding other, more promising 
research or used to fund clinical practice.  This case study highlighted that a 
lack of evidence (or poor quality evidence) does not necessarily mean that 
further research is required.  The primary CRC results illustrated considerable 
uncertainty in the cost and QALY outcomes from the probabilistic analysis (as 
detailed in Figures 4-1 and 4-2), however this did not translate into decision 
uncertainty.  If the analysis had not been extended beyond the PSA to consider 
decision uncertainty in the CEAC followed by EVPI, the cost-effectiveness 
outcomes may have been interpreted differently.  Limited DTA evidence in 
primary CRC along with uncertainty in the cost and QALY outcomes could have 
been considered to mean that further evidence in this area would be 
beneficial.  However, the EVPI showed that perfect information would not 
change the cost-effectiveness decision, and therefore there is no value in 
conducting further research.  This highlights the advantage of employing early 
decision modelling and using it to formally explore further research needs 
rather than deciding research needs subjectively on the basis of a lack of 
evidence. 
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The EVPI analyses for the recurrent CRC and metastatic patient populations 
demonstrated that further research is potentially worthwhile, with values in 
the region of £5 million and £10 million respectively.  As a research 
recommendation these EVPI outcomes are useful in terms of setting an upper 
limit on the cost of further research.  The EVPI sets an upper bound on the 
value of further research, so that research must cost less than the EVPI to be 
considered potentially worthwhile.  EVPPI analysis can be undertaken to help 
explore what type and scale of research is appropriate.  EVPPI analysis helps 
consider what parameters are driving the uncertainty in the cost-effectiveness 
decision, and it is through identifying the relevant parameters, that the 
appropriate type of research can be determined.  Further research does not 
necessarily mean that a large scale, randomised controlled trial is required, 
but rather, the type of research will depend on the different parameters that 
require further information.  Likewise, the cost of further research is also 
dependent upon the type, for example a large scale RCT with a 4 year follow-
up period may cost millions of pounds, which would be substantially greater 
than a smaller scale observational study, or an analysis of a routine dataset. 
Therefore, using value of information analyses to undertake EVPI, and then an 
EVPPI if it is potentially worthwhile is necessary to make the most use of 
outcomes and give informed recommendations to funders and decision-makers.  
The EVPPI results for the seven parameter groups identified were in line with 
expectations. In both the recurrent and metastatic models it was the DTA 
parameters that had the highest EVPPI value and were driving uncertainty, 
which makes sense as these were the parameters with most uncertainty 
identified from the literature.  If uncertainty had been restricted to 
parameters such as the utility or prevalence parameters then a clinical trial 
would not have been necessary, however for evidence on the diagnostic test 
accuracy of PET/CT, ceCT and MRI a trial would be required to determine 
unbiased test characteristics (but not necessarily a randomised controlled 
trial).  The duration of such a study could be relatively short term as the EVPPI 
determined that there would be little value in additional information regarding 
five year overall survival.  Both the recurrent and metastatic analyses 
indicated that the Trial information group (which included DTA, utility and cost 
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of PET/CT parameters) would be of value, however, the utilities and cost of 
PET/CT parameters have an effect of reducing uncertainty (in both the 
recurrent and metastatic analyses), resulting in a lower EVPPI value than when 
the DTA parameters are valued alone.  However, it can be concluded that at a 
value of £5 million and £10 million for recurrent and metastatic CRC 
respectively, if a trial was undertaken to gather evidence on DTA it would also 
be worthwhile collecting data on utility for the different disease groups and 
the cost of PET/CT. 
In summary, this chapter has demonstrated that even though early decision 
analytic modelling is not often funded and value of information analyses are 
even less frequently utilised in practice, it can be relatively straightforward 
and can have substantial benefits in terms of understanding outcomes and 
determining future research priorities when adequate funding and time is 
allocated to these activities.  Just because current evidence is limited or of 
poor quality, does not necessarily mean that further research is required, and 
therefore, applying early DAM and VOI techniques allows decision makers to 
make informed decisions as to whether a new intervention should be adopted 
(or rejected) based on current evidence, or whether further information is 
required to help make the decision, as opposed to making decisions based on 
subjective reasoning.  
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5 Designing clinical trials with economic 
evaluations 
Economic analyses are commonly undertaken alongside randomised controlled 
trials (RCTs) however; such trials are rarely designed with the economic 
outcomes in mind, and rarely involve the use of an early decision analytic 
model to aid in the trial design.  RCTs are typically designed to show evidence 
surrounding the clinical effectiveness of a new treatment or health technology 
in comparison to the current standard of care, and the economic component is 
often seen as an add-on to the trial (20;28).  Design considerations are 
different for clinical and economic analyses (44) and consequently when 
economic evaluations are conducted alongside clinical trials which were 
designed with only the effectiveness outcome in mind, they may be 
inadequately powered and designed for the cost-effectiveness analysis and 
therefore may represent a partial or limited form of economic analysis. 
If the purpose of the analysis is to inform decision making based on cost-
effectiveness outcomes then sample size and power calculations should be 
directly related to the cost-effectiveness result rather than to the 
effectiveness outcome alone.  Over the last decade there has been much 
discussion in the health economics community over alternative methods for 
undertaking such calculations (40;46;169-171) and the methodology for such an 
approach is now established.  Therefore considerations of economic 
assessments alongside clinical trials can and should be used to guide 
conventional trial design (39).  Despite the established methodology, in 
practice, health economists are rarely given the opportunity to contribute to 
trial design (46).   
This chapter reports on an atypical real life case in which a clinical and cost-
effectiveness trial was designed and powered to determine the sample size 
with regards to cost-effectiveness.  The Health Technology Assessment (HTA) 
programme (50) had issued a commissioning call for research to undertake an 
RCT and therefore the trial had already been planned without prior economic 
involvement, i.e. neglecting the first two stages of the iterative economic 
Chapter 5   237 
approach.  In principal there could/should have been a formal exploration of 
the decision problem followed by a literature review and evidence synthesis 
process involving a comprehensive decision analytic model built on the existing 
evidence.  If such an approach had been undertaken prior to the call for an 
RCT, probabilistic sensitivity analysis could have been undertaken to determine 
the potential cost-effectiveness of the new treatment and to formally explore 
uncertainty in the current evidence with regards to the cost-effectiveness 
decision. Value of information analyses (EVPI and EVPPI) could also have been 
undertaken to determine whether and what further evidence was potentially 
worthwhile with an EVSI analysis (as described in Chapter 2) undertaken to 
determine an appropriate sample size for any such trial.  EVSI is a technique 
used to quantify the expected value to the decision maker of obtaining sample 
information before making a decision (84).  EVSI and ENBS techniques are used 
to establish the efficiency of the proposed research design, ensuring a cost-
effective use of research funding.   
As is often the case, an iterative process such as this had not been followed, 
and an RCT was already planned, however, the opportunity arose to power the 
trial for economic endpoints.    Therefore a simple decision model was 
constructed as the proposal was being prepared and used to help inform the 
design of the trial. Even when there has been no prior economic modelling, 
involvement in the design of a trial from an economic perspective is still 
desirable and made possible by constructing a simple model within a short time 
frame.   
This chapter demonstrates the feasibility of sample size calculations from an 
economic perspective in the context of a standard frequentist trial, while 
simultaneously highlighting that a decision model can be constructed quickly 
and simply alongside the preparation of a trial proposal.  
The chapter discusses the proposed RCT of fetal fibronectin screening (fFN) for 
women with threatened pre-term labour, followed by the design of a 
preliminary model which was developed as the proposal was being prepared to 
inform the trial design calculation.  The predictions from this early ‘pre-trial’ 
model indicate potential cost-savings, but with a marginal detrimental impact 
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on the effectiveness endpoint, neonatal morbidity.  The atypical context of 
this situation, i.e. a trade-off between cost savings and a reduction in 
effectiveness, meant it may be appropriate to design the RCT as a non-
inferiority trial.  The aim of a non-inferiority trial is to demonstrate that the 
fFN test is not worse than the comparator (in terms of the outcome neonatal 
morbidity) by more than a pre-specified small amount known as the non-
inferiority margin (172). Therefore this chapter explores an appropriate design 
and sample size for the RCT using the outcomes from the pre-trial decision 
model.   The model predictions are discussed and used to explore sample size 
calculations based on each endpoint to determine their importance.  Following 
this, the net monetary benefits (NMB) approach for cost-effectiveness is 
discussed and used to calculate the required sample sizes at different powers.  
A non-inferiority approach, which is likely to be the best design for the trial, is 
then explored and a suitable non-inferiority margin determined.  The sample 
size calculations are then recalculated using the non-inferiority margin and 
compared with the NMB sample size, to select an optimal sample size for the 
trial which is sufficient for the cost-effectiveness endpoint and also to 
demonstrate non-inferiority for the effectiveness endpoint.   
5.1 Case study: fFN testing for pre-term labour 
Pre-term births (before 37 weeks) occur in nearly 8% of pregnancies in the UK 
(over 50,000 deliveries per annum); they are the leading cause of neonatal 
death and are also associated with both short and longer term morbidities 
(173).  Neonatal morbidities, including respiratory disease syndrome, are 
experienced by approximately 24% of pre-term infants (174), impacting on the 
infants’ future quality of life, but also affecting the parents and families 
quality of life.  There is currently no effective way of preventing pre-term 
labour; however, timely interventions such as administering steroids (175) to 
pregnant women who have symptoms of pre-term labour can help reduce 
morbidity and mortality experienced by preterm infants.   
In the UK approximately 15% of all pregnant women will experience symptoms 
of pre-term labour (120,000 annually) and under current practice these women 
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are hospitalised and receive steroids to lower the risk of infant morbidity and 
mortality.  Accurate diagnosis of preterm labour is challenging, and only 20% of 
women who are clinically diagnosed with symptoms actually experience 
premature births (174).  This clinical diagnostic uncertainty results in a large 
proportion of women with symptoms of pre-term labour being treated 
unnecessarily to ensure benefits to the small proportion of babies that do 
actually deliver pre-term.  While this ‘treat-all’ approach is clinically 
understandable, it is also detrimental, both for the women who are 
unnecessarily hospitalised and frequently transferred between maternity units 
causing considerable distress to them and their families (176), and also to the 
NHS which incurs a substantial cost burden.   
The fetal fibronectin (fFN) test is a diagnostic test which is easily performed 
and is potentially an effective means of diagnosing symptoms of pre-term 
labour.  A research study was proposed to explore whether using fetal 
fibronectin testing in women threatened with pre-term labour in the UK would 
lead to an improvement in patient management and resource use through 
reducing hospital admissions, transfers and intervention rates without 
increasing the risk of morbidities and mortality experienced by preterm 
infants.  The test was to be compared with standard practice in which 
diagnosis of pre-term labour amongst presenting women is based on clinical 
judgement and an ‘admit all to hospital’ approach.  This could be considered 
as an equivalence trial, assessing any improvements in patient management, 
with an expectation of similar endpoints in terms of actual pre-term births, 
neonatal mortality and neonatal morbidity.  There is, however, the potential 
for a slight increase in neonatal morbidity due to false negative test results, 
which needs to be considered.  Therefore the trial was designed based on the 
hypothesis that introduction of the fFN test would decrease unnecessary 
antenatal interventions, leading to substantial cost savings for health services, 
but that the existence of false negative test results could potentially increase 
neonatal morbidity.   Given this hypothesis, it is likely that a non-inferiority 
trial would be the most appropriate design, aiming to demonstrate that the fFN 
test is not worse than standard practice, (the admit all approach) in terms of 
neonatal morbidities, by more than a pre-specified small amount.  
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While infant death from pre-term labour is rare (177) pre-term labour is very 
common, with a resulting morbidity impact on approximately 9 in 1000 
pregnancies in the UK (178-180).  Therefore the RCT was designed in order to 
undertake a cost-effectiveness analysis of the fFN diagnostic test, in which cost 
savings that accrue through reduced hospitalisations could be accounted for, 
along with any potential impact on neonatal morbidities. 
5.1.1 A pre-trial model for fFN testing 
Prior to the commission of the RCT in fFN, there had been no economic 
involvement in the project, and therefore no funding or time allocated to the 
development of a comprehensive decision analytic model.  Such a situation is 
very common in the ‘real world’, where an economic component of the trial is 
not considered until the desire for and possibly the development of the trial is 
underway. However, such a situation does not necessarily negate economic 
input. A simple economic model can be constructed within a relatively short 
time frame and therefore it is still possible to have some economic input while 
the trial is being designed. Decision analytic models are simplified versions of 
reality and they can be as simple or complex as required without losing 
credibility (30).  Therefore, in the fFN case study, a simple ‘pre-trial’ decision 
model was developed with the intent of informing the trial sample size 
calculations.   
The model was populated with available data to assess the potential impact of 
introducing the fFN test on hospitalisations, neonatal morbidity and neonatal 
mortality in comparison to no test.  These model outcomes could then be used 
to aid the protocol design and undertake sample size calculations.  The model 
was developed in order to inform the trial design within the constraints of a 
grant submission timeframe utilising the most readily available evidence on the 
costs and effectiveness of fFN testing.  This model is therefore a simple, 
preliminary estimation, and like all models, subject to uncertainty in the 
parameter estimates.    
The two interventions of interest in the trial are (i) practice based on the 
results of the fFN test and (ii) standard practice in which there is no test and 
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diagnosis is based upon clinical judgement alone.  The pre-trial model was 
developed using a decision tree.  It was structured over a time horizon of 
months, representing the maximum time frame for women presenting with 
threatened pre-term labour (24+ weeks gestation) through to neonatal 
discharge (or until 3 months post birth).  Those women with a positive 
diagnosis (either based on clinical judgement or fFN test results) are 
hospitalised and receive steroids to lower the risk of pre-term related infant 
morbidity and mortality, while those diagnosed as negative are sent home and 
do not receive steroids.  The model timeframe ends at 3 months post-birth in 
order to capture the resultant neonatal morbidity and mortality impacts.  The 
decision tree detailed the patient pathway from a clinical diagnosis of 
threatened pre-term labour through to test outcome and actual birth term 
status to distinguish between accurate and inaccurate diagnoses and the 
resultant impact on hospitalisation, morbidity and mortality. The details of the 
decision tree are explained in the following section.  Once the patient pathway 
was depicted, model parameters (such as the costs, prevalence of pre-term 
delivery, diagnostic test accuracy and risk of morbidity) were assigned to the 
appropriate branches in the tree, to calculate the proportion of 
hospitalisations, pre-term neonatal morbidities and neonatal mortalities in 
each arm. 
5.1.2 Decision Tree 
The decision tree (Figure 5-1) was developed to illustrate the alternative 
pathways in the proposed trial.  The tree begins with the population of women 
in the UK who have been clinically diagnosed with pre-term labour (threatened 
pre-term labour) who will then be randomised to either the intervention arm 
(fFN Test) or the control arm (No test).  The tree has been designed based on 
the probability of actual term and pre-term births within the threatened pre-
term labour population. The tree splits the patient population according to 
pre-term and term prevalence prior to the test outcomes, so that accurate and 
inaccurate test diagnosis can be identified based on the sensitivity and 
specificity of the fFN test.   
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Prevalence Test Outcome Hospitalisation Morbidity Risk Mortality
Survive
Morbidity
Die
Hosp
No morbidity
Test +ve
True positive Survive
Morbidity
Die
No Hosp
No morbidity
Survive
Pre-term
Morbidity
Die
Hosp
No morbidity
Test -ve
False negative Survive
Morbidity
Die
fFN Test No Hosp
No morbidity
Hosp
Test +ve
False positive
Term No Hosp
Hosp
Test -ve 
True Negative
No Hosp
Clinical diagnosis Survive
threatened pre-term labour
Morbidity
Die
Hosp
No morbidity
Pre-term
Survive
No test Morbidity
Die
No Hosp
No morbidity
Hosp
Term
No Hosp
 
Figure 5-1: Decision tree for diagnosing pre-term labour 
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In the intervention arm (the top branch of Figure 5-1), those identified as 
“Test positive” by the test are diagnosed as pre-term labour (accurately and 
inaccurately) and are hospitalised and receive steroids which reduce the risk of 
neonatal morbidity.  Those identified as “Test negative” by the fFN test are 
diagnosed as a term labour (accurately and inaccurately) and are not 
hospitalised and therefore do not receive the morbidity reducing steroids.  
It is unrealistic to assume that the introduction of a diagnostic test will 
completely overrule clinical judgement and be adhered to fully, and therefore 
the structure of the model allows for the possibility of hospitalisation with 
negative test results and also for the possibility of no hospitalisation in some 
cases that had positive test results.  These assumptions were based on clinical 
advice and probabilities were determined from relevant audit data (181;182). 
By overruling the diagnostic test results with their clinical judgement the 
clinicians could be considered to be behaving irrationally, however, as clinical 
judgement has been the long standing current practice, this is more of an issue 
of professional trust in a new diagnostic test.  By overruling the test and 
‘admitting anyway’ the clinicians may in fact be (implicitly) addressing 
potential false negative results, possibly avoiding complications through failing 
to administer steroids and any potential resultant litigation proceedings for 
malpractice/incorrect diagnosis. 
The control arm (No test) is represented in the bottom half of the decision 
tree.  As in the top half of the tree, the population is split based on actual 
birth term status.  There is no test in this arm of the trial, and therefore all 
women clinically diagnosed with threatened pre-term labour would be 
hospitalised and receive steroids. While current clinical practice follows an 
‘admit all’ approach, a 100% admittance assumption was deemed to be 
unrealistic in consideration of obstetrician’s clinical judgement and therefore 
the model structure allows for the possibility that some women who were 
clinically diagnosed as pre-term would not be admitted to hospital. 
The model assumes that all pre-term infants are subject to a risk of neonatal 
morbidity, however those whose mothers were hospitalised in the model (and 
therefore received steroids) have a lower risk of morbidity, than those whose 
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mothers were not hospitalised, and did not receive steroids.  Therefore, 
women who experience false negative test results and so do not receive the 
risk reducing steroids may consequently have infants who experience greater 
neonatal morbidity than those in the control arm (under an ‘admit all’ 
approach).  The model does not attribute any negative effects of receiving 
steroids unnecessarily, as clinicians advised that any adverse effects would be 
experienced over the longer term (183;184) out with the time horizon of the 
model.  The clinical experts on the project team advised that in current 
practice (where there is an ‘admit all’ approach based on clinical judgement) 
the potential risk of future negative consequences from receiving steroids 
unnecessarily are likely to be outweighed by the short term risk to mother and 
child of not receiving steroids that are needed. The model assumes that only 
pre-term infants subject to neonatal morbidity are at risk of neonatal 
mortality.  Term infants are assumed not to be subject to either pre-term 
morbidity or mortality.    
The parameter estimates applied to the model were based on available 
evidence and are detailed in Table 5-1.  The sensitivity and specificity of the 
fFN test, probabilities of delivering pre-term, experiencing pre-term neonatal 
morbidity, mortality and the morbidity risk reduction from steroids were based 
on published evidence.   
The probabilities of hospitalisation in the intervention arm for test positive 
(93%) and test negative (32%), were based on recent UK audit data (181;182), 
and in the control arm an author assumption (based on clinician advice) was 
applied for probability of hospitalisation (90%), rather than assuming a protocol 
adherence of 100%. 
A scenario analysis was also undertaken, where the clinical judgement 
assumptions were relaxed and there was 100% adherence to protocol.  
Therefore 100% of women in the control (no test) arm would be hospitalised, 
and in the intervention arm 100% of positive diagnoses would hospitalised and 
100% of negative diagnoses would be sent home. 
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Table 5-1: Model parameters 
Item Unit Description Source 
        
fFN Sensitivity 0.822 Average sensitivity from 7, 14 & 21 days sensitivity outcomes (185) 
fFN Specificity 0.787 Average specificity from 7, 14 & 21 days sensitivity outcomes (185) 
        
Prob pre-term 0.2 Probability of delivering pre-term amongst threatened pre-term population (174)  
Prob pre-term morbidity 0.244 Probability of morbidity in pre-term births (ICU admissions only) (174)  
Steroid risk reduction 0.54 Relative risk pre-term morbidity reduction with steroids (175) 
Prob mortality 0.0257 Probability of mortality in pre-term births (average ≤36 weeks) (177) 
        
Prob hosp admit fFN +ive 0.93 Clinical judgement: Probability of hospital admission when fFN positive  (181;182) 
Prob hosp admit fFN -ive 0.32 Clinical judgement: Probability of hospital admission when fFN negative (181;182) 
Prob hosp admit NoTest 0.9 Clinical judgement: Probability of hospital admission when No Test  Author assumption 
    
Risk hospital transfer 0.321 Risk of hospitalised patients being transferred to another hospital (186) 
        
Cost fFN Test £50 Cost of administering test (185) 
Cost hospital admission £1,068 Maternity inpatient cost per stay (average 2.2days) including treatment (187) 
Cost hospital transfer £1,000 Estimate to reflect NHS cost of transfers between different hospitals Author & clinical expert assumption 
        
ICU=intensive care unit, prob=probability 
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5.1.3 Pre-trial model predictions 
The pre-trial model was used to calculate the proportion of women that were 
hospitalised and the proportion of infants that experienced pre-term neonatal 
morbidity and mortality, for the intervention (test) and control (no test) arms. 
These model outcomes are predictions based on the decision tree pathways, 
assumptions and parameter estimates.  Table 5-2 details the model 
predictions, showing that there are nearly 37.6% fewer hospitalisations in the 
test arm, while there is a minor increase in pre-term morbidity and mortality 
of 0.18% and 0.005% respectively.  So, in comparison to the current standard of 
care where there is no test administered, the introduction of the fFN test is 
likely to substantially reduce hospitalisations but at the expense of an 
additional 18 neonatal morbidities and 0.5 neonatal mortalities per 10,000 
threatened pre-term births. 
Table 5-2: Model predictions 
Model Arm 
Proportion 
Hospitalised 
Proportion 
Mortality  
Proportion 
Morbidity 
        
Test (intervention) 0.52423 0.00078 0.03036 
No test (control) 0.90000 0.00073 0.02860 
    
Difference -0.37577 0.00005 0.00176 
 
The average cost of hospitalisation was found to be £1439.  This is based upon 
the unit costs detailed in Table 5-1 for admissions, test and transfer and the 
associated probabilities of incurring these costs.  Therefore, a reduction in 
hospitalisations by 0.375 is equivalent to a cost saving of £541 per women with 
threatened pre-term labour. Considering that it is estimated approximately 
120,000 women are clinically diagnosed with threatened pre-term labour in the 
UK each year (173), an fFN screening test which reduced pre-term 
hospitalisation of these women by 37.5% at an average cost of £1439 per 
hospitalisation, could potentially save the NHS approximately £65 million per 
year through avoiding unnecessary hospitalisations, however, this strategy is 
likely to present an additional 211 cases of pre-term neonatal morbidity and 6 
additional cases of neonatal mortality annually.   
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In this case the model predictions would fall into the South West quadrant of 
the cost-effectiveness plane.  This is demonstrated in Figure 5-2, showing the 
model predictions of a reduction in effectiveness (an increase in probability of 
morbidity by 0.0018) accompanied by cost savings of £541 per women with 
threatened pre-term labour.  
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Figure 5-2: Cost-effectiveness plane for fFN model prediction 
 
Interventions that fall in the North East and South West quadrants require an 
estimate or ‘value judgement’ regarding societies willingness to pay (or 
willingness to accept savings) per unit of effectiveness gained (lost).  This 
value is the maximum acceptable cost-effectiveness ratio or ceiling ratio (λ), 
as discussed in Chapter 2 (section 2.4.3).  To determine whether the fFN model 
outcomes are cost-effective or not, the ceiling ratio needs to be determined7.   
                                         
7
 A detailed discussion of the ceiling ratio and how it was derived for the fFN trial is provided in 
section 5.2.2 
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Most commonly society is happy to accept a monetary threshold of willing to 
pay per unit of effectiveness gained, but many decision makers can become 
uncomfortable when considering the reverse, a willingness to accept a cost 
saving per unit of effectiveness lost.  Logically, if we are willing to accept a 
specified ceiling ratio for gaining effectiveness, we should be willing to accept 
the reverse.  However, in the South West quadrant ethical issues may come in 
to play and some decision makers may be less willing to accept the same 
ceiling ratio for this quadrant. O’Brien and colleagues make the case that 
consumers’ willingness to accept a payment to forego a benefit is greater than 
their willingness to pay to get the benefit and therefore, such considerations 
should be applied to the maximum cost-effectiveness ratio (78).  Under this 
approach decision makers may require a much greater cost saving in order to 
accept a reduction in effectiveness, resulting in a kinked ceiling ratio.   
This concept of a kinked ceiling ratio (78) is however, irrational as it results in 
a situation where for example, the ceiling ratio for the North East (NE) 
quadrant of the cost-effectiveness plane is £30,000 per QALY gained, but for 
the south west (SW) quadrant is £50,000 per QALY lost.  In such a situation 
society is not willing to accept an intervention which saves £30,000 but is 
accompanied by a reduction of 1 QALY; the intervention would have to save at 
least £50,000 per QALY lost.  However, this is irrational, and importantly it 
does not consider the opportunity cost of imposing a greater ceiling ratio in the 
SW quadrant. The £30,000 saved (at the expense of 1 QALY lost) could be spent 
more efficiently on another health technology in the NE quadrant which had 
for example an ICER of £15,000 per QALY, i.e. gaining 2 QALYs for £30,000.  So 
by setting a greater ceiling ratio for willingness to accept a reduction in 
effectiveness (SW quadrant) society is imposing an even greater opportunity 
cost in terms of other highly cost-effective technologies which could have been 
funded on the basis of accepting a technology which gives a saving of £30,000 
per QALY lost.   
 
 
Chapter 5   249 
Scenario: 100% protocol adherence 
Table 5-3 details alternative model predictions under a scenario where the 
clinical judgement assumptions are relaxed and patients in the intervention 
arm are only hospitalised when the fFN test is positive, and 100% of women in 
the control (no test) arm are hospitalised under the ‘admit all’ approach.  
Table 5-3: Scenario model predictions 
Model Arm 
Proportion 
Hospitalised 
Proportion 
Mortality  
Proportion 
Morbidity 
        
Test (intervention) 0.33480 0.00078 0.03035 
No test (control) 1.00000 0.00068 0.02635 
        
Difference -0.66520 0.00010 0.00400 
 
The scenario analysis predicts a 66% reduction in hospitalisations in the test 
arm compared to the control, with an increase in pre-term morbidity and 
mortality of 0.4% and 0.01% respectively.  In comparison to the baseline model 
predictions in Table 5-2, the reduction in hospitalisations is improved (as there 
are more hospitalisations in the control arm, and fewer under the test arm); 
however the negative impact on effectiveness in terms of mortality and 
morbidity is greater.  Under the assumption of no clinical judgement and 100% 
protocol adherence, the introduction of the fFN test is likely to substantially 
reduce hospitalisations by 66% but at the expense of an additional 40 neonatal 
morbidities and 1 neonatal mortality per 10,000 pre-term births in comparison 
to the current standard of care where all threatened pre-term labour women 
are admitted to hospital to receive risk reducing steroids.  By relaxing the 
clinical judgement assumptions the model outcomes are exaggerated in both 
directions.  The cost savings through reduced hospitalisations are even greater 
than in the baseline model; however, the cases of pre-term morbidity have 
more than doubled, increasing from 18 per 10,000 births in the baseline model 
predictions to 40 per 10,000 births in this extreme scenario.    In reality clinical 
judgement will always come into play alongside the results of a diagnostic test, 
and in the control arm, where only clinical judgement is used it is unrealistic 
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to assume that 100% of the threatened pre-term labour women would be 
admitted to hospital.  
The pre-trial model predicted that the new intervention (fFN test) is likely to 
be cost saving, with a small but potentially detrimental impact on 
effectiveness in terms of both a marginal increase in neonatal morbidity and 
also in neonatal mortality. Therefore it is important to investigate both the 
morbidity and mortality endpoints when designing the fFN trial in order to 
explore what can be considered an acceptable reduction in effectiveness, 
which in turn will impact on the sample size calculations.   
5.2 Sample Size calculations 
5.2.1 Superiority Sample Size  
The sample size for a trial is calculated at the design stage to ensure the study 
will have adequate power to show a significant difference between the two 
arms, this is known as a superiority trial design i.e. it is designed to detect a 
significant difference between treatments (188).  The endpoints of interest 
from the fFN trial are the differences in hospitalisations, neonatal morbidity 
and neonatal mortality, reported as proportions.  In this study hospitalisations 
represent the cost endpoint, but there are two effectiveness endpoints of 
potential interest, morbidity and mortality.  Superiority sample sizes were 
initially calculated for each of these three endpoints, in order to determine 
which of the two effectiveness endpoints was likely to be the most meaningful 
for the cost-effectiveness sample size calculation.  
The superiority sample size requirements were calculated using standard 
methods for proportions (72). Typically sample sizes are calculated by 
comparing the means of two populations which have the same known variance, 
however; when detecting a difference between two proportions, the approach 
is slightly different. A test of the null hypothesis is specified, that each 
proportion is equal to the pooled value of the two proportions and the variance 
of the difference between the proportions can be different for the null and 
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alternative hypotheses.  As this case study uses proportions from the pre-trial, 
for simplicity sake a normal distribution was assumed for the proportions (as n 
approaches infinity) to allow equal variance for the difference in effect under 
the null and alternative. Table 5-4 details the parameters used for these 
calculations and their values, where M represents the effectiveness outcome 
for the morbidity calculation, D represents the effectiveness outcome for 
mortality and H represents the hospitalisation outcome. 
Table 5-4: Sample size calculation parameters 
Abbreviation Value Description 
H 0.712114 Hospitalised proportion pooled 
HT 0.524228 Hospitalised proportion Treatment 
HC 0.9 Hospitalised proportion Control 
M 0.0294788 Morbidity proportion pooled 
MT 0.0303608 Morbidity proportion Treatment 
MC 0.0285968 Morbidity proportion Control 
D 0.0007576 Mortality proportion pooled 
DT 0.0007803 Mortality proportion Treatment 
DC 0.0007349 Mortality proportion Control 
λ £25,700 Value of avoiding morbidity 
C £1,439 Cost Hospitalisation  
Power 0.9 Beta (β) 
Significance 0.05 Alpha (α) 
Zα/2 1.96 Critical value of significance test 
Zβ 1.28 Critical value for desired power 
ρ 1 correlation of the difference in costs & effects 
      
 
The sample size (n) is required to show a significant difference in effect (∆Ε) 
between the two arms.  This is calculated using the algorithm detailed in 
Equation 5.1.  The sample size problem is expressed as one of determining the 
sample size given the power and magnitude of the specified effect to be 
detected (72).  Therefore, following the convention for statistical significance, 
alpha (α) was set to show a significant difference at the 5% level and the power 
was set at 90%.  zα is the 100 percentile for the standard normal distribution, 
so that zα/2 is the standard normal deviation with a two sided significance 
level, and given a specified power of 90%, zβ is the critical value.  The null 
hypothesis (∆ΕN) assumes there is no difference between the pre-term neonatal 
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morbidity in the two arms (ET = EC), i.e. the pooled proportion is used; and the 
alternative hypothesis (∆ΕA) assumes that there is a difference between the 
two arms (ET ≠ EC).  zα/2 is multiplied by the variance (v) of the change in 
morbidity under the null hypothesis, and zβ is multiplied by the variance (v) of 
the change in morbidity under the alternative hypothesis. 
( ) ( ) 2AβN2
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Ev*zEv*z
n 
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       (5.1) 
Equation 5.2 (72) provides a more detailed breakdown of this calculation, 
specifying the variance of the difference in morbidity under each hypothesis.  
As the null assumes no difference (∆Ε = 0) between the treatment and control 
arms, a pooled value for effect (E) is used, while the alternative hypothesis 
calculates the difference in effect (∆Ε = ET - EC) using the proportion of 
effectiveness in the intervention arm (ET) and the proportion of effectiveness 
in the control arm (EC).   
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This equation was solved for pre-term neonatal morbidity using the M values 
(M, MT and MC) detailed in Table 5-4 to represent Ε, ET and EC which are the 
pooled, treatment and control predictions for morbidity from the pre-trial 
model.  The calculation was then repeated solving for hospitalisations (using 
the H proportions in Table 5-4 to represent Ε, ET and EC) and for mortality 
(using the D proportions in Table 5-4 to represent Ε, ET and EC).  The sample 
sizes derived from each of these calculations are detailed in Table 5-5. 
Table 5-5: Superiority sample sizes for each endpoint 
Outcome Sample per arm Total sample size 
Hospitalisations (H) 28 56 
Morbidity (M) 193,222 386,444 
Mortality (D) 7,740,945 15,481,890 
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Using this superiority approach it can be seen that the mortality outcome 
measure predicts an enormous and unrealistic sample size requirement of over 
7 million participants per arm to show a significant difference between the 
intervention and control.  The sample size based on the morbidity measure is 
much smaller but also unrealistic at over 193,000 per arm; while the 
hospitalisation measure requires an extremely small sample size of only 28 
participants per arm to show a significant difference between the treatment 
and control.   
These outcomes illustrate that it is possible to base a superiority sample size 
calculation on the hospitalisation measure; however, this is only an indicator of 
cost and does not provide any information about safety or mortality outcomes.  
It is clear from the model predictions in Table 5-2 and the superiority sample 
size outcomes in Table 5-5 that the mortality outcome will only show a 
negligible difference between the intervention and control arms.  The 
morbidity outcome measure predicted from the pre-trial model indicates a 
slight increase in morbidity (18 per 10,000 threatened pre-term labours), and 
therefore has some potential to be a meaningful measure of effectiveness.  
Therefore it was deemed appropriate to explore the relevance of a non-
inferiority approach for morbidity as a measure of effectiveness, i.e. to show 
that the fFN test is not worse than the control, within a pre-specified margin 
of non-inferiority for morbidity (172;188).   
Ultimately the trial was concerned with calculating the sample size based on 
the cost-effectiveness outcome rather than the cost or effectiveness outcomes 
individually.  Therefore it was decided that the hospitalisation and morbidity 
predictions from the pre-trial model would be used in the cost-effectiveness 
sample size calculation using the net monetary benefit approach (NMB), and 
would then be double-checked against a non-inferiority calculation for the 
morbidity effect alone. 
The next section discusses the NMB approach and details the sample size 
calculation that was undertaken, followed by a discussion of the non-inferiority 
approach that was used to ensure the sample was large enough to show that 
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the test was no less effective than the control within a pre-specified margin of 
non-inferiority.   
5.2.2 Net Monetary Benefit Sample Size 
The NMB approach  
With regards to the fFN case study, neonatal morbidity is the effectiveness 
endpoint while hospitalisations are used to reflect any potential cost savings.  
As such the NMB approach will balance the monetarised value of the increase 
in neonatal morbidities against the cost savings resulting from reduced 
hospitalisations.  Therefore the two elements of the cost-effectiveness 
outcome are the difference in hospitalisations (∆H) and the difference in 
neonatal morbidity (∆E) between the two arms.  Equation 5.3 illustrates the 
net monetary benefit calculation, which requires a ‘willingness to pay’ value 
(λ) to reflect the monetary value of avoiding morbidity. This is multiplied with 
the difference in neonatal morbidity (∆E), while the average cost of 
hospitalisation (C) is combined with the difference in hospitalisations (∆H) and 
subtracted. 
H*CE*NMB ∆−∆=
λ
        (5.3) 
The ‘willingness to pay value’ (λ) is a subjective value.  In this case it is used 
to reflect the monetary value of avoiding pre-term neonatal morbidity and 
therefore some assumptions are used to derive an appropriate value.  In order 
to derive a realistic value, the statistical value of a life was taken to be a 
useful monetary indicator for the value of preventing an infant mortality and 
was multiplied by the probability of experiencing pre-term mortality, given 
pre-term morbidity in the model, to determine a value of avoiding an infant 
morbidity.  The European Union (2001) recommendations suggest that a value 
between €0.9 and €3.5 million (1€ ~ £0.6004, 2001) should be assigned to 
reflect the value of a life (189).  The UK Department for Transport recommend 
a value of £1.4million (190) while Abelson et al. (191) also report similar 
ranges in a review of studies that have estimated the value of a life, however 
they note that some studies have indicated that the top end of these ranges 
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are overestimations.  Given this evidence it was deemed to be reasonable to 
assign a value between £500,000 and £2.5million, and it was assumed that an 
estimate of £1million would be a realistic reflection of the statistical value of a 
newborn life which has not yet contributed to society.  The statistical value of 
avoiding a pre-term neonatal morbidity was then derived (by multiplying the 
probability of mortality amongst pre-term births (177) with the statistical value 
of a life at birth), and estimated to be £25,700. 
The NMB can then be calculated using the values from the model predictions, 
for the difference in neonatal morbidity (∆E) (effectiveness), the difference in 
hospitalisations (∆H) (cost) and the average cost of hospitalisation (C) and 
incorporating the willingness to pay estimate (λ) into the NMB formula. 
Using NMB to calculate sample size 
Over the last decade there has been much discussion on appropriate methods 
for calculating conventional trial sample sizes based on expected cost-
effectiveness outcomes (40;46;169-171).  Most typically this can be done 
following the net monetary benefit approach.  By using the NMB approach, a 
sample size for a cost-effectiveness outcome can be calculated in the standard 
way as typically used for mean effectiveness (72), but based on the expected 
change in NMB.  Briggs et al. (46), provides a thorough explanation of the 
theory and equations, which are briefly summarised here.    
The calculation is based on a hypothesised difference in both costs and effects 
with associated hypothesised variances and covariance along with a set 
monetary willingness to pay value (λ).  These are used to calculate a 
hypothesised net monetary benefit (NM B).  The null hypothesis (NM BN) assumes 
the net benefit is zero, i.e. there is no difference between the costs and 
effects of the interventions, while the alternative hypothesis (NM BA) assumes 
that there is a difference between the costs and effects, i.e. the net benefit is 
different from zero.   
Equation 5.4 illustrates the standard equation to show a hypothesised net 
monetary benefit (NM B) as different from zero.  Let zβ represent the critical 
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value from the standard normal distribution corresponding to a required power 
of 1-β and the variance expressions (v) for net-benefit are based on the 
hypothesised variance in cost and effect, and their covariance.  zα/2 is 
multiplied by the variance of the net monetary benefit under the null 
hypothesis, and zβ is multiplied by the variance of the net monetary benefit 
under the alternative hypothesis. Note that this is the same as the standard 
approach for effectiveness, as illustrated in Equations 5.1 and 5.2, with the 
difference in NMB under the null (NMBN) and alternative (NM BA) hypotheses 
replacing the difference in effectiveness under the null and alternative 
hypotheses. 
 ( ) ( )AβN2 BM~NvzBM~NvzBM~N ∆∗+∆∗> α       (5.4) 
Where: 
 HCENMB ∆∗−∆∗λ= ,        (5.3) 
and: 
( ) ( ) ( ) ( )C,Ecov2CvEv*BM~Nv 2 ∆∆λ−∆+∆λ=       (5.5). 
As the net monetary benefit calculation uses the cost and effect variables, 
which in this case are proportions, the standard methods are slightly modified 
for dealing with proportions (72), i.e. the null hypothesis uses the pooled 
proportions for cost and effect, and the variance for the NMB under the null 
and alternative hypotheses can differ.  A normal distribution was assumed for 
simplicity, allowing equal variance expressions for the null and alternative 
hypotheses.  Therefore, given Equations 5.4 and 5.5, the variance of the 
difference in NMB under the null hypothesis is: 
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and the variance of the difference in NM B under the alternative hypothesis is: 
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(5.7). 
By incorporating these variance expressions for the hypothesised null and 
alternative NM B (Equations 5.6 and 5.7) into the standard NM B significance 
expression (Equation 5.4) the variance expressions can then be divided by the 
required number of participants in the control and treatment arms (n), and 
rearranged to solve for the required sample size (n) to show a significant 
difference in hypothesised NM B.  Equation 5.8 illustrates this and is fully 
expanded in Equation 5.9 to detail the variance expressions.   
 
( ) ( ) 2AβN2
BM
~
N
BM
~
NvzBM
~
Nvz
n








∆
∆∗+∆∗
>
α
      (5.8) 
 
2
AAAA
2
βNNNN
2
2/
)∆CE(
)))C,Ecov(*2)C(v)E(v(*z()CEcov(*2)C(v)E(v*z(
n








−∆λ
λ−+λ+λ−+λ
> α  (5.9) 
This is the standard methodological approach for sample size calculations using 
the NMB approach, but in this case we have used proportions for the cost and 
effect variables, as opposed to continuous variables. This process was used to 
determine the sample size required for the fFN trial, in order to detect a net 
monetary benefit greater than zero.  The calculation was based on 
conventional power and significance levels, taken to be 90% power at the 5% 
significance level.  The inputs for this sample size calculation are the same as 
those used in the individual sample size calculations, (i.e. the pre-trial model 
prediction values for morbidity (M, MT, MC) (effectiveness), hospitalisations (H, 
HT, HC) (cost), and the average cost of hospitalisation in the model (C)), as 
detailed in Table 5-4, with the addition of the willingness to pay value (λ), and 
a correlation value for the covariance (ρ). 
Table 5-6 shows the outcomes from this calculation, detailing the sample sizes 
required in the trial to detect a NMB greater than zero at different levels of 
power.  As would be expected a stronger power for the study requires a larger 
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sample size per arm.  At a 90% power a total sample of 1850 participants would 
be adequate to detect a NMB greater than zero.   
Table 5-6: NMB sample sizes under different power specifications 
Power Sample per arm Total sample size 
   
90% 925 1850 
80%
 
701 1402 
70%
 
559 1118 
 
Choice of ceiling ratio 
As previously discussed the ceiling ratio or ‘willingness to pay’ value for the 
NMB expression is a subjective value; there is no universally accepted ceiling 
ratio which exists for decision making purposes.  In the UK, the threshold of 
£20,000-30,000 per QALY, recommended by NICE (24), tends to be adopted.     
The value of a statistical life was used in the fFN pre-trial model to reflect the 
value of preventing an infant mortality, and used to derive the value of 
preventing an infant morbidity.  This value was set at £1million, however there 
is considerable debate regarding the approaches used to derive this value (189) 
and the resultant monetary amount that appropriately reflects this value 
(190;191). It was felt that a value of £1million would be a realistic reflection of 
the value of a statistical life for a new-born who has not yet contributed to 
society, for the fFN case.  However, it may have been appropriate to use a 
value reflecting the cost of initial intensive care for neonates with pre-term 
morbidity to represent the willingness to pay value.  Costs of caring for low 
birth weight and premature babies are extremely variable with some sources 
reporting between £720 - £3280 per case depending on severity (192), while 
others report a mean cost of £5063 (price year 1998), which again varies 
considerably depending on gestational age (193).  Alternatively the monetary 
value of a QALY (194;195) could be used to reflect the willingness to pay value, 
rather than the monetary value of a statistical life or a hospitalisation cost of 
neonatal morbidity.   Using alternative methods to derive a willingness to pay 
value will generate different sample sizes.  Briggs & Gray (170) suggest plotting 
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the sample size requirements as a function of the maximum cost-effectiveness 
ratio to explore the impact of the choice of ceiling ratio on the sample size. 
In order to explore the structural uncertainty surrounding which approach and 
alternative values should be used; the sample size calculations were repeated 
using a variety of QALY thresholds for willingness to pay.   
The baseline model developed was based on morbidities avoided, applying a 
willingness to pay societal value per morbidity avoided.  Using this method the 
cost-effectiveness evaluation was directly related to the proposed trial primary 
outcome (pre-term morbidity).  Alternatively, a QALY model could have been 
developed.  This alternative was considered and a very rough assessment of 
QALY outcomes incorporated.  The present value of a QALY at birth was 
calculated using 2007 life expectancies for both males and females (196) and 
UK population norm QALY values (124), discounted at a rate of 3.5% (24).  This 
generated an estimated present value of a new life of 42.7 QALYs.  This QALY 
outcome was used to re-calculate the NMB sample size under different 
monetary thresholds for a QALY (λ).  Table 5-7 details the baseline sample size 
generated for the fFN RCT using the statistical value of avoiding morbidity 
(£25,700), alongside the sample sizes generated at alternative thresholds (λ) of 
£20,000, £30,000, £40,000 and £50,000 per QALY.  All calculations were 
undertaken using a power of 90% and significance at 5%. 
Table 5-7: NMB sample sizes under alternative monetary thresholds (λ) 
Monetary threshold(λ) Sample per arm Total sample size 
£25,700† 925 1850 
£20,000 per QALY 662 1324 
£30,000 per QALY 1537 3074 
£40,000 per QALY 2683 5366 
£50,000 per QALY 4045 8090 
†baseline WTP value to avoid morbidity derived from statistical value of a life at birth 
(assumed to be £1million) 
As the monetary threshold increases, the sample size requirements increase.  
Increasing the λ value reflects an increase in societies willingness to pay to 
avoid a neonatal morbidity (each neonatal morbidity has a greater cost to 
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society), and therefore the cost saving which accrue from fewer 
hospitalisations with the fFN test become outbalanced by the greater cost to 
society for the few false negative test cases who do experience a neonatal 
morbidity.  Therefore as the willingness to pay value increases, the fFN test 
will have a lower NMB gain against current practice, becoming less cost-
effective and requiring a greater sample size to show that the fFN test has a 
significantly positive NMB. 
In light of these alternative outcomes, potential funders should consider what 
society/they consider to be an appropriate ceiling ratio/willingness to pay 
(accept) value per QALY gained (lost).  The current recommended ceiling ratio 
in the UK is £30,000 per QALY, however, as the cost-effectiveness decision is in 
the south west quadrant of the cost-effectiveness plane, decision makers may 
require a much greater cost saving in order to accept a reduction in 
effectiveness (resulting in a kinked ceiling ratio), as previously discussed.  If 
the willingness to accept a cost saving per QALY loss is greater than £30,000 
per QALY, then funders should consider that a trial with a sample size of 
approximately 2000 is unlikely to show any conclusive results. For example, 
once funded, such a trial may well require an extension, or may well not show 
a significant difference.  However, given the current ceiling ratio of £30,000 
per QALY recommended by NICE in the UK, the sample size required to show a 
significant difference is feasible.   
5.2.3 Non-inferiority approach 
Standard approach to non-inferiority 
A non-inferiority trial aims to demonstrate the intervention is not worse than 
the control by more than a pre-specified, small amount known as the non-
inferiority margin (NI margin) (172). The NI margin is a criterion that is set so 
that the new interventions non-inferiority can be judged, i.e. that any 
difference in effect between the intervention and control is less than or equal 
to the NI margin, but not greater than this amount.  Therefore, non-inferiority 
designs require the specification of the NI margin in advance of a trial.  Setting 
an appropriate NI margin is essentially an arbitrary judgement; however, 
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guidelines on the choice of non-inferiority margin (172) are available.  These 
highlight important considerations for the choice, which should be based upon 
a combination of statistical reasoning and clinical judgement.  
In establishing an NI margin for a new intervention, it is common to base the 
margin on a proportion of the control effect size, for example less than a third 
of the established effect, and therefore, it is recommended to look historically 
at placebo-controlled trials for the active comparator and use statistical 
reasoning to determine an appropriate NI margin (197).  The Committee for 
Medicinal Products for Human use (CHMP)(172) propose that a systematic 
review be undertaken to identify studies relevant to the comparison of the 
control treatment with placebo in the disease area being considered. Using 
such literature, indirect comparisons can then be made with studies comparing 
the control with a placebo using the lower bound of a 95% confidence interval 
to establish an efficacy advantage over a placebo.  
The CHMP guidelines are concerned with establishing an NI margin based on an 
effectiveness endpoint, however, from an economic perspective we are 
interested in both the effect and cost endpoints and therefore acceptance of a 
new intervention is dependent on ‘non-inferiority’ in both clinical and cost 
terms.   
Non-inferiority in the fFN trial 
Due to the atypical nature of the fFN intervention (cost saving but with a 
potential marginal reduction in effectiveness), a non-inferiority design may be 
appropriate for the effectiveness endpoint, which aims to demonstrate that 
the fFN test is no worse in terms of the clinical outcomes than the control, by 
more than a pre-specified, small amount.  However, in terms of the cost 
endpoint the intervention is likely to show superiority over the control.  The 
pre-trial model predictions detailed in Table 5-2 and the superiority sample 
sizes in Table 5-5 illustrate that this is likely to be the case.  The trial is likely 
to show a substantial reduction in the number of hospitalisations, which will 
have considerable cost saving implications, without having a significant 
detrimental effect on neonatal morbidity.  Therefore, a non-inferiority sample 
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size calculation for morbidity (combined with a superiority outcome for costs) 
was undertaken in addition to the previously specified NMB sample size 
calculation.  This ‘additional’ NI sample size calculation was undertaken to 
ensure that the sample for the trial was also large enough to show that the test 
was no less effective than the control within a given cost-effectiveness defined 
margin of non-inferiority.   
The non-inferiority margin (NIm) was determined based upon a combination of 
statistical reasoning and clinical judgement, as recommended by the CHMP, 
using an economic definition of non-inferiority which incorporated both the 
cost and effectiveness considerations. NIm was determined from the cost-
savings that might accrue through reduced hospitalisations in the intervention 
arm and the willingness to pay value to avoid neonatal morbidity (λ). The 
difference in hospitalisations (∆H) between the intervention and control arms 
is multiplied with the average cost of hospitalisation (C), to give the cost 
savings which accrue through fewer unnecessary hospitalisations in the fFN test 
arm.  This is then divided by the value of avoiding neonatal morbidity (λ) to 
provide the non-inferiority margin from an economic perspective, as illustrated 
in Equation 5.10:   
 
λ
∆
=
C*H
NIm         (5.10), 
i.e. where the net health benefit equals zero( )0=NHB .  
For this calculation the model prediction values for the difference in 
hospitalisations and the average cost per hospitalisation were used, as detailed 
in Table 5-4, giving an expected saving of £541 per woman tested.  Populating 
Equation 5.10 with these values along with the willingness to pay to avoid 
morbidity value of £25,700 (λ), a non-inferiority margin of 0.02 was 
determined.  On this basis, an increase in morbidity of up to 0.02 would be 
considered “acceptable” in the trial.  Having specified this non-inferiority 
margin for morbidity, the standard sample size calculation can be used to 
determine the sample required to show that an expected difference of 0.00176 
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(pre-trial model prediction for morbidity, Table 5-2) has an upper confidence 
limit below 0.02.   
This specified non-inferiority margin (NIm) was incorporated into the basic 
sample size calculation previously detailed in Equations 5.1 and 5.2, utilising 
the morbidity outcomes (M probabilities: M, MT & MC) from Table 5-4 as the 
measure of effectiveness (E, ET & EC), using 90% power and a significance of 
5%.  Equation 5.11 details the sample size calculation based on the morbidity 
non-inferiority margin, and is expanded in Equation 5.12 to detail the variance 
under the null and alternative hypotheses.   
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The resultant non-inferiority sample size for morbidity is detailed in Table 5-8, 
indicating the variation in sample size requirements to changes in the power 
specification.   
Table 5-8: Non-inferiority sample size under different power specifications 
Power Sample per arm Total  sample size 
90% 1156 2312 
80% 864 1728 
70% 679 1358 
 
When the non-inferiority approach is used with the morbidity outcome 
measure, a trial with 90% power will require a sample size of 2312 participants.  
This is approximately 500 participants more than that required to show cost-
effectiveness using the NMB approach (Table 5-6).  Therefore, designing the 
trial with a total recruitment sample of 2312 participants has a 90% power, 
which is adequate to detect a NMB greater than zero and non-inferiority given 
a cost-effectiveness defined non-inferiority margin.  
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5.3 Discussion 
The ‘pre-trial’ model developed to inform the fFN trial sample size calculations 
predicted that potential cost-savings were likely, but with a marginal 
detrimental impact on neonatal morbidity, indicating that a non-inferiority 
trial design may be appropriate.  Therefore, the sample size calculations were 
undertaken using the NMB approach to demonstrate cost-effectiveness, and 
also using a non-inferiority design to ensure the trial sample size would be 
sufficient to demonstrate non-inferiority for the effectiveness endpoint, given 
a cost-effectiveness defined NI margin.  Adopting the NMB approach, a total 
sample size of 1850 with a power of 90% is required to demonstrate a NMB 
greater than zero; while a total trial sample size of 2312 would be required to 
demonstrate non-inferiority, given the cost-effectiveness defined non-
inferiority margin.  Therefore, the trial was powered at 90% requiring a total 
sample size of 2312, in order to satisfy both approaches.  
This real life application of a sample size calculation based on a cost-
effectiveness outcome demonstrates the feasibility of this approach, leading to 
appropriately sampled trials with respect to the cost and cost-effectiveness 
outcomes.  While calls for health economic involvement in trial design are 
abundant (39;44;169-171), very few trials which involve economic evaluation 
as a primary outcome actually undertake sample size calculations based on the 
economic outcome.   
In terms of practicality, the skills required for building a simple, early model to 
inform trial design and a funding application are feasible to health economists 
who undertake economic evaluations.  The skills required for calculating 
sample sizes, however, are slightly less generalisable.  Many health economists 
may not normally become involved with sample size calculations, or indeed the 
wider trial design, leaving the sample size aspect up to trial statisticians.  
However, given that the methodology for such an approach is now well 
established, and that the role of the health economist is becoming ever more 
statistical (particularly for economic evaluations undertaken alongside clinical 
trials) (40) , economic led sample size calculations are not such a barrier for 
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health economists as they might once have been.  As recommended in good 
practice guidelines, it is important that the economic requirements contribute 
to the study design to ensure that the structure of the trial will provide the 
necessary data for a high quality economic study (39).  
It is encouraging that in this case study the health economics perspective was 
included in time to influence the sample size calculation; however, this was 
possibly only due to the atypical context of this situation, i.e. a trade-off 
between cost savings and a reduction in effectiveness, as opposed to the 
typical trade-off between additional costs and an improvement in 
effectiveness. Had this been a typical scenario, the cost-effectiveness 
perspective may well have been ignored until after the design of the trial.  In 
trials where the cost-effectiveness trade-off is expected to be straightforward 
the design tends to focus solely on effectiveness, overlooking the importance 
of the cost-effectiveness outcome and not even considering whether a cost-
effectiveness based sample size may be appropriate. It should be further 
promoted and recognised within a wider clinical audience that these 
techniques are valid methodology for calculating cost-effectiveness based 
sample sizes in both typical and atypical situations. 
Diagnostic test accuracy evaluations present the possibility for litigation 
proceedings to the NHS, due to false negative test outcomes (failing to detect 
disease). Current NICE guidelines (24) recommend all relevant costs be 
incorporated into an evaluation, and in the case of DTA studies (particularly 
one such as fFN) it could be argued that litigation costs are likely to have a 
significant impact on cost the of introducing the fFN test to the NHS, given the 
probability for false negative outcomes and the increasing tendency in the UK 
for claims against the NHS.  The potential importance of litigation costs for the 
DTA evaluation could be explored in a scenario, by making an assumption 
about the proportion of false negative cases which result in morbidity that will 
proceed to legal/court proceedings and include the additional litigation costs.  
It is indeed worthwhile exploring the importance of and potential impacts of 
this on the model outcomes in a scenario analyses.  
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The design and development of trial protocols are typically undertaken in short 
periods of time in order to meet tight submission deadlines; however this can 
impact on the quality of the trial design.  In the fFN case study discussed in 
this chapter, a pre-trial model was developed over a relatively short time 
period utilising the most readily available secondary evidence in order to 
undertake sample size calculations.  This demonstrates that even without prior 
funding or support to develop a comprehensive decision analytic model, a 
simple DAM can be constructed relatively quickly which can be used to help 
design the study.   
A basic, deterministic model can still have considerable advantages (in terms 
of evaluating alternative endpoints of interest to select the most appropriate 
for the trial, and enabling sample size calculations based on economic 
endpoints) within the context of a standard frequentist trial design. Preferably 
uncertainty in the model and sample size estimates should be considered.  
Briggs & Gray (170) recommend increasing the sample size of the study beyond 
that suggested by the formulas in order to account for additional uncertainty 
to be quantified in sensitivity analysis.  They also propose increasing upon the 
initial recruitment target to account for potential drop-out in the study, as is 
standard practice when sample size calculations are based on effectiveness 
alone.  The role of uncertainty in sample size calculations has been given 
further attention in published literature and it has been proposed that 
probabilistic sensitivity analysis is a good way to deal with this uncertainty 
(198), however, in practical terms the time constraints imposed by protocol 
submission deadlines may interfere and dealing with this uncertainty may only 
be feasible after protocol submission. 
If a non-inferiority design is appropriate for a study, as opposed to the typical 
superiority design, then there is a further role for economists (or the research 
team) in defining an appropriate non-inferiority (NI) margin. While there are 
general guidelines to adhere to in choosing a non-inferiority margin (172), 
based upon a combination of statistical reasoning and clinical judgement, the 
approach taken will also need to incorporate economic considerations (for both 
cost and clinical outcomes) of non-inferiority when the trial is undertaken to 
determine cost-effectiveness. The NI margin is subjective by nature and for 
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example, different values used to reflect the value of a statistical life will 
generate different sample sizes.  The structural uncertainty surrounding which 
approach should be used to determine this value therefore has implications for 
the sample size estimate. 
There is also scope for assessing how variations in required sample sizes will 
affect recruitment costs and feasibility for a trial.  The greater the sample 
size, the more precise the estimates of the parameters and their differences, 
but the more expensive the trial will be.  Exploring the specific trade-off 
involved can be useful in determining the appropriate balance between 
precision and availability of resources, however, this line of enquiry leads back 
to the methodological advantages of using value of information analyses.  With 
regards to ‘frequentist’ type sample size calculations, uncertainty can be 
incorporated and there should be a trade-off considering the feasibility and 
cost of recruitment as well as the sample size to show a significant difference.  
However, when you are starting to formally consider the trade-offs in terms of 
the size, cost and feasibility of recruitment, the VOI approach is much more 
appropriate.  Rather than implicitly considering the trade-offs between size, 
cost and feasibility – which is the current state of play in practice– research 
funders could more formally be incorporating these trade-offs, explicitly 
considering further research on the basis of how it addresses current 
uncertainty and valuing it on that basis.  Expected value of sample information 
and ENBS as part of an iterative economic approach explicitly incorporates 
these considerations and trade-offs, rather than conventional trial design as 
explored in the case study for this chapter.  
The feasibility or cost of recruitment may also become an issue if a regulatory 
or funding body dictate what the power endpoint of interest should be for a 
trial and it yields an unrealistic sample size.  This was not the case in the fFN 
trial design as the researchers were given freedom to explore various endpoints 
(morbidity, mortality and hospitalisations) and also to determine the most 
appropriate method for the evaluation, i.e. a net monetary benefit approach 
or a non-inferiority design.     
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In the context of this thesis it would have been preferable to develop a 
comprehensive decision analytic model and undertake EVSI following an 
iterative approach to trial design; however, this was not feasible within the 
context of the case study research bid.  This chapter demonstrated that even 
without prior economic involvement (or funding) to develop a comprehensive 
decision analytic model, a simple DAM can be constructed relatively quickly 
(and fairly simply) which can be used to help design the study.  Given that a 
basic, deterministic model such as that developed for the fFN trial can help in 
the design and development of a standard frequentist trial, there is no reason 
for economists not to be involved in the design stage of a trial, when the 
purpose of that trial is to determine cost-effectiveness.  The fFN model helped 
determine the power and sample size for the study; exploring both a NMB 
approach and a non-inferiority approach for sample size calculation and 
demonstrating their feasibility, while simultaneously highlighting limitations 
and demonstrating the role for economic considerations to guide non-
inferiority.  Considerations of economic assessments alongside clinical trials 
can and should be used to guide conventional trial design.
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6 Designing trials following an iterative approach 
Following on from the fFN case study in the previous chapter it is of interest to 
consider whether the same, or an alternative conclusion would have been 
drawn had the iterative approach to health technology assessment been 
adopted. Under an iterative approach, formal evidence synthesis and early 
decision analytic modelling would have been undertaken in advance of 
designing the trial, helping to explore and set the research priorities.  
Following the development of an early probabilistic DAM, expected value of 
perfect information (EVPI) analysis could have been undertaken to explore 
whether further research was potentially worthwhile, and if so, expected value 
of perfect parameter information (EVPPI) analysis could have indicated the 
appropriate type of any further research (i.e. an RCT or observational study) 
based on the parameters that were driving uncertainty in the model outcomes. 
If a study was deemed potentially worthwhile then expected value of sample 
information (EVSI) analysis could be used to determine an appropriate sample 
size for the study.    
As discussed in Chapter 5, the UK Health Technology Assessment (HTA) 
programme (50) had issued a commissioning call for research to undertake a 
randomised controlled trial to explore the cost-effectiveness of fFN testing in 
women threatened with pre-term labour.  Therefore the desire for a study and 
specification for an RCT had already been planned without prior economic 
involvement.  The trial was under design with a planned duration of three 
years costing approximately £1.65 million, when the opportunity arose to 
power the trial for economic endpoints, in the context of a frequentist trial 
design. This chapter explores whether the same, or an alternative conclusion 
(in terms of the desire for an RCT, and the appropriate sample size) would 
have been drawn had an iterative approach been followed whereby a DAM had 
been developed in advance and explored to its full potential.  
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This chapter undertakes a re-analysis of the fFN study, adapting it so that the 
cost and effect estimates are determined probabilistically.  The probabilistic 
results are then used to explore the EVPI and EVSI to compare the resultant 
research priorities and sample size under an iterative approach with the 
outcomes that were determined through conventional methods for the trial 
proposal, as detailed in Chapter 5.  This chapter then discusses the 
practicalities of employing the EVSI approach and some of the complexities.  
 
6.1 Re-analysis of the fFN case study 
6.1.1 Probabilistic analysis of fFN model 
With regards to the fFN model developed in Chapter 5, naturally there is 
uncertainty surrounding the parameter point estimates in the pre-trial model; 
and variability in the willingness to pay value (λ) for the NMB calculation and 
the non-inferiority margin which are subjective (172), leading to uncertainty 
surrounding the model outcomes and variation in the sample size estimates.  
Therefore, it is appropriate to undertake a probabilistic sensitivity analysis 
(PSA) on the baseline model to reflect uncertainty in the model parameters 
and explore the impact that this has on the predicted net benefit for both the 
treatment and control arms, as well as allowing further analysis on the value of 
further information.   
The parameters from the pre-trial model for which we are most uncertain, are 
the diagnostic test accuracy (sensitivity and specificity) of the fFN test, the 
risk of hospital transfer, the risk reduction of pre-term morbidity provided by 
steroids and the probability of hospitalisation given the fFN test results.  The 
model in Chapter 5 used point estimates of these parameters to predict 
deterministic estimates for the outcome parameters of interest: the proportion 
of hospitalisations and the proportion of neonatal morbidity experienced in 
each arm.  The deterministic model parameters as detailed in Table 5-1 were 
used to produce the predictions detailed in Table 6-1. 
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Table 6-1: fFN model predictions 
Parameter Point estimate Source 
      
fFN test: Proportion hospitalised 0.52423 model prediction 
No test: Proportion hospitalised 0.90000 model prediction 
fFN test: Proportion morbidity 0.03036 model prediction 
No test: Proportion morbidity 0.02860 model prediction 
      
fFN = fetal fibronectin 
If a trial were undertaken, the model predictions are the key parameters which 
would be informed.  Therefore, for the purpose of the PSA and VOI analyses, 
these four key parameters of interest (proportion hospitalised and proportion 
of pre-term morbidity, for each arm) were assigned distributions. In this way 
the model was kept simple which was advantageous for undertaking the EVSI 
calculation.   
The four model prediction parameters are represented by proportions, so when 
considering distributions for the probabilistic analysis, Beta distributions were 
deemed appropriate (as detailed in Chapter 2).  There was no prior study 
information from which to determine the alpha and beta parameters.  Ideally 
formal elicitation of clinical opinion could have been undertaken (for example, 
using Delphi techniques), to inform the uncertainty surrounding the parameter 
mean estimates, however, due to time constraints a best guess approach was 
used.  Wide confidence intervals were applied to handle the resultant 
uncertainty in the model parameters in the probabilistic sensitivity analysis.  
Standard errors were assumed and the alpha and beta values were derived 
using the Method of Moments (4), as detailed in Chapter 2.  A standard error of 
20% of the mean value was assigned to the probability of pre-term morbidity in 
the model for both arms and to the probability of hospitalisation under the 
treatment (fFN test) arm.  There is less uncertainty about the probability of 
hospitalisation in the control arm, as current practice is an admit all approach, 
therefore a smaller standard error of 6% of the mean value was assumed to 
represent the uncertainty for this parameter.  Table 6-2 details the mean 
values and probabilistic details for the four key parameters which would be 
determined in a trial.  
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Table 6-2: fFN Parameters for probabilistic model 
Parameter of interest 
Mean 
value 
Standard 
error Distribution α β 
Hospitalisation treatment arm 0.524 0.105 Beta 11 10 
Hospitalisation control arm 0.9 0.05 Beta 31 3 
Morbidity treatment arm 0.03 0.0061 Beta 24 773 
Morbidity control arm 0.029 0.0057 Beta 24 824 
        
    
 
The PSA used Monte Carlo simulation to draw randomly from the specified beta 
distributions for the proportion of hospitalisations and proportion of neonatal 
morbidity in each arm, and generate 10,000 probabilistic results.  The average 
cost of hospitalisation was combined with the proportion of hospitalisation in 
each arm to determine the cost for each of the iterations, from which the 
incremental cost could be determined.  The incremental effect was 
determined as the difference in probability (neonatal morbidity) between each 
arm, for each of the iterations.  
Figure 6-1 depicts the resultant cost-effectiveness plane, plotting the 
incremental costs and incremental effects, for each of the 10,000 PSA 
iterations.  It illustrates that we can be almost certain that the treatment will 
reduce cost in comparison to control (only six of the iterations do not fall 
below the x axis), but as the probabilistic results cross through the y axis, we 
can not be certain that the two interventions differ in effectiveness.  The x 
axis in Figure 6-1 illustrates incremental effectiveness, where an improvement 
in effectiveness means a reduction in pre-term morbidity.  Therefore, points in 
the western quadrant reflect a reduction in effectiveness, where the 
treatment arm has a greater proportion of pre-term morbidity than the control 
arm; whereas points in the eastern quadrants reflect an improvement in 
effectiveness, i.e. where the treatment arm has less morbidity than the 
control arm.  The spread across the y axis is not unexpected in this non-
inferiority type situation, whereby we would expect a marginal reduction in 
effectiveness (increase in morbidity) in the treatment arm, within the pre-
specified margin of non-inferiority (as discussed in Chapter 5). 
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Figure 6-1: The CE plane for Treatment (fFN test) versus Control (no test) 
 
By employing the NMB approach as discussed in Chapter 5; the impact on 
effectiveness can be monetarised using a willingness to pay value (λ) to avoid 
morbidity, in this case the pre-defined value of £25,700 (as detailed in Chapter 
5). Given this monetary threshold (λ), in Figure 6-1 all points that fall to the 
right of the monetary threshold (λ) can be considered cost-effective, while all 
points that fall to the left are not cost-effectiveness. The NMB for each 
intervention was calculated for all 10,000 iterations.  The expected net 
benefits under the treatment and control arms were then calculated, that is, 
the average net benefit in each arm across the 10,000 iterations.  The 
treatment arm had the greatest ENB (£26) compared to the control arm (-
£559), and would therefore be the treatment of choice, maximising NB at the 
willingness to pay (λ) value of £25,700. It should be noted that in Chapter 5 it 
was the incremental net monetary benefit that was reported, i.e. the 
difference in net benefit between the treatment and control. Given the ENB 
for the treatment and control arms, the incremental net monetary benefit 
from the probabilistic analysis is £584, and therefore the treatment arm is the 
optimal strategy. In the fFN case study the NBs for both interventions are low 
and sometimes negative, which is due to the nature of the fFN case study, i.e. 
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in comparison to the control the treatment arm leads to cost savings in terms 
of hospitalisations avoided, but at the expense of a marginal reduction in 
effectiveness (some additional pre-term morbidity).   
Figure 6-2 illustrates the cost-effectiveness acceptability curve, showing the 
probability of the Treatment and Control interventions being cost-effective at 
different willingness to pay values for avoiding morbidity.    
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Figure 6-2: The CEAC for fFN 
 
At a willingness to pay value (λ) to avoid a case of morbidity of £30,000, the 
probability that the Treatment intervention is cost-effective is 98% and there is 
only a 2% probability that the Control is cost-effective.  Even if the ceiling 
ratio per pre-term morbidity is raised to £50,000, there remains a 92% 
probability that the Treatment will be cost-effective compared to the control.  
As the ceiling ratio increases, the probability of Treatment being the most 
cost-effective intervention falls, however, at a value of £100,000 per pre-term 
morbidity, the curves flattens out and there is still an 80% probability that 
Chapter 6   275 
Treatment is the cost-effective choice, with only a 20% probability that the 
Control is cost-effective. 
The CE plane in Figure 6-1 illustrated considerable uncertainty as to whether 
there was a difference in effectiveness, which is what we would expect in this 
non-inferiority type case.  However, when the willingness to pay threshold of 
£25,700 per morbidity avoid (λ) was added to Figure 6-1, it could be seen that 
the majority of points fall to the right of this threshold, indicating that they 
would be considered cost-effective.  Following this, the CEAC in Figure 6-2 
illustrates that there is little decision uncertainty, i.e. we can be confident 
that the Treatment is cost-effective in comparison to the Control over a wide 
range of ceiling ratios.  At the ceiling ratio of £25,700 per morbidity, the CEAC 
illustrates a 98.8% probability that the Treatment is cost-effective.  Utilising 
the probabilistic model results further, an expected value of perfect 
information analysis could be undertaken to explore whether it is worthwhile 
undertaking further research or make the decision to adopt or reject the 
Treatment intervention based on the current information.   
The EVPI was calculated (as described in Chapter 2) and at a ceiling ratio of 
£25,700 per morbidity the expected value of perfect information is £2.10 per 
decision/patient.  At a ceiling ratio of £30,000 the EVPI per patient is £3.13.  
Even if society were willing to pay a maximum of £50,000 per neonatal 
morbidity avoided, the EVPI per patient would only be £15.  These EVPI values 
are very low, and reflect the low level of uncertainty in the cost-effectiveness 
decision that was illustrated in the CEAC.  Figure 6-2 illustrated that at a 
ceiling ratio of £25,700 there is a 98.8% probability that Treatment is cost-
effective.  Given this very low uncertainty surrounding the cost-effectiveness 
of the optimal intervention (Treatment), the expected value of further 
information to aid the decision is low.   
The EVPI can be scaled up to the population of patients, multiplying the EVPI 
per person by the population over the technology life time, and can then be 
interpreted as the maximum amount the health care system should be willing 
to pay for additional evidence to inform this decision in the future, i.e. an 
upper bound on the value of conducting further research (4;86).  The 
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population EVPI for fFN was calculated, based on an annual population of 
120,000 suspected pre-term labour cases (181).  A four year technology 
lifetime was assumed on the basis that this is the appropriate time period 
(until it is replaced by another more accurate test).  Discounted at 3.5% (24) 
this gives an effective population who could potentially benefit from further 
information regarding the fFN test of 456,196 women suspected of pre-term 
labour. The EVPI for the population is depicted in Figure 6-3.   
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Figure 6-3: EVPI for fFN – population level 
 
Figure 6-3 indicates that at a willingness to pay of £30,000 per morbidity 
avoided the EVPI for the population is approximately £1.4 million; therefore, 
research which costs less than this value is potentially worthwhile.  However, 
when this ceiling ratio is lowered, i.e. at a monetary threshold of £10,000 per 
morbidity avoided, the EVPI is only £70,000.  At this lower EVPI value the cost 
of further research (such as an RCT) is likely to exceed the EVPI and therefore 
would not be worthwhile.  Implementing the pre-specified ceiling ratio of 
£25,700 as derived in Chapter 5, the EVPI is approximately £957,000.  If further 
research costs more than £957,000 then it is not worthwhile and current 
evidence can be regarded as sufficient to support the decision to accept fFN 
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technology. However, if research costs less than £957,000 then it may 
potentially be worthwhile undertaking that research in order to reduce 
uncertainty in the decision to adopt or reject the fFN test.  
If the maximum that society is willing to pay for avoiding a pre-term morbidity 
is £25,700, then the EVPI of £957,000 can be interpreted as the maximum 
amount the health care system should be willing to pay for additional evidence 
to inform the decision regarding the fFN test.  The fFN trial proposal estimated 
the cost of the proposed research to be approximately £1.65million, which is 
substantially greater than the maximum willingness to pay for the proposed 
research. Even at a greater ceiling ratio of £30,000 per morbidity avoided the 
population EVPI was £1.4 million, which is still lower than the research cost of 
£1.65 million.  Therefore it would be concluded that further research will cost 
more than the maximum amount the health care system is willing to pay for 
additional evidence, and therefore the fFN test should be adopted based on 
current evidence with no further research.   
This conclusion contradicts the funding body call for an RCT in fFN. Under an 
iterative approach the research priorities indicate that further research is 
unlikely to be worthwhile and therefore the research process would end, 
without undertaking any further value of information analyses.  An EVSI would 
only be undertaken if the EVPI had exceeded the fixed costs of research, i.e. if 
further research was potentially worthwhile.  However, for the sake of this 
thesis; it is of interest to demonstrate the EVSI process that could have been 
followed had a trial been deemed potentially worthwhile and again compare 
the resultant sample size with those determined through conventional methods 
for the trial proposal, as detailed in Chapter 5.   
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6.1.2 EVSI for the fFN case study 
In order to calculate the EVSI for the fFN case study, the steps and algorithms 
outlined in Ades, et al. (83) were followed.  The fFN pre-trial model was a 
simple linear model with four key parameters of interest, as described earlier 
in this chapter.  Therefore the EVSI algorithms for a linear model were used, 
i.e. utilising the posterior estimates directly to calculate net benefits, rather 
than re-running the probabilistic Monte Carlo simulation to sample from the 
posterior distribution as would be required in a non-linear model.  The EVSI 
process is based around specific parameters of interest, which are the 
uncertain parameters (θi) that require further information from the proposed 
piece of research. The calculation undertaken is now outlined as follows:    
1. A probabilistic sensitivity analysis (PSA) was undertaken on the model: 
Monte Carlo simulation generated 10,000 prior estimates (p1 to p10,000) for 
the four uncertain parameters of interest.  
2. A sample size (N) was assumed for a new piece of research.  
3. Data collection was simulated for the new sample size (N) from the 
binomial likelihood using the prior estimate for the parameter(s) of interest 
from the first iteration of the PSA in step 1 (p1).  
• Draw 1 sample result (x) from the binomial likelihood: ( )p,n~β  
where n is the new sample size and p is the prior probability 
estimate from the Monte Carlo simulation.  
• This draw represents the number of events (x) which can then be 
used to calculate a posterior probability. 
4. The prior estimate and the simulated number of events (x) are then used to 
calculate the Beta posterior distribution ( )xN,x −+β+αβ for the 
parameter(s) of interest.  The posterior estimate (Ppost) for the 
parameter(s) of interest can then be derived, as detailed in Equation 6.1.  
Chapter 6   279 
( )
N
x
ppost +β+α
+α
=          (6.1) 
5. The next step is to put the posterior probabilities (Ppost) for the 
parameter(s) of interest back into the model (replacing the prior estimates) 
in order to recalculate net benefit for treatment and control (NBT NBC) 
using the posterior probabilities for the parameters of interest and the prior 
probabilities of the other parameters in the model. The NBs for each 
intervention were stored.   
6. Steps 3 to 5 were repeated for each prior estimate from the PSA in step 1.  
I.e. in turn using p2, p3….p10,000  in step 3 to simulate new data (x2, 
x3…x10,000) and calculate the Beta posterior and net benefit for treatment 
and control each time (NBT2 NBC2, NBT3 NBc3….NBT10,000 NBC10,000). 
7. The Expected Net Benefit for Treatment and Control was calculated across 
the 10,000 posterior net benefits, as illustrated in Table 6-3 to establish the 
which intervention is the optimal choice[ ])ENB:ENBmax( CT given current 
information. 
Table 6-3: Net Benefits from posterior calculation 
 
Net Benefit Treatment 
 
Net Benefit Control 
 
Maximum Net Benefit 
NBT1 NBC1 max(NBT1:NBC1) 
 
NBT2 NBC2 max(NBT2:NBC2) 
   
NBT3 NBC3 max(NBT3:NBC3) 
…… ……. …… 
NBT10,000 NBC10,000 max(NBT10,000:NBC10,000) 
 
ENBT ENBC E max(NB) 
 
8. For each of the individual iterations the intervention which had the 
maximum net benefit was chosen and stored, essentially making the 
optimal decision based on sample information for each of the iterations.  
However, we still do not know the actual results of the sample in advance, 
and therefore the expected value of a decision taken with sample 
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information is found by averaging the maximum net benefits over the 
distribution of possible values (4).  The average (or expectation) of the 
maximum NBs is calculated [E max(NB)], as illustrated in Table 6-3. 
9. The intervention which has the greatest ENB across the 10,000 PSA 
outcomes is the intervention of choice under current information.  The 
average of the 10,000 maximum net benefits is the expected value of a 
decision made with sample information. Subtract the ENB of the 
intervention of choice from the maximum ENB; this is the expected value of 
sample information, as illustrated in Equation 6.1: 
[ ] [ ]( )[ ] [ ]CTiCiT ENB:ENBmaxNB,NBmaxE=EVSI -        (6.1), 
or 
( )( )[ ] ( )[ ]θθ θθθ ,tNBEmax,tNBEmaxEEVSI t −=      (6.2). 
In order to undertake the EVSI calculations in a timely manner, the fFN model 
was re-programmed into the programming language FORTRAN and the EVSI 
calculation was undertaken for sample sizes n = 1, 10, 20, 50, 100, 150, 250, 
500, 750, 1000, 2000, 3000; then it was re-run for all possible sizes between 1 
and 50,000 to explore where the maximum EVSI was reached.   
 
6.1.3 EVSI Results 
Table 6-4 presents the EVSI results for a range of sample sizes.  All values are 
calculated for a willingness to pay value (λ) of £25,700 as specified in Chapter 
5.   Table 6-4 also presents the probability that further research of size n 
would change the current decision regarding the cost-effective intervention 
(Treatment).  This is calculated using a similar process to that of the cost-
effectiveness acceptability curve, detailed in chapter 2.  For the set ceiling 
ratio and sample size n, the probability that each intervention will be cost-
effective under perfect sample information is calculated and the optimal 
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strategy given perfect information is chosen. Given that Treatment was the 
optimal strategy under current information, the probability of a change in 
decision is equivalent to the probability that Control is the optimal strategy 
given perfect information, i.e. 1 minus the probability that Treatment is cost-
effective under perfect sample information.   
Table 6-4: EVSI calculations for a range of sample sizes 
Sample size (n) 
EVSI 
per person 
EVSI 
population 
Probability of change in 
decision 
0 £0.00 £0 0.0000 
20 £0.00 £0 0.0000 
80 £0.00 £904 0.0001 
100 £0.00 £2,131 0.0001 
150 £0.01 £6,334 0.0003 
200 £0.02 £10,935 0.0005 
250 £0.04 £17,333 0.0007 
500 £0.12 £53,973 0.0020 
750 £0.22 £98,226 0.0031 
1000 £0.30 £136,234 0.0041 
1500 £0.44 £200,966 0.0058 
2000 £0.55 £249,086 0.0069 
3000 £0.70 £319,945 0.0083 
5000 £0.88 £399,780 0.0099 
10000 £1.04 £474,983 0.0114 
20000 £1.13 £516,572 0.0121 
30000 £1.17 £532,408 0.0124 
40000 £1.18 £540,431 0.0125 
50000 £1.20 £545,446 0.0126 
 
As the proposed sample size increases from 0 to 50,000 the value of sample 
information increases from 0 to £1.20 per person.  The EVSI results from this 
case study are extremely low, showing that a sample size of 500 is only valued 
at 12 pence per person, and even with a sample of 2000 participants in the 
treatment arm, the value is only 55 pence per person.  As with EVPI, the per 
person/decision level of EVSI can be scaled up by the estimated population 
(here judged to be 456,169 women over a four year period) in order to 
determine the population level EVSI.  At a sample size of 3000 the EVSI per 
person is only 70 pence; however this translates into a population level value 
of nearly £320,000.  
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The EVSI is clearly related to the probability that the proposed study will 
change the decision from that under current information; identified in Table 6-
3 as iterations where: max(NBT:NBC) ≠ max(ENBT:ENBC). In Table 6-4 the very 
low probabilities for a change in decision explain the extremely low EVSI 
results.  The probability that a study with 50,000 participants will change the 
decision on cost-effectiveness (from the treatment strategy being optimal) is 
only 0.013 and therefore, the value of such a study is also very low, £1.20 per 
person.  Figure 6-4 plots how the EVSI changes as the sample size increases 
from 0 to 50,000 in the treatment arm at a monetary threshold of £25,700.    
The EVSI is very low at all sample sizes, with the curve continuing to rise 
(albeit very slowly) beyond a sample size of 40,000 and 50,000.  
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Figure 6-4: EVSI with varying sample size – per patient/decision 
 
The shape of the curve is as would be expected, with the EVPI increasing with 
sample size but with diminishing returns (85;199), however, as sample size 
tends towards infinity the EVSI should tend towards the value of EVPI (200) and 
level off.  The EVPI per person at the monetary threshold of £25,700 (λ) is 
£2.09, and as can be seen from Figure 6-4, at a sample size of 50,000 the EVSI 
per person is only £1.20.  The value of sample information is still increasing 
beyond a sample size of 50,000, but at a diminishing rate, and therefore a 
sample much greater than 50,000 would be required to reach the EVPI value of 
£2.09.  The EVSI calculation for this example was not re-run for sample sizes 
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beyond 50,000 in order to limit the computational time, however, it can be 
concluded that a sample size beyond 50,000 in each arm of an RCT is 
unrealistic in terms of patient recruitment.   
Figure 6.5 presents the population level EVSI (assuming an annual incidence of 
threatened pre-term labour of 120,000 with a technology lifetime of 4 years 
discounted at 3.5%).  
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Figure 6-5: EVSI with varying sample size – population level 
 
With an effective population of 456,196 women, the population level EVSI is 
£136,000 for a sample size of 1000 per arm, while a sample size of 2000 per 
arm gives a value of £249,000 at the population level.   The EVSI at the 
population level is the same shape as that for the EVSI per decision/patient, 
and again the value of sample information is still increasing beyond a sample 
size of 50,000, but at an ever diminishing rate. 
The difference between the EVSI and the cost of acquiring the sample 
information is the expected net benefit of sample information (ENBS) (9;86); 
with the optimal sample being the value of N that generates the maximum 
expected net benefit of sampling.   The cost of the fFN trial as detailed in 
Chapter 5 was budgeted at £1.65million and therefore in order to generate an 
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expected net benefit with sample information, the EVSI would need to be 
greater than this value.  
In order to plot the cost of the research and the resultant ENBS for the fFN 
trial, the costs from the commissioned research proposal were consulted.  
There was no maximum budget set by the funders, and therefore the cost of 
the research was established based on the research professionals’ time and 
estimates of the resources involved in the trial.  The total cost of the proposed 
three year RCT aiming to recruit 2312 participants (1156 per arm as calculated 
in Chapter 5) was £1.65 million.    The variable costs incurred in a trial would 
incorporate the cost of the test (which at £50 a test would only be used in the 
participants randomised to the intervention arm, and would therefore cost £25 
per participant), plus an additional £5 per person to cover administration. 
Therefore the variable costs can be assumed to be approximately £30 per 
additional participant recruited.  The fixed costs of the trial can be assumed to 
be approximately £1,600,000 with a sample size of zero (to cover project set-
up, research staff time, travel etc).  Figure 6-6 plots the EVSI at the population 
level, along with the cost of the research and the resultant ENBS. The figure 
illustrates that the cost of the research exceeds the value, at all potential 
sample sizes.  
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Figure 6-6: EVSI, Cost & ENBS for fFN trial 
 
Figure 6-6 does not display the typical illustration of ENBS and cost in relation 
to the EVSI.  The cost of the research is greater than the EVSI at a sample size 
of zero (as is typically the case), however the EVSI rises with sample size but in 
this case the EVSI never reaches the cost of the trial and therefore the 
expected net benefit of sampling (which is the EVSI minus the cost) remains 
negative regardless of the sample size.  The sample size where ENBS is at its 
highest is a sample of 5000 participants per arm, at an ENBS of -£1.35 million.  
As this value is negative, clearly the optimal option would be not to undertake 
a trial of this magnitude (i.e. a sample size of zero).  
Out with the demonstration of EVSI for this thesis chapter, an EVSI would not 
have been undertaken in the fFN case study as it was found not to be 
worthwhile at the EVPI stage (EVPI < fixed cost of research).  To illustrate how 
the EVSI and ENBS curves would typically look, let us assume that the cost of 
research was lower than the EVPI value of £957,000 (i.e. much less than that 
for the fFN case study).  Had a six months observational study of fFN been 
commissioned (rather than a three year RCT) the cost of research may have 
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had a fixed cost of £100,000, with an additional variable cost of £10 per 
participant recruited.  If this were the case, the trial could potentially have 
been worthwhile, and the ENBS may have taken a more typical form, as 
illustrated in Figure 6-7. 
-£200,000
-£100,000
£0
£100,000
£200,000
£300,000
£400,000
£500,000
£600,000
0 5000 10000 15000 20000 25000 30000 35000 40000 45000 50000
Sample Size
EV
SI
 
-
 
po
pu
la
tio
n
Cost EVSI population ENBS
 
Figure 6-7: Alternative EVSI, Cost & ENBS for an observational study   
 
Figure 6-7 illustrates the hypothetical case where the fixed cost of the 
proposed research was £100,000 with a small variable cost of £10 per 
additional person recruited to the sample.  At the outset, where the sample 
size is zero, there is no value in the research and the ENBS is negative due to 
the fixed £100,000 cost of the trial.  As the sample size increases so does the 
EVSI, and at a sample size greater than approximately 900 participants the EVSI 
exceeds the cost of the research, and at this point the ENBS is no longer 
negative.  Figure 6-7 demonstrates that in this hypothetical case the ENBS 
reaches the maximum at a sample size of 9000 participants per arm, and 
therefore, this would be considered to be the optimal sample size for the 
study.  
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The purpose of this chapter was to explore whether the same or an alternative 
conclusion would have been drawn had the iterative Bayesian approach to 
health technology assessment been adopted in the design of the fFN trial, 
rather than the sample size being determined pragmatically through traditional 
methods to inform the design of the trial as it was being prepared.  Under the 
iterative approach outlined in this chapter, the EVSI outcomes indicate that a 
sample size of greater than 50,000 participants in the treatment arm will be 
required to be worth any value, as lower sample sizes are unlikely to change 
the cost-effectiveness decision based on current information.  A sample size of 
5,000 participants in each arm will generate the greatest expected net benefit 
of sampling (-£1.35 million), however, as this is a negative value clearly the 
optimal option would be not to undertake a trial (sample size of zero).  The 
sample conclusions that were determined previously, under the traditional 
approach described in Chapter 5, suggested a sample size of approximately 
1000 participants in each arm.  Table 6-5 details the alternative sample sizes 
for the fFN trial, derived from the various approaches, and shows that the EVSI 
approach highlights that any kind of trial is unlikely to be worthwhile in terms 
of altering the cost-effectiveness decision. 
Table 6-5: Sample sizes under different approaches 
Power Sample per arm  Total  sample size 
      
NMB approach 925 1850 
NI approach 1156 2312 
EVSI approach Zero/no trial Zero/no trial 
      
 
A study with a total sample of approximately 2000, as prescribed by the NI and 
NMB calculations in Chapter 5, is likely to be a waste of resources in terms of 
the opportunity cost for research spending.  The EVSI results in Table 6-4 
showed that at a sample size of 1000 per arm the EVSI is only 30 pence 
(£136,000 at the population level) and the probability of the study changing 
the decision from that under current information is 0.004, i.e. it is extremely 
unlikely that the study would change the decision, which under current 
information was to adopt the fFN test.  At a cost of £1.65 million the proposed 
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trial costs more than the expected value of sample information, £136,000, and 
therefore, undertaking a trial at this scale is not providing additional value in 
term of reducing uncertainty about cost-effectiveness.  The EVPI analysis in 
section 6.1.1 demonstrated that at a monetary threshold of £25,700 per 
morbidity avoided, the EVPI of £957,000 can be interpreted as the maximum 
amount the health care system should be willing to pay for additional research 
and therefore the fFN test should be adopted based on current evidence with 
no further research. This presents resource allocation issues when the 
opportunity cost of a study costing in the range of £1.6million is considered.   
The EVSI calculation highlights that a much larger study would be required to 
generate any value, however, considering the additional cost of a larger trial, 
it becomes clear that for this case study any kind of trial is unlikely to be 
worthwhile in terms of altering the cost-effectiveness decision. 
Based on these results, under an iterative framework the likely conclusions 
would have been that rather than undertaking a clinical trial the fFN test 
should be adopted in practice, freeing up research resources for more valuable 
research.  The fFN test could be filtered into practice on a small scale, and 
then the economic model updated at a later stage with routine data to further 
support the reimbursement of fFN by the NHS.  Given this suggestion, it is of 
interest to consider whether any funding body would change policy or practice 
without evidence from an RCT.  In the case of drugs, this is unlikely; however, 
in the context of health services and public health interventions, many NHS 
boards introduce new services without formal assessment of effectiveness in a 
trial/study setting.  In the case of fFN, this diagnostic test had begun to be 
implemented in some hospitals in the UK as the trial application was being put 
together.  As a result of this, the fFN trial was not funded.  Implicitly, the 
funding body for the fFN trial came to the same conclusion as this VOI analysis 
(which was undertaken post-application for demonstration purposes in the 
context of this thesis).  Ultimately the review committee queried the value of 
undertaking the trial because fFN had already begun to be implemented in 
some UK hospitals, given existing evidence from USA.  Implicitly the review 
committee judged the proposed trial to be not worthwhile, given current 
practice which was beginning to implementing it anyway.   
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6.2 Practicalities with employing the EVSI approach 
Having demonstrated the use and potential value in undertaking early 
modelling and incorporating an EVSI analysis to inform trial design, it is 
important to discuss some of the potential reasons that this approach may have 
been less well adopted in practice, despite strong support from some quarters 
of the health economics community (9;85;199).   
6.2.1 Interpretation of the EVSI process 
The EVSI process has been described by numerous authors (4;83;199) however, 
many health economists are still unfamiliar with the exact process, if not the 
methodology.  Unfamiliarity with the process may present problems with 
interpretation, particularly for researchers undertaking an EVSI analyses for 
the first time.  The outline and various algorithms presented by Ades et al. (83) 
are comprehensive, yet the EVSI calculation is complex, involving a choice 
between different algorithms and complexities depending on the situation and 
type of model employed.  In undertaking the EVSI calculation for this chapter, 
some interpretation issues were experienced with regards to the simulation of 
binomial data, and also with regards to the appropriate approach to adopt with 
a linear model design, which is different if the model design is non-linear.   
Simulating sample data  
In the various publications outlining the EVSI process, the terminology used to 
describe simulating the data under perfect sample information is open to 
misinterpretation.  Following the guidelines “simulate a dataset of a specified 
sample size and design” (199) or “draw a sample from the distribution of the 
sufficient statistics arising from a new study of size N” (83), it is unclear 
whether the sample drawn should be one single draw or numerous draws to 
generate a full sample, i.e. 1, 1000 or 10,000 draws for each prior estimate.  
After consultation with health economists who have previous experience of 
employing the EVSI technique (111), it was clarified that only one single draw 
is required, regardless of the type of model employed.  
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Therefore, in step 3 of the EVSI calculation, detailed in section 6.1.2, only one 
sample (x) is simulated from the beta binomial distribution, and this single 
draw can be assumed to reflect the distribution. The terminology used in the 
EVSI guidelines with regards to this does not make it clear that only one sample 
(x) is required to be drawn.  Misinterpretation of this step could lead to 
simulating an additional 9,999 binomial estimates for each prior estimate 
unnecessarily. It makes intuitive sense to draw from the beta binomial 
distribution numerous times for each prior estimate to reflect the true events 
across the whole distribution.  However, this is unnecessary in the EVSI 
calculation as the process (step3 to step 6) is repeated 10,000 times, drawing 
one sample (x) for each of the prior iterations from the Monte Carlo simulation 
and this is considered to be sufficient to represent the beta binomial 
distribution.  For each iteration of the outer loop of the EVSI calculation the 
single binomial draw each time is different (because it is an independent 
binomial draw) and therefore an additional inner loop of numerous binomial 
draws within each iteration is unnecessary.   
In order to check this premise, the EVSI calculation was re-run with a 
modification to step 3 in the process to draw 10,000 estimates from the beta 
binomial likelihood for each of the 10,000 prior estimates (rather than just 
once for each prior) and the outcomes were compared.   Table 6-6 details the 
results of this comparison, and shows that both approaches have very similar 
outcomes.   
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Table 6-6: EVSI results for 1 and 10,000 binomial draws  
Sample 
size (n) 
EVSI: 1 
binomial draw 
Probability of 
change decision 
EVSI: 10,000 
binomial draws 
Probability of 
change decision 
20 £0.00 0.0000 £0.00 0.0000 
50 £0.00 0.0000 £0.00 0.0000 
80 £0.00 0.0001 £0.00 0.0000 
100 £0.01 0.0002 £0.00 0.0001 
150 £0.01 0.0002 £0.01 0.0002 
250 £0.03 0.0006 £0.03 0.0006 
500 £0.11 0.0021 £0.11 0.0018 
1000 £0.31 0.0033 £0.28 0.0040 
5000 £0.83 0.0095 £0.78 0.0090 
10000 £0.99 0.0108 £0.92 0.0101 
20000 £0.93 0.0100 £1.00 0.0107 
30000 £1.03 0.0111 £1.02 0.0109 
40000 £1.00 0.0104 £1.04 0.0110 
50000 £1.06 0.0108 £1.04 0.0110 
          
 
As the sample becomes greater than 1000 the additional draw generates a 
slightly lower EVSI, but only marginally.  Therefore, it is appropriate and more 
efficient to just draw once from the binomial distribution for each of the prior 
estimates, substantially reducing computational running time. It is however, 
interesting to note that the 9,999 additional draws from the binomial 
generates a smoother EVSI curve than the single draw.   This is demonstrated 
in Figure 6-8. 
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Figure 6-8: EVSI curves under one and 10,000 binomial draws 
 
Figure 6-8 plots the EVSI results for each sample size using the two different 
approaches.  The 9,999 additional binomial draws generated a smoother curve, 
which is unsurprising given the increase in iterations.  If the initial number of 
iterations from the prior was increased from 10,000 to 100,000 the ‘noise’ 
shown in the one binomial draw curve would be ironed out, because as the 
number of iterations tends towards infinity, the true distribution is 
represented.      
Misinterpretation of this step could lead to simulating 10,000 draws 
unnecessarily, generating an additional (unnecessary) 9,999 binomial estimates 
for each prior estimate, and requiring a second loop in the EVSI calculation 
which substantially slows the EVSI computational time, i.e. running through the 
calculation 100,000,000 times rather than just 10,000 times.   
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Alternative approaches for linear and non-linear models  
Another area open to confusion and misinterpretation in the EVSI process is the 
alternative approaches and algorithms required depending on whether the 
model is linear or non-linear.  Following the steps and algorithms outlined by 
Ades et al. (83) the researcher must decide whether the model is linear or non-
linear for the parameters of interest (θi) and for the complementary 
parameters (θc) and then choose from four possible algorithms to calculate the 
posterior expected net benefits for each intervention.  Linearity is determined 
by whether the relationship between the parameters is directly proportional or 
not, i.e. in a linear model a change in one of the parameters would lead to a 
directly proportional change in the other parameters and the model outcomes, 
whereas in non-linear models outcomes are a multiplicative function of the 
input parameters (4;72).  In step 5 of the EVSI calculation, detailed in section 
6.1.2, the posterior probabilities for the parameters of interest (θip) must be 
put back into the model (replacing the prior estimates for the parameters of 
interest) in order to calculate the net benefit (NB) for each intervention (t), 
NB(t,θip).  A linear model requires only the posterior probability for the 
parameter(s) of interest to calculate the net benefits.  A non-linear model 
requires the use of the posterior distribution to re-run the Monte Carlo 
simulation, making the process considerably more time consuming for non-
linear models.  
Researchers undertaking an EVSI analysis for the first time may become 
confused as to which of the algorithms presented in the guidelines (83;85) is 
most appropriate for their model, and also in interpreting the algorithms.  
Table 6-7 sets out the four alternative procedures which can be used to 
calculate the posterior net benefits, depending on the type of model involved.  
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Table 6-7: Alternative methods for calculating posterior net benefits in EVSI 
 
Model specifications Process to calculate the posterior net benefits 
1 Linear parameters of interest 
(θi) & linear complementary 
parameters (θc) 
Use posterior mean for θi and the prior mean for 
θc.  Plug them into model and calculate NB for 
each intervention.  No need to re-run the PSA. 
2 Linear parameters of interest 
(θi) & non-linear 
complementary parameters (θc) 
 
Use posterior mean for θi and the prior distribution 
for θc.  Re-run the PSA drawing from the prior 
distribution for complimentary parameters but 
using the set posterior mean for parameters of 
interest. Calculate the ENB for each intervention. 
3 Non-linear parameters of 
interest (θi)& linear 
complementary parameters (θc) 
Use posterior distribution for θi and the prior mean 
for θc.  Re-run the PSA drawing from the posterior 
distribution for the parameters of interest but using 
the set prior mean for the complimentary 
parameters. Calculate the ENB for each 
intervention. 
4 Non-linear parameters of 
interest (θi) & non-linear 
complementary parameters (θc) 
Use posterior distribution for θi and the prior 
distribution for θc.  Re-run the PSA drawing from 
the prior distribution for complimentary parameters 
and the posterior distribution for the parameters of 
interest. Calculate the ENB for each intervention. 
Developed based on information in Ades et al. 2004 (83) & personal communication with 
experts (111) 
If either the complementary or parameters of interest in the model are non-
linear, then the EVSI process involves an inner loop to re-run the PSA (nested 
Monte Carlo integration(83)) with 10,000 iterations, for each of the prior 
estimates from the outer loop of the calculation.   The process is therefore 
more complex from step 5 onwards than the linear process followed in section 
6.1.2.  The non-linear process is as follows: 
1. Undertake a probabilistic sensitivity analysis (PSA) on the model: Monte 
Carlo simulation to generate 10,000 prior estimates (p1 to p10,000) for the 
uncertain parameters of interest.  
2. Assume a sample size (N) for a new piece of research.  
3. Simulate data collection for the new sample (N), from the binomial 
likelihood using the prior estimate for the parameter(s) of interest from the 
first iteration of the PSA in step 1 (p1).  
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• Draw 1 sample result (x) from the binomial likelihood 
4. Calculate the Beta posterior distribution β(α + x, β + N-x) for the 
parameter(s) of interest and derive the posterior estimate for the 
parameter of interest. 
5. Put the posterior distribution for the parameters of interest back into the 
model (along with the complimentary parameters and their prior 
distributions which have not changed).  Re-run the PSA using Monte Carlo 
simulation with 10,000 iterations, drawing from the posterior distributions 
for the parameters of interest and the prior distributions for the 
complimentary parameters.  This is the inner loop. 
6. Calculate the net benefit for treatment (NBT) and control (NBC) for each 
iteration of this inner loop and calculate the expected net benefit E(NB) 
across all 10,000 for each intervention. 
7. Store the ENB for each intervention and then choose the maximum of the 
expected net benefits max(ENBT:ENBC) and store this too. 
8. Repeat steps 3 to 7 for each prior estimate from the PSA in step 1.  I.e. use 
p2, p3….p10,000  in step 3 to simulate a single draw from the binomial for 
each (x2……x10,000) and calculate the posterior distribution for each, then re-
run the 10,000 iteration PSA Monte Carlo simulation each time.  Calculating 
the expected net benefit for treatment and control, storing the maximum 
each time as detailed in Table 6-8. 
9. Average across the maximum expected net benefits, as illustrated in Table 
6-8, this is the expected value of a decision based on sample information. 
The intervention which has the greatest ENB across the 10,000 PSA 
outcomes is the intervention of choice under current information.  Subtract 
the ENB of the intervention of choice from the maximum ENB, this is the 
expected value of sample information. 
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Table 6-8: Calculating ENB for EVSI in a non-linear model  
Net Benefit Treatment Net Benefit Control Maximum ENB 
ENBT p1 ENBCp1 max(ENBT : ENBC)  p1 
ENBTp2 ENBCp2 max(ENBT : ENBC)  p2 
ENBTp3 ENBCp3 max(ENBT : ENBC)  p3 
…… ……. …… 
ENBTp10,000 ENBCp10,000 max(ENBT : ENBC)  p10,000 
E(ENBT) E(ENBC) E(max(ENBT : ENBC) 
 
Interpreting the Value of Current Information 
A further potential area for confusion in undertaking an EVSI calculation is 
misinterpretation of what exactly the ‘value under current information’ is.    A 
researcher new to the EVSI process may interpret the ‘value under current 
information’ literally, and therefore misinterpret it as the value of ENB from 
the intervention of choice from the prior Monte Carlo simulation.  However, as 
with EVPPI and following the EVSI algorithm detailed in Equation 6.1, the 
‘value of current information’ is actually generated within the EVSI simulation.  
Given existing evidence the optimal decision is the intervention that generates 
the maximum expected net-benefit, so from the EVSI simulation we choose the 
intervention with the maximum net benefits over all the iterations because 
each iteration represents a possible future realisation of the existing 
uncertainty in the parameter(s) of interest (4).  Therefore the intervention 
with the greatest ENB across all 10,000 iterations in the EVSI simulation is the 
best we can do without sample information, aka ‘the value of current 
information’; while the Expected Maximum NB is the best we can do with 
sample information as it is the average of the ‘best choice’ chosen for each 
iteration. 
Current EVSI methodology papers provide the relevant EVSI algorithm (Equation 
6.1) and simply refer to it as the ‘value of current information’, however they 
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could be more explicit, explaining the reasoning behind its generation from 
within the EVSI simulation to avoid misinterpretation and confusion amongst 
first time or unfamiliar EVSI users.      
6.2.2 Computation 
As demonstrated throughout this chapter, undertaking an EVSI calculation can 
vary in complexity depending on the form of model used and the relationship 
between the model parameters.  The EVSI process requires intensive 
computation (83;86) and dependent on the complexity of the model can be 
even more burdensome.  The ability to undertake an EVSI analysis depends on 
the processing power of the computer and the programming language used to 
undertake the calculation.  Brennan and colleagues (85;199) discuss 
computational and mathematical issues surrounding EVSI calculations and 
explore alternative methods to try and reduce computational time, for 
example, using an approach called Laplace approximations (199;199). 
Health economists may be familiar with a variety of computer packages, such 
as TreeAge (201), R (202) and STATA (203), but for many researchers the basic 
Microsoft Office package Excel TM will suffice for developing a probabilistic 
model and using macros to run Monte Carlo simulations.  However, Excel TM is 
not sufficiently powerful to undertake EVSI calculations, even with a simple 
linear model such as that developed for the fFN case study.  The fFN EVSI 
calculation used a simple linear model with four parameters of interest, 
therefore requiring 10,000 iterations of the model simultaneously for each of 
the four parameters.  The calculation was initially attempted using Excel TM, 
but it was extremely cumbersome and the running time was approximately 66 
hours to complete the full 10,000 iterations (for the linear model with four 
parameters of interest) for just one sample size. The calculation then had to 
be repeated for a range of sample sizes.  Additionally, if a non-linear model 
had been used, 10 thousand iterations times 10 thousand would have been 
required, making a non-linear EVSI calculation impractical in Excel TM.  
Therefore, the model was reprogrammed using the programming language 
FORTRAN for the EVSI calculations. However, even in more sophisticated 
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languages, such as FORTRAN, it is still not an instant process and can be time 
consuming unless the code is manipulated to run efficiently.    
For the EVSI calculation 10,000 iterations from the prior distribution was 
deemed to be a sufficient number of iterations to be representative (85;111), 
however, after the initial calculation was undertaken, variation in the EVSI 
results was explored using alternative numbers of iterations from the prior. 
Figure 6-9 details variation in the EVSI curve under alternative numbers of 
draws from the prior distribution. 
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Figure 6-9: EVSI curves under alternative number of prior draws 
 
As can be seen drawing 1000 iterations is not nearly enough to generate a 
smooth curve, and as recommended (85) 10,000 simulations are more likely to 
give representative outcomes.  However, as can be seen, the 10,000 iteration 
draw is still subject to some ‘noise’ for this case study.  As the number of 
iterations increases, the EVSI curves converge towards the ‘true’ solution.  This 
figure shows that 100,000 to 1 million iterations are required in the fFN EVSI 
calculation to generate a realistic ‘smooth’ EVSI curve.  Therefore, the EVSI 
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calculation for this case study was re-run using 1 million iterations of the 
calculation as opposed to 10,000.  The EVSI results reported in section 6.1.3 
are these more thorough results8.   
Running the EVSI calculation with an ever increasing number of iterations from 
the prior substantially increases computational running time, and therefore 
necessitates efficient code manipulation to reduce the time.  Table 6-9 details 
the duration of the EVSI calculations in FORTRAN for the variety of prior 
iterations presented in Figure 6-9; for each iteration running the EVSI 
simulation for 5000 different sample sizes (simulating from n=10 to n=50,000 in 
increments of 10).   
Table 6-9: Duration to run linear simulation with alternative number of priors 
N iterations Time (minutes) (seconds) 
1,000  1.551 
10,000  14.363 
100,000 3 0.825 
1,000,000 39 48.004 
      
 
Increasing the iterations from 100,000 to 1 million puts a substantial strain on 
the time duration, and this was only for the simple linear fFN model.  Had the 
fFN model been non-linear, the calculation would have required an additional 
inner loop of 1 million Monte Carlo iterations for the posterior PSA; i.e. 1 
million times 1 million iterations.   
Therefore, in order to undertake an EVSI calculation a modern computer with 
strong processing power is required, as well as access to and knowledge of 
programming languages that are sufficiently powerful to undertake the 
complex simulations required.  Extensive knowledge of how to manipulate 
specific programming languages is also beneficial for eliciting more efficient 
running times for complex, multi-loop simulations. Therefore, health 
                                         
8
 Note that for consistency the binomial draws comparison in section 6.2.1 used 10,000 priors for 
both approaches. 
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economists or researchers considering utilising the EVSI methodology for the 
first time may not have the capacity, or programming know-how to undertake 
an EVSI calculation.  This is likely to be a considerable hindrance to the wide 
spread adoption of EVSI methodology.  
Eckermann, Karnon & Willan (81) contend that VOI needs to be useful in 
addressing real decisions yet simple enough to be applied by analysts and 
understood by decision makers in practice.  They suggest that calculating the 
EVSI over all possible ranges of sample size using the methods proposed by 
Ades et al. (83) is too complex and they advocate a simpler method based on 
assumptions using the central limit theorem (CLT).  They propose that EVSI can 
be considered equivalent to the current value of EVPI minus the expectation of 
EVPI with updated information from the trial, and that under the CLT the 
information from a new trial will reduce the EVPI; and as sample sizes 
increases, so does the amount that EVPI will be reduced by.  While this 
approach may be more straightforward than undertaking two-level Monte Carlo 
simulations under the approach proposed by Claxton and Ades (83), it does not 
consider what is driving the uncertainty regarding cost-effectiveness.  It is 
based upon the concept that a trial has already been designed based on a 
frequentist approach. As demonstrated in this Chapter, a trial commissioned by 
a funding body without early DAM may not be necessary in the first place, and 
will therefore have a specified sample size that does not add any value in 
terms of reducing uncertainty.  By using a decision analytic modelling 
approach, EVPPI can help inform on the type of research required. Brennan & 
Kharroubi (84;199) continue to explore ways to simplify the EVSI calculation, 
improve efficiency and reduce computational running time.  
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6.3 Conclusion 
This chapter has demonstrated the use of EVSI methodology and highlighted 
that it is a more efficient means of designing a trial through considering the 
value of additional information.  By calculating the expected net benefit of 
sampling the opportunity cost of research funding can be considered.  The EVPI 
analysis undertaken on the fFN case study at the beginning of this chapter 
showed that any additional research exceeding a cost of £957,000 would not be 
worthwhile and therefore, the EVSI approach (undertaken for illustrative 
purposes) called for an impractically high sample size in order to generate any 
value, and was therefore not worthwhile.  These findings are contrary to those 
in Chapter 5 where an external funding body commissioned a call for an RCT in 
fFN, signifying that they considered such research to be worthwhile, and in 
response to this call a trial was designed and powered on economic endpoints. 
The resultant sample determined by the conventional sample calculations in 
Chapter 5 was far too low to have an impact on reducing uncertainty about 
cost-effectiveness. It also demonstrated that the sample size prescribed by 
conventional methods in Chapter 5 (n=1156 per arm) would generate an 
expected population value of £136,000 and was therefore worth less than the 
cost of the study, budgeted at £1.65 million.  Based on these results, under an 
iterative framework the likely conclusions would have been: rather than 
undertaking a clinical trial the fFN test should be adopted in practice, freeing 
up research resources for more valuable research.  The fFN test could be 
filtered into practice on a small scale, and then the economic model updated 
at a later stage with routine data to further support the reimbursement of fFN 
by the NHS. Implicitly the peer review committee for the potential funders 
came to the same conclusion as the VOI undertaken for this thesis, that the fFN 
trial added little value, given current practice in some areas which was 
beginning to incorporate the fFN trial based on evidence from the USA, and 
therefore the fFN trial was not funded.  
Despite a strong case being presented in support of value of information 
techniques for designing trials, there remain some practical difficulties in 
employing the EVSI approach which may explain the reluctance amongst some 
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health economists, trial clinicians and statisticians to adopt this approach.  
There is a general perception in the medical decision making community that 
EVSI in particular is time-consuming, computationally expensive and has a 
reputation for being ‘too difficult’.  When these drawbacks are combined with 
the current research set-up, in which VOI in general is not supported (or 
required) by funding bodies in research applications, then it is unsurprising 
that many decision modellers and some health economists do not seem to think 
EVSI is a worthwhile exercise.  Another drawback appears to be lack of 
experience with EVSI (for both health economists and clinicians etc.) which 
may compound the negative perceptions with EVSI.  Despite these drawbacks, I 
maintain that VOI and EVSI is a worthwhile exercise, as demonstrated in this 
chapter.  Just because it is computationally heavy and time consuming, does 
not mean that it should not be attempted.  However, unless the current 
research funding set-up changes (i.e. unless a requirement for formal VOI to 
justify research applications is required), unfortunately many researchers are 
unlikely to adopt this ‘good practice’ in practice.  
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7 Summary & Conclusions 
7.1 Introduction 
The aim of this thesis was to examine the role of early decision analytic 
modelling for informing research priorities and the design of future studies in 
health care within the context of an iterative framework for economic 
evaluation.  The thesis explored the feasibility, merits and drawbacks of 
undertaking early decision analytic modelling in practice, and considered 
potential reasons as to why it is not more widely implemented. 
The iterative approach to economic appraisal is a framework that has been 
proposed as good practice (1) in which evaluations should begin with 
explorative modelling using indicative studies, and progress to more rigorous 
assessments, updating the model over time as more data becomes available.  
Therefore, decision analytic modelling is a key process within the iterative 
framework.  An ‘early’ DAM, undertaken prior to primary research, allows 
explorative evaluation of cost-effectiveness based on existing evidence and can 
be used to assess any uncertainty surrounding the cost-effectiveness decision.  
Developing a DAM and undertaking probabilistic analysis at an early stage also 
enables the use of value of information analyses which can be used to help 
inform research priorities, as recommended as part of the iterative framework 
(1).  If developed in advance of primary research, a decision model can enable 
full exploitation of VOI techniques and therefore help determine whether 
further research is potentially worthwhile, help explore the type of research 
required to address uncertainty in current evidence, and even help design a 
trial, for example with regards to an appropriate sample size.   Despite these 
advantages, in practice support and funding for early stage decision analytic 
modelling (and full exploitation of VOI techniques) is rare, and in the health 
care sector economic evaluations still tend to be funded as a one-off exercise 
alongside a trial to justify reimbursement decisions.   
This thesis explored the feasibility and benefits of decision analytic modelling 
in practice, using case study examples. Practical applications of building early 
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decision analytic models were used to demonstrate the importance of early 
DAM; in both an ‘ideal’ setting where early stage modelling was adequately 
funded and also in a less desirable, time-constrained setting where early DAM 
had not been funded but proved a valuable tool for informing trial design 
nonetheless.   This Chapter now provides an overview of the main points from 
the thesis followed by a section considering some practical limitations and 
finally, areas for future research.  
 
7.2 Overview 
7.2.1 Chapter 1 
Chapter 1 introduced the basic concepts and rationale for this thesis, as well as 
providing an overview of the structure of the thesis. Background was provided 
regarding economic evaluation in the health care sector and decision analytic 
modelling was introduced as a means to undertake these evaluations, 
regardless of whether the evaluation is being undertaken alongside a 
prospective trial, or from an entirely retrospective perspective. The iterative 
approach to economic evaluation has been proposed as a framework for good 
practice in economic evaluation (1), but in practice there has been little 
support and many stakeholders in the health care sector remain reluctant to 
adopt the iterative approach.  The aim of this thesis was to examine the role 
for early decision analytic modelling through case studies of practical 
applications.  
7.2.2 Chapter 2  
This chapter introduced economic evaluation in the context of public and 
commercial health care research.  An overview of economic evaluation in the 
health care sector was provided followed by a closer look at the role for 
decision analytic modelling.  The various methodologies involved in DAM for 
economic evaluation were described in detail, including building a decision 
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analytic model, undertaking probabilistic sensitivity analysis, analysing decision 
uncertainty, and using value of information (VOI) techniques in order to 
provide relevant conclusion to decision makers and recommendations for 
further research. 
The iterative approach to economic appraisal has been suggested as an 
appropriate framework for undertaking research in the health care sector, 
within which DAM plays a key role. Chapter 2 explored the benefits of an 
iterative approach for undertaking research in the health care sector, such as 
improvements for decision making in terms of reduced uncertainty, reduction 
of costs and efficiency gains.  Given these potential benefits, this chapter 
supported the case for early stage decision modelling as part of an iterative 
economic process.   
7.2.3 Chapter 3 
Chapter 3 demonstrated a case of good practice whereby the development of 
an early stage decision analytic model was funded by a research body. This 
case study highlighted that some (national) funding bodies do recognise the 
importance of undertaking explorative economic analysis prior to 
commissioning primary research and in some cases are willing to fund and 
support early stage economic research along with the more conventionally 
funded systematic reviews.   
The chapter detailed the development of three early DAMs to assess the 
potential cost-effectiveness of an emerging technology (PET/CT) and in doing 
so demonstrated the benefit and ease of synthesising current evidence and 
clinical expertise to develop such models.  Additionally the chapter illustrated 
the feasibility and viability of modelling techniques in the face of limited and 
poor quality evidence.  When little evidence is found from a systematic review 
it is still possible, and indeed appropriate, to develop a probabilistic model 
using clinical expertise and research group consensus decision making to verify 
the limited existing data, apply an appropriate mean estimate and wide 
uncertainty intervals to represent the uncertainty in probabilistic analysis. The 
economic models developed in Chapter 3 relied heavily on clinical expertise, 
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given the dearth of previous economic evaluations and poor quality, biased 
diagnostic test accuracy evidence in this area.  Some reviewers may consider 
this to be a major drawback to this type of decision analytic modelling 
approach; however, this is precisely the point of employing early decision 
analytic modelling: to attempt to capture what knowledge is available and 
what isn’t, in a systematic manner.  Just because evidence is of poor quality 
does not mean that the economic evaluation will be poor quality.   
Chapter 3 demonstrated the feasibility and benefit of synthesising current 
evidence and clinical expertise in an early decision analytic model, which is 
then used to assess potential cost-effectiveness given current information.  
7.2.4 Chapter 4 
Following on from the development of thee decision models for the PET/CT 
case study in Chapter 3, Chapter 4 explored uncertainty in the model results 
and demonstrated that in using cost-effectiveness acceptability curves the 
results can be examined in terms of decision uncertainty, followed by value of 
information techniques to give meaningful recommendations to funders and 
decision making bodies. This chapter demonstrated the advantages of early 
stage probabilistic models which can be used to inform on future research 
needs, as opposed to a more traditional approach whereby a research problem 
or lack of evidence is identified and used to support a case for primary 
research, without involving any decision analytic modelling.      
Using VOI can identify cases where further research is not worthwhile, and if 
undertaken would be a waste of resources which could be used elsewhere, i.e. 
funding other, more promising research or used to fund clinical practice.  As 
illustrated in the case of primary colorectal cancer, when current evidence is 
limited or of poor quality, this does not necessitate a trial.  Additionally, in 
cases where further research is warranted, a large scale, randomised 
controlled trial is not necessarily required.  Rather, the type of research will 
depend on the different parameters that require further information.  In the 
PET/CT case study, the recurrent and metastatic analyses determined that 
further research would be of potential value and that it was the DTA 
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parameters that were driving uncertainty in the cost-effectiveness decision.  
Therefore the type of further research that would be required is likely to be a 
randomised trial to evaluate unbiased DTA characteristics for the PET/CT, 
ceCT and MRI technologies, however, such a trial would not necessarily be a 
long term trial (as the EVPPI showed that there is little or no value in further 
research for the 5 year survival parameters).  A short term trial would be 
adequate to determine unbiased DTA characteristics, and could possibly also 
be used to derive more accurate data on patients’ quality of life and the cost 
of PET/CT. 
In addition to identifying research priorities, Chapter 4 demonstrated that 
applying the formal process of evidence synthesis and decision modelling at an 
early stage (in advance of a trial), can help ensure the appropriate research 
question is set.  The PET/CT case study highlighted that the original decision 
problem identified by the funding body was not quite appropriate with regards 
to primary CRC, and had the funding body undertaking an iterative process, 
whereby explorative research and possibly a DAM was used in defining the 
research question the research question for Primary CRC may have been re-
specified.   
Chapter 4 demonstrated that even though early decision analytic modelling is 
not often funded and value of information analyses are even less frequently 
utilised in practice, on occasion they are supported by funding bodies.  In such 
situations the practicality of undertaking these analyses is relatively 
straightforward and can have substantial benefits in terms of understanding 
outcomes and determining future research priorities. Just because current 
evidence is limited or of poor quality, does not necessarily mean that further 
research is required, and therefore, applying early DAM and VOI techniques 
allows decision makers to make informed decisions as to whether a new 
intervention should be adopted (or rejected) based on current evidence, or 
whether further information (and what kind of information) is required to help 
determine cost-effectiveness, as opposed to making decisions based on 
subjective reasoning.   
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7.2.5 Chapter 5 
Chapter 5 verified that even when early decision analytic modelling has not 
been funded, a simple DAM can be constructed relatively quickly and fairly 
simply which can be used to help inform the design of a study.  In the context 
of this thesis it would have been preferable to inform a clinical trial design 
following an iterative approach, whereby a comprehensive decision analytic 
model was developed and EVSI undertaken.  However, this was not feasible 
within the context of the fFN study research bid.  Chapter 5 offered a practical 
example of how an economic perspective can still be incorporated into trial 
design and sample size calculations in the context of a frequentist design.  
Given that a basic model constructed within a short time frame, such as that 
developed for the fFN trial, can help in the design and development of a 
standard frequentist trial, there is no reason for economists not to be involved 
in the design stage of a trial, when the purpose of that trial is to determine 
cost-effectiveness.  This chapter highlighted that economic considerations for 
evaluations alongside clinical trials can and should be used to guide 
conventional trial design when an iterative approach to economic evaluation is 
not possible.   
7.2.6 Chapter 6 
Chapter 6 developed the fFN case study from Chapter 5, expanding the analysis 
to consider whether the same or an alternative conclusion would have been 
drawn had it been possible to adopt an iterative economic approach for the 
fFN trial design.   
Formal exploration of uncertainty in the decision model highlighted that the 
fFN test was likely to be cost-effective, with a very high probability of being 
the optimal choice across a wide range of monetary thresholds.  Given the low 
decision uncertainty, the EVPI analysis showed that the value of further 
information per decision was very low, but given the large effective 
population, further research up to a cost of £957,000 could potentially be of 
value.  Considering that the cost associated with undertaking a randomised 
controlled trial is likely to exceed this level of population EVPI, the findings 
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under an iterative approach are in contrast to the research commission brief 
which called for research bids to undertake an RCT in fFN.  The EVSI 
calculation was undertaken for illustrative purposes and called for an 
impractically high sample size in order to generate any value, which is 
unsurprising given the low EVPI per decision.  The EVSI results illustrated that a 
sample of the size determined by the conventional calculations in Chapter 5, 
(n=1156 per arm) would generate an expected population value of £136,000 
and was therefore worth less than the cost of the trial, budgeted at £1.65 
million.  Therefore, at a cost of £1.65 million the proposed fFN trial was likely 
to be a waste of resources in terms of the opportunity cost for research 
spending.   
Based on these results, under an iterative framework the conclusions would 
have been that (rather than undertaking a clinical trial) the fFN test should be 
adopted in practice, freeing up resources for more valuable research.  The fFN 
test could be filtered into practice on a small scale, and then the economic 
model updated at a later stage with routine data to further support the 
reimbursement of fFN by the NHS.     
While the results of Chapter 6 promote the use of an iterative approach, and in 
particular the use of EVSI, there remain some practical difficulties in 
employing the EVSI approach (in terms of correct interpretation of the process, 
computation and time constraints) which may explain the reluctance amongst 
some health economists, trial clinicians and statisticians to adopt this 
approach. This chapter demonstrated the EVSI methodology and highlighted 
that it is a more efficient means of designing a trial through considering the 
value of additional information and through ENBS, the opportunity cost of 
research funding. 
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7.3 Practical limitations for early DAM & VOI 
Time constraints in the process of designing a piece of research are an 
important practical hindrance to undertaking VOI calculations.  The design and 
development of trial protocols are typically undertaken in short periods of time 
in order to meet tight protocol submission deadlines, and therefore, even if 
researchers have familiarity with the VOI methodology and processes, as well 
as knowledge and access to programming languages; a further constraint is the 
time required to develop a decision model, undertake a probabilistic analysis, 
followed by an EVPI analysis and finally undertake an EVSI calculation for a 
wide range of sample sizes.  
In practice the decision problem under question (stage 1 of the iterative 
approach to economic evaluation) will often have been identified by a funding 
body who issue a call for trial proposals to address the specific question of 
interest, as in the fFN case study described in Chapter 5. This method means 
the rigorous evidence synthesis and early modelling stage of the iterative 
process may have been skipped, and if health economists want to contribute to 
the design of the trial they must do so within a short time period specified by 
the funding body, potentially limiting the capacity for full exploration of VOI 
techniques.  In such circumstances adequate resources and time are not 
allocated to the development of a comprehensive early decision analytic model 
to inform the design of the trial, and any attempt to use the VOI process will 
likely involve a rushed, simplified analysis, open to considerable uncertainty. 
However, that is not to say that such an analysis should not be undertaken.   
Despite a strong case being presented in this thesis in support of value of 
information techniques for designing trials, there remain some practical 
difficulties in employing the EVSI approach in particular which may explain the 
reluctance amongst some health economists, trial clinicians and statisticians to 
adopt this approach.  There is a general perception in the medical decision 
making community that EVSI in particular is time-consuming, computationally 
expensive and has a reputation for being ‘too difficult’.  When these 
drawbacks are combined with the current research set-up, in which VOI in 
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general is not supported (or required) by funding bodies in research 
applications, then it is unsurprising that many decision modellers and some 
health economists do not consider undertaking VOI or EVSI analyses in practice. 
Despite these drawbacks, this thesis has demonstrated that VOI methodologies 
and even EVSI is a worthwhile useful exercise for explicitly informing research 
funding decisions. Just because EVSI techniques are computationally heavy and 
time consuming does not mean that they should not be attempted.  However, 
unless the current research funding set-up changes and formally require VOI 
analysis, unfortunately many researchers are unlikely to adopt VOI techniques. 
The fFN case study in Chapter 5 demonstrated that it is possible to build a 
simple model when subject to strict time constraints and that even a basic 
deterministic model can be informative. A simple DAM was constructed within 
a short time frame and was fit for purpose with regards to helping identify 
which of the potential clinical endpoints was the most appropriate (neonatal 
morbidity) and was then used to undertake the sample size calculation in the 
context of a frequentist trial design.  Chapter 6 demonstrated that if funding 
bodies adopted a more flexible, iterative approach to commissioning research, 
it would have been possible to apply VOI techniques to the simple model and 
potentially feedback to the funding body regarding a more appropriate 
research design, within the short timeframe.  A basic probabilistic analysis was 
undertaken on the fFN model using just the four key parameters of interest, 
and this in turn enabled an EVPI analysis which informed that further research 
is only likely to be worthwhile at a cost of less than £957,000.  Even though the 
model was simple and undertaken in a short time period, such a conclusion 
could be useful in terms of highlighting to the funding body that a 
commissioned call for a large scale RCT is likely to be an inefficient use of 
funding. In such a situation funding bodies could make better use of their 
finances by funding the researchers to develop the basic model into a more 
comprehensive model, and reanalyse the PSA to get a more accurate 
representation of uncertainty, and explore EVPPI to determine whether an 
alternative smaller scale study is appropriate, rather than the initially 
envisaged large scale RCT.  
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7.4 Areas for further research 
7.4.1 Fully exploiting VOI within an iterative context 
Chapter 4 demonstrated that in the PET/CT case study no further research was 
required in primary CRC, but that in recurrent and metastatic CRC further 
research was potentially worthwhile.  The EVPPI in both models determined 
that the diagnostic test accuracy parameters were the main drivers for 
uncertainty and therefore a short-term randomised trial would most likely be 
an appropriate future research design. Having submitted the research 
recommendations to the funding body, no further primary research has yet 
been commissioned.  If funding were made available for further research in 
this area, the early model developed for this piece of work could be fully 
exploited by extending the VOI analysis to undertake EVSI and explore ENBS in 
order to determine an appropriate sample size and design criteria for such a 
trial. This would also be optimal in the context of the iterative framework, and 
in the longer term the decision model could be updated with the new DTA 
information from the trial.  
7.4.2 Exploring uncertainty in sample size calculations 
Chapter 5 demonstrated the feasibility of developing a simple DAM and 
undertaking sample size calculations based on cost-effectiveness endpoints 
within the context of a frequestist trial design.  The design and development of 
trial protocols are typically undertaken in short periods of time in order to 
meet submission deadlines, resulting in potential uncertainty in the parameter 
estimates and sample size calculations. The role of uncertainty in sample size 
calculations has been given further attention in published literature and it has 
been proposed that probabilistic sensitivity analysis is a good way to deal with 
this uncertainty (198).  By making a ‘pre-trial’ decision model probabilistic, 
uncertainty regarding the probability of cost-effectiveness could be 
incorporated into the sample size calculations.  However, in practical terms 
the time constraints imposed by protocol submission deadlines may interfere 
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with such an approach and dealing with this uncertainty may only be feasible 
at a later time.  
7.4.3 A simple guide to undertaking EVSI 
Chapter 6 demonstrated the EVSI calculation; however this process also 
highlighted a number of issues, particularly with regards to complexity and 
interpretation, which is likely to hinder more widespread adoption of the EVSI 
technique.  In moving EVSI forward, a potential means to overcome some of 
these issues would be the development of a simple guide to EVSI.  The EVSI 
process has been described by numerous authors; however, existing guidelines 
are complicated to follow and are open to misinterpretation at numerous 
points, as highlighted in Chapter 6 (section 6.2).  A simple guide to EVSI which 
outlined the process involved at each step and explicitly addressed potential 
pitfalls could be of considerable help to first time users of EVSI or even for 
researchers less familiar with the process. Such a guide could address each of 
the misinterpretation issues described in Chapter 6. 
Additionally an area that could provide further clarity on EVSI would be with 
regards to determining whether a model is linear or non-linear in the 
parameters of interest and in the complementary parameters.  The four 
alternative model specifications detailed in Table 6-7 highlight the four 
different approaches for the EVSI calculation; however, a practical worked 
example of the process under each different specification would provide 
additional clarity on the appropriate specification to adopt for those 
undertaking EVSI calculations. Such examples could potentially be incorporated 
into the EVSI user guide discussed above.  
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7.5 Conclusions 
This thesis discussed and demonstrated the application of early decision 
analytic modelling in health care.  The aim was to examine the role for early 
decision analytic modelling through case studies of practical applications.   
The thesis has shown that developing ‘early’ decision modelling in advance of 
primary research is feasible and of considerable merit, regardless of whether 
the DAM was a fully funded comprehensive model, or an unfunded simple 
model constructed under relatively short/strict time constraints.  Undertaking 
early DAM can help explore appropriate endpoints for a planned trial and, in 
the context of an iterative framework for economic evaluation; it can help in 
determining whether further research is potentially worthwhile.  Applying 
early DAM and VOI techniques enables meaningful recommendations to decision 
makers, who can then make informed decisions as to whether a new 
intervention should be adopted (or rejected) based on current evidence, or 
whether further information is required to help make the decision, as opposed 
to making decisions based on subjective reasoning.  There is considerable merit 
in terms of efficiency with employing early DAM prior to primary research, such 
as reduced uncertainty, reduction of costs and efficiency gains, however, some 
drawbacks exists.  It may not always be viable to fully exploit VOI analyses 
and, with regards to undertaking EVSI calculations to inform the design of a 
trial, some issues remain which hinder the widespread support both inside and 
out-with the health economics community. 
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Appendix 1: Literature Search Histories 
Medline (OvidSP) 1950-Nov week 2 2009  
Base search for PET/CT and Colorectal cancer 
1. exp Colorectal Neoplasms/ 
2. ((rectal or rectum or colonic or colon or colorectal or bowel* or sigmoid or anus or 
anal) adj3 (cancer* or carcinoma* or neoplas* or tumor* or tumour* or sarcoma* or 
adenocarcinoma* or adeno?carcinoma* or adenom* or lesion* or CRC)).mp. 
3. or/1-2 
4. exp Tomography, emission-computed/ 
5. positron emission tomography.ti,ab,rw,sh. 
6. pet$.ti,ab,rw,sh. 
7. animal/ not (human/ and animal/) 
8. 6 not 7 
9. exp Deoxyglucose/ 
10. deoxyglucose.ti,ab,rw,sh. 
11. deoxy-glucose.ti,ab,rw,sh. 
12. fluorodeoxyglucose.ti,ab,rw,sh. 
13. 18fluorodeoxyglucose.ti,ab,rw,sh. 
14. fludeoxyglucose.ti,ab,rw,sh. 
15. 18FDG$.ti,ab,rw,sh. 
16. 1818FDG.ti,ab,rw,sh. 
17. f-18-dg.ti,ab,rw,sh. 
18. fluoro-2-deoxy-d-glucose.ti,ab,rw,sh. 
19. 2fluoro-2deoxyglucose.ti,ab,rw,sh. 
20. fluoro-d-glucose.ti,ab,rw,sh. 
21. or/4-5,8-20 
22. animals/ not (humans/ and animals/) 
23. (3 and 21) not 22 
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Economics search 
1. exp "Costs and Cost Analysis"/ 
2. Economics/ 
3. Cost allocation/ 
4. Cost control/ 
5. Cost savings/ 
6. Cost of illness/ 
7. Cost sharing/ 
8. Health care costs/ 
9. Direct service costs/ 
10. Drug costs/ 
11. Employer health costs/ 
12. Hospital costs/ 
13. Health expenditures/ 
14. Capital expenditures/ 
15. Value of life/ 
16. exp economics, hospital/ 
17. exp economics, medical/ 
18. Economics, nursing/ 
19. Economics, pharmaceutical/ 
20. exp "fees and charges"/ 
21. exp budgets/ 
22. (low adj cost).mp. 
23. (high adj cost).mp. 
24. (health?care adj cost$).mp. 
25. (fiscal or funding or financial or finance).tw. 
26. (cost adj estimate$).mp. 
27. (cost adj variable).mp. 
28. (unit adj cost$).mp. 
29. (economic$ or pharmacoeconomic$ or price$ or pricing).tw. 
30. exp models, economic/ 
31. ec.fs. 
32. or/1-31 
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Toxicity, Adverse events, QoL search 
1. ae.xs. 
2. "Quality of Life"/ 
3. mo.fs. 
4. quality-adjusted life years/ 
5. "cost of illness"/ 
6. (QALY or QALM or Quality-Adjusted Life Month or DALY or Disability Adjusted Life-
Years).mp 
7. or/1-6 
 
Decision-making search 
1. Decision Trees/ 
2. algorithms/ 
3. exp decision making, computer-assisted/ or exp decision support techniques/ or 
decision support systems, clinical/ 
4. Decision Making/ 
5. exp Patient Care Planning/ 
6. or/1-5 
 
Embase (OvidSP) 1980 to 2009 Week 47 
Base search for PET/CT and Colorectal cancer 
1. exp anus tumor/ or exp colon tumor/ or exp rectum tumor/ 
2. ((rectal or rectum or colonic or colon or colorectal or bowel* or sigmoid or anus or 
anal) adj3 (cancer* or carcinoma* or neoplas* or tumor* or tumour* or sarcoma* or 
adenocarcinoma* or adeno?carcinoma* or adenom* or lesion* or CRC)).mp. 
3. 1 or 2 
4. exp computer assisted emission tomography/ or exp positron emission 
tomography/ or exp whole body tomography/ 
5. positron emission tomography.mp. 
6. (pet* not (animal not (human and animal))).mp. 
7. Deoxyglucose/ 
8. Fluorodeoxyglucose/ 
9. Fluorodeoxyglucose F 18/ 
10. deoxyglucose.mp. 
11. deoxy-glucose.mp. 
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12. fluorodeoxyglucose.mp. 
13. 18fluorodeoxyglucose.mp. 
14. fludeoxyglucose.mp. 
15. 18FDG*.mp. 
16. 1818FDG.mp. 
17. f-18-dg.mp. 
18. fluoro-2-deoxy-d-glucose.mp. 
19. 2fluoro-2deoxyglucose.mp. 
20. fluoro-d-glucose.mp. 
21. exp tomography/ 
22. or/ 4-21 
23. (rat or rats or mouse or mice or monkey* or rabbit* or hamster* or bovine or 
sheep).mp.  
24. animal/ or experimental animal/ 
25. 23 or 24 
26. (3 and 22) not 25 
 
Economics search 
1. Socioeconomics/ 
2. Cost benefit analysis/ 
3. Cost effectiveness analysis/ 
4. Cost of illness/ 
5. Cost control/ 
6. Economic aspect/ 
7. Financial management/ 
8. Health care cost/ 
9. Health care financing/ 
10. Health economics/ 
11. Hospital cost/ 
12. (fiscal or financial or finance or funding).tw. 
13. Cost minimization analysis/ 
14. (cost adj estimate$).mp. 
15. (cost adj variable$).mp. 
16. (unit adj cost$).mp. 
17. pe.fs. 
18. or/1-17 
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Toxicity, Adverse events, QoL search 
1. exp "Quality of Life"/ 
2. "cost of illness"/ 
3. (QALY or QALM or Quality-Adjusted Life Month or DALY or Disability Adjusted Life-
Years).mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer name] 
4. ae.fs. 
5. to.fs. 
6. or/1-5 
 
Decision-making search 
1. "decision tree"/ 
2. decision support system/ 
3. decision making/ 
4. algorithm/ 
5. clinical pathway/ 
6. or/1-5 
 
Web of Science all content up to 25 Nov 2009 
Base search for PET/CT and Colorectal cancer 
Topic=(((rectal or rectum or colonic or colon or colorectal or bowel* or sigmoid 
or anus or anal) same (cancer* or carcinoma* or neoplas* or tumor* or tumour* 
or sarcoma* or adenocarcinoma* or adeno-carcinoma* or adenom* or lesion* or 
CRC)) AND (positron emission tomography or Fluorodeoxyglucose or 
18fluorodeoxyglucose or deoxy-glucose or Deoxyglucose or fludeoxyglucose or 
18FDG* or 1818FDG or f-18-dg or fluoro-2-deoxy-d-glucose or 2fluoro-
2deoxyglucose or fluoro-d-glucose or (PET* same (CT or computer 
tomography))) NOT (rat or rats or mouse or mice or monkey* or rabbit* or 
hamster* or bovine or sheep))  
Economics search 
Topic=(Economic* OR cost* ) 
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Toxicity, Adverse events, QoL search  
Topic= (toxic* or adverse or "quality of life" or QALY or "quality adjusted life years" or 
QALM or "quality adjusted life month" or DALY or "disability adjusted life years") 
 
Decision-making search 
Topic= (decision* OR algorithm* OR pathway* OR (patient SAME management)) 
 
CINAHL Plus via Ebsco download (30 Nov 2009) 
Base search for PET/CT and Colorectal cancer 
((MH "Colorectal Neoplasms+") or ( TX (cancer* OR carcinoma* OR neoplas* OR tumor* 
OR tumour* OR sarcoma* OR adenocarcinoma* OR adeno?carcinoma* OR adenom* OR 
lesion* OR CRC) AND (rectal OR rectum OR colonic OR colon OR colorectal OR bowel* 
OR sigmoid OR anus OR anal))) AND ((MH "Tomography, Emission-Computed+") or TX 
("positron emission tomography" OR "18FDG PET-CT" OR "18FDG PET*" ) or TX 
fluorodeoxyglucose or ( (MH "Fludeoxyglucose F 18")))  
 
Economics search 
MW EC OR (TX cost or costs or economic* OR pharmacoeconomic* OR price* OR 
pricing*) OR (MH "Health Resource Utilization") OR (MH "Health Resource Allocation") 
OR (MH "Business+") OR (MH "Financing, Organized+") OR (MH "Financial Support+") OR 
(MH "Financial Management+") OR (MH "Economics+")   
 
Toxicity, Adverse events, QoL etc search 
( QALY or QALM or DALY ) OR quality adjusted life years OR quality adjusted life 
months OR disability adjusted life years OR (MH "Ferrans and Powers Quality of Life 
Index") OR MW "AE" OR MW "TO" OR MW "MO" OR (MH "Quality of Life") 
 
Decision-making search 
(MH "Decision Making+") OR (MH "Algorithms") OR (MH "Triage") OR pathway* OR policy 
OR policies 
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Cochrane Library (NHSEED, HTA, CENTRAL, DARE) Issue 
4, 2009 
#1 MeSH descriptor Colorectal Neoplasms explode all trees 
#2 (rectal OR rectum OR colonic OR colon OR colorectal OR bowel* OR sigmoid OR 
anus OR anal) NEAR/3 (cancer* OR carcinoma* OR neoplas* OR tumor* OR tumour* OR 
sarcoma* OR adenocarcinoma* OR adeno?carcinoma* OR adenom* OR lesion* OR CRC) 
#3 MeSH descriptor Tomography, Emission-Computed explode all trees 
#4 (positron emission tomography OR Fluorodeoxyglucose OR 18fluorodeoxyglucose 
OR deoxy-glucose OR Deoxyglucose OR fludeoxyglucose OR 18FDG* OR 1818FDG OR f-18-
dg OR fluoro-2-deoxy-d-glucose OR 2fluoro-2deoxyglucose OR fluoro-d-glucose OR 
(PET* NEAR/5 (CT OR computer tomography))) 
#5 MeSH descriptor Deoxyglucose explode all trees 
#6 (( #1 OR #2 ) AND ( #3 OR #4 OR #5 )) 
 
HMIC Health Management Information Consortium 
(OvidSP) November 2009 
1. positron emission tomography.mp. 
2. 18FDG PET-CT.mp. 
3. computed tomography scanners/ or tomography/ 
4. colorectal cancer/ 
5. ((rectal or rectum or colonic or colon or colorectal or bowel* or sigmoid or anus or 
anal) adj3 (cancer* or carcinoma* or neoplas* or tumor* or tumour* or sarcoma* or 
adenocarcinoma* or adeno?carcinoma* or adenom* or lesion* or CRC)).mp. 
6. 1 or 2 or 3 
7. 4 or 5 
8. 6 and 7 
 
CEA Registry 
“positron emission tomography” 
(Anything more detailed yielded nil results) 
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